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New antibiotics to combat drug-resistant Gram-negative pathogens are urgently needed. 
Most small molecules are unable to rapidly traverse the outer membrane of Gram-negative bacteria 
and accumulate inside these cells, making the discovery of drugs against these pathogens 
challenging. Current understanding of the physicochemical properties that dictate small-molecule 
accumulation in Gram-negative bacteria is largely based on retrospective analyses of antibacterial 
agents, which suggest that polarity and molecular weight are key factors. A few compound 
accumulation studies in whole cells have been performed. These accumulation studies support the 
retrospective studies, but broad conclusions cannot be drawn from these small data sets (10–20 
compounds and all within a single structural class). Both the retrospective studies and the 
accumulation studies have major limitations, and the canonical view about the importance of 
polarity and molecular weight for Gram-negative activity has not led to general strategies to 
discover new broad-spectrum antibiotics. 
With the goal of developing predictive guidelines for compound accumulation in Gram-
negative bacteria, here we assess the ability of over 180 diverse compounds to accumulate in 
Escherichia coli. Most of the compounds were synthesized using the Complexity-to-Diversity 
method to rapidly obtain a diverse collection of natural product-like compounds. The CtD 
collection allowed us to be successful where others were not due to unique features of the 
collection, particularly in that the CtD library has significantly more compounds with contiguous 
and/or overlapping ring systems than standard commercially available libraries. Structure-activity 
relationship studies and computational analyses of the accumulation results reveal that small 
molecules are most likely to accumulate if they contain an amine, are amphiphilic and rigid, and 
have low globularity. These guidelines were then applied to convert deoxynybomycin, a natural 
product that is active only against Gram-positive organisms, into an antibiotic with activity against 
a diverse panel of multi-drug-resistant Gram-negative pathogens.  
In addition, with the compound collection, assay conditions, and machine learning method 
in hand, we are performing mechanistic studies to understand how different bacterial components 
contribute to accumulation, and we are studying accumulation in other Gram-negative pathogens. 
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Chapter 1: Challenges in developing broad-spectrum antibacterials 
 
1.1 The rise of drug-resistant bacteria 
 The rise in multidrug resistant bacteria is a major health concern. Resistance has been 
observed to every antibiotic that has been introduced to the clinic,1 including drugs-of-last resort 
such as vancomycin,2-6 daptomycin,7-8 and colistin.9-11 Despite the increase in resistance, the rate 
of discovery and development of new antibiotics has been declining in recent decades.12-15 
Pathogens now exist that are resistant to all or almost all available antibiotics, resulting in an 
increased number of bacteria-related deaths.16-18 In 2013, the Centers for Disease Control (CDC) 
estimated that at least 23,000 people die per year in the United States from drug-resistant bacteria.19 
Without drastic changes in antibacterial drug discovery and development, this problem is only 
expected to get worse; in fact, it has been predicted that 10 million people worldwide will die per 
year by 2050 due to drug-resistant bacterial infections.20  
1.2 Gram-negative bacteria as a major public health concern 
Gram-negative bacteria have emerged as some of the most problematic pathogens in the 
last couple of decades.21-23 In 2008, Louis B. Rice published an editorial highlighting the pathogens 
that cause the most hospital-acquired infections and frequently “escape” the action of traditional 
therapeutics.14 The pathogens highlighted are collectively referred to as the ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae/Escherichia coli 
(Enterobacteriaceae), Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter 
species). Four of the six ESKAPE pathogens (K. pneumoniae/E. coli, A. baumannii, P. aeruginosa, 
and Enterobacter species) are Gram-negative species. Increased hospital surveillance, the approval 
of new drugs, and hygiene have helped combat the rise in multidrug-resistant (MDR) Gram-
positive infections,24-30 but the prevalence of MDR Gram-negative infections has continued to 
increase.13, 25, 31 More recently in February of 2017, the World Health Organization issued a list of 
‘Priority Pathogens’ for which new antibiotics are urgently needed.32 The list is broken down into 
three categories: critical, high, and medium priority. Nine out of the 12 pathogens listed are Gram-
negative bacteria including all three Critical Priority Pathogens (carbapenem-resistant 
Enterobacteriaceae (CRE), A. baumannii, and P. aeruginosa). Part of the challenge in treating 
Gram-negative infections is that many antibiotics are ineffective against Gram-negative species 
(Fig. 1.1, green box), limiting the number of drugs available as resistance begins to arise. Despite 
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this rise in multidrug resistance, no new class of antibiotics effective against Gram-negative 
bacteria has been introduced into the clinic since the fluoroquinolones in 1968.33 Clinicians have 
had to rely on colistin, a drug that was previously removed from the clinic due to high toxicity (50-
60% of people on colistin experience acute kidney injury),34-36 but unfortunately resistance has 
already emerged to colistin as well.10-11, 37 The rise in MDR Gram-negative pathogens and lack of 


































Fig. 1.1. Antibiotic structures. Gram-positive-only antibiotics and broad-spectrum antibiotics 
(effective against Gram-negative pathogens). Antibiotics can enter Gram-negative bacteria 
through porins, the self-promoted uptake, or through a combination of both. The metal-binding 
motif of tetracycline and ciprofloxacin is shown.  *Colistin is Gram-negative only.  
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The lack of development of new Gram-negative antibiotics is not due to a lack of effort. 
The screening of standard compound collections for Gram-negative antibacterial leads has proven 
ineffective.1, 38-40 As one example, researchers at GlaxoSmithKline reported a whole-cell screen of 
500,000 compounds against E. coli, but no promising leads were identified.40 In a review of this 
failure, Payne and coworkers note that greater molecular diversity in screening libraries and a 
better understanding of which physical chemical properties are important for antibacterials is 
necessary.40 
1.2.1 Gram-negative bacteria are impermeable to most small molecules 
A major obstacle in Gram-negative antibacterial discovery is finding compounds that can 
permeate the Gram-negative outer membrane and persist inside the cell.41-43 Unlike Gram-positive 
bacteria, Gram-negative bacteria have two cellular membranes (Fig. 1.2A). The outer leaflet of the 
outer membrane is unique to Gram-negative bacteria and is composed of lipopolysaccharides 
(LPS).44 LPS have three parts: lipid A, the core polysaccharide, and the O-antigen.45 Lipid A 
molecules contain 5-6 carbon chains attached to a phosphorylated polysaccharide (Fig. 1.2B). The 
core polysaccharide is attached directly to lipid A, and is usually negatively charged. The O-
antigen is linked to the core polysaccharide and differs by strain.46 The negative charges of lipid 
A and the core polysaccharides are stabilized by divalent cations.47-48 This stabilization, along with 
the fact that LPS lipid chains are predominately saturated (Fig. 1.2B),46 allows LPS molecules to 
stack together very tightly, preventing the passive diffusion of essentially all small molecules. 
Certain compounds, including β-lactams, chloramphenicol, tetracyclines, and 
fluoroquinolones can enter Gram-negative bacteria through channel proteins called porins (Fig. 
1.1, red and purple boxes).41 Porins are relatively narrow water-filled β-barrels lined interiorly 
with charged amino acids. OmpF is the major porin of E. coli and the prototypical porin (Fig. 
1.2C). OmpF contains a negatively-charged loop that extends into the barrel, across from a 
positively-charged wall.49 This ‘constriction zone’ is approximately 7 by 11 Å,49 allowing only 
certain molecules to rapidly diffuse through the channel.  
Other small molecules can pass through the outer membrane via the self-promoted uptake 
pathway by displacing the divalent cations, and temporarily destabilizing the LPS layer.50-53 
Compounds that utilize the self-promoted pathway are typically polycationic,53-54 and include the 
polymyxins,55-56 the aminoglycosides,57 and azithromycin58 (Fig. 1.1, blue box). However, many 
hypothesize that compounds with metal-binding motifs can also utilize the self-promoted 
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pathway.59 For example, fluoroquinolones contain a metal-binding β-ketoacid,58, 60-62 and 
tetracyclines are known to bind metals through their 1,3-keto-enol system.63-65 (Fig. 1.1, purple 
box). The permeation of fluoroquinolones and tetracyclines through the self-promoted uptake 
pathway is debated in the literature.66-67 Self-promoted uptake is most often determined by one of 
two assays. In one assay, additional Mg2+ is added to solution; if the antibiotic activity is 
significantly decreased, compounds are predicted to enter through the self-promoted uptake system 
because they can no longer compete with the level of Mg2+ present.59 In the other assay, bacteria 
are incubated with the antibiotic of interest and a fluorescent small molecule. Self-promoted uptake 
requires temporary destabilization of the LPS layer, and compounds that utilize the self-promoted 
pathway should cause the bacteria to uptake the fluorescent compounds.58 The activity of 
tetracyclines and fluoroquinolones is decreased in the presence of Mg2+, but there is no consistency 
in the literature about whether they promote uptake of fluorescent small molecules.15, 66-67 It is also 
important to note that the addition of Mg2+ reduces activity of Gram-positive bacteria to the 
fluoroquinolones.66 This has led to the hypothesis that the addition of magnesium simply causes 
increased interaction between the cell wall of both Gram-positive and Gram-negative bacteria and 
the fluoroquinolones, preventing diffusion into the cells. Although it is challenging to completely 
understand compound uptake into Gram-negative bacteria, it is important to consider the many 
mechanisms that can be involved.  
Compounds that can cross the outer membrane are then subject to highly promiscuous 
efflux pumps (Fig. 1.2A).68 Essentially all small molecules are believed to be efflux substrates, but 
there may be some compounds that are better substrates than others. To accumulate inside Gram-
negative bacteria, small molecules must cross the outer membrane faster than they are pumped 
out.  As such, many antibiotics cannot accumulate in Gram-negative species and are inactive 
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Figure 1.2. Components of the Gram-negative cellular envelope. A) The cellular envelope 
of Gram-negative bacteria (right) contains two lipid membranes, while Gram-positive bacteria 
(left) have only one lipid membrane. The outer leaflet of the outer-membrane of Gram-negative 
cells is composed of lipopolysaccharides (LPS). Most small molecules are unable to passively 
diffuse at an appreciable rate through the LPS layer. Instead, molecules enter through channel 
proteins called porins (yellow). All compounds, however, are subject to multidrug efflux 
pumps. B) The structure of lipid A. The core polysaccharide is linked to the 6’ carbon. C) Top 
view of OmpF, the prototypical porin from E. coli. A negatively-charged loop extends into the 
center of the loop across from a positively-charged wall, creating a narrow constriction site and 
preventing the passage of many compounds.  
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1.3 Understanding small-molecule accumulation in Gram-negative bacteria 
 In an effort to improve drug discovery efforts for Gram-negative antibacterials, both 
retrospective and prospective studies to determine the properties of Gram-negative antibacterials 
have been performed. The insights gained from these studies, as well as the limitations, are 
discussed below. 
1.3.1 Retrospective studies of Gram-negative antibacterials 
 Prior to our work to experimentally develop predictive guidelines for small-molecule 
accumulation in Gram-negative bacteria (discussed in Chapter 3),69 retrospective studies provided 
the foundation for understanding small-molecule accumulation. The first retrospective study to 
compare broad-spectrum antibiotics (those that are effective against both Gram-positive and 
Gram-negative bacteria) versus Gram-positive-only antibiotics, was performed in 2008 by O’Shea 
and Moser.70 In this study, physicochemical properties were calculated for 147 marketed 
antibiotics and several thousand non-antibacterial drugs represented by a shortened list of the 
Comprehensive Medicinal Chemistry Database (CMC). They determined that antibiotics with 
Gram-negative activity tend to be smaller than Gram-positive-only antibiotics, with a molecular 
weight cutoff around 600 Da (Fig 1.3A), consistent with the narrow porin channel. Additionally, 
Gram-negative active antibiotics are much more polar on average than both Gram-positive-only 
antibacterials and non-antibacterial drugs. The difference in polarity is most clearly observed by 
comparing ClogD7.4 values (Fig 1.3A), which accounts for charge at physiological pH. However, 
relative polar surface area and number of hydrogen bond donors and acceptors also demonstrate 
the increased polarity of Gram-negative antibacterials. In summary, O’Shea and Moser observed 
that Gram-negative antibacterials have unique physicochemical properties that generally do not 
follow Lipinski’s rules of five, and attributed this difference to the structure of the Gram-negative 
cellular envelope.  
 Although the study by O’Shea and Moser clearly highlighted that marketed Gram-negative 
antibacterials have unique physicochemical properties, there are several limitations to this study. 
The biggest limitation is the diversity of the compound collection. O’Shea and Moser analyzed 
clinically employed antibiotics. Therefore, most of the compounds studied were from only a few 
drug classes. The Gram-negative-active antibiotics are predominately from only five classes 
(tetracyclines, sulfa drugs, Gram-negative β-lactams, fluoroquinolones, and aminoglycosides) 
(Fig. 1.3B), and the properties of each class cluster together. Other limitations include an inability 
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to validate that their observations are necessary for accumulation inside Gram-negative bacteria, 
and no explanation for why certain antibacterials are small and relatively polar, but are still only 
active against Gram-positive species is given. Despite providing some understanding about the 
properties of Gram-negative antibacterials, this study has unfortunately not been reliably 
Figure 1.3. Retrospective studies of the physicochemical properties of Gram-negative 
antibiotics. A) ClogD7.4 values plotted against molecular weight (MW) for non-antibacterial 
drugs represented by the Comprehensive Medicinal Chemistry Database (grey dots), Gram-
positive-only antibiotics (red squares), and broad-spectrum antibiotics (blue diamonds). 
Antibacterial data was generated from a list of 147 clinically relevant antibiotics in 2008. B) 
ClogD7.4 values plotted against MW for broad-spectrum antibiotics from (A) broken down by 
antibiotic class. Broad-spectrum antibiotics are predominately from only five classes. C) 
Average ClogD7.4 value of compounds active against each pathogen. Data is generated from 
existing antibacterial programs at AstraZeneca. D) Analysis of ionic charge of compounds from 
existing antibacterial programs at AstraZeneca. Sections A and B were adapted from “O'Shea, 
R.; Moser, H. E., Physicochemical properties of antibacterial compounds: implications for drug 
discovery. J. Med. Chem. 2008, 51, 2871-8.” with permission. Sections C and D are taken from 
“Brown, D. G.; May-Dracka, T. L.; Gagnon, M. M.; Tommasi, R., Trends and exceptions of 
physical properties on antibacterial activity for Gram-positive and Gram-negative pathogens. J. 


















































actionable in attempts to facilitate the conversion of Gram-positive-only antibacterials into broad-  
spectrum agents.   
 Another retrospective study was published by scientists at AstraZeneca in 2014.39 In 
comparison to the O’Shea and Moser study, this article focuses significantly more on the 
challenges of advancing initial hits into leads with respect to physicochemical properties. 
However, like the O’Shea and Moser study, the AstraZeneca study begins with an analysis of 
antibacterial property space for compounds with whole-cell antibacterial activity. AstraZeneca 
assessed more than 3,000 compounds generated from existing antibacterial drug programs. In the 
analysis, they examined each species of bacteria independently, and looked at net charge in 
addition to many of the properties O’Shea and Moser assessed. The results of this assessment are 
largely similar to those of O’Shea and Moser, with antibacterials with Gram-negative activity 
having much lower ClogD7.4 values on average than antibacterials with Gram-positive-only 
activity (Fig. 1.3D). The analysis of ionic charge showed that most compounds with Gram-
negative antibacterial activity are charged, and this is split between acids and bases (Fig. 1.3D). A 
major limitation of this study is that the diversity of the collection cannot be determined because 
compound structures are not provided. A large percentage of Gram-negative-active compounds 
contain carboxylic acids, but the authors note that these are almost all β-lactams, where the acid is 
required for activity. The inability to differentiate properties necessary for target engagement from 
those necessary for accumulation is a major weakness of retrospective studies in general, which 
rely solely on antibiotic activity as a readout.  
1.3.2 Whole-cell studies of small-molecule accumulation in Gram-negative bacteria  
Compound accumulation studies are an excellent method to understand small-molecule 
accumulation in Gram-negative bacteria because they do not rely on the level of antibacterial 
activity, which is not necessarily correlated with accumulation; importantly, this analysis enables 
the assessment of many more structural classes, as the readout is accumulation, not antibacterial 
activity. Although accumulation studies can be highly informative, the use of accumulation studies 
to understand the properties necessary for permeation of small molecules into Gram-negative 
bacteria have been relatively limited. For a long time, large studies were not performed due to the 
lack of a general assay. Small numbers of compounds could be assessed with radiolabeling or by 
taking advantage of certain physical or reactive properties of a single antibiotic class.71-75 More 
recently, this complication has been resolved with liquid chromatography-tandem mass 
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spectrometry (LC-MS/MS), but the diversity of compounds tested for Gram-negative 
accumulation has still been very limited. Until our recent accumulation study (discussed in Chapter 
3), most studies were very small (10-15 compounds), and, as discussed herein, broad conclusions 
could not be made.   
Many of the earliest accumulation assays were performed with β-lactams. The permeation 
of penicillins can be assessed using a micro-iodometric assay.76-78 The micro-iodometric assay is 
a colorimetric assay that relies on the deep blue color of triiodide complexed with starch (Fig. 1.4). 
In an aqueous solution of iodine and potassium iodide, triiodide is present at equilibrium (Fig 
1.4A). Penicillins hydrolyzed by β-lactams to penicilloic acid reduce iodine much more readily 
than intact penicillins, resulting in a decrease in triiodide and decolorization of the starch-triiodide 
mixture (Fig. 1.4C). In Gram-negative bacteria, β-lactamases are present in the periplasm. 
Assuming β-lactams are hydrolyzed immediately in the presence of β-lactamases, the micro-
iodometric assay can be used with whole cells expressing β-lactamases to estimate diffusion rates 
of β-lactams across the outer membrane.78  
Nikaido and coworkers employed the micro-iodometric assay to measure the diffusion of 
cephalosporins through different porins in intact cells.79 The permeability of six monoanionic 
cephalosporins were measured in E. coli expressing only the OmpF, OmpC, or PhoE porin 
(compound structures shown in Fig. 1.5A). Using experimentally determined octanol-water 
partition coefficients of the unionized compound forms (Pu) as an approximation of 
hydrophobicity, Nikaido and coworkers observed the permeability of the monoanionic 
cephalosporins decreases with increased hydrophobicity in E. coli expressing only one of the three 
porins (Fig 1.5B).79  From these results, Nikaido and coworkers speculate that hydrophilic 
A) B) C)
Figure 1.4. Micro-iodometric assay. A) Triiodide is present at equilibrium in an aqueous 
solution of iodine and an iodide salt. Molecular iodine is reduced to iodide. Thus, reducing iodine 
can result in less triiodide present in solution. B) Triiodide forms a complex with starch that is a 
deep blue/purple color. C) In the presence of penicilloic acid, an aqueous mixture of iodine, 
potassium iodide, and starch turns from deep blue/purple (left) to yellow (right).  
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compounds permeate the porins more rapidly because it is energetically more favorable for 
hydrophilic compounds to disrupt the hydrogen bonds between the channel walls and water 
molecules. They also measured the permeability of three zwitterions. To compare the permeability 
of zwitterions and their monoanionic analogs, the permeability of the hypothetical monoanionic 
analogs were predicted based on the predicted Pu. From this comparison, Nikaido and coworkers 
conclude that the zwitterions permeate porins much more readily than monoanionic cephalosporins 
(Fig. 1.5C).79          A similar analysis was performed with a di-anionic cephalosporin compared to 
a hypothetical monoanionic analog. Permeability of the dianionic cephalosporin is slower through 
the porins than the hypothetical monoanionic analog (Fig 1.5C). Acknowledging that the use of 
hypothetical compounds could lead to doubts about the reliability of the study, Nikaido and 
coworkers also measured the permeability of cephaloridine and cefsulodin, two real compounds 
that are structurally similar but have different net charges.79 Cephaloridine is a zwitterion and 
cefsulodin has one positive charge and two negative charges (Fig 1.5A).   Cefsulodin permeates 
much more slowly than cephaloridine into E. coli expressing OmpF and OmpC, and more rapidly 
into E. coli expressing PhoE (Fig. 1.5C). These studies suggest that OmpF and OmpC are cation 
selective, and PhoE is slightly anion selective, which is supported by the fact that PhoE is 
expressed in phosphate starvation conditions.80-81 Despite the fact that the low substrate number, 
limited structurally diversity, overuse of estimations and assumptions, and no consideration of the 
role of efflux pumps prevent a more in depth understanding of the types of compounds best able 
to accumulate in Gram-negative bacteria, this permeation study provides a rudimentary 



































































































Figure 1.5. Permeability of cephalosporins into E. coli expressing one of three porins. A) 
Structures of the cephalosporins assessed and experimentally determined octanol-water partition 
coefficients of the unionized compound forms (P
u
) as an approximation of hydrophobicity. N/A, 
not applicable. B) Permeability coefficient in cm/s plotted against hydrophobicity measured in 
logP
u
, for E. coli expressing PhoE (open triangles), OmpF (closed circles), or OmpC (open 
circles). In all three cases, permeability decreases with increasing hydrophobicity. C) Effect of 
charge on the permeability coefficient (PC) (cm/s) of cephalosporins. The monoanionic analogs 
are hypothetical compounds with estimated PC values. Data taken from “Nikaido, H.; 
Rosenberg, E. Y.; Foulds, J., Porin channels in Escherichia coli: studies with beta-lactams in 





 The relationship between hydrophobicity and compound accumulation in Gram-negative 
bacteria has also been examined with fluoroquinolones. Intracellular concentrations of the 
fluoroquinolones can be assessed by measuring fluorescence of the lysed cells.72-73, 82-86  In an 
analysis by Bazile and coworkers, the permeability of eleven fluoroquinolones (Fig. 1.6A) were 
assessed for accumulation in S. aureus, E. coli, and P. aeruginosa.82 Like the accumulation studies 
performed with β-lactams, the relationship between hydrophobicity and permeability of the 
fluoroquinolones was assessed for each species of bacteria. As is shown in Fig. 1.6B-D, 
accumulation increases with hydrophobicity in S. aureus, whereas accumulation decreases with 
hydrophobicity in E. coli and P. aeruginosa. As can be seen by the R2 values, the accumulation is 
not well-correlated with hydrophobicity, and, despite this weak correlation, other properties are 
not considered. For example, BMY 40397 is a poor accumulator in both E. coli and P. aeruginosa. 
Bazile and coworkers attribute the low accumulation to its hydrophobicity, but it is also the largest 
compound tested and the only compound with two negatively-charged groups. Without additional 
compounds, a full panel of controls, and the consideration of more properties, it is impossible to 























































































































Figure 1.6. Accumulation of fluoroquinolones in bacteria. A) Structures of the 
fluoroquinolones assayed and experimentally determined LogD values. The relationship 
between accumulation and logD for S. aureus (B), E. coli (C), and P. aeruginosa (D). Linear 
trendlines and the coefficient of determination (R
2
) values are provided on each graph. Error 
bars were not provided. Data taken from “Bazile, S.; Moreau, N.; Bouzard, D.; Essiz, M., 
Relationships among antibacterial activity, inhibition of DNA gyrase, and intracellular 
accumulation of 11 fluoroquinolones. Antimicrob. Agents Chemother. 1992, 36, 2622-2627.” 
with permission.  
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In 2009, Cai and coworkers introduced a LC-MS/MS based accumulation assay to study 
the accumulation of  ciprofloxacin.87 They were able to demonstrate that the accumulation levels 
measured were  consistent with using a fluorescence based assay or a radiometric assay, and they 
observed increased sensitivity. LC-MS/MS is highly generalizable, and can be utilized to measure 
diverse compounds for accumulation in bacteria.  
 LC-MS/MS enabled Derek Tan and coworkers to measure the accumulation of ten 
sulfonyladenosines (structures shown in Fig. 1.7A).88 The ten compounds were assayed in three 
species of bacteria with diverse cellular envelopes: E. coli (Gram-negative) (Fig. 1.7B), Bacillus 
subtilis (Gram-positive) (Fig. 1.7C), and Mycobacterium smegmatis (Fig. 1.7D). The compounds 
are displayed in increasing order of hydrophobicity (values shown in Fig. 1.7A). The authors note 
that these data indicate that hydrophobicity is insufficient to predict compound accumulation in 
bacteria and that other structural and physicochemical parameters likely influence compound 
uptake. To obtain a quantitative assessment of the impact of 20 chemical parameters individually 
upon accumulation, a Pearson analysis was performed. The Pearson analysis suggests that 
hydrophobicity, ring content, and size all positively correlate with accumulation in E. coli, and 
ring complexity, hydrogen bonding capacity, and heteroatom counts (O and N) all negatively 
correlate with accumulation in E. coli. Unfortunately, it is unclear how well these compounds 
accumulate compared to clinically useful antibiotics due to a lack of control data, limiting the 
impact of this study. Additionally, like the accumulation studies with cephalosporins and 
fluoroquinolones, lack of compound number and diversity in this study severely hampers the 
interpretation and generalizability of these results.  
In summary, studies to understand the relationship between chemical parameters and 
accumulation in Gram-negative bacteria have been very limited. The retrospective analyses are on 
only a handful of antibacterial classes, and all the accumulation assessments were performed on 
single structural classes, even after the introduction of LC-MS/MS. Additionally, comparing the 
results from study-to-study is essentially impossible due to a lack of assay validation with known 
controls. To more accurately predict compound accumulation in Gram-negative bacteria to aid in 






















Figure 1.7. Accumulation of sulfonyladenosines in bacteria. A) Structures of the 
sulfonyladenosines assayed and ALogPs values. The accumulation of sulfonyladenosines in E. 
coli (B), B. subtilis (C), and M. smegmatis (D). No control data with known antibacterials was 
provided. Data and figures taken from “Davis, T. D.; Gerry, C. J.; Tan, D. S., General platform 
for systematic quantitative evaluation of small-molecule permeability in bacteria. ACS Chem. 
Biol. 2014, 9, 2535-44.” with permission.  
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1.4 Converting Gram-positive-only antibacterials into broad-spectrum agents 
Based on the limited understanding of the physicochemical parameters that promote 
compound accumulation in Gram-negative bacteria, we performed a systematic analysis of the 
accumulation of an unbiased and structurally diverse set of small molecules in E. coli.69 As will be 
discussed in Chapter 3, we thoroughly validated a LC-MS/MS based accumulation assay with 
antibiotic controls and studied the accumulation of almost 200 structurally diverse compounds.69 
From this study, we found that compounds are most likely to accumulate in E. coli if they contain 
a non-sterically hindered amine, are relatively rigid (≤ 5 rotatable bonds (RB)) , and have low 
three-dimensionality (globularity (Glob) value ≤ 0.25). Most antibacterial targets are highly 
conserved across species, and lack of compound accumulation is the main reason antibiotics are 
not active against Gram-negative species. In fact, Gram-negative bacteria with a permeabilized 
outer membrane or deficient efflux pumps are generally susceptible to many antibiotics that are 
not active against wild-type Gram-negatives. We therefore speculated that a Gram-positive-only 
antibacterial with the proper rigidity and three-dimensionality could be converted to a broad-
spectrum antibacterial by the addition of an amine that that does affect the ability of the compound 
to interact with its target. We applied the Gram-negative accumulation guidelines to convert 
deoxynybomycin (DNM), a natural product that inhibits DNA gyrase and is only against Gram-
positive organisms, into 6DNM-NH3, an antibiotic with activity against a diverse panel of 
multidrug resistant Gram-negative pathogens (Fig 1.8). The conversion of DNM into broad-
spectrum 6DNM-NH3 through the addition of an amine was deliberate, but we were curious if 
other serendipitous examples already existed. As described below and armed with our discovery 
about the importance of shape, flexibility, and the presence of a primary amine, by going back 
through 50+ years of antibacterial research and 1000s of derivatives, we can look for patterns in 
this historical data set and see if they are consistent with our predictive guidelines.  
For this study, we focused on compounds with activity against Enterobacteriaceae (E. coli 
and Klebsiella), P. aeruginosa, and/or A. baumannii, which are all nonfastidious Gram-negative 
organisms. Fastidious bacteria, such as Neisseria gonorrhoeae and Helicobacter pylori, have 
complex nutritional requirements, and their outer membranes are significantly different than those 
of nonfastidious organisms. The same is true for Mycobacteria, which are often considered Gram-
negative because they do not stain with Gram stain. However, unlike traditional Gram-negative 
species that contain a LPS layer, Mycobacteria contain a mycolic acid layer. Due to the membrane 
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differences between nonfastidious Gram-negative species, fastidious Gram-negative species, and 
Mycobacteria, the guidelines for compound accumulation are likely different. Thus far, we are 
only studying accumulation in nonfastidious species, and cannot conjecture about the permeability 
requirements of these other organisms. Throughout the rest of the chapter, the term Gram-negative 
will only be used to describe nonfastidious Gram-negative organisms.   
1.4.1 Successful Gram-positive to Gram-negative conversions 
 
Fig 1.8. Appending a sterically-unencumbered amine on relatively flat and rigid 
antibiotics can enhance their activity against Gram-negative bacteria. RB = rotatable 
bonds; Glob = globularity; Broad-spectrum = activity against both Gram-positive and Gram-
negative bacteria; PA = P. aeruginosa; MIC = minimum inhibitory concentration.  
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The best example of the conversion of a Gram-positive-only antibacterial into a broad-
spectrum agent through the addition of a primary amine is the conversion of penicillin to 
ampicillin. Penicillin G has flexibility/shape parameters that make it an outstanding candidate for 
conversion (RB = 4, Glob = 0.17), and addition of an amine results in ampicillin (RB = 4, Glob = 
0.12), which now meets all criteria for accumulation (Fig. 1.8). Penicillin G has virtually no 
activity against Gram-negative pathogens, whereas ampicillin kills E. coli below 4 µg/mL.89 
Ampicillin was the first β-lactam with Gram-negative activity, and represented a major public 
health advance because other antibacterials with Gram-negative activity available in the 1960s 
worked poorly in vivo. Although there are third and fourth generation β-lactams with Gram-
negative activity that do not meet the predictive guidelines for accumulation in Gram-negative 
bacteria, these β-lactams have greatly reduced accumulation in Gram-negative bacteria compared 
to their zwitterionic and positively-charged analogues that meet the flexibility/shape parameters.90 
However, the third and fourth generation β-lactams are significantly more stable to β-lactamases 
than the early generation β-lactams, thus requiring lower levels of accumulation for antibacterial 
activity.90   
Although β-lactams are the only examples of successful conversions through the addition 
of primary amines that have reached the market, there are several additional conversions that can 
be found in the literature. Many conversion examples inhibit DNA gyrase and/or topoisomerases. 
DNA gyrase and topoisomerase are well-validated targets that are inhibited by the 
fluoroquinolones. However, fluoroquinolone resistance is wide-spread, and new broad-spectrum 
DNA gyrase and/or topoisomerase inhibitors that do not exhibit cross-resistance with 
fluoroquinolones could be beneficial. For example, 6DNM-NH3 retains single digit µg/mL 
activity against Gram-negative pathogens that are highly resistant to fluoroquinolones.  
Another example of DNA gyrase/topoisomerase IV inhibitors were developed by RedX 
Pharma.91 REDX04139 has potent activity against Gram-positive species, including 
fluoroquinolone-resistant S. aureus, but shows no activity (minimum inhibitory concentration 
(MIC) >128 µg/mL) against Gram-negative bacteria (Fig. 1.8). Being relatively flat (Glob = 0.07) 
and rigid (RB = 2), REDX04139 is an ideal compound for conversion. REDX05931 is structurally 
identical to REDX04139, except for the addition of a primary amine. The amine does not affect 
its ability to inhibit DNA gyrase and topoisomerase IV, as demonstrated by both in vitro enzyme 
activity assays and activity against Gram-positive bacteria. REDX05931 shows significantly 
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improved activity against E. coli with an MIC of 0.5 µg/mL. It is also moderately active against P. 
aeruginosa (MIC = 16 µg/mL) and Klebsiella pneumoniae (MIC = 8 µg/mL).91 An interesting 
aspect of REDX04139 is that it contains an aniline. Anilines are the only ionizable nitrogen on 
many broad-spectrum antibiotics, such as the sulfa drugs. Although most anilines are neutral at 
physiological pH, we have hypothesized that in certain cases, the aniline is sufficient to aid in 
Gram-negative accumulation. In the case of these RedX Pharma tricyclic inhibitors, the aniline is 
not sufficient for accumulation in Gram-negative pathogens, as evidenced by the lack of activity 
of REDX04139 and other structurally similar compounds. 
Another class of DNA gyrase/topoisomerase inhibitors with broad-spectrum activity are a 
pyrimidoindole inhibitor series developed by Trius Therapeutics. Unlike the fluoroquinolones 
which target the catalytic sites of the enzymes, the pyrimidoinoles target the ATP-binding subunits. 
The inhibitors were developed through structure guided discovery, beginning with a 
crystallographic fragment screen.92 The scientists at Trius Therapeutics recognized that 
compounds capable of Gram-negative penetration and retention would need to have low molecular 
weight, sufficient hydrophilic character, and functional groups with ionizable centers at 
physiological pH. They therefore chose a pyrrolopyrimidine scaffold as a candidate for 
optimization because it contained a site for the introduction of charged functional groups. This 
scaffold is very flat and has only 4 RBs. This initial fragment was optimized to various 
pyrimidoindoles (Fig. 1.8), with the pyrimidoindoles being more potent than the 
pyrrolopyrimidines. These optimized inhibitors meet the guidelines for Gram-negative 
accumulation (Glob = 0.05; RB = 4, for Pyrimidoindole 799), and have single-digit MIC activity 
against Gram-negative species, including fluoroquinolone resistant E. coli, K. pneumoniae, A. 
baumannii, and P. aeruginosa. Fortuitously, the amine aids in both enzyme inhibition potency and 
accumulation. Many derivatives lacking a primary amine are therefore inactive in both Gram-
positive and Gram-negative bacteria. A patent on these pyrimidoindoles contains hundreds of 
compounds,93 and the patent does include a few example where compounds without a primary 
amine are inactive against E. coli, even though they retain activity against S. aureus (examples in 
Fig. 1.8). Overall, the pyrimidoindoles are an excellent example of how important it is to consider 




An example of a series of compounds where a primary amine is helpful for activity, but the 
target is not DNA gyrase/topoisomerase, is the hydroxamic acid LpxC inhibitors. LpxC is 
responsible for the first committed step of lipid A biosynthesis, which is necessary for the growth 
of most Gram-negative species. Many LpxC inhibitors have been developed, but none have 
reached the market due to challenges with low solubility and in vitro toxicity. LpxC has a large, 
solvent-exposed pocket surrounded by hydrophilic amino acids. Researchers at Novartis 
hypothesized that they could improve existing LpxC inhibitors by linking water-solubilizing 
groups onto the amine on Hydroxamic acid 2  (Fig. 1.8; Glob = 0.06; RB = 7) to extend into this 
pocket.94 In doing so, they observe a decrease in antimicrobial activity against wild-type P. 
aeruginosa even though the compounds retain activity against a strain of P. aeruginosa with its 
major efflux pumps knocked out (example in Fig. 1.8). These derivatives demonstrate the 
importance of using chemical intuition; although technically these hydroxamic acid derivatives 
have too many rotatable bonds to be predicted to accumulate, the compound is not as flexible as 
others with 7 RBs. We are using the number of RBs to estimate flexibility, but rotatable bonds do 
not always add significant flexibility, as is the case of these biphenyl compounds.  There are 
examples of effective LpxC inhibitors that do not have a primary amine, but these contain amines 
at other sites on the compounds. Interestingly, the amine on Hydroxamic acid 2 appears to aid in 
accumulation, even though it is on a sterically congested site. During our accumulation studies in 
E. coli, compounds with primary amines on tertiary carbons did not accumulate. However, there 
is no difference in MIC for LpxC inhibitors with the primary amine on a secondary carbon or a 
tertiary carbon, suggesting that sterically hindered amines are capable of accumulating in Gram-
negative bacteria for certain compounds. 
Another example that suggests the amine aids in accumulation are the 
aminomethylbenzoxaboroles, which inhibit bacterial leucyl-tRNA synthetase (LeuRS).95 AN3334 
contains an aminomethyl off of the 5-membered ring, AN3016 contains an O-propanol off of the 
aromatic ring and has no amine,  and AN3365  (Fig. 1.8; Glob = 0.33; RB = 5) is a derivative that 
combines both modifications (Fig. 1.8) (note: modeling in the gas phase predicts intramolecular 
hydrogen-bonding between amine and alcohol resulting in a high Glob. This interaction is likely 
not as prominent in aqueous solution).95 AN3334, AN3016, and AN3365 are all equally potent 
against a strain of E. coli lacking the efflux pump TolC (MIC = 2 µg/mL). However, against Gram-
negative strains with efflux pumps intact, the two derivatives containing the aminomethyl retain 
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activity, while AN3016 is less active (Fig. 1.8). The change in MIC between the derivatives is 
relatively modest against wild-type E. coli, with the MICs for AN3334 and AN3365 being 1 
µg/mL, and the MIC of AN3016 being 4 µg/mL. However, against an extended-spectrum β-
lactamase (ESBL) producing strain of E. coli, the difference is more pronounce, with the neutral 
derivative having essentially no activity.95  
 The addition of a primary amine can have a large effect on the physicochemical properties 
of a compound, and can therefore negatively affect target binding. The challenge of increasing 
accumulation and retaining target engagement is demonstrated by efforts to broaden the spectrum 
of oxazolidinones. The first oxazolidinone, linezolid, was approved by the FDA in 2000, and is 
used for severe Gram-positive antibacterial infections, including methicillin-resistant S. aureus. 
Linezolid is a protein synthesis inhibitor that prevents tRNA from binding to the ribosome. In an 
effort to broaden the spectrum of oxazolididones, Takrouri and coworkers synthesized over 70 
polar derivatives and tested their activity in S. aureus and E. coli.96 DP-326 has a primary amine 
and is the most active compound in wild-type E. coli (MIC = 51 µg/mL), but is more than six times 
less active against S. aureus than linezolid (Fig. 1.8). The corresponding cyano-analog DP-63 
shows no activity in wild-type E. coli, although it is more active than DP-326 against S. aureus 
than DP-326 (Fig. 1.8).96  DP-326 and DP-64 were also tested in a strain of E. coli missing two 
components of the major efflux pump (E. coli ∆acrAB), and neither compound was potent against 
this strain with defective efflux abilities. The lack of activity in S. aureus and E. coli ∆acrAB 
suggests that the primary amine can enhance compound accumulation, but the SAR challenges 
prevented the synthesis of a broad-spectrum oxazolidinone.  
 Gratifyingly, all the examples thus far have the properties that are predicted to aid in 
compound accumulation in Gram-negative bacteria (primary amine, RB ≤ 5, Glob ≤ 0.25), but 
there are also examples where the flexibility and/or globularity parameters do not match the 
predicted values. One example is a series of pleuromutilin derivatives developed at Nabriva 
Therapeutics. Researchers at Nabriva found that by inverting the stereocenter at carbon 12 of 
pleuromutilin (Fig. 1.8, highlighted in pink), and appending amine-containing tails both at position 
12 and off the ester tail, pleuromutilin can be converted into a broad-spectrum agent.97 For 
example, Pleuromutilin derivative 1, which has an amine-containing heterocycle off the ester 
tail, is active only against Gram-positive bacteria. Pleuromutilin 66, on the other hand, has the 
same heterocycle, but also contains a long tail with a primary amine on the end, and has potent 
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broad-spectrum activity (Fig. 1.8). Pleuromutilin 66 contains multiple amines, but is not predicted 
to accumulate based on flexibility (RB = 13) and globularity (glob = 0.41). A similar pattern is 
observed with the tetrahydropyran-based bacterial topoisomerase inhibitors.98 Tetrahydropyran-
4 and Tetrahydropyran-21 are identical except the alcohol on Tetrahydropyran-4 is replaced 
with a primary amine on Tetrahydropyran-21 (Fig. 1.8). Both derivatives are not predicted to 
accumulate based on flexibility (RB = 7), but are mildly active against Gram-negative species (Fig. 
1.8). With the addition of the primary amine, however, Tetrahydropyran-21is 4-8x more potent 
against Gram-negative species than Tetrahydropyran-4 (Fig. 1.8).  
A key difference between the pleuromutilin and tetrahydropyran derivatives with Gram-
negative activity and the other compounds discussed thus are is that the pleuromutilin and 
tetrahydropyran derivatives are both polycationic. As was discussed in Section 1.2, polycationic 
compounds are prone to entry via the self-promoted uptake pathway. Shown in Chapter 4, we 
demonstrate that most of the compounds within our test set accumulate through porin channels. 
Thus, it is likely that the shape and flexibility parameters are related to porin uptake, but do not 
apply to compounds that utilize the self-promoted uptake mechanism. Looking at colistin, 
kanamycin, and azithromycin in Fig. 1.1, it is clear these compounds are typically larger and more 
flexible than Gram-negative antibiotics that permeate through porins. It is highly likely, therefore, 
that these pleuromutilin and tetrahydropyran derivatives do not follow the same guidelines as they 
have a different mode of uptake.  
1.4.2 Examples when the addition of an amine does not result in broad-spectrum activity 
A primary amine on an antibacterial is often not sufficient to aid in Gram-negative 
accumulation because the primary amine needs to be embedded on a compound with proper 
flexibility and shape parameters (unless the compound is polycationic and can accumulate via the 
self-promoted uptake pathway).  As a result, there are many examples of Gram-positive-only 
antibacterials containing primary amines, including vancomycin (Glob = 0.28, RB = 13), 
daptomycin (Glob = 0.38, RB = 35), and the DNA gyrase inhibitor cyclothialidine99-101 (Glob = 
0.23, RB = 10) (Fig. 1.9).   
The need for proper flexibility and shape parameters is further demonstrated by derivatives 
of macrolides and pleuromutilins. As one example from the macrolide class, there are no 
differences in the spectrum of activity observed for erythromycin versus 9(S)-
erythromycylamine102-103 because these compounds do not possess the appropriate RB and/or Glob 
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parameters for accumulation (Fig. 1.9). It is worth noting that the macrolide azithromycin (Glob = 
0.24, RB = 7) is potently active against E. coli and is one of the recommended antibacterials for 
E. coli infections,104-107 but azithromycin enters Gram-negative bacteria through the self-promoted 
pathway.58 Pleuromutilin derivatives containing a single primary amine (and no other cationic 
groups) also lack Gram-negative antibacterial activity, including valnemulin, which is approved 
for veterinary use.108 A direct comparison of a pleuromutilin derivative with a cyano-group on the 
side-chain versus an amino-group on the side-chain shows no change in antibiotic-spectrum (Fig. 
1.9).109 These examples provide further evidence about the importance of choosing compounds 
with the proper flexibility and shape parameters before attempting to broaden the spectrum of 
Gram-positive only antibiotics.  
 
Fig 1.9. Appending a sterically-unencumbered amine on large and flexible compounds 
does not enhance their activity against Gram-negative bacteria. RB = rotatable bonds; Glob 
= globularity.  
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1.5 Summary and outlook 
 With the rise in MDR Gram-negative infections, the development of new antibacterials 
with Gram-negative activity is increasingly essential. Gram-negative antibacterial discovery has 
been hindered by a lack of understanding of the types of compounds that can accumulate in Gram-
negative species. Both retrospective studies and permeation studies on small sets of compounds 
have been performed, but neither have resulted in a reliable set of guidelines to understand 
compound accumulation in Gram-negative bacteria.  
Permeation/accumulation studies have great potential for developing a set of predictive 
guidelines for accumulation in Gram-negative bacteria because they do not rely on the level of 
antibacterial activity, which is not necessarily correlated with accumulation. Such studies, 
however, have been hindered by a lack of robust analyses. Limited controls have been utilized, 
preventing comparisons from assay-to-assay. In certain studies, it is unclear if any of the 
compounds accumulate as well as known broad-spectrum antibacterials. Furthermore, 
accumulation studies have lacked compound diversity. In every case discussed in section 1.3, the 
compounds were from a single structural class, and the lack of controls makes it unfeasible to 
compile all the data into a single knowledge set. Without diversity, it is impossible to know if 
observed trends are broadly applicable. In our own accumulation studies, the larger and more 
diverse our test library became, the more “outliers” we initially observed. By adding even more 
compounds to the library, we quickly learned these were not outliers, but rather the initial 
parameters were not based on a diverse enough set of compounds to encapsulate all the properties 
that affect accumulation. With a diverse set in hand, the studies also require an unbiased analysis. 
Frequently, accumulation studies are only assessed with one or two parameters, such as polarity 
and size. This can easily result in misinterpretations of the data.  
Learning from these limitations, we conducted an unbiased assessment for compound 
accumulation in E. coli, and utilized the results to develop predictive guidelines for compound 
accumulation in Gram-negative bacteria (discussed in Chapter 3). Results suggest that compounds 
are most likely to accumulate if they contain an unhindered amine, are relatively rigid, and have 
low three-dimensionality. The accumulation rules explain why the spectrum of certain antibiotics 
can be broadened with the addition of a primary amine, while others cannot (section 1.4). The 
predictive guidelines are not perfect at predicting Gram-negative activity, and we speculate that 
this is likely due to some compounds accumulating through the self-promoted uptake pathway. We 
25 
 
hope these predictive guidelines will facilitate the conversion of Gram-positive-only antibiotics 
into broad-spectrum antibiotics in the future, and expedite the discovery of much-needed Gram-
negative antibacterials.  
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Chapter 2: Synthesis of complex and diverse compounds for studying accumulation 
in Gram-negative bacteria 
 
Portions of this Chapter are reprinted with permission from Richter, M. F.; Drown, B. S.; Riley, 
A. P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J., Predictive compound accumulation 
rules yield a broad-spectrum antibiotic. Nature 2017, 545, 299-304.1 and Huigens, R. W.; 
Morrison, K. C.; Hicklin, R. W.; Flood, T. A.; Richter, M. F.; Hergenrother, P. J., A ring-distortion 
strategy to construct stereochemically complex and structurally diverse compounds from natural 
products. Nat. Chem. 2013, 5, 195-202.2 Contributions of others are noted where applicable. 
2.1 Introduction – the need for a library of complex and diverse compounds 
As is discussed in both Chapter 1 and Chapter 3, new antibacterials to combat multidrug 
resistant Gram-negative bacteria are urgently needed.3-9 Discovering new Gram-negative 
antibiotics is especially challenging due to the impermeable nature of the Gram-negative outer-
membrane (discussed in Chapter 1). We and others hypothesized that a better understanding of the 
types of small molecules that can accumulate in Gram-negative bacteria will greatly facilitate the 
discovery of new antibiotics for these problematic pathogens.5, 8  
 In 2001, Lipinski and coworkers published a set of guidelines (now known as Lipinski’s 
Rule of Five) to predict drug oral bioavailability by extracting the useful properties from a large 
set of known drugs and drug candidates.10 As will be discussed in Chapter 3, Professor Kim Lewis 
advocates for a similar set of guidelines to predict compound accumulation in Gram-negative 
bacteria, but notes, “The missing piece is the availability of such a set of compounds [able to 
permeate Gram-negative bacteria], particularly as the existing panel of compounds that effectively 
penetrate Gram-negative bacteria is very small.”5 Therefore, we proposed to utilize non-
antibacterial compounds in tandem with a compound accumulation assay to develop predictive 
guidelines for small-molecule accumulation in Gram-negative bacteria. The assay and the 
development of the predictive guidelines will be discussed in Chapter 3. Discussed herein is the 
synthesis of the compounds for testing.  
2.2 Complexity-to-Diversity as the main method for synthesizing the test library 
 The success of developing guidelines to predict compound accumulation in Gram-negative 
bacteria hinged on identifying a panel of compounds that are actually able to accumulate. Large 
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commercial screening libraries have continuously failed to produce new antibiotics effective 
against Gram-negative bacteria.8-9, 11-12 Thus, although easily obtainable, we decided to not use 
commercial screening collections for the accumulation study. Given that most antibiotics are 
natural products and their derivatives, we speculated that a library of natural product-like 
compounds would give us the best chance of finding a large enough set of compounds to develop 
the predictive guidelines. 
 In 2013, the Hergenrother lab published a 
method, called Complexity-to-Diversity (CtD), for 
the rapid synthesis of natural product-like 
compounds.2, 13-16 Using CtD, structurally complex 
natural products are converted into new scaffolds that 
are structurally distinct. Through ring-distortion 
reactions, including ring cleavage, ring expansion, 
ring fusion, and ring rearrangement, new complex 
scaffolds are obtained in an average of three steps 
(Fig. 2.1). Thus far, the CtD strategy has enabled the 
synthesis of about 100 unique scaffolds, and over 600 
compounds. A key aspect of developing the predictive 
guidelines for accumulation is the ability to validate 
any observations through structure-activity relationship (SAR) studies. As the synthetic sequences 
are short, the compounds are amenable to SAR studies, making CtD an ideal method.  
Retrospective analyses of antibacterials and accumulation studies on small sets of 
compounds in Gram-negative bacteria (discussed in Chapter 1.3) suggest that small molecules are 
most likely to accumulate in Gram-negative bacteria if they are relatively small (molecular weight 
(MW) < 600 Da), relatively polar (ClogD7.4 < 2), and charged.
12, 17-20 For the first phase of the 
project, we decided to test a collection of 100 CtD compounds biased for Gram-negative 
accumulation according to previous studies. Most of the compounds in the CtD library have a MW 
under 600 Da. Thus, the initial synthetic focus was on further increasing the polarity of CtD 
compounds and adding charged functional groups. Testing of these first 100 compounds suggests 
that the presence of a primary amine aids in compound accumulation (discussed in Chapter 3). 
Therefore, non-primary amine derivatives of some of the high-accumulating compounds were 
Fig 2.1. Ring-distortion reactions 
can be used readily to convert 




synthesized to perform an in-depth SAR study, which confirmed the importance of the primary 
amine. Finally, to better understand the other properties that dictate compound accumulation in 
Gram-negative bacteria, additional primary amines were synthesized. To further increase 
compound diversity in this final phase of the study, derivatives of simple commercially available 
compounds were also utilized. The compound names provided are from previous publications,1-2 
and are therefore not in numerical order within the text. Many compounds have multiple names; 
for simplicity, only one name is in the text, but all additional names are provided in the schemes. 
Below is the discussion of compounds that I synthesized for the test library. In addition to the 
compounds discussed herein, compounds derived from sinomenine and quinine, as well as other 
compounds from gibberellic acid and adrenosterone, were included in the library; these 
compounds were contributed by others on the CtD and antibacterial teams (particularly Bryon 
Drown, Dr. Andrew Riley, Alfredo Garcia, Tomohiro Shirai, and Riley Svec).1-2, 13, 16  
2.3 Synthesis of CtD compounds in the initial test set 
2.3.1 Synthesis of compounds from gibberellic acid 
The natural product gibberellic acid was highly utilized in the synthesis of the biased 
library because it is very polar without synthetic modifications (ClogD7.4 = -2.71). A small handful 
of compounds were synthesized directly from the gibberellic acid scaffold itself. An amide 
coupling between gibberellic acid and ethanol produced 2-72 (Scheme 2.1A), and a Curtius 
rearrangement on gibberellic acid resulted in alloc-carbamate 2-85 (Scheme. 2.1B). 2-85 was 
further derivatized via a Dess-Martin periodinane oxidation of the allylic alcohol on the A-ring of 
2-85 to form enone 2-93 (Scheme 2.1B). To obtain an amine on gibberellic acid, a palladium (0)- 
catalyzed alloc-deprotection was performed on 2-85, which resulted in a simultaneous 
rearrangement of the lactone to form 4-30 (Scheme 2.1C). The lactone of 4-30 was then 
hydrolyzed, resulting in zwitterion 2-99 (Scheme 2.1C). To obtain an amine on gibberellic acid 
without rearranging the lactone, the acid on gibberellic acid was reduced to an alcohol (3-29). The 
alcohol was then tosylated and displaced by azide (3-30). Finally, the azide was reduced to amine 
2-9 with triphenyl phosphine (Scheme 2.1D).  During tosylation, di-tosylated gibberellic acid was 
also obtained. This di-tosyl bi-product was converted to di-azide 3-21, and then to diamine 2-6 
(Scheme 2.1D). Thus, although gibberellic acid is negatively charged, uncharged, zwitterionic, and 




Scheme 2.1. Library compounds directly from gibberellic acid 
 
 
Compounds were also synthesized from G8, a compound derived from gibberellic acid in 
single base-promoted ring rearrangement of the A-ring (Scheme 2.2). A small collection of 
compounds was synthesized by appending various R-groups through amide couplings to the 
carboxylic acid of G8 (G16 derivatives, Scheme. 2.2).  To further increase the polarity of the G16 
derivatives and to introduce charge, many of the G16 compounds were derivatized (Scheme 2.3). 
PyBOP = benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; TsCl = tosyl chloride 
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The polarity of derivative G16m was increased by treatment with three equivalents of 
trifluoroperacetic acid, resulting in epoxidation of the alkene on the A-ring, and Wagner-Meerwein 
rearrangement of the C/D rings (compound 2-81, Scheme 2.3A). To introduce positive charge, the 
alcohol of 2-81 was oxidized to an aldehyde to form 2-82. From the aldehyde, two secondary 
amines were synthesized via reductive aminations to afford 2-21 and 2-24 (Scheme 2.3A). A 
similar sequence of reactions was performed with another G16 derivative (Precursor AA to 2-26) 
to obtain 2-26, but only one equivalent of trifluoroperacetic acid was used in the first step, 
preventing epoxidation of the A-ring (Scheme 2.3B). Finally, to introduce negative charge to the 
G8 compounds, the lactones of six of the G16 derivatives were hydrolyzed with base (Scheme 
2.3C). The syntheses from G8 highlights the benefit of the CtD strategy. Every compound along 
the synthetic routes are valuable. Thus, functional group and scaffold diversity was rapidly 




Scheme 2.2. G16 derivatives 
 
  
PyBOP = benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate 
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Scheme 2.3. Further derivatization of G16 derivatives 
 
 
Additional compounds for the collection were synthesized from the G10 and G11 
scaffolds. G10 is synthesized by heating gibberellic acid in dilute hydrochloric acid, resulting in 
aromatization of the A-ring (Scheme 2.4A). Alternatively, gibberellic acid in refluxing 
hydrochloric acid both aromatizes the A-ring and rearranges the C/D rings, resulting in G11 
(Scheme 2.4A). G10 and G11 have less polar functionality than gibberellic acid and G8; thus, the 
synthetic focus for G10 and G11 was the introduction of charge. The carboxylic of G10 was 
reduced to primary alcohol G10a (Scheme 2.4B). To introduce an amine, G10a was tosylated, the 
tosyl group was displaced with sodium azide, and the azide was reduced to amine 1 via a 
hydrogenation (Scheme 2.4B). A similar reaction series was performed with G11. However, the 
ketone of G11 was also reduced while reducing the carboxylic acid, resulting in di-alcohol 3-15 
(Scheme 2.4C) (stereochemistry determination is shown in Fig. 2.2). As a result, both alcohols 
were sulfonylated, converted to the di-azide, and the azides were reduced to the amines to yield 
diamine 2-4 (Scheme 2.4C). 2-5 and 3-50 were synthesized via Curtius rearrangements on G10 
42 
 
and G11, respectively, followed by carbamate deprotections under basic conditions (Scheme 
2.4D). Carbamate-protected 2-5 (called G10c) was treated with trifluoroperacetic acid to rearrange 
the C/D rings followed by reductive deprotection of the carbamate resulting in 4-22 (Scheme 
2.4E). Reductive aminations with various aldehydes on 2-5, 3-50, and 4-22 results in secondary 
amines 2-16, 2-17, 2-23, and 2-25 (Scheme 2.4F). Additionally, G10 was methylated and treated 
with trifluoroperacetic acid to afford 3-48 (Scheme 2.4G), followed by oxidation to the aldehyde. 
This aldehyde was used for a series of reductive aminations to afford 2-27, 2-28, and the Precursor 
to 2-55. 2-55 was synthesized via hydrolysis of the three methyl esters on the precursor compound. 




Scheme 2.4. Chemistry on G10 and G11 
 




Fig. 2.2. Stereochemical determination of 3-15. A) COSY spectrum of 3-15. The signals for 
protons d, e, f, h, and o were determined based on chemical shift and the spectra of similar 
compounds. These known protons were used to determine the chemical shift of protons g, i, n, 
m, k, and q. The stereochemistry of proton f (*) was unknown. B) NOE spectrum of 3-15. 
Irradiation of proton h shows a correlation with proton n, suggesting that proton n is down and 
proton i is up, as drawn. Irradiation of proton f shows a correlation with proton i, suggesting f 
and i are both pointing out of the plane of the paper. The stereochemistry of f is further evidenced 


















2.3.2 Synthesis of compounds from adrenosterone 
The natural product adrenosterone was also utilized in synthesizing the initial test library. 
A small library was synthesized from A8, which is derived from adrenosterone in a single oxidative 
ring cleavage of the A-ring enone (Scheme 2.5). Various R-groups were appended to A8 through 
amide couplings with PyBOP to generate an A12 library. The derivative 2-39 contains a tertiary 
amine to introduce positive charge to the derivative set. To introduce negative charge to the A12 
library, any methyl and ethyl esters were hydrolyzed to generate carboxylic acid derivatives 
(Scheme 2.5, A12l – A12p).  
Scheme 2.5. A12 derivatives 
 
  
PyBOP = benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate; cat. = catalytic 
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2.3.3 Synthesis of compounds from isomannide 
Derivatives of isomannide were also included in the initial test set. Although not technically 
a natural product, derivatizing isomannide is a valuable compliment to the CtD strategy because 
isomannide has densely packed stereochemistry (Scheme 2.6). Treatment of isomannide with 
brosyl chloride results in a mixture of mono- and di-brosyl isomannide (Scheme 2.6A). Reaction 
of the dibrosyl derivative with sodium azide results in a mixture of di-azido isommanide and a 
mono-brosyl-mono-azido isomannide derivative (Scheme 2.6B). The azides on both derivatives 
can be reduced, resulting in diamine 2-13 and mono-amine 2 (Scheme 2.6C). 2 was also mono-
methylated to add a secondary amine isomannide derivative to the library. The mono-brosyl 
isomannide derivative can also be reacted with sodium azide, resulting in isomannide azide 
(Scheme 2.6D). Reduction of the azide resulted in mono-amine 2-14 (Scheme 2.6D). Isomannide 
azide was used as a building block to synthesize additional amine-containing derivatives by either 
sulfonylating or alkylating the secondary hydroxyl, followed by reduction of the azides (Scheme 
2.6D). One of the azide derivatives contained a methyl ester, which was hydrolyzed to form the 
corresponding carboxylic acid 2-45 (Scheme 2.4D). Symmetrical modifications were also 
performed on isomannide, to obtain neutral derivatives 2-62 and 2-91 (Scheme 2.6E). Finally, we 
also wanted to include anilines in the library. Thus, isomannide was coupled with 4-nitrosulfonyl 
and 2-nitrosulfonyl chloride, resulting in both the mono- and di-sulfonated versions with each. The 
aromatic nitro-groups on all four derivatives were reduced to the corresponding anilines, to afford 









2.4 Synthesis for SAR studies 
Testing of the initial library (discussion in Chapter 3), suggested that primary amines aid 
in compound accumulation. To examine the importance of the primary amine, a SAR analysis was 
performed for multiple different classes of accumulating compounds by replacing the primary 
amines with a carboxylic acid, an amide, an ester, an azide, a secondary amine, a tertiary amine, 
and/or a quaternary amine. Most of the amines were synthesized from carboxylic acids via Curtius 
rearrangement, or from alcohols via displacement of the tosylated alcohol with azide, and 
subsequent azide reduction. Thus, the carboxylic acid, alcohol, and azide derivatives for SAR were 
already present in the initial test collection or were set aside as intermediates. However, other 
derivatives needed to be synthesized. Additional chemistry is shown in Scheme 2.7. 
Scheme 2.7. Synthesis for SAR 
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2.5 Synthesis of extended primary amine library 
 The final round of synthesis focused on expanding the library of primary amine-containing 
compounds. The chemistry is similar to the chemistry in section 2.2, and includes chemistry on 
gibberellic acid (Scheme 2.8A), abietic acid (2.8B), isomannide (2.8C), and lovastatin (2.8D). To 
further confirm the importance of the primary amine, additional SAR studies were performed, and 
the synthesis of the necessary compounds is included in Scheme 2.8.  
 Finally, the primary amine library contained some commercially available compounds, to 
more closely mimic the types of compounds found in traditional screening libraries. Most of these 
compounds were used without modification, except for oseltamivir and Lisinopril (Scheme 2.9). 
The ester of oseltamivir was hydrolyzed and ethylene diamine was coupled onto the resulting acid 
in order to obtain a diamine (Scheme 2.9), and the acid of Lisinopril was methylated so that the 




Scheme 2.8. Synthesis of additional primary amines using the CtD strategy 
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Scheme 2.9. Synthesis of additional primary amines from commercially available compounds 
 
 
2.6 Summary and outlook 
In summary, discussed above is the synthesis of more than 100 compounds used to assess 
accumulation in E. coli. Using the CtD method, complex and diverse compounds were rapidly 
synthesized, and almost all intermediates were useful for biological testing. As will be discussed 
in Chapter 3, this compound set enabled the successful development of predictive guidelines for 
compound accumulation in Gram-negative bacteria. Additionally, most of the compounds 
discussed above have been added to a larger CtD library, and are available for additional biological 
testing. 
In hindsight, we were successful where others were not due to unique features of the 
collection. First, the CtD library has significantly more compounds with contiguous and/or 
overlapping ring systems than commercially available libraries such as ChemBridge. This is 
visually apparent by comparing structures of typical commercially available compounds to typical 
CtD compounds (Fig. 2.3A), and this difference can be quantified using the Ring Fusion Density 
index (Fig. 2.3B-C). One of the key features that promote compound accumulation in Gram-
negative is compound rigidity, with more rigid compounds accumulating more readily. Had our 
test set collection not contained rigid compounds like those in the CtD collection, it is unlikely we 
would have discovered enough accumulating compounds with which to develop our predictive 
guidelines for compound accumulation in Gram-negative bacteria. In addition, the CtD method 
enabled the rapid synthesis of derivatives for SAR analyses. The first accumulating compound we 
discovered contains a primary amine. We were able to rapidly convert the amine to a carboxylic 
acid, an alcohol, and an acyl group to confirm the amine was necessary for accumulation. Had we 
been working with a collection of compounds that was not amenable to rapid synthetic 
modification, we would not have been able to validate many of our observations, which was vital 
in developing our predictive guidelines. Finally, the introduction of charged compounds proved to 
be essential, as primary amines are a key component of accumulation in Gram-negative bacteria; 
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this highlights the importance of considering compound diversity in numerous aspects when 
designing a compound library for biological testing. Many commercial libraries are lacking 
primary amines (see Chapter 3), and using such a library as the test set would have likely failed to 
produce compounds able to accumulate in E. coli. Overall, our work to develop predictive 
guidelines for compound accumulation in Gram-negative bacteria demonstrates the importance of 
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Fig. 2.3. Compound rigidity in screening collections. A) Visually, commercial compounds have 
less contiguous and/or overlapping ring systems than CtD compounds. B) The Ring fusion density 
index is the number of ring bridges divided by the number of atoms belonging to ring systems. C) 
Histogram of Ring fusion density index of ChemBridge and CtD compounds. Using the Ring fusion 
index to quantify contiguous and/or overlapping ring systems, it is evident that the CtD library 
contains significantly more compounds with high numbers of contiguous and/or overlapping rings.  
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2.7 Experimental procedures 
2.7.1 Synthesis of compounds from Huigens et al.2 
Synthesis of Compounds based on A12 
 
General procedure for the preparation of A12 amides: In an oven-dried vial, A8 (1 equiv.) and 
benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (1.2 equiv.) were dissolved 
in dichloromethane (0.1 M). Diisopropylethylamine (1 equiv.) was added, and the reaction was 
stirred at room temperature for 1-2 hours. After complete complexation by TLC, an amine (1-3 
equiv.) and additional diisopropylethylamine (1-3 equiv.) were added, and the reaction was 
allowed to stir at room temperature for 12-16 hours. The reaction was concentrated under reduce 
pressure and purified by flash chromatography on silica gel (hexanes/ethyl acetate or 
dichloromethane/methanol) to provide the amide.  
 
A12a: Prepared from L- aspartic acid dimethyl ester hydrochloride. 
Yield: 75.1 mg, 32%. 
1H NMR (CDCl3, 500 MHz): δ 6.62 (d, J = 8.1 Hz, 1H), 4.75 (dt, J = 8.5, 4.5 
Hz, 1H), 3.72 (s, 3H), 3.68 (s, 3H), 2.98 (dd, J = 17.2, 4.4 Hz, 1H), 2.83 (dd, J = 17.2, 4.6 Hz, 1H), 
2.62 - 2.43 (m, 3H), 2.40 - 1.92 (m, 12H), 1.70 (tt, J = 12.4, 9.2 Hz, 1H), 1.53 (tdd, J = 13.4, 11.7, 
4.8 Hz, 1H), 1.29 (s, 3H), 0.87 (s, 3H). 
HRMS(ESI): m/z calc. for C24H34NO8 [M+H]
+: 464.2284, found: 464.2279. 
 
A12b: Prepared from L-valine methyl ester hydrochloride.  
Yield: 113.6 mg, 34%. 
1H NMR (CDCl3, 500 MHz): δ 6.24 (d, J = 8.7 Hz, 1H), 4.42 (dd, J = 8.7, 
5.0 Hz, 1H), 3.69 (s, 3H), 2.63 - 2.50 (m, 2H), 2.44 (d, J = 13.1 Hz, 1H), 2.39 - 1.89 (m, 13H), 
1.68 (tt, J = 12.4, 9.2 Hz, 1H), 1.50 (qd, J = 13.0, 4.5 Hz, 1H), 1.29 (s, 3H), 0.90 (d, J = 7.0 Hz, 
3H), 0.88 (d, J = 7.5 Hz, 3H), 0.86 (s, 3H). 
HRMS(ESI): m/z calc. for C24H36NO6 [M+H]




A12c: Prepared from L-serine methyl ester hydrochloride.  
Yield: 43.6 mg, 10%. 
1H NMR (CDCl3, 500 MHz): δ 6.62 (d, J = 6.6 Hz, 1H), 4.43 (dt, J = 6.4, 3.1 
Hz, 1H), 3.94 (dd, J = 12.0, 3.0 Hz, 1H), 3.85 (dd, J = 11.5, 3.0 Hz, 1H), 3.77 (s, 3H), 2.92 (d, J = 
11.0 Hz, 1H), 2.61 - 2.50 (m, 2H), 2.48 (d, J = 13.5 Hz, 1H), 2.46 - 2.22 (m, 6H), 2.22 - 2.09 (m, 
4H), 2.08 - 1.93 (m, 2H), 1.68 (dtt, J = 16.5, 11.8, 7.0 Hz, 2H), 1.26 (s, 3H), 0.88 (s, 3H). 
HRMS(ESI): m/z calc. for C22H32NO7 [M+H]
+: 422.2179, found: 422.2185. 
 
A12d: Prepared from 4-methoxybenzylamine.  
Yield: 25.0 mg, 76%. 
1H NMR (CDCl3, 400 MHz): δ 7.20 (d, J = 8.6 Hz, 2H), 6.85 (d, J = 8.6 Hz, 
2H), 5.89 (t, J = 5.8 Hz, 1H), 4.32 (dd, J = 14.4, 5.6 Hz, 1H), 4.27 (dd, J = 14.4, 
5.2 Hz, 1H), 3.79 (s, 3H), 2.66 - 1.86 (m, 15H), 1.70 (tt, J = 12.5, 9.2 Hz, 1H), 
1.52 (tdd, J = 13.6, 11.5, 4.7 Hz, 1H), 1.31 (s, 3H), 0.88 (s, 3H). 
HRMS(ESI): m/z calc. for C26H34NO5 [M+H]
+: 440.2437, found: 440.2445. 
 
A12e: Prepared from piperidine. 
Yield: 144 mg, 92%. 
1H NMR (CDCl3, 500 MHz): δ 3.52 - 3.30 (m, 4H), 2.65 (d, J = 11.1 Hz, 1H), 
2.61 - 2.47 (m, 2H), 2.46 - 2.31 (m, 3H), 2.31 - 1.95 (m, 8H), 1.68 (tt, J = 12.3, 9.2 Hz, 1H), 1.62 
- 1.51 (m, 4H), 1.50 - 1.42 (m, 2H), 1.40 - 1.32 (m, 2H), 1.28 (s, 3H), 0.85 (s, 3H).  
HRMS(ESI): m/z calc. for C23H34NO4 [M+H]
+: 388.2488, found: 388.2498. 
 
A12f: Prepared from cyclopropylamine.  
Yield: 25.4 mg, 87%. 
1H NMR (CDCl3, 500 MHz): δ 5.79 (br s, 1H), 2.65 - 2.46 (m, 5H), 2.39 (ddd, J 
= 15.2, 4.8, 2.4 Hz, 1H), 2.37 - 2.13 (m, 7H), 2.02 - 1.88 (m, 3H), 1.75 - 1.61 (m, 2H), 1.30 (s, 
3H), 0.89 (s, 3H), 0.75 - 0.69 (m, 2H), 0.50 - 0.45 (m, 2H). 
HRMS(ESI): m/z calc. for C21H30NO4 [M+H]




A12g: Prepared from furfurylamine.  
Yield: 18.7 mg, 63%. 
1H NMR (CDCl3, 500 MHz): δ 7.34 (dd, J = 1.9, 0.8 Hz, 1H), 6.31 (dd, J = 3.2, 
1.9 Hz, 1H), 6.22 (dd, J = 3.1, 0.9 Hz, 1H), 5.95 (t, J = 5.5 Hz, 1H), 4.40 (dd, J = 
15.5, 5.5 Hz, 1H), 4.36 (dd, J = 15.5, 5.5 Hz, 1H), 2.66 - 2.53 (m, 2H), 2.49 (d, J = 13.2 Hz, 1H), 
2.43 (d, J = 11.2 Hz, 1H), 2.39 (ddd, J = 15.1, 4.8, 2.4 Hz, 1H), 2.36 - 1.90 (m, 10H), 1.71 (tt, J = 
12.5, 9.2 Hz, 1H), 1.58 - 1.47 (m, 1H), 1.32 (s, 3H), 0.89 (s, 3H). 
HRMS(ESI): m/z calc. for C23H30NO5 [M+H]
+: 400.2124, found: 400.2121. 
 
A12h: Prepared from L-isoleucine methyl ester hydrochloride.  
Yield: 60.0 mg, 43%. 
1H NMR (CDCl3, 500 MHz): δ 6.37 (d, J = 8.5 Hz, 1H), 4.44 (dd, J = 8.5, 
5.1 Hz, 1H), 3.68 (s, 3H), 2.62 - 2.48 (m, 2H), 2.41 (d, J = 13.1 Hz, 1H), 2.38 
- 1.77 (m, 12H), 1.82 (tdd, J = 11.4, 5.8, 2.2 Hz, 1H), 1.68 (tt, J = 12.4, 9.2 Hz, 1H), 1.57 - 1.46 
(m, 1H), 1.38 (dtd, J = 14.8, 7.4, 4.6 Hz, 1H), 1.27 (s, 3H), 1.13 (ddt, J = 14.5, 9.0, 7.3 Hz, 1H), 
0.89 (m, 6H) 0.85 (s, 3H). 
HRMS(ESI): m/z calc. for C25H38NO6 [M+H]
+: 448.2699, found: 448.2698. 
 
A12i: Prepared from β-alanine ethyl ester hydrochloride.  
Yield: 70.4 mg, 29%. 
1H NMR (CDCl3, 500 MHz): δ 6.28 - 6.14 (t, J = 5.5 Hz, 1H), 4.14 (q, J = 
7.1 Hz, 2H), 3.46 - 3.40 (m, 2H), 2.62 - 2.52 (m, 2H), 2.51 – 2.44 (m, 4H), 
2.41 - 2.11 (m, 8H), 2.05 - 1.89 (m, 3H), 1.70 (tt, J = 12.5, 9.2 Hz, 1H), 1.59 - 1.47 (m, 1H), 1.29 
(s, 3H), 1.25 (t, J = 7.1 Hz, 3H), 0.87 (s, 3H). 
HRMS(ESI): m/z calc. for C23H34NO6 [M+H]
+: 420.2386, found: 420.2378. 
 
A12j: Prepared from L-tryptophan methyl ester hydrochloride.  
Yield: 30.0 mg, 5%. 
1H NMR (CDCl3, 500 MHz): δ 8.56 (d, J = 2.4 Hz, 1H), 7.53 (d, J = 8.0 Hz, 
1H), 7.30 (dd, J = 8.1, 1.0 Hz, 1H), 7.16 - 7.11 (m, 1H), 7.09 - 7.03 (m, 1H), 
7.04 (d, J = 2.0 Hz, 1H), 6.26 (d, J = 7.8 Hz, 1H), 4.84 (dt, J = 7.5, 5.5 Hz, 1H), 3.64 (s, 3H), 3.30 
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(dd, J = 15.0, 5.5 Hz, 1H), 3.25 (dd, J = 15.0, 6.0 Hz, 1H), 2.59 - 2.49 (m, 2H), 2.43 (d, J = 13.1 
Hz, 1H), 2.36 - 1.90 (m, 11H), 1.84 - 1.76 (m, 1H), 1.65 (tt, J = 12.3, 9.2 Hz, 1H), 1.43 (qd, J = 
13.0, 5.0 Hz, 1H), 1.26 (s, 3H), 0.85 (s, 3H). 
HRMS(ESI): m/z calc. for C30H37N2O6 [M+H]
+: 521.2652, found: 521.2648. 
 
A12k: Prepared from 3-fluorobenzylamine.  
Yield: 40.7 mg, 99%. 
1H NMR (CDCl3, 500 MHz): δ 7.30 - 7.25 (m, 1H), 7.05 (ddd, J = 7.6, 1.7, 0.9 
Hz, 1H), 6.98 (dt, 10.0, 1.5 Hz, 1H), 6.94 (td, J = 8.5, 2.0 Hz, 1H), 6.10 (t, J = 
5.5 Hz, 1H), 4.39 (dd, J = 15.0, 6.0 Hz, 1H), 4.34 (dd, J = 15.0, 5.5 Hz, 1H), 2.65 - 2.53 (m, 2H), 
2.48 (d, J = 13.2 Hz, 1H), 2.44 (d, J = 11.2 Hz, 1H), 2.38 (ddd, J = 15.0, 4.7, 2.4 Hz, 1H), 2.35 - 
1.90 (m, 10H), 1.78 - 1.65 (tt, J = 12.5, 9.5 Hz, 1H), 1.59 - 1.47 (m, 1H), 1.31 (s, 3H), 0.89 (s, 3H). 
HRMS(ESI): m/z calc. for C25H31NO4F [M+H]
+: 428.2237, found: 428.2237. 
 
General procedure for the preparation of acids from A12 amides: In a vial with stir bar, amide 
(1 equiv.) and lithium hydroxide (20-30 equiv.) were dissolved in a 1:1 mixture of tetrahydrofuran 
and water (0.005 M), and stirred at room temperature for 12-16 hours. The reaction mixture was 
acidified to pH 2 with concentrated hydrochloric acid and extracted with ethyl acetate (3x). The 
organic layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated 
under reduced pressure. The residue was purified by flash chromatography on silica gel 
(dichloromethane/methanol/formic acid) to yield the desired acid.  
 
A12l: Prepared from A12a.  
Yield: 17.6 mg, 60%. 
1H NMR (CDCl3, 500 MHz): δ 7.45 (br s, 1H), 4.75 (br s, 1H), 2.97 (d, J = 
16.5 Hz, 1H), 2.85 (d, J = 16.5 Hz, 1H), 2.70 - 2.06 (m, 15H), 1.75 - 1.50 (m, 2H), 1.28 (s, 3H), 
0.86 (s, 3H). 
HRMS(ESI): m/z calc. for C22H30NO8 [M+H]




A12m: Prepared from A12b.  
Yield: 23.3 mg, 59%. 
1H NMR (CDCl3, 500 MHz): δ 6.46 (d, J = 8.5 Hz, 1H), 4.41 (dd, J = 8.4, 5.0 
Hz, 1H), 2.65 - 2.52 (m, 2H), 2.47 (d, J = 13.2 Hz, 1H), 2.44 - 1.93 (m, 13H), 1.71 (tt, J = 12.4, 
9.2 Hz, 1H), 1.53 (qd, J = 13.0, 4.5 Hz, 1H), 1.31 (s, 3H), 0.97 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 7.5 
Hz, 3H), 0.89 (s, 3H). 
HRMS(ESI): m/z calc. for C23H34NO6 [M+H]
+: 420.2386, found: 420.2390. 
 
A12n: Prepared from A12h.  
Yield: 21.8 mg, 38%. 
1H NMR (CDCl3, 500 MHz): δ 6.45 (d, J = 8.3 Hz, 1H), 4.47 (dd, J = 8.3, 
4.9 Hz, 1H), 2.65 - 2.52 (m, 2H), 2.47 (d, J = 13.2 Hz, 1H), 2.44 - 1.88 (m, 13H), 1.71 (tt, J = 12.4, 
9.2 Hz, 1H), 1.58 - 1.45 (m, 2H), 1.31 (s, 3H), 1.21 (ddd, J = 13.5, 9.3, 7.1 Hz, 1H), 0.94 (d, J = 
6.5 Hz, 3H), 0.92 (t, 7.0 Hz, 3H), 0.88 (s, 3H). 
HRMS(ESI): m/z calc. for C24H36NO6 [M+H]
+: 434.2543, found: 434.2535. 
 
A12o: Prepared from A12j.  
Yield: 5.1 mg, 20%. 
1H NMR (CDCl3, 500 MHz): δ 8.66 (br s, 1H), 7.56 (d, J = 7.9 Hz, 1H), 7.29 
- 7.25 (m, 1H), 7.10 (t, J = 7.5 Hz, 1H), 7.07 - 6.99 (m, 2H), 6.51 (s, 1H), 4.79 
(d, J = 7.3 Hz, 1H), 3.36 - 3.19 (m, 2H), 2.60 - 1.82 (m, 13H), 1.74 - 1.52 (m, 2H), 1.48 - 1.23 (m, 
2H), 1.21 (s, 3H), 0.81 (s, 3H). 
HRMS(ESI): m/z calc. for C29H35N2O6 [M+H]
+: 507.2495, found: 507.2499. 
 
Procedure: In a vial with stir bar, A12i (106.0 mg, 0.253 mmol) and lithium hydroxide hydrate 
(306.2 mg, 7.30 mmol) were dissolved in a tetrahydrofuran (10 mL) and methanol (10 mL), and 
stirred at room temperature for 12 hours. The reaction was diluted with water (10 mL), acidified 
58 
 
to pH 2 with concentrated hydrochloric acid, and extracted with ethyl acetate (3x). The organic 
layer was washed with brine, dried over magnesium sulfate, filtered, and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel 
(dichloromethane/methanol 9:1) to yield A12p (19.0 mg, 19.2%). 
 
1H NMR (CDCl3, 500 MHz): δ 6.50 (t, J = 6.1 Hz, 1H), 3.51 - 3.39 (m, 2H), 2.64 - 2.11 (m, 14H), 
2.08 - 1.95 (m, 3H), 1.70 (tt, J = 12.3, 9.2 Hz, 1H), 1.56 (tdd, J = 13.2, 11.6, 4.8 Hz, 1H), 1.30 (s, 
3H), 0.88 (s, 3H). 
HRMS(ESI): m/z calc. for C21H30NO6 [M+H]
+: 392.2073, found: 392.2079. 
 
Synthesis of G16 Derivatives 
 
General procedure for the preparation of G16 amides: In an oven-dried vial, G8 (1 equiv.) and 
benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (1.2 equiv.) were dissolved 
in dichloromethane (0.1 M). Diisopropylethylamine (1 equiv.) was added, and the reaction was 
stirred at room temperature for 1-2 hours. After complete complexation by TLC, amine (1-3 
equiv.) and additional diisopropylethylamine (1-3 equiv.) were added, and the reaction was 
allowed to stir at room temperature for 12-16 hours. The reaction was concentrated and purified 
by flash silica chromatography (hexanes/ethyl acetate) to provide the amide. (Note:  G16a can be 
isolated and purified prior to the addition of amine.)  
 
G16a: Prepared from G8. 
Yield: N.A./aliquot purified for screening. 
1H NMR (d6-acetone, 500 MHz): δ 8.10 (dt, J = 8.5, 0.9 Hz, 1H), 7.73 - 7.66 (m, 
2H), 7.54 (ddd, J = 8.5, 6.5, 1.5 Hz, 1H), 5.95 (dt, J = 5.0, 2.5 Hz, 1H), 5.21 (d, J 
= 5.2 Hz, 1H), 5.17 (ddd, J = 3.1, 1.9, 0.9 Hz, 1H), 5.07 - 5.05 (m, 1H), 4.80 (t, J = 5.3 Hz, 1H), 
4.41 (t, J = 5.2 Hz, 1H), 4.05 (s, 1H), 3.41 (ddt, J = 6.3, 2.6, 0.8 Hz, 1H), 3.07 - 3.00 (m, 2H), 2.67 
(d, J = 5.9 Hz, 1H), 2.56 (ddt, J = 15.5, 2.5, 1.0 Hz, 1H), 2.03 - 1.98 (m, 1H), 1.81 - 1.72 (m, 2H), 
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1.64 (dd, J = 10.9, 2.9 Hz, 1H), 1.58 (ddd, J = 10.8, 2.7, 1.1 Hz, 1H), 1.54 (tt, J = 4.2, 1.6 Hz, 1H), 
1.39 (s, 3H). 
HRMS(ESI): m/z calc. for C25H26N3O6 [M+H]
+: 464.1822, found: 464.1823. 
 
G16b: Prepared from 3-chlorobenzylamine.  
Yield: 130.0 mg, 91%. 
1H NMR (CD3OD, 500 MHz): δ 7.35 (t, J = 1.8 Hz, 1H), 7.33 - 7.22 (m, 4H), 
5.78 (dt, J = 5.5, 2.0 Hz, 1H), 5.05 (t, J = 2.5Hz, 1H), 4.91 (t, J = 1.9 Hz, 1H), 
4.70 (t, J = 5.3 Hz, 1H), 4.38 (d, J = 15.0 Hz, 1H), 4.34 (d, J = 15.0 Hz, 1H), 4.19 (d, J = 5.3 Hz, 
1H), 3.38 - 3.33 (m, 1H), 2.68 (d, J = 6.0 Hz, 1H), 2.49 (dt, J = 16.3, 3.0 Hz, 1H), 2.38 (d, J = 6.0 
Hz, 1H), 2.16 (ddt, J = 16.0, 2.0, 1.0 Hz, 1H), 2.02 - 1.88 (m, 1H), 1.76 - 1.62 (m, 2H), 1.51 - 1.46 
(m, 1H) 1.46 (dd, J = 11.0, 3.0 Hz, 1H), 1.36 (dd, J = 11.0, 2.5Hz, 1H), 1.15 (s, 3H). 
HRMS(ESI): m/z calc. for C26H29NO5Cl [M+H]
+: 470.1734, found: 470.1740. 
 
G16c: Prepared from aminoacetonitrile bisulfate.  
Yield: 36.0 mg, 63%. 
1H NMR (d6-acetone, 500 MHz): δ 8.20 (t, J = 5.7 Hz, 1H), 5.76 (dt, J = 4.9, 2.1 
Hz, 1H), 5.05 (dt, J = 3.0, 1.5 Hz, 1H), 4.96 (d, J = 5.1 Hz, 1H), 4.89 - 4.86 (m, 1H), 4.68 (t, J = 
5.3 Hz, 1H), 4.28 (d, J =  4.5 Hz, H), 4.27 (d, J = 4.5, 1H), 4.26 - 4.22 (m, 1H), 3.84 (s, 1H), 3.37 
(dd, J = 5.9, 2.7 Hz, 1H), 2.64 (d, J = 5.5 Hz, 1H), 2.58 (dt, J = 16.4, 3.0 Hz, 1H), 2.33 (d, J = 5.9 
Hz, 1H), 2.21 (ddt, J = 16.0, 2.5, 1.5 Hz, 1H), 1.96 - 1.88 (m, 1H), 1.73 - 1.60 (m, 2H), 1.48 - 1.41 
(m, 1H),1.43 (dd, J = 10.9, 2.9 Hz, 1H), 1.31 (dd, J = 10.0, 2.0 Hz, 1H), 1.09 (s, 3H). 
HRMS(ESI): m/z calc. for C21H24N2O5Na [M+Na]
+: 407.1583, found: 407.1594. 
 
G16d: Prepared from 4-methoxyphenethylamine.  
Yield: 70 mg, 92%. 
1H NMR (d6-acetone, 500 MHz): δ 7.56 (t, J = 5.7 Hz, 1H), 7.16 (d, J = 8.6 Hz, 
2H), 6.83 (d, J = 8.6 Hz, 2H), 5.71 (dt, J = 5.5, 2.0 Hz, 1H), 5.02 (p, J = 1.0 Hz, 
1H), 4.95 (d, J = 5.2 Hz, 1H), 4.85 - 4.83 (m, 1H), 4.64 (t, J = 5.3 Hz, 1H), 4.21 (t, J = 5.0 Hz, 
1H), 3.78 (s, 1H), 3.74 (s, 3H), 3.75 - 3.72 (m, 1H), 3.51 - 3.45 (m, 2H), 3.37 (dd, J = 5.8, 2.7 Hz, 
1H), 2.78 (t, J = 7.2 Hz, 2H), 2.64 (d, J = 7.0 Hz, 1H), 2.42 (dt, J = 16.5, 2.9 Hz, 1H), 2.18 (d, J = 
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5.8 Hz, 1H), 1.92 - 1.83 (m, 1H), 1.72 - 1.52 (m, 2H), 1.44 - 1.39 (m, 1H), 1.38 (dd, J = 10.8, 2.9 
Hz, 1H), 1.23 (dd, J = 10.5, 2.0 Hz, 1H), 1.05 (s, 3H). 
HRMS(ESI): m/z calc. for C28H34NO6 [M+H]
+: 480.2386, found: 480.2381. 
 
G16e: Prepared from 2,4-dimethoxybenzylamine.  
Yield: 84.4 mg, 99%. 
1H NMR (d6-acetone, 500 MHz): δ 7.71 (t, J = 5.6 Hz, 1H), 7.18 (d, J = 8.3 
Hz, 1H), 6.52 (d, J = 2.4 Hz, 1H), 6.45 (dd, J = 8.3, 2.4 Hz, 1H), 5.71 (dt, J = 
5.5, 2.0 Hz, 1H), 5.02 (dt, J = 2.5, 2.0 Hz, 1H), 4.96 (d, J = 5.4 Hz, 1H), 4.87 - 4.79 (m, 1H), 4.64 
(t, J = 5.3 Hz, 1H), 4.32 (d, J = 5.5 Hz, 2H), 4.20 (t, J = 4.9 Hz, 1H), 3.81 (s, 3H), 3.79 - 3.77 (m, 
1H), 3.77 (s, 3H), 3.40 (dd, J = 5.8, 2.6 Hz, 1H), 2.64 (d, J = 7.0 Hz, 1H), 2.53 (dt, J = 16.6, 3.0 
Hz, 1H), 2.29 (d, J = 5.8 Hz, 1H), 2.14 - 2.11 (m, 1H), 1.88 (dd, J = 13.5, 5.5 Hz, 1H), 1.71 - 1.55 
(m, 2H), 1.45 - 1.40 (m, 1H), 1.38 (dd, J = 10.9, 2.9 Hz, 1H), 1.29 (dd, J = 11.1, 2.0 Hz, 1H), 1.08 
(s, 3H). 
HRMS(ESI): m/z calc. for C28H34NO7 [M+H]
+: 496.2335, found: 496.2333. 
 
G16f: Prepared from 2,6-difluorobenzylamine.  
Yield: 40.8 mg, 57%. 
1H NMR (d6-acetone, 500 MHz): δ 7.87 (t, J = 5.2 Hz, 1H), 7.42 - 7.30 (m, 1H), 
7.04 - 6.94 (m, 2H), 5.71 (dt, J = 5.5, 2.0 Hz, 1H), 5.01 (dt, J = m.0, 1.5 Hz, 1H), 
4.92 (br s, 1H), 4.82 - 4.80 (m, 1H), 4.63 (t, J = 5.3 Hz, 1H), 4.53 (ddt, J = 14.0, 5.5, 1.0 Hz, 1H), 
4.48 (ddt, J = 12.0, 5.5, 1.5 Hz, 1H) 4.41 (s, 1H), 4.19 (d, J = 5.4 Hz, 1H), 3.38 (dd, J = 6.0, 2.5 
Hz, 1H), 2.62 (d, J = 7.5 Hz, 1H), 2.50 (dt, J = 16.5, 2.9 Hz, 1H), 2.26 (d, J = 5.8 Hz, 1H), 2.00 - 
1.91 (m, 1H), 1.91 - 1.84 (m, 1H), 1.71 - 1.56 (m, 2H), 1.45 - 1.39 (m, 1H), 1.38 (dd, J = 10.9, 2.9 
Hz, 1H), 1.26 (dd, J = 10.9, 2.8 Hz, 1H) 1.04 (s, 3H). 
HRMS(ESI): m/z calc. for C26H28NO5F2 [M+H]
+: 472.1936, found: 472.1938. 
 
G16g: Prepared from 2-bromoethylamine hydrobromide.  
Yield: 40.2 mg, 58%. 
1H NMR (d6-acetone, 500 MHz): δ 7.86 (t, J = 5.0 Hz, 1H), 5.74 (dt, J = 5.5, 3.0 
Hz, 1H), 5.06 - 5.03 (m, 1H), 4.91 (d, J = 5.6 Hz, 1H), 4.89 - 4.86 (m, 1H), 4.66 (t, J = 5.3 Hz, 
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1H), 4.22 (t, J = 5.4 Hz, 1H), 3.77 (s, 1H), 3.67 - 3.61 (m, 2H), 3.61 - 3.51 (m, 2H), 3.38 (dd, J = 
5.9, 2.8 Hz, 1H), 2.69 - 2.62 (m, 1H), 2.28 (d, J = 5.8 Hz, 1H), 2.20 (ddt, J = 16.5, 2.5, 2.0 Hz, 
1H), 1.93 - 1.87 (m, 1H), 1.73 - 1.58 (m, 2H), 1.46 - 1.38 (m, 2H), 1.32 - 1.26 (m, 2H), 1.11 (s, 
3H). 
HRMS(ESI): m/z calc. for C21H27NO5Br [M+H]
+: 452.1073, found: 452.1077. 
 
G16h: Prepared from 3,4-methylenedioxyphenethylamine.  
Yield: 52.9 mg, 70%. 
1H NMR (d6-acetone, 500 MHz): δ 7.53 (t, J = 5.7 Hz, 1H), 6.78 (d, J = 1.6 
Hz, 1H), 6.76 - 6.68 (m, 2H), 5.92 (dd, J = 1.5, 1.0 Hz, 2H), 5.71 (dt, J = 5.9, 
2.5 Hz, 1H), 5.02 (dt, J = 2.5, 1.0 Hz, 1H), 4.95 (d, J = 5.5 Hz, 1H), 4.86 - 4.84 (m, 1H), 4.64 (t, J 
= 5.3 Hz, 1H), 4.20 (t, J = 5.4 Hz, 1H), 3.77 (s, 1H), 3.52 - 3.42 (m, 2H), 3.37 (dd, J = 5.8, 2.7 Hz, 
1H), 2.78 (d, J = 7.1, 1H), 2.76 (d, J = 7.1 Hz, 1H), 2.63 (d, J = 7.0 Hz, 1H), 2.42 (dt, J = 16.6, 3.0 
Hz, 1H), 2.17 (d, J = 5.7 Hz, 1H), 2.11 (m, 1H), 1.90 - 1.85 (m, 1H), 1.71 - 1.53 (m, 2H), 1.45 - 
1.39 (m, 1H), 1.38 (dd, J = 10.9, 2.9 Hz, 1H), 1.22 (dd, J = 10.9, 2.8 Hz, 1H), 1.05 (s, 3H). 
HRMS(ESI): m/z calc. for C28H32NO7 [M+H]
+: 494.2179, found: 494.2177. 
 
G16i: Prepared from 3-chloro-4-fluorobenzylamine.  
Yield: 47.6 mg, 65%. 
1H NMR (d6-acetone, 500 MHz): δ 8.09 (t, J = 6.1 Hz, 1H), 7.50 (dd, J = 7.2, 
2.2 Hz, 1H), 7.35 (ddd, J = 8.4, 4.6, 2.2 Hz, 1H), 7.26 (dd, J = 9.3, 8.5 Hz, 1H), 5.74 (dt, J = 5.2, 
2.1 Hz, 1H), 5.03 (dt, J = 2.5, 2.0 Hz, 1H), 4.93 (d, J = 5.5 Hz, 1H), 4.85 - 4.83 (m, 1H), 4.66 (t, J 
= 5.3 Hz, 1H), 4.46 (dd, J = 14.5, 6.0 Hz, 1H), 4.40 (dd, J = 15.0, 6.0 Hz, 1H), 4.23 (t, J = 5.4 Hz, 
1H), 3.39 (dd, J = 5.8, 2.7 Hz, 1H), 2.95 (s, 1H), 2.65 (d, J = 6.5 Hz, 1H), 2.51 (dt, J = 16.4, 3.0 
Hz, 1H), 2.29 (d, J = 5.8 Hz, 1H), 2.19 - 2.12 (m, 1H), 1.15 (ddt, J = 16.5, 2.5, 1.5 Hz, 1H), 1.72 
- 1.58 (m, 2H), 1.46 - 1.43 (m, 1H), 1.41 (dd, J = 10.8, 3.0 Hz, 1H), 1.28 (dd, J = 10.9, 2.8 Hz, 
1H), 1.09 (s, 3H). 
HRMS(ESI): m/z calc. for C26H28NO5ClF [M+H]




G16j: Prepared from 6-amino-1-hexanol.  
Yield: 42.6 mg, 62%.  
1H NMR (d6-acetone, 500 MHz): δ 7.55 (t, J = 5.7 Hz, 1H), 5.72 (dt, J = 5.2, 
2.1 Hz, 1H), 5.04 (dt, J = 2.0, 1.0 Hz, 1H), 4.96 (d, J = 5.5 Hz, 1H), 4.89 - 4.86 (m, 1H), 4.65 (t, J 
= 5.3 Hz, 1H), 4.22 (t, J = 5.4 Hz, 1H), 3.81 (s, 1H), 3.55 - 3.47 (m, 3H), 3.38 (dd, J = 5.8, 2.7 Hz, 
1H), 3.24 (td, J = 6.9, 5.7 Hz, 2H), 2.97 (s, 1H), 2.66 (d, J = 4.0 Hz, 1H), 2.57 (dt, J = 16.4, 3.0 
Hz, 1H), 2.24 - 2.18 (m, 2H), 1.91 - 1.86 (m, 1H), 1.72 - 1.57 (m, 2H), 1.56 - 1.47 (m, 4H), 1.46 - 
1.40 (m, 1H), 1.40 - 1.34 (m, 4H), 1.28 (dd, J = 10.9, 2.8 Hz, 1H), 1.09 (s, 3H). 
HRMS(ESI): m/z calc. for C25H36NO6 [M+H]
+: 446.2543, found: 446.3536. 
 
G16k: Prepared from furfurylamine.  
Yield: 52.9 mg, 83%. 
1H NMR (d6-acetone, 500 MHz): δ 7.94 (t, J = 5.7 Hz, 1H), 7.46 (dd, J = 1.9, 
0.9 Hz, 1H), 6.36 (dd, J = 3.2, 1.9 Hz, 1H), 6.27 - 6.25 (m, 1H), 5.74 (dt, J = 5.9, 2.5 Hz, 1H), 5.03 
(dt, J = 3.0, 1.5 Hz, 1H), 4.94 (d, J = 5.5 Hz, 1H), 4.86 - 4.83 (m, 1H), 4.66 (t, J = 5.3 Hz, 1H), 
4.45 (dd, J = 15.5, 5.5 Hz, 1H), 4.41 (dd, J = 15.5, 5.5 Hz, 1H), 4.23 (t, J = 5.4 Hz, 1H), 3.79 (s, 
1H), 3.41 (dd, J = 5.8, 2.7 Hz, 1H), 2.65 (d, J = 6.5 Hz, 1H), 2.53 (dt, J = 16.5, 3.0 Hz, 1H), 2.31 
(d, J = 5.8 Hz, 1H), 2.14 (ddt, J = 16.5, 2.5, 1.5 Hz, 1H), 1.93 - 1.87 (m, 1H), 1.73 - 1.57 (m, 2H), 
1.47 - 1.43 (m, 1H), 1.41 (dd, J = 11.0, 2.5 Hz, 1 H), 1.30 (dd, J = 11.0, 2.5 Hz, 1H), 1.09 (s, 3H). 
HRMS(ESI): m/z calc. for C24H28NO6 [M+H]
+: 426.1917, found: 426.1913. 
 
G16l: Prepared from 2-fluorobenzylamine.  
Yield: 21.0 mg, 60%. 
1H NMR (d6-acetone, 500 MHz): δ 8.00 - 7.93 (m, 1H), 7.45 (td, J = 7.7, 1.7 
Hz, 1H), 7.34 - 7.27 (m, 1H), 7.15 (t, J = 7.5 Hz, 1H), 7.09 (t, J = 8.5 Hz, 1H), 
5.74 - 5.71 (m, 1H), 5.02 (dt, J = 3.3, 1.6 Hz, 1H), 4.94 - 4.88 (m, 1H), 4.83 - 4.80 (m, 1H), 4.65 
(t, J = 5.3 Hz, 1H), 4.51 (dd, J = 15.0, 6.0 Hz, 1H), 4.45 (dd, J = 15.0, 5.5 Hz, 1H), 4.21 (t, J = 5.0 
Hz, 1H), 3.78 - 3.74 (m, 1H), 3.40 (dd, J = 6.0, 2.6 Hz, 1H), 2.90 - 2.80 (m, 1H), 2.64 (d, J = 5.5 
Hz, 1H), 2.52 (dt, J = 16.5, 3.0 Hz, 1H), 2.31 (d, J = 5.8 Hz, 1H), 2.11 (ddt, J = 16.5, 3.0, 1.5 Hz, 
1H), 1.93 - 1.86 (m, 1H), 1.72 - 1.56 (m, 2H), 1.45 - 1.41 (m, 1H), 1.40 (dd, J = 11.0, 2.5 Hz, 1H), 
1.28 (dd, J = 10.8, 2.6 Hz, 1H), 1.08 (s, 3H). 
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HRMS(ESI): m/z calc. for C26H29NO5F [M+H]
+: 454.2030, found: 454.2034.  
 
G16m: Prepared from cyclopropylamine.  
Yield: 19.3 mg, 66%.  
1H NMR (d6-acetone, 500 MHz): δ 7.56 (d, J = 2.5 Hz, 1H), 5.72 (dt, J = 5.0, 2.0 
Hz,  1H), 5.04 (ddd, J = 3.3, 2.0, 1.2 Hz, 1H), 4.92 (d, J = 5.6 Hz, 1H), 4.89 - 4.87 (m, 1H), 4.65 
(t, J = 5.3 Hz, 1H), 4.21 (t, J = 5.5 Hz, 1H), 3.76 (s, 1H), 3.38 (dd, J = 5.5, 2.5 Hz, 1H), 2.79 - 2.73 
(m, 1H), 2.64 (d, J = 6.0 Hz, 1H), 2.53 (dt, J = 16.4, 3.0 Hz, 1H), 2.20 (ddt, J = 16.5, 2.5, 2.0 Hz, 
1H), 2.14 (d, J = 5.8 Hz, 1H), 1.92 - 1.85 (m, 1H), 1.71 - 1.58 (m, 2H), 1.46 - 1.40 (m, 1H), 1.39 
(dd, J = 10.8, 2.9 Hz, 1H), 1.24 (dd, J = 10.9, 2.9 Hz, 1H), 1.07 (s, 3H), 0.71 - 0.64 (m, 2H), 0.53 
- 0.44 (m, 2H). 
HRMS(ESI): m/z calc. for C22H28NO5 [M+H]
+: 386.1967, found: 386.1961.  
 
G16n: Prepared from morpholine.  
Yield: 23.9 mg, 75%. 
1H NMR (CD3OD, 500 MHz): δ 5.80 (dt, J = 5.0, 2.5 Hz, 1H), 5.11 - 5.07 (m, 
1H), 5.00 - 4.96 (m, 1H), 4.72 (t, J = 5.3 Hz, 1H), 4.20 (d, J = 5.3 Hz, 1H), 3.76 - 3.55 (m, 8H), 
3.45 (dd, J = 6.5, 2.6 Hz, 1H), 2.84 (d, J = 6.5 Hz, 1H), 2.68 (d, J = 3.0 Hz, 1H), 2.42 (dt, J = 16.0, 
2.5 Hz, 1H), 2.24 (ddt, J = 16.0, 2.5, 2.0 Hz, 1H), 1.98 - 1.92 (m, 1H), 1.78 - 1.66 (m, 2H), 1.54 - 
1.48 (m, 2H), 1.40 (dd, J = 11.0, 1.5 Hz, 1H), 1.38 - 1.34 (m, 2H), 1.10 (s, 3H). 
HRMS(ESI): m/z calc. for C23H30NO6 [M+H]
+: 416.2073, found: 416.2067. 
 
G16o: Prepared from 4-amino-1-butanol.  
Yield: 19.4 mg, 61%. 
1H NMR (d6-acetone, 500 MHz): δ 7.53 (t, J = 5.7 Hz, 1H), 5.72 (dt, J = 5.5, 
3.0 Hz, 1H), 5.04 (ddd, J = 3.3, 2.0, 1.2 Hz, 1H), 4.93 (d, J = 5.4 Hz, 1H), 4.88 
- 4.86 (m, 1H), 4.65 (t, J = 5.3 Hz, 1H), 4.22 (t, J = 5.2 Hz, 1H), 3.78 (s, 1H), 3.59 - 3.50 (m, 2H), 
3.39 (dd, J = 5.8, 2.7 Hz, 1H), 3.30 - 3.20 (m, 2H), 2.66 (d, J = 6.6 Hz, 1H), 2.57 (dt, J = 16.4, 3.0 
Hz, 1H), 2.30 - 2.17 (m, 2H), 1.92 - 1.86 (m, 1H), 1.72 - 1.51 (m, 7H), 1.46 - 1.42 (m, 1H), 1.41 
(dd, J = 10.9, 2.9 Hz, 1H), 1.28 (dd, J = 10.9, 2.8, Hz, 1H), 1.09 (s, 3H). 
HRMS(ESI): m/z calc. for C23H32NO6 [M+H]




G16p: Prepared from 4-hydroxypiperidine.  
Yield: 15.5 mg, 47%. 
1H NMR (d6-DMSO, 500 MHz): δ 5.87 (t, J = 5.0 Hz, 1H), 5.70 (dt, J = 5.1, 
2.4 Hz, 1H), 5.01 - 4.97 (m, 1H), 4.87 (d, J = 14.5 Hz, 1H), 4.83 - 4.80 (m, 2H), 4.67 (t, J = 5.0 
Hz, 1H), 4.10 (q, J = 5.0 Hz, 1H), 3.94 - 3.64 (m, 3H), 3.36 - 3.24 (m, 2H), 3.18 (ddd, J = 13.2, 
9.2, 3.1 Hz, 1H), 2.91 (ddd, J = 13.4, 10.8, 3.1 Hz, 1H), 2.68 (t, J = 7.0 Hz, 1H), 2.27 (ddt, J = 
24.5, 16.5, 2.5 Hz, 1H), 2.08 (s, 1H), 1.87 - 1.64 (m, 3H), 1.61 - 1.44 (m, 2H), 1.39 - 1.10 (m, 5H), 
0.96 (d, J = 13.7 Hz, 3H). Note: The doublet at 0.96 ppm gave partial coalescence at 95 °C. Higher 
temperatures were not attempted.  
HRMS(ESI): m/z calc. for C24H32NO6 [M+H]
+: 430.2230, found: 430.2233. 
 
G16q: Prepared from L-isoleucine methyl ester hydrochloride.  
Yield: 36.7 mg, 25%. 
1H NMR (CDCl3, 500 MHz): δ 6.75 (d, J = 8.7 Hz, 1H), 5.76 (dt, J = 5.0, 2.2 
Hz, 1H), 5.08 (t, J = 2.5 Hz, 1H), 4.94 (t, J = 2.0 Hz, 1H), 4.76 (t, J = 5.3 Hz, 
1H), 4.56 (dd, J = 8.7, 5.3 Hz, 1H), 4.23 (d, J = 5.4 Hz, 1H), 3.74 (s, 3H), 3.32 (dd, J = 5.8, 2.6 
Hz, 1H), 2.79 (br s, 1H), 2.73 (d, J = 6.7 Hz, 1H), 2.59 (dt, J = 16.6, 3.0 Hz, 1H), 2.40 (d, J = 5.8 
Hz, 1H), 2.23 (ddt, J = 17.0, 3.0, 2.0 Hz, 1H), 1.96 - 1.86 (m, 2H), 1.78 - 1.63 (m, 2H), 1.57 - 1.50 
(m, 1H), 1.51 (dd, J = 10.8, 2.8 Hz, 1H), 1.46 - 1.35 (m, 2H), 1.27 - 1.11 (m, 2H), 1.20 (s, 3H), 
0.90 (t, J = 7.0 Hz, 3H), 0.89 (d, J = 6.5, 3H). 
HRMS(ESI): m/z calc. for C26H36NO7 [M+H]
+: 474.2492, found: 474.2499. 
 
G16r: Prepared from L-tryptophan methyl ester hydrochloride.  
Yield: 60.6 mg, 33%. 
1H NMR (CDCl3, 500 MHz): δ 8.64 (br s, 1H), 7.53 (d, J = 7.9 Hz, 1H), 7.30 
(d, J = 8.0 Hz, 1H), 7.16 (t, J = 8.0 Hz, 1H), 7.09 (t, J = 7.0, 2H), 6.98 (d, J = 
2.3 Hz, 1H), 5.69 (dt, J = 5.2, 2.1 Hz, 1H), 5.04 (t, J = 2.4 Hz, 1H), 4.97 - 4.90 (m, 1H), 4.90 (s, 
1H), 4.66 (t, J = 5.3 Hz, 1H), 4.02 (d, J = 5.4 Hz, 1H), 3.70 (s, 3H), 3.31 (dd, J = 15.0, 4.5 Hz, 1H) 
3.28 - 3.19 (m, 2H), 2.68 - 2.59 (m, 2H), 2.26 (d, J = 5.7 Hz, 1H), 2.18 (d, J = 17.0 Hz, 1H), 1.85 
(d, J = 9.1 Hz, 1H), 1.69 - 1.56 (m, 2H), 1.53 - 1.50 (m, 1H), 1.42 - 1.39  (m, 2H), 0.84 (s, 3H). 
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HRMS(ESI): m/z calc. for C31H35N2O7 [M+H]
+: 547.2444, found: 547.2438. 
 
Synthesis of G10 Derivatives 
 
Procedure: In an oven-dried round bottom flask with a stir bar under nitrogen, loaded G10 (39.7 
mg, 0.140 mmol) and dissolved in tetrahydrofuran (2.0 mL). Added lithium aluminum hydride 
(103.7 mg, 2.73 mmol) and refluxed for 16 hours. The reaction was cooled to 0°C and quenched 
with water (0.12 mL), followed by 15% aqueous sodium hydroxide (0.12 mL) and additional water 
(3.0 mL). The mixture stirred for 15 minutes, at which point anhydrous magnesium sulfate was 
added. After an additional 15 minutes of stirring, the solids were filtered and washed thoroughly 
with ethyl acetate. The aqueous layer was extracted with ethyl acetate (3x). The combined organic 
layers were washed with brine, dried over magnesium sulfate, filtered, and concentrated under 
reduced pressure.  The residue was purified by flash chromatography on silica gel (1:4 
hexanes/ethyl acetate) to yield the product as a white solid (18.4 mg, 49%). 
 
1H NMR (CDCl3, 500 MHz): δ 7.09 (t, J = 7.5 Hz, 1H), 6.95 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 8.0 
Hz, 1H), 5.02 (t, J = 2.6 Hz, 1H), 4.79 (t, J = 2.2 Hz, 1H), 4.33 (dd, J = 11.1, 4.4 Hz, 1H), 4.06 
(dd, J = 11.1, 7.3 Hz, 1H), 3.26 (dd, J = 7.5, 4.5 Hz, 1H), 2.71 (dd, J = 12.6, 5.0 Hz, 1H), 2.47 (dt, 
J = 17.0, 3.0 Hz, 1H), 2.39 (s, 3H), 2.32 (dd, J = 10.1, 2.5 Hz, 1H), 2.22 (dtd, J = 13.1, 5.1, 1.7 
Hz, 1H), 2.16 - 2.06 (m, 2H), 2.00 - 1.91 (m, 2H), 1.84 (dd, J = 10.1, 2.6 Hz, 1H), 1.73 (ddt, J = 
11.7, 5.1, 2.0 Hz, 1H), 1.55 (qd, J = 12.7, 5.3 Hz, 1H). 
 
HRMS(ESI): m/z calc. for C18H23O2 [M+H]
+: 271.1698, found: 271.1704. 
 
Procedure: In an oven-dried round bottom flask with a stir bar under nitrogen, loaded G10 (321.0 
mg, 1.13 mmol) and dissolved in benzene (11 mL). Added triethylamine (170 μL, 1.22 mmol) and 
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diphenylphosphoryl azide (250 μL, 1.21 mmol) and refluxed. When G10 had fully dissolved, 
benzyl alcohol (240 μL, 2.32 mmol) was added and the reaction refluxed for 14 hours.  The 
reaction was cooled to room temperature, quenched with water (10 mL), extracted with ethyl 
acetate (3x), washed with brine, dried over magnesium sulfate, filtered, and concentrated under 
reduced pressure.  The residue was purified by flash chromatography on silica gel (9:1 to 1:9 
hexanes/ethyl acetate) to yield the product as a white solid (151.2 mg, 34%). 
1H NMR (CDCl3, 500 MHz): δ 7.41 - 7.30 (m, 5H), 7.11 (t, J = 7.4 Hz, 1H), 6.97 - 6.91 (m, 2H), 
5.31 (d, J = 10.3 Hz, 1H), 5.21 (d, J = 12.1 Hz, 1H), 5.13 (d, J = 12.2 Hz, 1H), 5.04 (t, J = 2.5 Hz, 
1H), 4.97 (d, J = 10.3 Hz, 1H), 4.79 (t, J = 2.1 Hz, 1H), 2.75 (dd, J = 12.5, 5.2 Hz, 1H), 2.34 - 2.19 
(m, 2H), 2.27 (s, 3H), 2.06 (dd, J = 10.5, 2.5 Hz, 1H), 1.95 (td, J = 12.0, 5.0 Hz, 1H), 1.90 - 1.84 
(m, 2H), 1.77 - 1.68 (m, 2H), 1.55 (qd, J = 12.8, 5.2 Hz, 1H). 
HRMS(ESI): m/z calc. for C25H28NO3 [M+H]
+: 390.2069, found: 390.2063. 
 
Procedure: In a round bottom flask with a stir bar, dissolved G10 (41.5 mg, 0.107 mmol) and 
potassium hydroxide (237.3 mg, 4.23 mmol) in methanol (2 mL) and water (2 mL). The reaction 
was refluxed for 24 hours, and then the reaction was cooled to room temperature, extracted with 
dichloromethane (3x), washed with brine, dried over magnesium sulfate, and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (98:1:1 to 97:2:1 
dichloromethane/methanol/triethylamine) to yield the product as a white solid (13.6 mg, 50%).  
 
1H NMR (CDCl3, 500 MHz): δ 7.08 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 6.92 (d, J = 7.0 
Hz, 1H), 5.02 (t, J = 2.6 Hz, 1H), 4.79 (t, J = 2.2 Hz, 1H), 4.29 (s, 1H), 2.66 (dd, J = 12.3, 4.9 Hz, 
1H), 2.49 (s, 3H), 2.40 (dt, J = 17.0, 2.9 Hz, 1H), 2.25 (dtd, J = 13.1, 5.2, 1.7 Hz, 1H), 2.09 (dd, J 
= 10.3, 2.3 Hz, 1H), 1.97 (td, J = 12.2, 5.2 Hz, 1H), 1.80 (q, J = 2.0 Hz, 1H), 1.77 (q, J = 2.4 Hz, 
1H), 1.74 (q, J = 2.5 Hz, 1H), 1.72 (q, J = 2.5 Hz, 1H), 1.56 (qd, J = 12.7, 5.3 Hz, 1H). 
HRMS(ESI): m/z calc. for C17H22NO [M+H]




2.7.2 Synthesis of compounds from Richer et al.1 
General procedures for compounds in tables 
General Procedure A: 
 
In a round bottom flask, isomannide azide was dissolved in pyridine (0.1 M), and cooled to 0˚C. 
A sulfonyl chloride (3 equiv.) was added in one portion, slowly warmed to room temperature, and 
stirred for 12-24 hours. The reaction was then diluted with water. The layers were separated and 
the product was extracted from the aqueous layer with dichloromethane (3x). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo. The remaining pyridine was evaporated with a stream of nitrogen. The residue was purified 
by silica gel chromatography with hexanes/ethyl acetate to afford the desired product.  
 
General Procedure B: 
 
In a flame dried round bottom flask, 10% palladium on activated charcoal (0.1 equiv.) was loaded 
under nitrogen, and dampened with toluene. Anhydrous methanol (0.2 M) was slowly added, and 
purged with nitrogen. The isomannide azide derivative was then transferred to the round bottom 
with anhydrous methanol (0.2 M) and re-purged with nitrogen gas. The round bottom was then 
fitted with a balloon of hydrogen gas and purged for 1 min. The reaction was stirred under an 
atmosphere of hydrogen gas at room temperature for 4-8 hours. The palladium was then filtered 
over Celite and the flow through was concentrated to afford the desired product.  
 




In a flame dried round bottom flask, an aldehyde was dissolved in 1,2-dichloroethane (0.1 M). A 
primary amine (2-3 equiv.) and sodium triacetoxyborohydride (3 equiv.) were added and the 
reaction was stirred for 12-18 hours. The reaction was then quenched with a saturated solution of 
sodium bicarbonate and extracted with ethyl acetate (3x). The combined organic layers were 
washed with brine, dried over Na2SO4, filtered, and concentrated. The resulting residue was 
purified via silica gel chromatography with ethyl acetate/methanol to yield the desired product.   
 
General Procedure D: 
 
G16-amide and sodium hydroxide (5-7 equiv.) were dissolved in water (0.05 M), and stirred at 
room temperature for 12-18 hours. The reaction mixture was acidified to pH 2 with 1 M HCl and 
then extracted with ethyl acetate (5-8x). The combined organic layers were washed with brine, 
dried over Na2SO4, filtered, and concentrated. The resulting residue was purified via silica gel 
chromatography with methanol/formic acid/dichloromethane to yield the desired product.  
 
Synthesis of compounds in tables  
 
 
Procedure: In a dry round bottom flask under nitrogen, isomannide (510.1 mg, 3.49 mmol) and 
triethylamine (0.5 mL, 3.66 mmol) were dissolved in dichloromethane (34.0 mL). 4-
bromobenzenesulfonyl chloride (875.3 mg, 3.42 mmol) was added in five portions over the course 
of one hour and the reaction was allowed to stir at room temperature for 14 hours. The reaction 
was then diluted in water and extracted with ethyl acetate (3x). The combined organic layers were 
washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting 
residue was purified via silica gel chromatography (6:4 to 7:3 ethyl acetate/hexanes) to afford 




1H NMR (CDCl3, 500 MHz): δ 7.86 – 7.78 (m, 2H), 7.75 – 7.68 (m, 2H), 4.97 (td, J = 6.7, 5.2 Hz, 
1H), 4.51 (t, J = 4.9 Hz, 1H), 4.44 (t, J = 5.1 Hz, 1H), 4.29 (dtd, J = 8.4, 6.8, 5.5 Hz, 1H), 4.05 
(dd, J = 9.5, 6.4 Hz, 1H), 3.94 (dd, J = 9.4, 6.4 Hz, 1H), 3.84 (dd, J = 9.5, 7.1 Hz, 1H), 3.53 (dd, J 
= 9.4, 7.2 Hz, 1H), 2.48 (d, J = 8.5 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 135.31, 132.74, 129.58, 129.56, 81.62, 80.15, 79.01, 74.14, 72.37, 
70.40. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H14O6SBr [M+H]
+: 364.9694, found: 364.9688.  
 
 
Procedure: In a dry round bottom flask under nitrogen monobrosyl isomannide (1.06 g, 2.90 
mmol) was dissolved in N,N-dimethylformamide (30.0 mL). Sodium azide (565.6 mg, 8.70 mmol) 
was added and the reaction was stirred at 80°C for 18 hours. The reaction was cooled to room 
temperature, quenched with water and extracted with dichloromethane (3x). The combined organic 
layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The 
remaining N,N-dimethylformamide was evaporated with a stream of nitrogen. The resulting 
residue was purified via silica gel chromatography (1:1 ethyl acetate/hexanes) to afford 
isomannide azide (236.0 mg, 48 % yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 4.63 (t, J = 4.9 Hz, 1H), 4.47 (dt, J = 4.4, 0.9 Hz, 1H), 4.32 (dq, J 
= 6.9, 5.6 Hz, 1H), 4.11 – 4.05 (m, 2H), 3.96 (dd, J = 10.2, 4.1 Hz, 1H), 3.88 (dd, J = 9.6, 5.9 Hz, 
1H), 3.61 (dd, J = 9.6, 5.6 Hz, 1H), 2.56 (d, J = 6.8 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 89.85, 81.55, 76.31, 74.04, 72.24, 58.57. 






Procedure for the precursor to 16: Prepared with biphenyl-4-sulfonyl chloride according to 
general procedure A.  
Yield: 94.6 mg, 87%. 
 
1H NMR (CDCl3, 500 MHz): δ 8.05 – 7.98 (m, 2H), 7.79 – 7.74 (m, 2H), 7.64 – 7.59 (m, 2H), 
7.52 – 7.47 (m, 2H), 7.47 – 7.42 (m, 1H), 4.97 (q, J = 5.8 Hz, 1H), 4.67 (t, J = 4.9 Hz, 1H), 4.45 
(d, J = 4.4 Hz, 1H), 4.05 – 3.98 (m, 2H), 3.96 (dd, J = 10.4, 3.9 Hz, 1H), 3.92 (dd, J = 10.0, 6.0 
Hz, 1H), 3.83 (dd, J = 10.0, 6.0 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 147.21, 139.01, 134.67, 129.26, 128.95, 128.61, 128.00, 127.50, 
86.48, 80.58, 78.73, 72.89, 70.39, 65.98. (14 carbons due to symmetry)  
HRMS(ESI): m/z calc. for C18H18O5S [M+H]




Procedure for 16 (2-1, 3-1, 4-1): Prepared according to general procedure B.  
Yield: 48.8 mg, quantitative yield. 
 
1H NMR (CDCl3, 500 MHz): δ 8.04 – 7.99 (m, 2H), 7.79 – 7.71 (m, 2H), 7.61 (dt, J = 6.2, 1.4 Hz, 
2H), 7.52 – 7.46 (m, 2H), 7.47 – 7.41 (m, 1H), 4.95 (q, J = 5.9 Hz, 1H), 4.71 (t, J = 4.8 Hz, 1H), 
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4.28 (d, J = 4.4 Hz, 1H), 3.95 (dd, J = 9.5, 4.2 Hz, 1H), 3.88 (dd, J = 9.8, 6.1 Hz, 1H), 3.80 (dd, J 
= 9.8, 6.2 Hz, 1H), 3.76 (d, J = 9.6 Hz, 1H), 3.57 – 3.55 (m, 1H), 1.83 (br s, 2H). 
13C NMR (CDCl3, 125 MHz): δ 147.05, 139.06, 134.88, 129.24, 128.90, 128.59, 127.94, 127.49, 
89.91, 80.06, 79.15, 76.48, 69.93, 58.37. (14 carbons is correct due to symmetry)  
HRMS(ESI): m/z calc. for C18H20NO5S [M+H]
+: 362.1062, found: 362.1058. 
 
 
Procedure: In a round bottom flask, isomannide (1.03 g, 7.05 mmol) was dissolved in pyridine 
(70.0 mL), and cooled to 0 ˚C. 4-bromobenzenesulfonyl chloride (5.6 g, 21.9 mmol) was added in 
a single portion and the reaction was stirred for 16 hours, slowly warming to room temperature. 
The reaction was then quenched with water, and the aqueous layer was extracted three times with 
dichloromethane. The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and the dichloromethane was removed in vacuo. The remaining pyridine was removed 
with a stream of nitrogen and the residue was purified via column chromatography (1:1 to 7:3 ethyl 
acetate:hexanes) to afford di-brosyl isomannide as a white solid (2.7 g, 66% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.81 – 7.77 (m, 4H), 7.72 – 7.68 (m, 4H), 4.92 – 4.87 (m, 2H), 
4.50 (dd, J = 3.9, 1.5 Hz, 2H), 3.94 (dd, J = 9.7, 6.5 Hz, 2H), 3.76 (dd, J = 9.7, 7.2 Hz, 2H). 
13C NMR (CDCl3, 125 MHz): δ 135.26, 132.82, 129.69, 129.59, 80.18, 78.29, 70.47.  (7 carbons 
due to symmetry) 
HRMS(ESI): m/z calc. for C18H17Br2O8S2 [M+H]
+: 582.8732, found: 582.8723. 
 
 
Procedure: In a round bottom flask, di-brosyl isomannide (3.08 g, 5.28 mmol) was dissolved in 
N,N-dimethylformamide. Sodium azide (298.7 mg) was added in one portion, and the reaction was 
stirred at 80˚C for 15 hours. The reaction was then cooled to room temperature, quenched with 
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water, and the aqueous layer was extracted with dichloromethane (3x). The combined organic 
layers were washed with brine and the dichloromethane was concentrated in vacuo. The remaining 
N,N-dimethylformamide was removed with a stream of air and the residue was purified via column 
chromatography (8:2 to 1:1 hexanes/ethyl acetate) to afford the precursor to 2 (662.9 mg, 37% 
yield) as a white solid and the known di-azido isommanide (12% yield) as a clear oil. Spectral data  
for di-azido isomannide was consistent with reported values71.  
 
Precursor to 2: 
 
1H NMR (CDCl3, 500 MHz): δ 7.83 – 7.79 (m, 2H), 7.74 – 7.69 (m, 2H), 4.95 (q, J = 5.6 Hz, 1H), 
4.65 (t, J = 4.9 Hz, 1H), 4.44 (dt, J = 4.6, 0.9 Hz, 1H), 4.03 (d, J = 3.6 Hz, 1H), 3.97 (dt, J = 10.4, 
1.0 Hz, 1H), 3.93 –  3.87 (m, 2H), 3.83 (dd, J = 10.1, 5.6 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 135.39, 132.82, 129.62, 129.59, 86.59, 80.60, 79.11, 72.90, 70.58, 
65.94. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H12BrN3O5SNa [M+Na]




Procedure: In a round bottom flask, the precursor to 2 (637.5 mg, 1.63 mmol) was dissolved in 
tetrahydrofuran (16.0 mL), and triphenylphosphine (1.28 g, 4.88 mmol) was added in a single 
portion. Distilled water (0.8 mL) was added and the reaction was stirred at room temperature. After 
24 hours, the reaction was concentrated and purified by C18 chromatography to give 2 (2-2, 3-3, 
4-5) (247.7 mg, 39% yield).   
 
1H NMR (CDCl3, 500 MHz): δ 7.83 –  7.79 (m, 2H), 7.71 –  7.67 (m, 2H), 4.93 (qd, J = 7.6, 5.1 
Hz, 1H), 4.65 (t, J = 4.8 Hz, 1H), 4.22 (d, J = 4.4 Hz, 1H), 3.90 –  3.86 (m, 1H), 3.86 –  3.82 (m, 
1H), 3.79 (ddd, J = 9.9, 5.9, 2.2 Hz, 1H), 3.68 (d, J = 9.4 Hz, 1H), 3.52 (d, J = 4.0 Hz, 1H), 1.21 
(br s, 2H). 
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13C NMR (CDCl3, 125 MHz): δ 135.61, 132.74, 129.60, 129.44, 90.06, 80.10, 79.57, 76.50, 70.17, 
58.31. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H15BrNO5S [M+H]
+: 363.9854, found: 363.9855. 
Stereochemistry was determined for G10 (named here as 2-52 (3-18)), G10a (named here as 
Reduced 2-52), G10b (named here as 30-Cbz), G10c (named here as 30 (2-5, 3-16, 4-13)), and 
G11 (named here as 2-42 (3-51)). Stereochemical assignment of 2-52 (3-18) is shown below: 
 
 
1H  1H 1D NOESY NMR (d6-acetone) 
 
 
Procedure: In a round-bottom flask with a stir bar, Reduced 2-52 (named as G10a in Huigens et 
al.) (104.0 mg, 0.3819 mmol) and 4-toluenesulfonylchloride (205.6 mg, 1.078 mmol) were 
dissolved in pyridine and stirred under nitrogen for 32 hours. The reaction was quenched with a 
saturated solution of sodium bicarbonate and extracted with dichloromethane (4x). The organic 











The residue was purified via silica gel column chromatography (2:1 hexanes/ethyl acetate) to 
afford tosylated 2-52 (158.4 mg, 98% yield) as a white solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.83 (d, J = 8.2 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 7.07 (t, J = 7.5 
Hz, 1H), 6.90 (t, J = 6.4 Hz, 2H), 5.03 (t, J = 2.5 Hz, 1H), 4.83 (dd, J = 10.1, 5.3 Hz, 1H), 4.70 (t, 
J = 2.0 Hz, 1H), 4.33 – 4.13 (m, 1H), 3.39 (dd, J = 8.8, 5.3 Hz, 1H), 2.67 (dd, J = 12.5, 5.0 Hz, 
1H), 2.45 (s, 3H), 2.24 (s, 3H), 2.19 (dd, J = 15.2, 2.3 Hz, 1H), 2.10 (d, J = 5.4 Hz, 1H), 2.04 – 
1.97 (m, 1H), 1.93 (td, J = 12.2, 5.2 Hz, 1H), 1.86 – 1.76 (m, 2H), 1.76 – 1.67 (m, 1H), 1.49 (qd, 
J = 12.7, 5.2 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 154.47, 145.17, 145.10, 138.95, 133.80, 132.65, 130.05, 129.53, 
128.07, 127.19, 120.17, 103.66, 80.01, 68.96, 53.26, 51.50, 49.32, 47.85, 39.28, 31.46, 21.96, 
21.75, 20.83. 
HRMS(ESI): m/z calc. for C25H28O4SNa  [M+Na]
+: 447.1606, found: 447.1598. 
 
 
Procedure: In a round-bottom flask with a stir bar, tosylated 2-52 (158.4 mg, 0.3731 mmol) and 
sodium azide (65 mg, 0.9998 mmol) were dissolved in N,N-dimethylformamide (20.0 mL). The 
flask was attached to a reflux condenser and was stirred in an oil bath at 80 ºC. After 10 hours, the 
reaction was diluted with water and a saturated solution of sodium bicarbonate. The reaction was 
extracted with ethyl acetate (4x). The organic layers were combined, dried with anhydrous sodium 
sulfate, and concentrated in vacuo. The crude residue was purified by C18 chromatography to 
afford azide 2-52 (88.7 mg, 80% yield) as a white solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.09 (t, J = 7.4 Hz, 1H), 6.94 (dd, J = 10.9, 7.4 Hz, 2H), 5.04 (t, J 
= 2.7 Hz, 1H), 4.81 (t, J = 2.2 Hz, 1H), 4.21 (dd, J = 12.6, 5.3 Hz, 1H), 3.62 (dd, J = 12.6, 8.8 Hz, 
1H), 3.30 (dd, J = 8.8, 5.4 Hz, 1H), 2.72 (dd, J = 12.5, 5.1 Hz, 1H), 2.37 (s, 3H), 2.35 – 2.31 (m, 
1H), 2.29 (dd, J = 17.3, 2.9 Hz, 1H), 2.23 (dtd, J = 12.5, 5.2, 1.7 Hz, 1H), 1.98 (dd, J = 12.2, 5.2 
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Hz, 1H), 1.92 (dq, J = 17.1, 2.5 Hz, 1H), 1.87 (dd, J = 10.2, 2.7 Hz, 1H), 1.74 (ddt, J = 11.8, 4.6, 
2.1 Hz, 1H), 1.70 – 1.64 (m, 1H), 1.54 (qd, J = 12.7, 5.2 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 154.91, 145.26, 140.30, 134.04, 129.73, 127.14, 120.24, 103.74, 
80.31, 53.61, 51.65, 50.86, 49.33, 48.07, 39.53, 31.70, 22.19, 21.06. 
HRMS(ESI): m/z calc. for C18H21N3ONa  [M+Na]
+: 318.1582, found: 318.1581. 
 
 
Procedure: In a vial with a stir bar, azide 2-52 (114.2 mg, 0.3866 mmol) and triphenylphosphine 
(235.9 mg, 0.8994 mmol) were dissolved in tetrahydrofuran (8 mL). Deionized water (0.1 mL) 
was added to the vial and was stirred under nitrogen for 10 hours. The tetrahydrofuran was 
evaporated under reduced pressure. The reaction mixture was taken up in water, acidified with 1 
M HCl, and was extracted with diethyl ether. The aqueous layer was basified with 15% NH4OH 
and extracted with dichloromethane. The dichloromethane organic mixture dried over anhydrous 
sodium sulfate and concentrated under reduced pressure. The crude residue was purified by C18 
chromatography to afford 1 (2-3, 3-8, 4-7) as a white solid (61.2 mg, 59% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.07 (t, J = 7.5 Hz, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.92 (d, J = 7.2 
Hz, 1H), 5.02 (t, J = 2.6 Hz, 1H), 4.80 (t, J = 2.00 Hz, 1H), 3.56 – 3.48 (m, 1H), 3.15 – 3.07 (m, 
2H), 2.71 (dd, J = 12.5, 4.8 Hz, 1H), 2.39 (s, 3H), 2.36 (t, J = 2.6 Hz, 1H), 2.28 (dd, J = 10.3, 2.4 
Hz, 1H), 2.23 (dtd, J = 13.2, 5.00, 1.7 Hz, 1H), 2.01 – 1.92 (m, 2H), 1.89 (dd, J = 10.1, 2.5 Hz, 
1H), 1.73 (ddt, J = 11.9, 5.2, 2.00 Hz, 1H), 1.60 (bs, 2H), 1.54 (qd, J = 12.6, 5.4 Hz, 1H). (22 non-
exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 155.45, 145.48, 141.86, 134.17, 129.65, 126.61, 120.08, 103.53, 
80.38, 53.73, 51.91, 50.30, 41.09, 39.70, 32.02, 29.89, 22.28, 20.96. 
HRMS(ESI): m/z calc. for C18H24NO  [M+H]





Procedure: In a dry round bottom flask under nitrogen, 2-42 (3-51) (named as G11 in Huigen et 
al.)  (606.0 mg, 2.13 mmol) was dissolved in acetone (23.0 mL). Potassium carbonate (2.10 g, 15.2 
mmol) and iodomethane (0.40 mL, 6.43 mmol) were added and the reaction was stirred for 13 
hours at room temperature. The reaction was diluted with water and extracted with ethyl acetate 
(3x). The combined organic layers were washed with brine, dried over sodium sulfate, filtered and 
concentrated in vacuo. The resulting residue was purified via silica gel chromatography (1:1 ethyl 
acetate/hexanes) to afford 3-52 (380.0 mg, 60% yield) as a white solid.  
 
1H NMR (500 MHz, CDCl3): 7.23 – 7.17 (m, 1H), 7.10 – 7.03 (m, 1H), 6.99 (d, J = 7.5 Hz, 1H), 
4.17 (s, 1H), 3.78 (s, 3H), 3.01 (t, J = 7.9 Hz, 1H), 2.68 (d, J = 17.9 Hz, 1H), 2.48 (dd, J = 17.9, 
3.7 Hz, 1H), 2.17 (s, 3H), 2.09 (dtd, J = 14.2, 7.0, 5.3 Hz, 1H), 2.02 (dd, J = 12.1, 3.7 Hz, 1H), 
1.89 (dtd, J = 14.2, 8.8, 7.5 Hz, 1H), 1.77 (dddd, J = 14.0, 9.2, 6.8, 1.3 Hz, 1H), 1.63 (ddd, J = 
14.1, 7.0, 5.4 Hz, 1H), 1.21 (dt, J = 12.1, 1.1 Hz, 1H), 1.05 (d, J = 0.9 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 221.64, 172.33, 146.08, 137.68, 135.27, 129.05, 128.28, 120.50, 
56.00, 51.98, 51.18, 50.70, 50.05, 48.11, 39.07, 34.50, 22.91, 21.69, 19.49. 
HRMS(ESI): m/z calc. for C19H23O3  [M+H]
+: 299.1647, found: 299.1644. 
 
 
Procedure: In a dry round bottom flask under nitrogen, lithium aluminum hydride (16.6 mg, 0.437 
mmol) was added to tetrahydrofuran (1.0 mL) at 0˚C. 3-52 (46.1 mg, 0.162 mmol) was slowly 
added in tetrahydrofuran (0.8 mL) to the round bottom flask. The reaction was allowed to reflux 
for 16 hours. After cooling to 0˚C, the reaction was quenched with water (0.05 mL), 15% sodium 
hydroxide (0.05 mL), and finally water (0.15 mL). The mixture was stirred for 30 minutes, and 
then filtered over celite. The solvent was concentration in vacuo and the resulting residue was 
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purified via silica gel chromatography (1:1 ethyl acetate/hexanes) to afford 3-15 as a white solid 
(27.3 mg, 62% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.13 (t, J = 7.5 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 6.97 (d, J = 7.6 
Hz, 1H), 4.15 (tdd, J = 9.4, 4.7, 3.2 Hz, 1H), 4.09 (dd, J = 11.6, 2.8 Hz, 1H), 3.88 (dd, J = 10.3, 
4.7 Hz, 1H), 3.23 (dd, J = 5.9, 2.8 Hz, 1H), 2.84 (t, J = 8.0 Hz, 1H), 2.50 (dd, J = 13.7, 10.3 Hz, 
1H), 2.40 (s, 3H), 2.23 – 2.12 (m, 1H), 2.04 – 1.95 (m, 1H), 1.69 (dddd, J = 13.5, 9.6, 8.1, 6.8 Hz, 
1H), 1.56 (ddd, J = 13.7, 4.9, 2.7 Hz, 1H), 1.38 (dd, J = 11.9, 2.8 Hz, 1H), 1.32 – 1.22 (m, 2H), 
1.05 (s, 3H). (22 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 148.41, 139.14, 134.35, 129.04, 127.18, 120.59, 79.14, 60.67, 
53.21, 52.94, 52.88, 46.27, 41.93, 37.76, 28.11, 26.72, 21.95, 20.33. 
HRMS(EI): m/z calc. for C18H24O2,  M
+: 272.1776, found: 272.1768. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 3-15 (130.0 mg, 0.477 mmol) was 
dissolved in pyridine (1.0 ml) and cooled to 0˚C. 4-bromobenzenesulfonyl chloride (589.9 mg, 
2.31 mmol) was slowly added, and the reaction was slowly warmed to room temperature. After 
stirring for 17 hours, the reaction was diluted in water (3.0 mL) and extracted with 
dichloromethane (3x). The combined organic layers were washed with brine, dried over anhydrous 
sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified via silica 
gel chromatography (8:2 hexanes/ethyl acetate) to afford di-brosyl 3-15 (170.0 mg, 8% yield) as 
a white solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.85 – 7.71 (m, 8H), 7.12 (t, J = 7.5 Hz, 1H), 6.97 – 6.89 (m, 2H), 
4.70 (dd, J = 10.2, 3.7 Hz, 1H), 4.41 (dd, J = 10.2, 4.3 Hz, 1H), 4.27 (dd, J = 10.2, 8.4 Hz, 1H), 
3.36 (dd, J = 8.5, 3.6 Hz, 1H), 2.81 (t, J = 7.5 Hz, 1H), 2.42 (dd, J = 14.4, 10.2 Hz, 1H), 2.17 (s, 
3H), 2.17 – 2.07 (m, 1H), 1.98 – 1.86 (m, 1H), 1.72 (dddd, J = 15.6, 13.7, 5.5, 2.1 Hz, 2H), 1.30 
(dt, J = 13.6, 6.6 Hz, 1H), 1.24 (dd, J = 11.9, 3.1 Hz, 1H), 0.93 (d, J = 12.0 Hz, 1H), 0.83 (s, 3H). 
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13C NMR (CDCl3, 125 MHz): δ 146.79, 137.51, 136.07, 135.04, 134.17, 133.00, 132.85, 129.62, 
129.62, 129.61, 129.58, 129.16, 127.90, 120.64, 88.01, 69.29, 53.34, 52.69, 49.04, 43.25, 42.12, 
36.92, 29.59, 26.08, 21.11, 20.63. (26 carbons due to symmetry) 
HRMS(EI): m/z calc. for C30H29Br2O6S2, [M–H]
+: 706.9773, found: 706.9771. 
 
 
Procedure: In a round bottom flask, di-brosyl 3-15 (139.5 mg, 0.196 mmol) was dissolved in 
DMF (2.0 mL). Sodium azide (71.3 mg, 1.10 mmol) was added in one portion, and the reaction 
was stirred at 60˚C for 15 hours. The reaction was then cooled to room temperature, quenched 
with water, and the aqueous layer was extracted three times with ethyl acetate. The combined 
organic layers were washed with brine and the ethyl acetate was concentrated in vacuo. The 
remaining DMF was removed with a stream of air, and the residue was purified via column 
chromatography (9:1 hexanes/ethyl acetate) to afford di-azido 3-15 (40.2 mg, 64% yield) as a clear 
oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.11 (t, J = 7.5 Hz, 1H), 6.95 (m, 2H), 3.96 (dd, J = 3.51, 12.9 Hz, 
1H), 3.77 (dd, J = 7.38, 12.9 Hz, 1H), 3.60 (ddd, J = 1.3, 4.0, 7.6 Hz, 1H), 3.28 (dd, J = 3.4, 7.6 
Hz, 1H), 2.70 (t, J = 7.5 Hz, 1H), 2.38 (s, 3H), 2.25 (ddd, J = 2.1, 7.6, 14.0 Hz, 1H), 2.04 (m, 1H), 
1.99 (m, 1H), 1.72 (ddt, J = 7.1, 8.9, 14.3 Hz, 1H), 1.61 (dt, J = 6.5, 13. 2 Hz, 1H), 1.46 (dddd, J 
= 1.3, 6.5, 9.0, 13.9 Hz, 1H), 1.29 (d, J = 10.5 Hz, 1H), 1.23 (d, J = 1.4 Hz, 1H), 1.13 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 146.68, 139.76, 134.26, 129.44, 127.44, 120.30, 70.30, 54.10, 
51.73, 50.67, 49.23, 44.57, 43.45, 37.07, 36.25, 23.75, 21.75, 20.66. 
HRMS(CI): m/z calc. for C18H23N4,  [M–N2+H]





Procedure: To an oven-dried round bottom flask was added 10% palladium on activated charcoal 
(20 mg) under nitrogen and dampened with toluene. Anhydrous methanol (1.0 mL) was added and 
purged with nitrogen. Di-azido 3-15 (86.8 mg, 0.269 mmol) was then transferred to the reaction 
vessel as a solution in methanol (2.0 mL). The reaction vessel was then purged with hydrogen gas 
for 2 min. The reaction mixture was stirred under an atmosphere of hydrogen at RT for 16 h. The 
reaction mixture was filtered through celite and filtrate evaporated. The resulting residue was 
purified by C18 chromatography (0.1% formic acid in gradient water to acetonitrile) to provide 
the di-formate salt of 2-4 (3-14, 4-8) (34.3 mg, 35%) as a white solid.  
 
1H NMR (CD3OD, 500 MHz): δ 8.53 (s, 2H), 7.17 – 7.11 (m, 1H), 7.01 (t, J = 7.9 Hz, 2H), 3.74 
(dd, J = 13.9, 3.4 Hz, 1H), 3.53 – 3.48 (m, 1H), 3.46 (dd, J = 8.2, 3.2 Hz, 1H), 3.36 – 3.31 (m, 
1H), 2.85 – 2.81 (m, 1H), 2.47 – 2.41 (m, 1H), 2.40 (s, 3H), 2.12 – 1.97 (m, 3H), 1.70 – 1.54 (m, 
3H). 
13C NMR (CD3OD, 125 MHz): δ 170.13, 146.98, 139.83, 135.20, 130.96, 128.77, 121.10, 58.40, 
55.83, 52.02, 43.27, 41.35, 39.40, 38.81, 37.82, 22.47, 21.01, 20.46. 
HRMS(ESI): m/z calc. for C18H27N2  [M+H]
+: 271.2174, found: 271.2177.  
 
 
Procedure: In a round bottom flask, gibberellic acid (2.00 g, 5.786 mmol), benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (3.10 g, 5.96 mmol), and Hunig’s base (1.0 
mL, 24.0 mmol) were dissolved in dichloromethane (80.0 mL, and the reaction was stirred at room 
temperature. After one hour, the reaction was concentrated in vacuo and the intermediate was 
purified via silica gel chromatography (3:2 ethyl acetate/hexanes) (1.63 g, 3.52 mmol obtained).  
The intermediate (1.63 g, 3.52 mmol) was loaded into a round bottom flask under nitrogen, and 
dissolved in tetrahydrofuran (20.0 mL). Sodium borohydride (263.2 mg, 6.95 mmol) was added 
and the reaction was stirred at room temperature for 3.5 hours. The reaction was quenched with 
water and saturated aqueous sodium bicarbonate, and the combined aqueous layers were extracted 
three times with ethyl acetate. The combined organic layers were washed with bring, dried over 
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anhydrous magnesium sulfate, filtered, and concentrated in vacuo. The resulting residue was 
purified via silica gel chromatography (100% ethyl acetate) to afford 3-29 as a white solid (642.0 
mg, 33% over two steps).  
 
1H NMR (CD3OD, 500 MHz): δ 6.35 (dd, J = 9.3, 1.0 Hz, 1H), 5.82 (dd, J = 9.3, 3.6 Hz, 1H), 
5.17 – 5.12 (m, 1H), 4.97 – 4.91 (m, 1H), 3.97 (dd, J = 3.6, 1.0 Hz, 1H), 3.70 (dd, J = 11.3, 3.9 
Hz, 1H), 3.62 (dd, J = 11.3, 8.2 Hz, 1H), 2.87 (dt, J = 15.8, 3.0 Hz, 1H), 2.49 (d, J = 10.1 Hz, 1H), 
2.25 – 2.16 (m, 1H), 1.98 – 1.90 (m, 3H), 1.90 – 1.84 (m, 3H), 1.79 – 1.66 (m, 2H), 1.29 (s, 3H). 
(21 non-exchangeable protons).  
13C NMR (CD3OD, 125 MHz): δ 181.64, 158.71, 133.84, 133.67, 106.51, 92.90, 78.44, 71.12, 
63.13, 55.11, 53.06, 51.65, 51.39, 48.17, 47.71, 42.26, 39.77, 18.15, 15.47. 
HRMS(ESI): m/z calc. for C19H25O5 [M+H]
+: 333.1715, found: 333.1711.  
 
 
Procedure: In a round bottom flask under nitrogen, 3-29 (820.0 mg, 2.47 mmol) was dissolved in 
pyridine (13.0 mL) and cooled to 0 °C. 4-Toluenesulfonyl chloride (728.3 mg, 3.82 mmol) was 
added in one portion and the reaction was slowly allowed to warm to room temperature. The 
reaction was stirred at room temperature for 17 hours and was then diluted in water and extracted 
with ethyl acetate (3x). The combined organic layers were washed with brine, dried over sodium 
sulfate, filtered, and concentrated. The resulting residue was purified via silica gel chromatography 
(6:4 ethyl acetate/hexanes) to afford mono-tosyl 3-29 (600.0 mg, 50% yield) and di-tosyl 3-29 as 




1H NMR (CDCl3, 500 MHz): δ 7.78 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 6.29 (d, J = 9.2 
Hz, 1H), 5.85 (dd, J = 9.2, 3.6 Hz, 1H), 5.22 (s, 1H), 4.93 (s, 1H), 4.17 – 3.99m, 3H), 2.56 (d, J = 
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10.2 Hz, 1H), 2.49 – 2.41 (m, 1H), 2.46 (s, 3H), 2.23 – 1.59 (m, 10H), 1.54 (d, J = 10.8 Hz, 1H), 
1.19 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 178.36, 156.61, 145.54, 133.22, 132.45, 132.32, 130.19, 128.13, 
107.31, 90.48, 77.99, 70.42, 69.44, 53.64, 51.72, 50.45, 50.12, 46.47, 43.99, 41.59, 38.20, 21.85, 
17.22, 14.84. (24 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C26H30O7SNa  [M+Na]
+: 509.1610, found: 509.1627.  
 
 
Procedure: In a dry round bottom flask under nitrogen, di-tosyl 3-29 (208 mg, 0.3246 mmol) was 
dissolved in N,N-dimethyformamide (3.2 mL). Sodium azide (126 mg, 1.94 mmol) was added and 
the reaction was allowed to stir for 24 hours at 80°C. The reaction was then diluted in water and 
extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried with 
sodium sulfate, filtered, and concentrated. The remaining N,N-dimethyformamide was removed 
with a stream of nitrogen. The resulting residue was purified via silica gel chromatography to 
afford 3-21 (37 mg, 30% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 6.44 (dd, J = 9.3, 2.1 Hz, 1H), 5.90 (dd, J = 9.3, 2.7 Hz, 1H), 5.25 
(dd, J = 3.2, 1.8 Hz, 1H), 5.01 (t, J = 2.1 Hz, 1H), 4.00 (t, J = 2.4 Hz, 1H), 3.53 (dd, J = 12.7, 4.3 
Hz, 1H), 3.44 (dd, J = 12.7, 7.0 Hz, 1H), 2.59 (dt, J = 15.7, 3.0 Hz, 1H), 2.28 (d, J = 9.4 Hz, 1H), 
2.19 (ddt, J = 15.7, 3.3, 1.7 Hz, 1H), 2.09 – 1.62 (m, 8H), 1.59 (dd, J = 10.8, 1.7 Hz, 1H), 1.44 (s, 
3H). 
13C NMR (CDCl3, 125 MHz): δ 175.40, 156.21, 133.81, 128.38, 107.52, 88.95, 78.07, 65.00, 
58.14, 53.49, 52.14, 50.28, 50.05, 47.26, 44.27, 41.64, 38.36, 17.61, 15.59. 
HRMS(ESI): m/z calc. for C19H22N6O3  [M+Na]





Procedure: In a round bottom flask, 3-21 (27.0 mg, 0.0706 mmol) and triphenylphosphine (54.5 
mg, 0.208 mmol) were dissolved in tetrahydrofuran (1.6 mL) and water (0.1 mL). The reaction 
was stirred at 50°C for 3 hours, at which point additional water (0.5 mL) was added and the reaction 
was stirred for 1 hour at 50°C. The reaction was cooled to room temperature and diluted in water 
(2 mL). The aqueous layer was then washed with dichloromethane (3x). The aqueous layer was 
concentrated to afford 2-6 (3-20, 4-24) (8.0 mg, 34% yield) as a clear oil.  
 
1H NMR (CD3OD, 500 MHz): δ 6.27 (dd, J = 9.3, 2.3 Hz, 1H), 5.78 (dd, J = 9.3, 2.6 Hz, 1H), 
5.17 (dd, J = 3.2, 1.7 Hz, 1H), 4.98 (t, J = 1.8 Hz, 1H), 3.52 (t, J = 2.5 Hz, 1H), 2.84 (dd, J = 13.2, 
7.5 Hz, 1H), 2.75 – 2.65 (m, 2H), 2.29 (d, J = 8.9 Hz, 1H), 2.23 (ddt, J = 15.5, 3.2, 1.7 Hz, 1H), 
2.00 – 1.80 (m, 5H), 1.80 – 1.67 (m, 2H), 1.63 (dd, J = 10.7, 1.7 Hz, 1H), 1.36 (s, 3H). (21 non-
exchangeable protons) 
HRMS(ESI): m/z calc. for C19H27N2O3  [M+H]
+: 331.2022, found: 331.2021. 
 
Procedure: Prepared with 4-nitrobenzenesulfonyl chloride according to general procedure A.  
Yield: 73.2 mg, 68% Yield.  
 
1H NMR (CDCl3, 500 MHz): δ 8.43 – 8.39 (m, 2H), 8.18 – 8.14 (m, 2H), 5.07 (q, J = 5.4 Hz, 1H), 
4.68 (t, J = 5.0 Hz, 1H), 4.44 (d, J = 4.6 Hz, 1H), 4.04 (d, J = 3.8 Hz, 1H), 3.94 – 3.89 (m, 3H), 
3.87 (dd, J = 10.3, 3.8 Hz, 1H). 
13C NMR (CDCl3, 125 MHz) δ: 151.02, 142.18, 129.45, 124.57, 86.69, 80.58, 79.96, 72.82, 70.80, 
65.74. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H12N4O7NaS  [M+Na]






Procedure for 21 (2-8, 4-34): Prepared according to general procedure B.  
Yield: Quantitative yield.  
 
1H NMR (CD3OD, 500 MHz): δ 7.62 – 7.55 (m, 2H), 6.74 – 6.68 (m, 2H), 4.80 (q, J = 5.8 Hz, 
1H), 4.60 (t, J = 4.8 Hz, 1H), 4.23 (d, J = 4.4 Hz, 1H), 3.88 (dd, J = 9.3, 4.4 Hz, 1H), 3.73 (dd, J 
= 9.6, 6.0 Hz, 1H), 3.71 – 3.66 (m, 1H), 3.61 (dd, J = 9.6, 6.1 Hz, 1H), 3.40 – 3.36 (m, 1H). (12 
non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 155.65, 131.16, 122.12, 114.28, 90.20, 81.52, 79.93, 76.65, 
70.87, 59.14. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H17N2O5S [M+H]
+: 301.0858, found 301.0857. 
 
 
Procedure: In a dry round bottom flask under nitrogen, mono-tosyl 3-29 (396.0 g, 1.11 mmol) 
was dissolved in N,N-dimethylformamide (9.5 mL). Sodium azide (210.0 mg, 3.23 mmol) was 
added and the reaction was stirred at 80°C for 18 hours. The reaction was cooled to room 
temperature, quenched with water and extracted with ethyl acetate (3x). The combined organic 
layers were washed with brine, dried with sodium sulfate, filtered, and concentrated in vacuo. The 
remaining N,N-dimethylformamide was removed with a stream of nitrogen. The resulting residue 
was purified via silica gel chromatography (1:1 ethyl acetate/hexanes) to afford 3-30 (236.0 mg, 




1H NMR (CD3OD, 500 MHz): δ 6.37 (dd, J = 9.3, 1.0 Hz, 1H), 5.85 (dd, J = 9.3, 3.6 Hz, 1H), 
5.19 (dt, J = 2.6, 1.3 Hz, 1H), 4.99 (t, J = 1.8 Hz, 1H), 4.05 – 3.97 (m, 1H), 3.61 (dd, J = 12.8, 4.3 
Hz, 1H), 3.47 (dd, J = 12.8, 8.1 Hz, 1H), 2.68 (dt, J = 15.6, 3.0 Hz, 1H), 2.60 (d, J = 9.7 Hz, 1H), 
2.24 (ddt, J = 15.6, 3.3, 1.7 Hz, 1H), 2.01 (ddd, J = 9.8, 8.3, 4.3 Hz, 1H), 1.98 – 1.84 (m, 4H), 1.78 
– 1.70 (m, 2H), 1.67 (d, J = 10.7 Hz, 1H), 1.32 (s, 3H). (21 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 181.17, 157.87, 133.91, 133.43, 107.07, 92.52, 78.36, 71.12, 
55.03, 54.16, 53.43, 51.43, 51.20, 47.43, 45.14, 42.34, 39.69, 18.20, 15.44. 
HRMS(ESI): m/z calc. for C19H24N3O4  [M+H]
+: 358.1767, found: 358.1768. 
 
 
Procedure: In a round bottom flask, 3-30 (156 mg, 0.436 mmol) and triphenylphosphine (356 mg, 
1.36 mmol) were dissolved in tetrahydrofuran (10.5 mL) and water (0.75 mL). The reaction was 
stirred at room temperature for 16 hours, at which point it the tetrahydrofuran was removed in in 
vacuo. The reaction was diluted in water (3 mL) and the aqueous layer was washed 
dichloromethane (3x). The aqueous layer was concentrated to afford 2-9 (3-27, 4-32) (18 mg, 13% 
yield) as a white solid.  
 
1H NMR (CD3OD, 500 MHz): δ 6.37 (d, J = 9.3 Hz, 1H), 5.84 (dd, J = 9.2, 3.6 Hz, 1H), 5.19 (t, 
J = 2.3 Hz, 1H), 4.99 (s, 1H), 3.99 (d, J = 3.6 Hz, 1H), 2.88 – 2.74 (m, 2H), 2.70 (dt, J = 15.7, 3.0 
Hz, 1H), 2.49 (d, J = 9.7 Hz, 1H), 2.29 – 2.18 (m, 1H), 2.01 – 1.81 (m, 5H), 1.74 (td, J = 8.6, 7.5, 
3.6 Hz, 2H), 1.64 (d, J = 10.7 Hz, 1H), 1.32 (s, 3H). (21 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 181.48, 157.94, 133.90, 133.65, 107.04, 92.62, 78.44, 71.34, 
55.10, 54.81, 51.56, 51.43, 48.16, 48.01, 43.73, 42.15, 39.73, 18.28, 15.55. 
HRMS(ESI): m/z calc. for C19H26NO4  [M+H]
+: 332.1862, found: 332.1859. 
 
 
Procedure for 2-13 (4-56): Prepared with di-azido isomannide according to general procedure B. 
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Yield: 44.8 mg, quantitative yield.  
 
1H NMR (CDCl3, 500 MHz): δ 4.41 (s, 2H), 3.88 (dd, J = 9.2, 4.4 Hz, 2H), 3.63 (dd, J = 9.2, 1.8 
Hz, 2H), 3.51 (m, 2H). (8 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 89.37, 75.26, 58.31. (3 carbons due to symmetry) 
HRMS: m/z calc. for C6H13N2O2 [M+H]
+: 145.0977, found: 145.0973. 
 
 
Procedure for 20 (2-14, 4-61): Prepared from isomannide azide according to general procedure 
B. 
Yield: 216.9 mg, quantitative yield.  
 
1H NMR (CDCl3, 500 MHz): δ 4.63 (t, J = 5.0 Hz, 1H), 4.27 (q, J = 5.6 Hz, 1H), 4.23 (d, J = 4.4 
Hz, 1H), 3.93 (dd, J = 9.1, 4.1 Hz, 1H), 3.84 – 3.78 (m, 2H), 3.62 – 3.55 (m, 2H). (8 non-
exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 89.85, 81.55, 76.31, 74.04, 72.24, 58.57. 
HRMS(ESI): m/z calc. for C6H12NO3 [M+H]
+: 146.0817, found: 146.0817. 
 
 
Procedure: In a flame-dried round bottom flask added G10c (70.9 mg, 0.278 mmol) and 
glycolaldehyde (70.2 mg, 1.169 mmol). Material was dissolved in anhydrous methanol (5.0 mL) 
and stirred at RT for 15 min. Sodium cyanoborohydride (73.8 mg, 1.174 mmol) was added and the 
reaction was stirred at RT for 16 h. The reaction was quenched with the addition of satd aq 
NaHCO3 and extracted with ethyl acetate (3x). Combined organic layers were dried over MgSO4, 
filtered, and evaporated. The resulting residue was purified by silica gel chromatography (8:2 to 




1H NMR (CDCl3, 500 MHz) δ 7.09 (t, J = 7.4 Hz, 1H), 6.95 (d, J = 7.6 Hz, 1H), 6.91 (d, J = 7.3 
Hz, 1H), 5.04 (t, J = 2.6 Hz, 1H), 4.82 (t, J = 2.1 Hz, 1H), 4.09 (s, 1H), 3.68 (dt, J = 10.8, 4.4 Hz, 
1H), 3.59 (ddd, J = 11.1, 8.3, 3.5 Hz, 1H), 3.13 (ddd, J = 12.4, 4.7, 3.5 Hz, 1H), 3.04 (ddd, J = 
12.4, 8.3, 4.1 Hz, 1H), 2.64 (dd, J = 12.5, 5.1 Hz, 1H), 2.46 (s, 3H), 2.45 (dt, J = 16.7, 2.9 Hz, 1H), 
2.25 (dtd, J = 12.7, 5.2, 1.8 Hz, 1H), 2.15 (dd, J = 9.9, 2.5 Hz, 1H), 1.96 (td, J = 12.3, 5.2 Hz, 1H), 
1.90 – 1.81 (m, 2H), 1.73 (ddt, J = 11.8, 4.7, 2.1 Hz, 1H), 1.55 (qd, J = 12.7, 5.3 Hz, 1H). 
13C NMR (CDCl3, 126 MHz) δ 155.00, 144.04, 141.68, 134.54, 129.76, 127.20, 120.12, 103.71, 
80.63, 67.01, 61.64, 55.96, 51.17, 49.26, 49.25, 39.61, 31.20, 22.60, 19.92. 
HRMS(ESI): m/z calc. for C19H26NO2 [M+H]
+: 300.1971, found: 300.1964.  
 
 
Procedure: In an oven-dried vial with a stir bar under nitrogen, 30 (2-5, 3-16, 4-13) (named as 
G10c in Huigens et al.) (70.0 mg, 0.274 mmol) and from 2,3-dihydroxybenzaldehyde (72.2 mg, 
0.523 mmol) were dissolved in methanol (5.6 mL) and stirred at room temperature for 2 hours. 
Sodium borohydride (19.0 mg, 0.502 mmol) was added and the reaction continued to stir for 8 
hours. The reaction was quenched with a saturates solution of sodium bicarbonate, extracted with 
ethyl acetate (3x), dried over magnesium sulfate, filtered, and concentrated in vacuo. The resulting 
residue was purified via C18 chromatography to yield 2-17 (12.3 mg, 12% yield) as a off white 
solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.12 (t, J = 7.4 Hz, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.94 (d, J = 7.4 
Hz, 1H), 6.89 (dd, J = 8.0, 1.5 Hz, 1H), 6.74 (t, J = 7.8 Hz, 1H), 6.62 (dd, J = 7.6, 1.4 Hz, 1H), 
5.11 (t, J = 2.6 Hz, 1H), 4.87 (t, J = 2.1 Hz, 1H), 4.29 (d, J = 13.5 Hz, 1H), 4.22 (s, 1H), 4.18 (d, 
J = 13.5 Hz, 1H), 2.64 (dd, J = 12.5, 5.1 Hz, 1H), 2.47 (s, 3H), 2.42 (dt, J = 17.1, 2.8 Hz, 1H), 2.29 
– 2.22 (m, 2H), 2.00 – 1.84 (m, 3H), 1.76 (ddt, J = 11.7, 5.1, 1.9 Hz, 1H), 1.56 (qd, J = 12.7, 5.3 
Hz, 1H).  (23 non-exchangeable protons) 
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13C NMR (CDCl3, 125 MHz): δ 154.25, 145.12, 144.67, 144.38, 140.51, 133.79, 130.22, 127.73, 
123.00, 120.59, 120.05, 119.89, 114.80, 104.53, 80.48, 66.21, 55.82, 52.48, 49.36, 49.26, 39.47, 
31.05, 22.55, 20.23. 
HRMS(ESI): m/z calc. for C24H28NO3 [M+H]
+: 378.2077, found: 378.2069. 
 
 
Procedure: To a 20-mL reaction vial added Q1 (117.8 mg, 0.292 mmol), potassium iodide (52 
mg, 0.313 mmol) and tetrahydrofuran (3.0 mL). To the stirring solution at RT, added methylamine 
(1.0 mL, 359 mg, 11.6 mmol) as a 40% wt. solution in water. Vial was sealed with a Teflon cap 
and heated to 60 °C and stirred for 20 h. Reaction mixture was cooled to RT and volatiles removed 
by rotary evaporation with azeotropic drying with toluene. The resulting residue was purified by 
silica gel chromatography eluting with 89:10:1 CHCl3:CH3OH:NH4OH to provide 6 (2-18, 3-23) 
(6.0 mg, 5%) as a yellow solid. 
 
1H NMR (CDCl3, 500 MHz) δ 8.79 (d, J = 4.6 Hz, 1H), 8.08 (d, J = 9.2 Hz, 1H), 7.63 (d, J = 4.6 
Hz, 1H), 7.43 (dd, J = 9.2, 2.7 Hz, 1H), 7.25 (d, J = 2.6 Hz, 1H), 5.46 (ddd, J = 17.1, 10.2, 9.3 Hz, 
1H), 5.20 (dd, J = 10.1, 1.7 Hz, 1H), 5.14 (dd, J = 17.0, 1.7 Hz, 1H), 5.10 (d, J = 7.9 Hz, 1H), 4.09 
(ddd, J = 11.3, 7.8, 3.2 Hz, 1H), 4.01 – 3.96 (m, 1H), 3.97 (s, 3H), 3.00 (td, J = 13.1, 3.1 Hz, 1H), 
2.56 – 2.43 (m, 2H), 2.37 – 2.25 (m, 1H) 2.31 (s, 3H), 2.01 (dq, J = 13.6, 2.7 Hz, 1H), 1.90-1.85 
(m, 1H), 1.82 (dddd, J = 32.6, 13.6, 11.4, 5.8 Hz, 2H), 1.63 (ddt, J = 14.0, 12.9, 4.4 Hz, 1H). (26 
non-exchangeable protons) 
13C NMR (CDCl3,125 MHz) δ 170.46, 158.53, 147.92, 144.91, 141.46, 139.07, 132.45, 127.85, 
122.06, 119.66, 118.73, 100.93, 60.03, 55.80, 53.97, 47.77, 43.25, 39.18, 36.41, 33.44, 33.11, 
26.47. 
HRMS(ESI): m/z calc. for C22H28N3O2 S[M+H]






Procedure:  In a flame dried round bottom flask under nitrogen, 2 (2-2, 3-3, 4-5) (92.9 mg, 0.255 
mmol) was dissolved in dichloromethane (2.6 mL). Diisopropylethylamine (70.0 µL, 0.402 mmol) 
and di-tert-butyl-dicarbonate (90.0 µL, 0.434) were added and the reaction was stirred at room 
temperature for 12 hours. The reaction was concentrated in vacuo and purified by C18 
chromatography to give the precursor to 5 (95.5 mg, 81% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.83 – 7.76 (m, 2H), 7.72 – 7.66 (m, 2H), 4.92 (q, J = 5.6 Hz, 1H), 
4.79 – 4.70 (m, 1H), 4.59 (t, J = 4.9 Hz, 1H), 4.41 – 4.35 (m, 1H), 4.13 (d, J = 7.1 Hz, 1H), 3.88 
(dd, J = 9.8, 4.4 Hz, 1H), 3.85 – 3.77 (m, 2H), 3.75 (d, J = 9.8 Hz, 1H), 1.41 (s, 9H). 
13C NMR (CDCl3, 125 MHz): δ 155.00, 135.48, 132.70, 129.48, 129.41, 87.35, 80.14, 79.41, 
73.63, 70.34, 57.46, 28.42. (12 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C17H22BrNO7SNa [M+Na]
+: 486.0198, found: 486.0199. 
 
 
Procedure: In a dry round bottom flask under nitrogen, lithium aluminum hydride (16.4 mg, 0.432 
mmol) was dissolved in tetrahydrofuran (2.0 mL) and cooled to 0°C. A solution of the precursor 
to 5 (71.5 mg, 0.154 mmol) in tetrahydrofuran (0.40 mL) was slowly added and the reaction was 
heated to reflux for 9 hours. The reaction was then cooled to 0°C, quenched with water (20 µL), 
10% sodium hydroxide (20 µL), and water (20 µL). The mixture was slowly warmed to room 
temperature and stirred for one hour. The reaction was filtered over Celite, concentrated in vacuo, 




1H NMR (CDCl3, 500 MHz): δ 7.81 (dq, J = 8.6, 2.2 Hz, 2H), 7.74 – 7.65 (m, 2H), 4.92 (q, J = 
5.7 Hz, 1H), 4.59 (t, J = 5.0 Hz, 1H), 4.33 (d, J = 4.7 Hz, 1H), 3.91 – 3.80 (m, 3H), 3.77 – 3.72 
(m, 1H), 3.21 (dt, J = 4.9, 1.3 Hz, 1H), 2.43 (s, 3H). (15 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 135.57, 132.69, 129.57, 129.38, 87.10, 80.23, 79.49, 73.89, 70.04, 
66.80, 34.66. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C13H17NO5SBr [M+H]
+: 378.0011, found: 378.0008. 
 
 
Procedure: In a vented round bottom flask, 30% hydrogen peroxide in water (0.11 mL, 0.970 
mmol), trifluoroacetic anhydride (0.62 mL, 4.68 mmol), and trifluoroacetic acid (0.75 mL, 9.79 
mmol) were dissolved in dichloromethane (6.0 mL). G16m (123.0 mg, 0.319 mmol) in 
dichloromethane (1.0 mL) was slowly added to the trifluoroperacetic acid and stirred at room 
temperature. After 15 minutes, the organic layer was washed once with water and then 2 times 
with a saturated solution of sodium bicarbonate. The combined aqueous layers were then extracted 
with ethyl acetate (3x). The combined organic layers were washed with brine, dried over sodium 
sulfate, filtered and concentrated. The resulting residue was purified via silica gel chromatography 
to afford 2-81 (76.3 mg, 57% Yield) of a white solid.  
1H NMR (d6-acetone, 500 MHz): δ 7.80 – 7.76 (m, 1H), 5.01 – 4.96 (m, 1H), 4.07 – 4.02 (m, 1H), 
3.98 (d, J = 3.4 Hz, 1H), 3.67 (d, J = 11.0 Hz, 1H), 3.39 (d, J = 11.0 Hz, 1H), 3.16 (d, J = 3.9 Hz, 
1H), 2.86 – 2.74 (m, 3H), 2.35 (dd, J = 11.4, 1.9 Hz, 1H), 2.15 (dd, J = 18.4, 3.8 Hz, 1H), 1.85 (d, 
J = 18.4 Hz, 1H), 1.57 (dd, J = 11.4, 3.8 Hz, 1H), 1.54 – 1.45 (m, 2H), 1.43 – 1.35 (m, 1H), 1.09 
(s, 3H), 1.08 – 1.02 (m, 1H), 0.75 – 0.68 (m, 2H), 0.56 – 0.48 (m, 2H). (25 non-exchangeable 
protons) 
13C NMR (d6-acetone, 125 MHz): δ 217.48, 177.28, 174.72, 76.90, 71.97, 68.33, 63.62, 57.29, 
56.61, 50.04, 49.26, 47.28, 46.21, 46.02, 43.71, 41.35, 31.55, 23.46, 19.57, 17.67, 6.61, 6.52. 
HRMS(ESI): m/z calc. for C22H28NO7 [M+H]





Procedure: In a flame-dried round bottom flask under N2, 2-81 (99.6 mg, 0.241 mmol) was 
dissolved in dichloromethane (5.0 mL). Dess Martin Periodinane (101.7 mg, 0.240 mmol) was 
added in one portion and the reaction stirred at room temperature. After 16 hours, the reaction was 
quenched with 10% sodium thiosulfate (5.0 mL). After stirring for 1 hour, the layers were 
separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers 
were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The 
resulting residue was purified via silica gel chromatography (10:1 ethyl acetate/hexanes) to afford 
2-82 (40.7 mg, 41% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 9.56 (s, 1H), 7.75 (s, 1H), 5.00 (ddd, J = 5.5, 3.5, 0.9 Hz, 1H), 
4.21 (d, J = 11.2 Hz, 1H), 4.08 – 4.01 (m, 2H), 3.16 (d, J = 3.9 Hz, 1H), 2.87 – 2.78 (m, 7H), 2.60 
(dd, J = 11.6, 2.1 Hz, 1H), 2.22 (dd, J = 18.5, 3.7 Hz, 1H), 2.09 (s, 1H), 1.71 (dd, J = 11.6, 3.7 Hz, 
1H), 1.64 – 1.56 (m, 2H), 1.25 – 1.13 (m, 1H), 0.91 – 0.83 (m, 1H), 0.76 – 0.68 (m, 2H), 0.52 
(dddd, J = 10.4, 7.1, 5.1, 3.1 Hz, 2H). 
13C NMR (CDCl3, 125 MHz): δ 212.21, 176.63, 173.56, 110.00, 76.25, 71.34, 67.34, 65.37, 56.61, 
49.06, 47.89, 47.27, 45.53, 45.18, 43.04, 39.65, 22.81, 18.55, 16.99, 5.99, 5.78. (21 carbons due 
to symmetry) 
HRMS(ESI): m/z calc. for C22H26NO7 [M+H]
+: 416.1709, found: 416.1710. 
 
 
Procedure for 2-21: Prepared with t-butylamine according to general procedure C.  




1H NMR (CD3OD, 500 MHz) δ 4.98 – 4.93 (m, 1H), 4.04 (dd, J = 5.7, 1.2 Hz, 1H), 3.86 (d, J = 
3.4 Hz, 1H), 3.11 (d, J = 12.7 Hz, 1H), 3.07 (d, J = 3.9 Hz, 1H), 2.89 – 2.81 (m, 3H), 2.72 (tt, J = 
7.4, 3.9 Hz, 1H), 2.24 (d, J = 3.6 Hz, 1H), 2.09 (dd, J = 11.3, 2.1 Hz, 1H), 1.72 (dd, J = 11.8, 3.6 
Hz, 1H), 1.58 (tt, J = 12.6, 9.1 Hz, 2H), 1.37 – 1.24 (m, 1H), 1.31 (s, 9H), 1.20 – 1.07 (m, 2H), 
1.15 (s, 3H), 0.83 – 0.71 (m, 2H), 0.59 – 0.48 (m, 2H). (33 non-exchangeable protons) 
HRMS(ESI): m/z calc. for C26H37N2O6 [M+H]
+: 473.2652, found: 473.2648. 
 
 
Procedure: In a round bottom flask open to the atmosphere, 30% hydrogen peroxide (650 µL, 
5.73 mmol), trifluoroacetic anhydride (4.0 mL, 28.3 mmol), and trifluoroacetic acid (4.5 mL, 58.8 
mmol) were dissolved in dichloromethane (30.0 mL). 30-Cbz (named as G10b in Huigens et al.) 
(827.3 mg, 2.12 mmol) was added in dichloromethane (10.0 mL), and the reaction was stirred for 
10 minutes at room temperature. The trifluoroperacetic acid was quenched with water (10 mL), 
followed by saturated sodium bicarbonate (aqueous). The combined aqueous layers were extracted 
three times with ethyl acetate. The combined organic layers were then washed with brine, dried 
over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified via 
silica gel chromatography (6:4 hexanes/ethyl acetate) to afford precursor to 3-45 as a white foam 
(290 mg, 34% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.41 – 7.31 (m, 5H), 7.22 – 7.17 (m, 1H), 7.04 – 6.98 (m, 2H), 
5.45 (d, J = 10.0 Hz, 1H), 5.22 (d, J = 12.1 Hz, 1H), 5.13 (d, J = 12.2 Hz, 1H), 4.98 (d, J = 10.1 
Hz, 1H), 3.69 (d, J = 11.4 Hz, 1H), 3.48 (d, J = 11.3 Hz, 1H), 2.94 (t, J = 7.3 Hz, 1H), 2.70 (d, J = 
18.2 Hz, 1H), 2.45 (dd, J = 18.1, 3.7 Hz, 1H), 2.28 (s, 3H), 2.10 (dq, J = 14.0, 6.9 Hz, 1H), 1.95 – 
1.73 (m, 3H), 1.62 (dt, J = 13.9, 7.0 Hz, 1H), 1.51 (dd, J = 11.5, 3.6 Hz, 1H). (26 non-exchangeable 
protons) 
13C NMR (CDCl3,150 MHz,) δ 222.19, 156.57, 144.97, 138.30, 136.59, 135.53, 129.93, 128.80, 
128.72, 128.50, 128.34, 120.66, 67.39, 65.70, 59.80, 53.61, 52.18, 49.85, 49.50, 32.18, 29.93, 
22.13, 18.60. (23 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C25H28NO4 [M+H]






Procedure: In a vial with a stir bar, the precursor to 3-45 (19.2 mg, 0.0473 mmol) was dissolved 
in ethanol (2 mL) along with 10% palladium on activated charcoal (20.3 mg). The vial was purged 
with nitrogen and fitted with a balloon of hydrogen gas. The reaction was allowed to stir for 10 
hours under an atmosphere of hydrogen. Next, the contents of the vial were filtered through Celite 
and washed with methanol. The filtrate was concentrated under reduced pressure and the residue 
was purified by silica gel chromatography (15:1 dichloromethane/methanol) to yield white solid 
3-45 (4-22) (3.9 mg, 30% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.16 (t, J = 7.5 Hz, 1H), 7.02 (d, J = Hz, 1H), 7.00 (d, J = 7.2 Hz, 
1H), 4.38 (s, 1H), 3.69 (d, J = 11.4 Hz, 1H), 3.47 (d, J = 11.3 Hz, 1H), 2.90 (t, J = 6.5 Hz, 1H), 
2.64 (d, J = 17.9 Hz, 1H), 2.51 (s, 3H), 2.33 (dd, J = 18.0, 3.7 Hz, 1H), 2.10 - 1.98 (m, 4H), 1.93 
(d, J = 11.6 Hz, 1H), 1.81 (qd, J = 6.9, 1.5 Hz, 1H), 1.58 (dt, J = 13.7, 7.8 Hz, 1H), 1.36 (dd, J = 
11.4, 3.7 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 222.97, 144.54, 141.80, 135.32, 129.83, 127.69, 120.10, 109.93, 
65.58, 60.51, 53.76, 53.27, 48.74, 48.42, 31.38, 30.50, 21.32, 19.53. 
HRMS(ESI): m/z calc. for C17H21NO2 [M+H]
+: 272.1651, found: 272.1658. 
 
 
Procedure: In a vial with a stir bar, 3-45 (4-22) (21.3 mg, 0.0785 mmol) and glycolaldehyde (24.5 
mg, 0.4080 mmol) were dissolved in methanol (4 mL) and stirred at room temperature for 20 
minutes capped under nitrogen. Sodium cyanoborohydride (34.6 mg, 0.5506 mmol) was added to 
the reaction and was stirred for 4 hours. The reaction was quenched with a saturated solution of 
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sodium bicarbonate, extracted with dichloromethane (3x), and dried with sodium sulfate. 
Combined organic layers were concentrated under reduced pressure. The residue was purified by 
silica gel chromatography (100% ethyl acetate) to yield white solid 2-23 (5.9 mg, 24% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.17 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H) 6.99 (d, J = 7.4 
Hz, 1H), 4.24 (s, 1H), 3.71 (d, J = 11.2 Hz, 1H), 3.73 – 3.68 (m, 1H), 3.67 – 3.62 (m, 1H), 3.50 
(d, J = 11.4 Hz, 1H), 3.12 (ddd, J = 11.9, 5.1, 4.0 Hz, 1H), 3.06 (ddd, J = 12.1, 7.5, 4.2 Hz, 1H), 
2.85 (t, J = 6.6 Hz, 1H), 2.62 (d, J = 17.9 Hz, 1H), 2.47 (s, 3H), 2.43 (dd, J = 18.0, 3.6 Hz, 1H), 
2.09 – 1.96 (m, 4H), 1.81 (dtd, J = 13.5, 6.9, 1.1 Hz, 1H), 1.59, (dt, J = 13.7, 7.5 Hz, 1H), 1.50 
(dd, J = 11.7, 3.6 Hz, 1H). (23 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 222.93, 144.63, 141.05, 135.54, 129.94, 127.93, 120.22, 67.45, 
65.75, 62.25, 53.63, 53.51, 51.62, 50.62, 49.72, 32.04, 30.49, 21.56, 19.88. 
HRMS(ESI): m/z calc. for C19H25NO3 [M+H]
+: 316.1913, found: 316.1909. 
 
 
Procedure for 2-24: Prepared with cyclopropylamine according to general procedure C.  
Yield: 14.7 mg, 34%. 
 
1H NMR (CDCl3, 500 MHz): δ 6.15 (br s, 1H), 4.89 (dd, J = 5.7, 3.3 Hz, 1H), 4.02 – 3.97 (m, 
1H), 3.73 (d, J = 3.4 Hz, 1H), 3.19 (d, J = 3.9 Hz, 1H), 2.97 – 2.86 (m, 2H), 2.79 (tt, J = 7.1, 3.6 
Hz, 1H), 2.62 (d, J = 3.9 Hz, 1H), 2.55 (d, J = 12.5 Hz, 1H), 2.22 (dd, J = 18.6, 3.7 Hz, 1H), 2.16 
(dd, J = 11.7, 1.6 Hz, 1H), 2.09 (tt, J = 6.8, 3.6 Hz, 1H), 1.89 (d, J = 18.6 Hz, 1H), 1.63 – 1.52 (m, 
3H), 1.40 (td, J = 13.1, 5.3 Hz, 1H), 1.16 (s, 3H), 0.97 (qd, J = 13.4, 5.5 Hz, 1H), 0.92 – 0.76 (m, 
2H), 0.60 – 0.46 (m, 2H), 0.44 – 0.37 (m, 2H), 0.27 (ddd, J = 11.7, 3.6, 2.0 Hz, 1H), 0.23 – 0.14 
(m, 1H). (30 non-exchanged protons) 
13C NMR (CDCl3, 125 MHz): δ 218.20, 176.95, 174.23, 76.66, 71.16, 67.71, 56.44, 54.83, 52.01, 




HRMS(ESI): m/z calc. for C25H33N2O6 [M+H]
+: 457.2339, found: 457.2332. 
 
 
Procedure: In an oven-dried round bottom flask with a stir bar under nitrogen, dissolved 2-42 (3-
51) (616.5 mg, 217 mmol) in benzene (22.0 mL). Added triethylamine (450.0 µL, 3.25 mmol), 
diphenylphosphorylazide (720 µL, 3.35 mmol), and benzyl alcohol (360 µL, 3.46 mmol), and 
refluxed for 16 hours. The reaction was cooled to room temperature, quenched with water, and the 
layers were separated. The aqueous layer was extracted with ethyl acetate (3x), and the combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo. The resulting residue was purified by silica gel chromatography (8:2 to 7:3 hexanes/ethyl 
acetate) and then by C13 chromatography to afford the precursor to 3-50 (169.3 mg, 20% Yield) 
as a white foam.  
 
1H NMR (CDCl3, 500 MHz): δ 7.40 – 7.30 (m, 5H), 7.17 (t, J = 7.4 Hz, 1H), 7.00 (d, J = 7.6 Hz, 
2H), 5.38 (d, J = 10.2 Hz, 1H), 5.20 (d, J = 12.4 Hz, 1H), 5.14 (d, J – 12.3 Hz, 2H), 2.86 (t, J = 
6.9 Hz, 1H), 2.62 (d, J = 17.9 Hz, 1H), 2.37 (dd, J = 17.9, 3.6 Hz, 1H), 2.29 (s, 3H), 2.06 – 1.89 
(m, 2H), 1.73 (dtd, J = 13.6, 6.8, 1.6 Hz, 1H), 1.59 – 1.49 (m, 2H), 1.44 (dt, J = 11.5, 1.4 Hz, 1H), 
1.02 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 221.67, 156.41, 144.87, 138.26, 136.46, 135.27, 129.61, 128.62, 
128.31, 128.29, 128.13, 120.23, 67.12, 59.40, 52.44, 48.48, 48.23, 47.70, 37.60, 35.28, 21.74, 
21.54, 18.43. (23 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C25H28NO3 [M+H]





Procedure: In a round bottom flask with a stir bar, loaded the precursor to 3-50 (316.5 mg 0.781 
mmol), and dissolved in a 1:1 mixture of tetrahydrofuran/water (8 mL). Potassium hydroxide (1.74 
g, 31.0 mmol) was added, and refluxed for 14 hours. The reaction was cooled to room temperature, 
and extracted with ethyl acetate (5x). The combined organic layers were washed with brine, dried 
over sodium sulfate, filtered, and concentrated in vacuo. The residue was then purified by C18 
chromatography to afford 3-50 (4-23) as a white solid (123.7 mg, 62% yield).   
 
1H NMR (CDCl3, 500 MHz): δ 7.20 (t, J = 7.5 Hz 1H), 7.00 (m, 2H), 4.51 (s, 1H), 2.83 (dd, J = 
7.9, 4.3 Hz, 1H), 2.48 (d, J = 17.7 Hz, 1H), 2.55 (s, 3H), 2.33 (dd, J = 17.7, 3.7 Hz, 1H), 2.14 – 
1.93 (m, 2H), 1.80 – 1.71 (m, 1H), 1.59 – 1.50 (m, 2H), 1.03 (s, 3H). (19 non-exchangeable 
protons) 
13C NMR (CDCl3, 125 MHz): δ 222.51, 144.67, 142.15, 135.21, 129.66, 127.37, 119.79, 60.37, 
53.76, 48.04, 47.71, 47.27, 36.94, 36.04, 21.57, 21.13, 19.48. 
HRMS(EI): m/z calc. for C17H20NO, [M–H]
+: 254.1545, found: 254.1554. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 3-50 (4-23) (40.8 mg, 0.160 mmol) was 
dissolved in methanol (3.5 mL). Glycolaldehyde (25.2 mg, 0.450 mmol) and sodium 
cyanoborohydride (42.3 mg, 0.673 mmol) were added and the reaction stirred at room temperature 
for 15 hours. The reaction was then diluted a saturated solution of sodium bicarbonate and 
extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried over 
sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified via silica 
gel chromatography (ethyl acetate) to afford 2-25 (30.6 mg, 81% yield) as a clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.15 (td, J = 7.5, 0.8 Hz, 1H), 7.01 (dd, J = 7.6, 1.0 Hz, 1H), 6.99 
(d, J = 7.4 Hz, 1H), 4.50 (td, J = 4.5, 1.5 Hz, 1H), 4.18 (s, 1H), 3.87 – 3.83 (m, 1H), 3.71 (dt, J = 
10.9, 4.6 Hz, 1H), 3.64 (ddd, J = 11.0, 7.1, 4.3 Hz, 1H), 3.16 – 3.01 (m, 2H), 2.83 – 2.76 (m, 1H), 
2.61 (d, J = 17.7 Hz, 1H), 2.47 (s, 3H), 2.39 (dd, J = 17.7, 3.7 Hz, 1H), 2.08 – 1.92 (m, 2H), 1.73 
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(dddd, J = 14.2, 7.1, 5.5, 1.9 Hz, 1H), 1.67 (dt, J = 11.7, 1.5 Hz, 1H), 1.58 – 1.50 (m, 2H), 1.04 (s, 
3H). 
13C NMR (CDCl3, 125 MHz): δ 222.75, 144.71, 141.09, 135.25, 129.78, 127.61, 119.88, 67.27, 
62.09, 53.95, 51.54, 49.20, 48.47, 47.87, 37.68, 35.95, 21.64, 21.27, 19.76. 
HRMS(ESI): m/z calc. for C19H26NO2 [M+H]
+: 300.1964, found: 300.1959. 
 
 
Procedure: In a round bottom flask under nitrogen, G8 (64.8 mg, 0.187 mmol) and benzotriazol-
1-yloxytripyrrolidinophosphonium hexafluorophosphate (117.0 mg, 0.231 mmol) were dissolved 
in dichloromethane (2.5 mL). Diisopropylethylamine (33.0 µL, 0.189 mmol) was then added  and 
the reaction stirred at room temperature for 2 hours. Cyclobutylamine (20.0 µL, 0.234 mmol) and 
additional diisopropylethylamine (50 µL, 0.287 mmol) were then added and stirred at room 
temperature for 16 hours. The reaction was concentrated, and the residue was purified via silica 
gel chromatography (100% ethyl acetate) to afford precursor A to 2-26 (68.2 mg, 91%) as a white 
solid.   
 
1H NMR (d6-acetone, 500 MHz): δ 7.81 (d, J = 7.7 Hz, 1H), 5.71 (dt, J = 5.2, 2.2 Hz, 1H), 5.05 – 
5.01 (m, 2H), 4.87 (dt, J = 2.3, 1.3 Hz, 1H), 4.65 (t, J = 5.3 Hz, 1H), 4.40 – 4.30 (m, 1H), 4.21 (t, 
J = 5.3 Hz, 1H), 3.87 (s, 1H), 3.36 – 3.31 (m, 1H), 3.09 (s, 2H), 2.62 (dd, J = 7.3, 2.0 Hz, 1H), 
2.56 (dt, J = 16.5, 3.0 Hz, 1H), 2.32 – 2.14 (m, 4H), 1.97 (tdt, J = 10.3, 8.9, 1.3 Hz, 2H), 1.74 – 
1.56 (m, 3H), 1.47 – 1.42 (m, 1H), 1.39 (dd, J = 10.9, 2.9 Hz, 1H), 1.29 (ddd, J = 11.0, 2.8, 1.1 
Hz, 1H), 1.08 (s, 3H). 
13C NMR (d6-acetone, 125 MHz): δ 177.97, 173.78, 156.09, 152.90, 113.78, 106.00, 79.05, 75.93, 
75.03, 50.96, 50.09, 49.27, 49.18, 46.29, 46.06, 45.71, 39.64, 38.69, 31.49, 31.17, 19.40, 17.36, 
15.73. 
HRMS(ESI): m/z calc. for C23H30NO5 [M+H]





Procedure: In a dry round bottom flask under nitrogen, precursor A to 2-26 ( 99.6 mg, 0.240 
mmol) was dissolved in 1,2-dichloroethane (5.0 mL) and cooled to 0°C. Dess Martin periodinane 
(101.7 mg, 0.240 mmol) was added in one portion, and the reaction was allowed to slowly warm 
to room temperature. After stirring for 18 hours, the reaction was quenched with a 10% solution 
of sodium thiosulfate (5.0 mL) , and allowed to stir at room temperature for 1 hour. The layers 
were separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic 
layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated 
in vacuo. The residue was purified via silica gel chromatography (91:9 ethyl acetate/hexanes) to 
afford precursor B to 2-26 (40.7 mg, 41% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 9.65 (s, 1H), 5.76 (dt, J = 4.9, 2.3 Hz, 1H), 4.74 (t, J = 5.3 Hz, 
1H), 4.38 (dt, J = 10.1, 7.7 Hz, 1H), 4.27 (d, J = 5.4 Hz, 1H), 3.44 (dd, J = 5.7, 2.6 Hz, 1H), 2.88 
– 2.80 (m, 1H), 2.44 – 2.35 (m, 1H), 2.35 – 2.30 (m, 2H), 2.24 – 2.14 (m, 2H), 2.06 – 1.83 (m, 
7H), 1.82 – 1.72 (m, 2H), 1.61 (td, J = 13.2, 5.3 Hz, 1H), 1.41 – 1.29 (m, 1H), 1.20 (s, 3H). (26 
non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 213.12, 200.44, 178.30, 172.07, 151.80, 114.99, 75.33, 74.10, 
65.39, 50.68, 48.65, 47.74, 47.25, 45.37, 45.19, 38.75, 31.15, 30.85, 29.82, 29.50, 20.04, 17.07, 
15.42. 
HRMS(ESI): m/z calc. for C23H28NO6 [M+H]





Procedure: In a dry round bottom flask under nitrogen, precursor B to 2-26 (34.7 mg, 0.0839 
mmol) and furfurylamine (7.41 µL, 0.0839 mmol) were dissolved in 1,2-dichloroethane (1.36 mL). 
After stirring at room temperature for 5 minutes, sodium triacetoxyborohydride was added and the 
reaction stirred at room temperature for 19 hours. The reaction was quenched with a saturated 
solution of sodium bicarbonate, and the layers were separated. The aqueous layer was extracted  
with ethyl acetate (6x) and the combined organic layers were washed with brine, dried over 
anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified via silica 
gel chromatography (49:1 ethyl acetate/methanol) to afford 2-26 (6.0 mg, 15% yield) as a yellow 
oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.33 (dd, J = 1.9, 0.9 Hz, 1H), 6.29 (dd, J = 3.2, 1.9 Hz, 1H), 6.22 
(d, J = 7.6 Hz, 1H), 6.16 (d, J = 3.1 Hz, 1H), 5.71 (dt, J = 5.1, 2.3 Hz, 1H), 4.70 (t, J = 5.3 Hz, 
1H), 4.38 (h, J = 8.1 Hz, 1H), 4.24 (d, J = 5.4 Hz, 1H), 3.78 – 3.68 (m, 2H), 3.42 (dd, J = 5.8, 2.6 
Hz, 1H), 2.83 – 2.78 (d, J = 12.4 Hz, 2H), 2.47 (d, J = 12.4 Hz, 1H), 2.43 – 2.32 (m, 2H), 2.30 (d, 
J = 5.7 Hz, 1H), 2.25 – 2.18 (m, 1H), 2.11 (dd, J = 18.8, 3.6 Hz, 1H), 1.97 – 1.84 (m, 3H), 1.81 – 
1.70 (m, 3H), 1.65 (dd, J = 11.4, 3.6 Hz, 1H), 1.60 (dd, J = 13.1, 5.2 Hz, 1H), 1.48 (td, J = 13.1, 
5.4 Hz, 1H), 1.31 – 1.21 (m, 2H), 1.19 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 218.58, 184.65, 177.47, 172.25, 152.81, 142.04, 114.42, 110.30, 
107.41, 75.46, 73.84, 55.01, 51.45, 49.06, 48.38, 47.56, 47.41, 46.84, 45.44, 45.33, 41.23, 32.80, 
31.31, 31.06, 20.43, 17.19, 15. (27 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C28H35N2O6 [M+H]
+: 495.2495, found: 495.2489. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 2-52 (3-18) (named as G10 in Huigens et 
al.) (604.0 mg, 2.12 mmol) was dissolved in toluene (21.0 mL) and methanol (7.0 mL). 
Trimethylsilyldiazomethane (2 M in hexanes, 1.05 mL, 2.10 mmol) was added and the reaction 
stirred at room temperature for 45 minutes. The reaction was then concentrated in vacuo. 
The resulting residue was dissolved in dichloromethane (20.0 mL). In a separate round bottom 
flask, trifluoroperacetic acid was generated in situ by dissolving hydrogen peroxide (30% solution, 
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720.0 µL, 6.2035 mmol), trifluoroacetic anhydride (4.4 mL, 31.7 mmol), and trifluoroacetic acid 
(4.8 mL, 62.7 mmol) in dichloromethane (24.0 mL). The crude methylated 2-52 (3-18) in 
dichloromethane was slowly added to the solution of trifluoroperacetic acid, and stirred at room 
temperature for 12 minutes. The reaction was then washed with water, followed by a saturated 
solution of sodium bicarbonate. The combined aqueous layers were extracted with 
dichloromethane (3x). The combined organic layers were washed with brine, dried over anhydrous 
sodium sulfate, filtered, and concentrated. The resulting residue was purified via silica gel 
chromatography with 1:1 hexanes/ethyl acetate to afford 3-48 (250.0 mg, 38% yield) as a yellow 
solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.19 (t, J = 7.5 Hz, 1H), 7.04 (d, J = 7.4 Hz, 1H), 6.97 (d, J = 7.6 
Hz, 1H), 4.19 (s, 1H), 3.77 (s, 3H), 3.69 (d, J = 11.3 Hz, 1H), 3.43 (d, J = 11.3 Hz, 1H), 3.10 - 
2.96 (m, 1H), 2.68 (d, J = 17.9 Hz, 1H), 2.60 (bs,1H), 2.49 (dd, J = 18.0, 3.5 Hz, 1H), 2.16 (s, 3H), 
2.11 (dtd, J = 10.7, 7.7, 5.2 Hz, 1H), 1.94 (dd, J = 12.0, 3.6 Hz, 1H), 1.80 (dq, J = 13.9, 9.2 Hz, 
1H), 1.72 - 1.60 (m, 2H), 1.55 (d, J = 12.0 Hz, 1H). (21 non-exchangeable protons) 
13C NMR (CDCl3, 125MHz): δ 221.86, 172.38, 146.00, 137.57, 135.17, 129.05, 128.38, 120.67, 
65.02, 56.07, 53.97, 52.05, 52.03, 51.88, 49.44, 33.27, 29.03, 22.97, 19.40. 
HRMS(ESI): m/z calc. for C19H23O4 [M+H]
+: 315.1596, found: 315.1592. 
 
 
Procedure: In a flame-dried round bottom flask under nitrogen, 3-48 (198.3 mg, 0.631 mmol) was 
dissolved in dichloromethane (6.3 mL). Dess Martin Periodinane (280.8 mg, 0.662 mmol) was 
added in one portion and the reaction stirred at room temperature. After 14 hours, the reaction was 
quenched with 10% sodium thiosulfate (5.0 mL). After stirring for 1 hour, the layers were 
separated and the aqueous layer was extracted with ethyl acetate (3x). The combined organic layers 
were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The 
resulting residue was purified via silica gel chromatography (1:1 ethyl acetate/hexanes) to afford 




1H NMR (CDCl3, 500 MHz): δ 9.61 (s, 1H), 7.21 (t, J = 7.8 Hz, 1H), 7.07 (d, J = 7.4 Hz, 1H), 
6.99 (d, J = 7.6 Hz, 1H), 4.23 (s, 1H), 3.80 (s, 3H), 3.09 (dd, J = 9.6, 6.5 Hz, 1H), 2.82 (d, J = 18.0 
Hz, 1H), 2.57 (dd, J = 18.0, 3.4 Hz, 1H), 2.26 – 2.21 (m, 2H), 2.17 (s, 3H), 2.10 (dd, J = 12.4, 3.1 
Hz, 1H), 2.06 - 1.95 (m, 1H), 1.88 - 1.80 (m, 1H), 1.78 (d, J = 12.3 Hz, 1H). 
13C NMR (CDCl3, 125MHz): δ 215.01, 199.20, 172.09, 145.37, 137.28, 135.33, 129.37, 128.62, 
120.73, 64.01, 55.85, 52.24, 51.91, 51.43, 49.98, 32.54, 27.53, 22.68, 19.44. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 3-48 aldehyde (125.2 mg, 0.401 mmol), 
serine methyl ester hydrochloride (64.0 mg, 0.411 mmol), and diisopropylethylamine (60.0 µL, 
0.344 mmol) were dissolved in dichloromethane and stirred at room temperature for 15 minutes. 
Sodium triacetoxyborohydride (86.2 mg, 0.407 mmol) was added in one portion and the reaction 
was allowed to stir at room temperature for 17 hours, followed by reflux for 3 hours. The reaction 
was them cooled to room temperature, quenched with a saturated solution of sodium bicarbonate, 
and the aqueous layer was extracted with dichloromethane (3x). The combined organic layers were 
washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo. The resulting 
residue was purified via silica gel chromatography (1:1 ethyl acetate/hexanes to 100% ethyl 
acetate) to afford 2-27 (85.8 mg, 52% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.20 (t, J = 7.5 Hz, 1H), 7.08 – 7.04 (m, 1H), 6.98 (d, J = 7.5 Hz, 
1H), 4.20 (s, 1H), 3.79 (s, 3H), 3.75 – 3.71 (m, 1H), 3.73 (s, 3H), 3.55 (dd, J = 10.9, 7.0 Hz, 1H), 
3.32 (dd, J = 7.0, 4.5 Hz, 1H), 3.08 – 3.00 (m, 1H), 2.98 (d, J = 12.4 Hz, 1H), 2.67 (d, J = 18.0 Hz, 
1H), 2.50 (dd, J = 17.9, 3.5 Hz, 1H), 2.36 (d, J = 12.4 Hz, 1H), 2.17 (s, 3H), 2.16 – 2.10 (m, 1H), 
1.98 (dd, J = 11.8, 3.5 Hz, 1H), 1.88 – 1.74 (m, 2H), 1.70 – 1.62 (m, 1H), 1.53 (d, J = 11.8 Hz, 
1H). (27 non-exchangeable protons) 
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13C NMR (CDCl3, 125 MHz): δ 220.80, 173.23, 172.35, 145.99, 137.56, 135.28, 129.13, 128.43, 
120.66, 63.46, 62.16, 56.10, 53.33, 52.33, 52.09, 51.89, 51.63, 51.42, 49.68, 34.32, 30.51, 23.15, 
19.48. 
HRMS(ESI): m/z calc. for C23H30N2O6 [M+H]
+: 416.2073, found: 416.2070. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 3-48 aldehyde (69.2 mg, 0.222 mmol) L-
alanine methyl ester hydrochloride (31.6 mg, 0.226 mmol), and diisopropylethylamine (40.0 µL, 
0.229 mmol) were dissolved in dichloromethane and stirred at room temperature for 15 minutes. 
Sodium triacetoxyborohydride (156.7 mg, 0.739 mmol) was added in one portion and the reaction 
was allowed to stir at room temperature for 13 hours. The reaction was them cooled to room 
temperature, quenched with a saturated solution of ammonium chloride, and the aqueous layer was 
extracted with dichloromethane (3x). The combined organic layers were washed with brine, dried 
over sodium sulfate, filtered, and concentrated in vacuo. The resulting residue was purified via 
silica gel chromatography (1:1 ethyl acetate/hexanes) to afford 2-28 (51.2 mg, 58% yield) as a 
white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.20 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 7.4 Hz, 1H), 6.98 (d, J = 7.6 
Hz, 1H), 4.19 (s, 1H), 3.79 (s, 3H), 3.78 – 3.72 (m, 1H), 3.69 (s, 3H), 3.22 (q, J = 7.0 Hz, 1H), 
3.02 (t, J = 7.9 Hz, 1H), 2.83 (d, J = 12.2 Hz, 1H), 2.66 (d, J = 17.8 Hz, 1H), 2.47 (dd, J = 17.8, 
3.5 Hz, 1H), 2.30 (d, J = 12.2 Hz, 1H), 2.17 (s, 3H), 2.11 (dtd, J = 10.6, 7.4, 3.6 Hz, 1H), 1.95 (dd, 
J = 11.8, 3.5 Hz, 1H), 1.88 – 1.58 (m, 3H), 1.52 (d, J = 11.9 Hz, 1H), 1.22 (d, J = 7.0 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 221.07, 176.15, 172.42, 146.19, 137.62, 135.22, 129.04, 128.38, 
120.70, 57.67, 56.13, 53.23, 52.00, 51.97, 51.88, 51.78, 51.55, 49.70, 34.40, 30.39, 23.29, 19.47, 
19.07. 
HRMS(ESI): m/z calc. for C23H30NO5S [M+H]





Procedure: In a round bottom flask under nitrogen, A8 (22) (248.4 mg, 0.78 mmol) and 
benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (448.4 mg, 0.86 mmol) 
were dissolved in dichloromethane (7.0 mL). Diisopropylethylamine (140.0 μL, 0.804 mmol) was 
then added and the reaction stirred at room temperature for 2 hours. 3-(dimethyl)-1-propylamine 
(100.0 μL, 0.79 mmol) and additional diisopropylethylamine (140.0 μL, 0.804 mmol) were then 
added and stirred at room temperature for 16 hours. The reaction was poured into a separatory 
funnel and washed with water (x1) and saturated aqueous sodium bicarbonate (x1) before being 
dried over sodium sulfate and concentrated. The residue was purified via silica gel chromatography 
(9:1 dichloromethane: methanol containing 1% ammonium hydroxide) to afford 2-39 as a yellow 
oil (8.7 mg, 3% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.14 (t, J = 5.1 Hz, 1H), 3.38 – 3.23 (m, 2H), 2.77 – 2.67 (m, 2H), 
2.64 – 2.60 (m, 1H), 2.59 – 2.53 (m, 2H), 2.51 (s, 6H), 2.43 – 2.36 (m, 2H), 2.35 – 2.31 (m, 1H), 
2.31 – 2.26 (m, 2H), 2.25 – 2.20 (m, 2H), 2.19 – 2.13 (m, 2H), 2.10 – 1.96 (m, 3H), 1.87 – 1.77 
(m, 2H), 1.71 (ddd, J = 12.5, 9.3, 3.2 Hz, 1H), 1.65 – 1.54 (m, 1H), 1.30 (s, 3H), 0.89 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 216.89, 212.21, 207.67, 173.76, 57.27, 56.96, 50.48, 50.34, 50.03, 
49.66, 44.43, 37.84, 37.22, 36.15, 35.67, 32.67, 30.01, 29.45, 25.31, 21.84, 21.00, 14.98. (22 
carbons due to symmetry) 
HRMS(ESI): m/z calc. for C23H37N2O4 [M+H]
+: 405.2753, found: 405.2746. 
 
Procedure: In a round bottom flask under nitrogen, dissolved sodium hydride (60% in mineral 
oil) (44.0 mg, 1.10 mmol) in THF (3.0 mL). The solution was cooled to 0°C in an ice bath, and 
isomannide azide (101.1 mg, 0.591 mmol) was slowly added in additional THF (3.0 mL). The 
reaction was stirred at 0°C for 20 minutes, and then methyl bromoacetate (90.0 µL, 0.951 mmol) 
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was slowly added. The reaction was then slowly warmed to room temperature with continued 
stirring. After 23 hours, the reaction was cooled to 0°C and quenched with a saturated solution of 
sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (4x). The combined 
organic layers were washed with brined, dried over sodium sulfate, and concentrated in vacuo. The 
residue was purified via silica gel chromatography (1:1 ethyl acetate:hexanes) to afford the 
precursor to 2-45 and 4-41 as a clear oil (63.2 mg, 44% yield).  
 
1H NMR (CDCl3, 400 MHz): δ
 4.69 (t, J = 4.7 Hz, 1H), 4.48 (dd, J = 4.6, 0.9 Hz, 1H), 4.32 (d, J 
= 16.4 Hz, 1H), 4.18 (d, J = 16.5 Hz, 1H), 4.20 – 4.14 (m, 1H), 4.05 – 4.00 (m, 3H), 3.94 (dd, J = 
9.4, 6.3 Hz, 1H), (dd, J = 9.4, 6.7, 1H), 3.75 (s, 3H). 
13C NMR (CDCl3, 101 MHz): δ 170.54, 86.80, 80.77, 80.33, 72.92, 71.24, 67.73, 66.26, 52.07. 
HRMS(ESI): m/z calc. for C9H14N3O5 [M+H]
+: 244.0933, found: 244.0935. 
 
 
Procedure: In a round bottom flask, the precursor (47.1 mg, 0.193 mmol) was dissolved in 
tetrahydrofuran (0.7 mL) and water (0.7 mL). Lithium hydroxide (36.7 mg, 1.53 mmol) was added 
and the reaction stirred at room temperature for 8 hours. The reaction was then acidified to pH 2 
with 10% hydrochloric acid, and extracted with ethyl acetate (4x). The combined organic layers 
were washed with brine, dried over sodium sulfate, filtered, and concentrated in vacuo to afford 2-
45 (43.2 mg, 97% yield) as a clear oil.  
1H NMR (CDCl3, 500 MHz): δ 10.68 (br s, 1H), 4.73 (t, J = 4.8 Hz, 1H), 4.50 (d, J = 4.4 Hz, 1H), 
4.32 (d, J = 17.0 Hz, 1H), 4.27 (d, J = 16.9 Hz, 1H),  4.17 (td, J = 6.0, 5.0 Hz, 1H), 4.09 – 4.02 
(m, 3H), 3.92 (dd, J = 9.6, 6.1 Hz, 1H), 3.78 (dd, J = 9.6, 5.9 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 173.25, 86.83, 81.27, 80.80, 72.99, 71.61, 68.28, 66.08. 
HRMS: m/z calc. for C8H12N3O5 [M+H]




Procedure. In a round bottom flask with a stir bar, 3-48 (50.0 mg, 0.159 mmol) was dissolved in 
methanol (0.8 mL) and water (0.8 mL). Lithium hydroxide (41.2 mg, 0.977 mmol) was added in 
one portion and the reaction was stirred at room temperature for 19 hours. The reaction was then 
adjusted to pH 2 with hydrochloric acid, and extracted with ethyl acetate (5x). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo. The resulting to residue was purified via silica gel chromatography (80:19:1 hexanes/ethyl 
acetate/formic acid) to afford 2-46 (3-47) (19.3 mg, 40% yield) as a white solid.  
 
1H NMR (CD3OD, 500 MHz): δ 7.17 (t, J = 7.5 Hz, 1H), 7.06 – 7.00 (m, 2H), 3.81 (s, 1H), 3.68 
(d, J = 11.2 Hz, 1H), 3.49 (t, J = 6.4 Hz, 1H), 3.28 (d, J = 11.2 Hz, 1H), 2.62 (d, J = 17.8 Hz, 1H), 
2.48 (dd, J = 17.8, 3.6 Hz, 1H), 2.29 (s, 3H), 2.08 – 1.98 (m, 2H), 1.95 (d, J = 11.9 Hz, 1H), 1.72 
(dd, J = 11.7, 3.5 Hz, 1H), 1.58 – 1.53 (m, 2H). (18 non-exchangeable protons)  
13C NMR (CD3OD, 125 MHz): δ 222.16, 175.71, 147.67, 140.54, 136.17, 129.07, 128.96, 121.33, 
64.55, 58.38, 55.65, 51.77, 50.41, 49.28, 40.69, 31.62, 21.83, 18.86. 
HRMS: m/z calc. for C18H21O4 [M+H]




Procedure. In an oven dried round bottom flask, gibberellic acid (2.01 g, 5.8 mmol) was dissolved 
in pyridine (10.0 mL, 124 mmol) and cooled to 0˚C. Acetic anhydride was added (10.0 mL, 106 
mmol), and the reaction was stirred at 0˚C for 2 hours. The reaction was quenched with acidic 
water (60.0 mL, final pH = 2) and the product was extracted with ethyl acetate. The combined 
organic layers were washed with 1 M HCl and brine, dried over anhydrous magnesium sulfate, 




1H NMR (d6-acetone, 500 MHz): δ 6.58 (dd, J = 9.3, 0.9 Hz, 1H), 5.86 (dd, J = 9.3, 3.8 Hz, 1H), 
5.27 (dd, J = 3.7, 0.9 Hz, 1H), 5.22 (ddd, J = 3.0, 2.0, 1.0 Hz, 1H), 4.89 (td, J = 1.7, 0.8 Hz, 1H), 
3.25 (d, J = 10.8 Hz, 1H), 2.73 (d, J = 10.8 Hz, 1H), 2.35 (dt, J = 15.6, 2.9 Hz, 1H), 2.31 – 2.25 
(m, 1H), 2.05 (s, 3H), 2.09 – 2.04 (m, 2H), 1.93 (dd, J = 10.7, 2.7 Hz, 1H), 1.88 – 1.80 (m, 2H), 
1.79 – 1.70 (m, 2H), 1.13 (s, 3H). (22 non-exchangeable protons) 
13C NMR (d6-acetone, 125 MHz): δ 177.60, 173.11, 170.44, 158.84, 135.76, 129.47, 106.88, 
90.95, 78.10, 70.83, 54.02, 52.82, 51.67, 51.47, 50.59, 45.32, 43.66, 39.73, 20.70, 17.58, 14.71. 
HRMS: m/z calc. for C21H24O27Na [M+Na]
+: 411.1420, found: 411.1422. 
 
 
Procedure for 2-48: Prepared from G16k according to general procedure D.  
Yield: 26.7 mg, 78%. 
 
1H NMR (CD3OD, 500 MHz): δ 7.43 – 7.41 (m, 1H), 6.35 (dd, J = 3.1, 1.8 Hz, 1H), 6.25 (d, J = 
3.2 Hz, 1H), 5.35 (d, J = 2.9 Hz, 1H), 5.04 (t, J = 2.2 Hz, 1H), 4.42 (d, J = 15.5 Hz, 1H), 4.27 (d, 
J = 15.5 Hz, 1H), 4.07 – 4.01 (m, 1H), 3.87 (br s, 1H), 3.15 – 3.07 (m, 1H), 2.90 (d, J = 5.3 Hz, 
1H), 2.68 – 2.59 (m, 1H), 2.49 (dt, J = 16.5, 3.0 Hz, 1H), 2.15 – 2.06 (m, 1H), 2.01 – 1.90 (m, 1H), 
1.76 – 1.59 (m, 4H), 1.52 – 1.39 (m, 2H), 1.28 (s, 3H). (24 non-exchangable protons) 
13C NMR (CD3OD, 125 MHz): 179.47, 177.47, 156.05, 153.30, 145.79, 143.08, 115.12, 111.29, 
108.14, 106.34, 79.89, 76.22, 71.97, 52.23, 51.22, 47.73, 47.25, 40.19, 38.76, 37.09, 22.14, 19.64. 
HRMS: m/z calc. for C24H30NO7 [M+H]
+: 444.2022, found: 444.2016. 
 
 
Procedure for 2-50: Prepared from G16m according to general procedure D.  




1H NMR (CD3OD, 750 MHz): δ 5.35 (q, J = 2.9 Hz, 1H), 5.07 (t, J = 2.4 Hz, 1H), 4.99 – 4.93 (m, 
1H), 4.05 (p, J = 2.8 Hz, 1H), 3.86 (d, J = 2.6 Hz, 1H), 3.11 (dt, J = 4.4, 1.7 Hz, 1H), 2.78 (d, J = 
5.5 Hz, 1H), 2.66 – 2.61 (m, 2H), 2.52 (dt, J = 16.3, 2.9 Hz, 1H), 2.21 (ddt, J = 16.5, 3.1, 1.8 Hz, 
1H), 2.01 – 1.94 (m, 1H), 1.75 – 1.64 (m, 3H), 1.49 (tdd, J = 6.4, 5.8, 4.8, 2.7 Hz, 1H), 1.43 (ddd, 
J = 10.8, 2.9, 1.3 Hz, 1H), 1.27 (s, 3H), 0.75 – 0.69 (m, 2H), 0.49 (tt, J = 5.4, 2.5 Hz, 2H). (24 non-
exchangeable protons) 
13C NMR (CD3OD, 188 MHz): δ 179.22, 179.14, 155.91, 145.76, 115.16, 106.53, 79.84, 76.16, 
71.88, 51.98, 51.23, 49.32, 48.32, 47.68, 47.37, 40.22, 38.80, 23.36, 21.87, 19.65, 6.64, 6.46. 
HRMS(ESI): m/z calc. for C22H30NO6 [M+H]
+: 404.2073, found: 404.2069. 
 
 
Procedure: In a round bottom flask under nitrogen, G8  (1.03 mg, 2.97 mmol) and benzotriazol-
1-yloxytripyrrolidinophosphonium hexafluorophosphate (1.54 mg, 2.95 mmol) were dissolved in 
dichloromethane (30.0 mL). Diisopropylethylamine (600.0 µL, 3.45 mmol) was then added and 
the reaction stirred at room temperature for 2 hours. 2-thiophenemethylamine (310.0 µL, 3.02 
mmol) and additional diisopropylethylamine (600.0 µL, 3.45 mmol) were then added and stirred 
at room temperature for 16 hours. The reaction was concentrated, and the residue was purified via 
silica gel chromatography (2:8 hexanes/ethyl acetate to 100% ethyl acetate) to afford the 
precursor to 2-51 (1.074 g, 82% yield) as a white solid.   
 
1H NMR (500 MHz, CD3OD): δ 7.29 (dd, J = 5.1, 1.3 Hz, 1H), 7.00 (dt, J = 3.3, 1.0 Hz, 1H), 6.94 
(dd, J = 5.1, 3.4 Hz, 1H), 5.81 – 5.75 (m, 1H), 5.04 (ddd, J = 3.0, 1.9, 0.9, 1H), 4.91– 4.89 (m, 
1H), 4.69 (t, J = 5.3 Hz, 1H), 4.55 (dt, J = 5.9, 1.1 Hz, 2H), 4.18 (d, J = 5.4 Hz, 1H), 3.37 (dd, J = 
6.1, 2.7 Hz, 1H), 2.72 – 2.65 (m, 1H), 2.49 (dt, J = 16.4, 3.0 Hz, 1H), 2.34 (d, J = 6.0 Hz, 1H), 
2.22 – 2.14 (m, 1H), 2.03 – 1.90 (m, 2H), 1.77 – 1.61 (m, 3H), 1.52 – 1.46 (m, 1H), 1.45 (dd, J = 
10.9, 2.9 Hz, 1H), 1.35 (ddd, J = 11.0, 2.8, 1.1 Hz, 1H), 1.12 (s, 3H). (25 non-exchangable protons) 
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13C NMR (CD3OD, 125 MHz): δ 179.78, 176.21, 155.32, 153.12, 142.77, 127.57, 127.02, 125.93, 
114.37, 106.76, 79.54, 76.18, 75.93, 51.62, 50.73, 49.86, 46.86, 46.69, 40.04, 38.90, 38.78, 38.49, 
19.65, 17.47. 
HRMS(ESI): m/z calc. for C24H28NO5S [M+H]
+: 442.1688, found: 442.1678. 
 
 
Procedure for 2-51: Prepared according to general procedure D.  
Yield: 376.0 mg, 39%. 
 
1H NMR (CD3OD, 500 MHz): δ 8.74 (t, J = 5.9 Hz, 1H), 7.28 (dd, J = 5.1, 1.3 Hz, 1H), 6.99 (d, 
J = 3.4 Hz, 1H), 6.95 – 6.92 (m, 1H), 5.36 (q, J = 3.1 Hz, 1H), 5.07 – 5.03 (m, 1H), 4.90 – 4.87 
(m, 1H), 4.62 – 4.54 (m, 1H), 4.54 – 4.46 (m, 1H), 4.06 (tt, J = 3.4, 2.0 Hz, 1H), 3.91 – 3.86 (m, 
1H), 3.16 – 1.12 (m, 1H), 2.89 (d, J = 5.4 Hz, 1H), 2.69 – 2.63 (m, 1H), 2.52 (dt, J = 16.5, 3.0 Hz, 
1H), 2.15 (d, J = 16.3 Hz, 1H), 2.03 – 1.90 (m, 1H), 1.76 – 1.59 (m, 3H), 1.53 – 1.46 (m, 1H), 1.46 
– 1.40 (m, 1H), 1.29 (s, 3H). (25 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 179.02, 177.25, 155.86, 145.85, 142.91, 127.51, 126.88, 125.80, 
114.95, 106.45, 79.83, 76.09, 71.89, 52.24, 51.37, 48.49, 48.16, 47.72, 47.19, 40.28, 38.87, 38.74, 
21.97, 19.59. 
HRMS(ESI): m/z calc. for C24H30NO6S [M+H]
+: 461.1857, found: 461.1854. 
 
 
Procedure for 2-53: Prepared from G16h  according to general procedure D.  




1H NMR (CD3OD, 500 MHz): δ 6.75 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 7.9 Hz, 1H), 6.69 (dd, 8.0, 
2.0 Hz, 1H), 5.89 – 5.87 (m, 2H), 5.35 – 5.31 (m, 1H), 5.03 (t, J = 2.4 Hz, 1H), 4.91 (s, 1H), 4.03 
– 4.00 (m, 1H), 3.85 (s, 1H), 3.46 (dt, J = 13.2, 7.5 Hz, 1H), 3.34 (dt, J = 13.7, 7.0 Hz, 1H), 3.05 
(s, 1H), 2.81 (d, J = 5.2 Hz, 1H), 2.73 (t, J = 7.1 Hz, 2H), 2.64 – 2.59 (m, 1H), 2.35 (dt, J = 16.4, 
3.0 Hz, 1H), 2.05 (d, J = 16.7 Hz, 1H), 1.98 -1.92 (m, 1H), 1.78 - 1.55 (m, 3H), 1.49 – 1.44 (m, 
1H), 1.42- 1.34 (m, 1H), 1.24 (s, 3H). (28 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 177.64, 156.05, 149.13, 147.50, 145.77, 134.26, 122.83, 115.11, 
110.12, 109.09, 106.37, 102.08, 79.90, 76.23, 72.05, 52.39, 51.09, 49.38, 49.28, 49.11, 47.72, 
47.27, 41.84, 40.18, 38.77, 36.19, 22.29, 19.63. 
HRMS(ESI): m/z calc. for C28H34NO8 [M+H]
+: 512.2284, found: 512.2286. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 3-48 aldehyde (85.7 mg, 0.274 mmol), 
L-aspartic acid dimethyl ester hydrochloride (56.0 mg, 0.283 mmol), and diisopropylethylamine 
(50.0 µL, 0.287 mmol) were dissolved in dichloromethane (2.75 mL) and stirred at room 
temperature for 10 minutes. Sodium triacetoxyborohydride (181.3 mg, 0.855 mmol) was added in 
one portion and the reaction was allowed to stir at room temperature for 17 hours. The reaction 
was then quenched with a saturated solution of ammonium chloride. They layers were separated 
and the organic layer was washed with a saturated solution of sodium bicarbonate. The wash was 
extracted three times with dichloromethane and concentrated in vacuo to afford the precursor to 
2-55 (59.4 mg, 47% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.18 (t, J = 7.5 Hz, 1H), 7.07 – 7.01 (m, 1H), 6.96 (d, J = 7.6 Hz, 
1H), 4.17 (s, 1H), 3.80 (s, 3H), 3.71 (s, 3H), 3.66 (s, 3H), 3.54 (dd, J = 8.0, 5.7 Hz, 1H), 3.00 (t, J 
= 8.0 Hz, 1H), 2.95 (d, J = 12.3 Hz, 1H), 2.70 – 2.64 (m, 1H), 2.62 (d, J = 18.3 Hz, 1H), 2.50 (dd, 
J = 15.5, 8.0 Hz, 1H), 2.45 (dd, J = 17.9, 3.5 Hz, 1H), 2.28 (d, J = 12.4 Hz, 1H), 2.16 (s, 3H), 2.13 
– 2.00 (m, 2H), 1.91 (dd, J = 11.9, 3.5 Hz, 1H), 1.83 – 1.69 (m, 2H), 1.64 – 1.56 (m, 1H), 1.53 (d, 
J = 11.9 Hz, 1H). 
109 
 
13C NMR (CDCl3, 125 MHz): δ 220.92, 174.02, 172.33, 171.21, 146.11, 137.59, 135.13, 128.97, 
128.31, 120.63, 58.92, 56.09, 53.38, 52.18, 51.98, 51.92, 51.90, 51.74 (2C), 49.55, 38.05, 34.04, 
30.28, 23.22, 19.39. 
HRMS(ESI): m/z calc. for C25H32NO7 [M+H]
+: 458.2179, found: 458.2187. 
 
 
Procedure: In a round bottom flask, the precursor to 2-55 (19.8 mg, 0.0433 mmol) was dissolved 
in tetrahydrofuran (0.4 mL) and water (0.3 mL). Lithium hydroxide monohydrate (23.1 mg, 0.55 
mmol) was added and the reaction was stirred at 60 C for 16 h. The reaction mixture was cooled 
to RT, adjusted to pH 2 with conc. HCl, and purified via C18 chromatography to afford 2-55 (13.4 
mg, 74%) as a white solid, a mixture of diastereomers. 
 
1H NMR (500 MHz, Methanol-d4) δ 7.19 (t, J = 7.5 Hz, 1H), 7.07 (d, J = 7.5 Hz, 1H), 7.05 – 7.01 
(m, 1H), 3.85 (dd, J = 9.8, 3.8 Hz, 1H), 3.83 (s, 1H), 3.57 (dd, J = 7.8, 4.6 Hz, 1H), 3.23 (d, J = 
12.7 Hz, 1H), 3.13 (d, J = 12.7 Hz, 1H), 3.01 (dd, J = 17.9, 3.8 Hz, 1H), 2.82 (dd, J = 18.0, 8.8 
Hz, 2H), 2.59 (dd, J = 18.3, 3.0 Hz, 1H), 2.30 (s, 3H), 2.20 – 2.03 (m, 2H), 1.96 – 1.74 (m, 4H). 
(21 non-exchangeable protons) 
13C NMR (126 MHz, MeOD) δ 220.65, 220.60, 175.29, 174.67, 171.33, 147.16, 140.41, 136.33, 
129.21, 129.18, 121.39, 60.64, 58.13, 58.11, 52.32, 52.23, 52.13, 51.06, 49.90, 49.88, 47.96, 41.57, 
41.54, 34.63, 32.38, 21.52, 21.50, 18.87. 
HRMS(ESI): m/z calc. for C22H24NO7 [M-H]
-: 414.1553, found: 414.1541. 
 
LC/MS resolution of diastereomers 
As the 13C NMR indicated the presence of multiple species and 2-55 contains an easily 
epimerizable stereocenter, LC/MS analysis was performed to confirm the presence of two isomers 
with identical mass. 2-55 was injected on Agilent 6230 LC/MS TOF system. Mass spectra were 
obtained with negative electrospray ionization at the ion spray voltage of -4000 V operating in 
low-resolution mode. The resulting chromatogram monitoring at 254 nm showed two peaks (13.3 
and 15.2 min) that corresponded to an observed ion 414 m/z. 
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Column: Agilent ZORBAX Eclipse Plus C18 Rapid Resolution HT 2.1x100mm, 1.8-micron 
Solvent A: 0.1% formic acid in water, Solvent B: 0.1% formic acid in acetonitrile 








Procedure for 2-58: Prepared from G16e  according to general procedure D.  




1H NMR (CD3OD, 500 MHz) δ 7.17 (d, J = 8.2 Hz, 1H), 6.52 (d, J = 2.3 Hz, 1H), 6.46 (dd, J = 
8.3, 2.4 Hz, 1H), 5.36 – 5.31 (m, 1H), 5.03 (d, J = 2.4 Hz, 1H), 4.31 (d, J = 14.3 Hz, 1H), 4.23 (d, 
J = 14.2 Hz, 1H), 4.02 (s, 1H), 3.86 (s, 1H), 3.83 (s, 3H), 3.81 – 3.86 (m, 1H), 3.78 (s, 3H), 3.06 
(d, J = 3.9 Hz, 1H), 2.90 (d, J = 5.1 Hz, 1H), 2.64 (d, J = 6.8 Hz, 1H), 2.48 (dt, J = 16.5, 3.0 Hz, 
1H), 2.12 – 2.05 (m, 1H), 2.01 – 1.92 (m, 1H), 1.74 – 1.58 (m, 3H), 1.45 (d, J = 8.5 Hz, 1H), 1.39 
(d, J = 10.4 Hz, 1H), 1.27 (s, 3H). (30 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 179.14, 177.14, 162.04, 159.82, 156.13, 146.01, 131.39, 119.91, 
114.90, 106.28, 104.99, 99.14, 79.88, 76.17, 71.91, 55.79, 55.77, 52.16, 51.35, 48.26, 47.68, 47.12, 
40.22, 39.70, 39.57, 38.79, 21.89, 19.61. 
HRMS(ESI): m/z calc. for C28H36NO8 [M+H]
+: 514.4221, found: 514.4226. 
 
 
Procedure for 2-59: Prepared from G16o according to general procedure D.  
Yield: 7.2 mg, 22%. 
 
1H NMR (CD3OD, 500 MHz) δ 5.34 (d, J = 3.1 Hz, 1H), 5.05 (t, J = 2.4 Hz, 1H), 4.93 (s, 1H), 
4.26 (p, J = 8.1 Hz, 1H), 4.01 (s, 1H), 3.86 (s, 1H), 3.77 – 3.70 (m, 1H), 3.00 (s, 1H), 2.87 (d, J = 
5.0 Hz, 1H), 2.64 (s, 1H), 2.54 (dt, J = 16.3, 3.0 Hz, 1H), 2.36 – 2.22 (m, 2H), 2.18 (d, J = 16.4 
Hz, 1H), 2.02 – 1.91 (m, 3H), 1.87 (td, J = 5.8, 5.0, 2.5 Hz, 1H), 1.81 – 1.59 (m, 4H), 1.42 (ddd, J 
= 27.3, 16.3, 7.5 Hz, 2H), 1.25 (s, 3H). (27 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 176.31, 176.22, 154.63, 144.37, 113.75, 105.05, 78.50, 74.84, 
70.58, 61.12, 51.10, 51.04, 49.73, 46.35, 45.97, 38.98, 38.93, 38.86, 37.40, 29.61, 25.63, 20.82, 
18.27. 
HRMS(ESI): m/z calc. for C23H34NO7 [M+H]





Procedure: In a dry round bottom flask under nitrogen, isomannide (210.7 mg, 1.44 mmol) was 
dissolved in tetrahydrofuran (12.8 mL) and N,N-dimethylformamide (0.8 mL). Potassium tert-
butoxide (477.5 mg, 4.26 mmol) and allyl bromide (360.0 µL, 4.17 mmol) were added and the 
reaction was stirred at room temperature for 2 hours, at which point the reaction was quenched 
with a saturated solution of sodium bicarbonate. The layers were separated and the aqueous layer 
was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried 
with sodium sulfate, filtered and concentrated. The resulting residue was purified via silica gel 
chromatography (1:1 hexanes/ethyl acetate) to afford known 2-62 (125.0 mg, 38% yield) as a clear 
oil. Spectral data is consistent with reported values72.  
 
 
Procedure: In a round bottom flask, A8 (248 mg, 0.77 mmol), (benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (409 mg, 0.92 mmol), L-histidine 
methyl ester hydrogen chloride (187 mg, 0.77 mmol), and diisopropylethylamine (0.53 mL, 3.1 
mmol) were combined in N,N-dimethylacetamide (2.6 mL). The reaction was stirred at room 
temperature before being quenched by a saturated solution of sodium bicarbonate. The product 
was extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried 
with sodium sulfate, filtered and concentrated. The resulting residue was purified via silica gel 
chromatography (9:1 dichloromethane/methanol) to afford 2-63 (8.7 mg, 2% yield).  
 
1H NMR (CDCl3, 500 MHz) δ 7.61 (d, J = 1.1 Hz, 1H), 6.77 (m, 2H), 4.67 (dt, J = 7.0, 4.6 Hz, 
1H), 3.73 (s, 3H), 3.16 (dd, J = 14.9, 4.7 Hz, 1H), 3.09 (dd, J = 14.9, 4.7 Hz, 1H), 2.90 (d, J = 11.0 
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Hz, 1H), 2.64 – 1.94 (m, 12H), 1.80 – 1.66 (m, 2H), 1.29 (s, 3H), 1.28 – 1.20 (m, 1H), 0.89 (s, 
3H). (31 non-exchangeable protons) 
HRMS(ESI): m/z calc. for C25H34N3O6[M+H]
+: 472.2448, found: 472.2448. 
 
 
Procedure: In a round bottom flask under nitrogen, G8 (204.3 mg, 0.590 mmol) and benzotriazol-
1-yloxytripyrrolidinophosphonium hexafluorophosphate (315.2 mg, 0.606 mmol) were dissolved 
in dichloromethane (6.0 mL). Diisopropylethylamine (100.0 µL, 0.574 mmol) was then added and 
the reaction stirred at room temperature for 2 hours. L-serine methyl ester hydrochloride (115.1 
mg, 0.740 mmol) and additional diisopropylethylamine (200.0 µL, 1.15 mmol) were then added 
and stirred at room temperature for 16 hours. The reaction was quenched with water (pH 4) and 
extracted with ethyl acetate (9x). The combined organic layers were washed with brine, dried over 
magnesium sulfate, filtered, and concentrated. The resulting residue was purified via silica gel 
chromatography (10% methanol in dichloromethane) to afford 2-65 (134.2 mg, 30% yield) as a 
white solid.  
 
1H NMR (d6-acetone, 500 MHz):  δ 7.91 (d, J = 7.9 Hz, 1H), 5.74 (dt, J = 5.0, 2.5 Hz, 1H), 5.05 
(td, J = 2.1, 1.0 Hz, 1H), 4.95 (d, J = 5.6 Hz, 1H), 4.89 – 4.87 (m, 1H), 4.67 (t, J = 5.3 Hz, 1H), 
4.58 (ddd, J = 7.8, 5.0, 4.2 Hz, 1H), 4.22 (t, J = 5.2 Hz, 2H), 3.94 (dt, J = 10.4, 5.0 Hz, 1H), 3.84 
(s, 1H), 3.70 (s, 3H), 3.39 (dd, J = 5.8, 2.7 Hz, 1H), 2.82 (dt, J = 16.8, 2.9 Hz, 1H), 2.63 (d, J = 
6.9 Hz, 1H), 2.43 (d, J = 5.9 Hz, 1H), 2.18 (dq, J = 16.8, 2.1 Hz, 1H), 2.05 (p, J = 2.2 Hz, 1H), 
1.94 – 1.86 (m, 1H), 1.74 – 1.59 (m, 2H), 1.48 – 1.37 (m, 3H), 1.12 (s, 3H).  
13C NMR (CD3OD, 125 MHz): δ 179.86, 176.75, 172.17, 155.59, 153.12, 114.34, 106.62, 79.55, 
76.15, 75.94, 62.82, 56.30, 52.68, 51.21, 50.82, 49.92, 49.29, 46.93, 46.80, 40.04, 38.48, 19.64, 
17.36. 
HRMS(ESI): m/z calc. for C23H30NO8 [M+H]





Procedure: In a round bottom flask with a stir bar, 3-31 (192.g mg, 0.543 mmol) was dissolved 
in 1,2-dichloroethane (2.5 mL) and water (0.5 mL). A 0.035 M solution of ruthenium chloride (2.0 
mL, 0.07 mmol) and sodium periodate (496.0 mg, 2.32 mmol) were added and the reaction stirred 
at room temperature for 14 hours. The reaction was quenched with a saturated solution of sodium 
thiosulfate and stirred at room temperature for 15 minutes. The layers were separated and the 
aqueous layer was extracted with ethyl acetate (3x). The combined organic layers were washed 
with water and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuo. 
The resulting residue was purified via silica gel chromatography (6:4 to 1:1 hexanes/ethyl acetate) 
to afford 2-69 (31.6 mg, 12% yield).   
 
1H NMR (d6-acetone, 500 MHz): δ 6.48 (d, J = 9.3 Hz, 1H), 5.93 (dd, J = 9.3, 3.6 Hz, 1H), 4.78 
(d, J = 6.8 Hz, 1H), 4.12 (dd, J = 6.7, 3.6 Hz, 1H), 3.75 (s, 3H), 3.40 (d, J = 10.2 Hz, 1H), 3.33 – 
3.27 (m, 2H), 2.91 – 2.82 (m, 2H), 2.33 – 2.25 (m, 1H), 2.25 – 2.18 (m, 2H), 2.16 – 2.09 (m, 1H), 
1.85 – 1.75 (m, 2H), 1.59 – 1.53 (m, 1H), 1.48 (qd, J = 13.0, 5.1 Hz, 1H), 1.26 (s, 3H). 
13C NMR (d6-acetone, 125 MHz): δ 213.64, 178.91, 173.79, 134.67, 131.27, 89.78, 71.07, 70.97, 
56.18, 55.08, 53.31, 52.29, 51.61, 50.35, 50.09, 46.57, 35.19, 19.63, 14.75, 11.06. 
HRMS(ESI): m/z calc. for C20H24O6I [M+H]
+: 487.0618, found: 487.0617. 
 
 
Procedure: In a round bottom flask under nitrogen, A8 (226 mg, 0.71 mmol) and benzotriazol-1-
yloxytripyrrolidinophosphonium hexafluorophosphate (404 mg, 0.78 mmol) were dissolved in 
dichloromethane (8.0 mL). Diisopropylethylamine (120.0 µL, 0.71 mmol) was then added and the 
reaction stirred at room temperature for 1 hours. Glycine methyl ester hydrochloride (143 mg, 1.14 
mmol) andadditional diisopropylethylamine (400 µL, 2.27 mmol) in dichloromethane (0.4 mL) 
were then added and stirred at room temperature for 16 hours. The reaction was concentrated, and 
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the residue was purified via silica gel chromatography (5% methanol in dichloromethane) to afford 
2-70 (197.3 mg, 70% yield) as a white solid.   
 
1H NMR (CDCl3, 500 MHz): δ 6.24 (t, J = 5.3 Hz, 1H), 4.00 (dd, J = 18.3, 5.3 Hz, 1H), 3.94 (dd, 
J = 18.4, 5.2 Hz, 1H), 3.73 (s 3H), 2.67 – 2.50 (m, 2H), 2.49 – 1.79 (m, 12H), 1.70 (tt, J = 12.6, 
9.3 Hz, 1H), 1.59 – 1.47 (m, 1H), 1.31 (s, 3H), 0.88 (s, 3H). (28 non-exchangeable protons) 
13C NMR (CDCl3, 126 MHz): δ 216.76, 212.56, 207.18, 173.46, 170.66, 57.31, 52.43, 50.50, 
50.36, 49.87, 49.59, 41.34, 37.17, 36.06, 35.62, 32.46, 29.70, 24.01, 21.74, 20.54, 14.89. 
HRMS(ESI): m/z calc. for C21H30NO6 [M+H]
+: 392.2073, found: 392.2067. 
 
 
Procedure: In a round bottom flask under nitrogen, G8 (64.8 mg, 0.187 mmol) and benzotriazol-
1-yloxytripyrrolidinophosphonium hexafluorophosphate (117.0 mg, 0.231 mmol) were dissolved 
in dichloromethane (2.5 mL). Diisopropylethylamine (33.0 µL, 0.189 mmol) was then added  and 
the reaction stirred at room temperature for 2 hours. Ethanolamine (40.0 µL, 0.663 mmol) and 
additional diisopropylethylamine (50 µL, 0.287 mmol) were then added and stirred at room 
temperature for 16 hours. The reaction was concentrated, and the residue was purified via silica 
gel chromatography to afford 2-71(70.0 mg, 96%) as a white solid.   
 
1H NMR (CD3OD, 500 MHz): δ 5.78 (dt, J = 5.1, 2.6 Hz, 1H), 5.06 (dt, J = 2.7, 1.5 Hz, 1H), 4.95 
(t, J = 1.9 Hz, 1H), 4.70 (t, J = 5.3 Hz, 1H), 4.18 (d, J = 5.3 Hz, 1H), 3.60 (t, J = 6.0 Hz, 2H), 3.35 
(dt, J = 8.7, 5.3 Hz, 2H), 3.30 – 3.24 (m, 1H), 2.68 (d, J = 6.5 Hz, 1H), 2.59 (dt, J = 16.4, 3.0 Hz, 
1H), 2.35 (d, J = 6.0 Hz, 1H), 2.27 – 2.20 (m, 1H), 1.99 – 1.94 (m, 1H), 1.78 – 1.64 (m, 2H), 1.52 
– 1.48 (m, 1H), 1.46 (dd, J = 10.9, 2.8 Hz, 1H), 1.42 – 1.35 (m, 1H), 1.15 (s, 3H). (23 non-
exchangable protons) 
13C NMR (CD3OD, 125 MHz): δ 179.84, 176.83, 155.38, 153.20, 114.34, 106.81, 79.60, 76.20, 
75.96, 61.64, 51.68, 50.53, 49.91, 49.28, 46.85, 46.64, 42.98, 40.00, 38.52, 19.67, 17.36. 
HRMS(ESI): m/z calc. for C21H28NO6 [M+H]





Procedure: In a round bottom flask under nitrogen, gibberellic acid (103.6 mg, 0.229 mmol) and 
benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (119.7 mg, 0.230 mmol) 
were dissolved in dichloromethane (2.3 mL). Diisopropylethylamine (0.1 mL, 0.575 mmol) was 
then added and the reaction stirred at room temperature for 2 hours. Ethanolamine (40.0 µL, 0.663 
mmol) and additional diisopropylethylamine (0.1 mL, 0.575 mmol) were then added and stirred at 
room temperature for 16 hours. The reaction was concentrated, and the residue was purified via 
silica gel chromatography (9:1 dichloromethane/methanol) to afford 2-72 (54.1 mg, 46%) as a 
white solid.   
 
1H NMR (CD3OD, 500 MHz): δ 6.38 (dd, J = 9.3, 1.0 Hz, 1H), 5.87 (dd, J = 9.4, 3.6 Hz, 1H), 
5.18 (t, J = 2.4 Hz, 1H), 4.93 (d, J = 2.1 Hz, 1H), 3.98 (dd, J = 3.6, 1.0 Hz, 1H), 3.59 (t, J = 5.9 
Hz, 2H), 3.36 (dt, J = 13.7, 5.9 Hz, 1H), 3.30 – 3.23 (m, 3H), 2.66 (d, J = 10.2 Hz, 1H), 2.24 (t, J 
= 2.4 Hz, 2H), 2.03 – 1.65 (m, 8H), 1.21 (s, 3H). (25 non-exchangeable protons)  
13C NMR (CD3OD, 125 MHz): δ 181.36, 173.96, 158.31, 134.09, 133.25, 107.25, 92.81, 78.80, 
70.72, 61.65, 55.04, 54.26, 53.39, 52.03, 51.72, 46.04, 44.49, 42.97, 39.78, 18.06, 14.84. 
HRMS(ESI): m/z calc. for C21H28NO6 [M+H]






Procedure: In a round-bottom flask with a stir bar, tosylated 2-52 (23.2 mg, 0.0546 mmol) and 
sodium cyanide (11.5 mg, 0.2347 mmol) were dissolved in 5 mL of N,N-dimethylformamide. The 
reaction flask was attached to a reflux condenser, stirred in an oil bath at 85 ºC for 15 hours, and 
was diluted with a saturated solution of sodium bicarbonate and brine. The mixture was extracted 
with ethyl acetate (4x). The organic layers were combined, dried with sodium sulfate, and were 
concentrated under reduced pressure. Excess N,N-dimethylformamide was blow-dried with a 
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stream of nitrogen. The crude residue was purified by column chromatography (4:1 hexanes/ethyl 
acetate to 100% ethyl acetate) on silica gel to afford 2-76 (3-13) (13.6 mg, 89% yield) as a white 
solid. 
1H NMR (CDCl3, 500 MHz): δ 7.12 (t, J = 7.4 Hz, 1H), 6.98 (d, J = 7.7 Hz, 1H), 6.95 (d, J = 7.4 
Hz, 1H), 5.07 (t, J = 2.5 Hz, 1H), 4.84 (t, J = 2.0 Hz, 1H), 3.41 (dd, J = 8.4, 4.8  Hz, 1H), 3.03 (dd, 
J = 17.3, 4.8 Hz, 1H), 2.78 – 2.71 (m, 2H), 2.41 (s, 3H), 2.35 – 2.29 (m, 2H), 2.25 (dtd, J = 13.4, 
5.2, 1.5 1H), 2.04 – 1.94 (m, 2H), 1.85 (dd, J = 10.3, 2.5 Hz, 1H), 1.78 – 1.73 (m, 1H), 1.57 (qd, J 
= 12.7, 5.3 Hz, 1H). (20 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 154.1, 144.6, 139.7, 133.9, 130.1, 127.6, 120.4, 119.4, 104.3, 
80.4, 54.1, 51.7, 48.4, 44.9, 39.4, 31.9, 22.2, 20.7, 17.2. 
HRMS(ESI): m/z calc. for C19H22NO  [M+H]
+: 280.1701, found: 280.1700. 
 
 
Procedure: In a round bottom flask under nitrogen, G8 (97.2 mg, 0.281 mmol) and benzotriazol-
1-yloxytripyrrolidinophosphonium hexafluorophosphate (181.2 mg, 0.346 mmol) were dissolved 
in dichloromethane (2.8 mL). Diisopropylethylamine (170.0 µL, 0.976 mmol) was then added and 
the reaction stirred at room temperature for 2 hours. ß-alanine ethyl ester hydrogen chloride (60.4 
mg, 0.393 mmol) was then added and stirred at room temperature for 16 hours. The reaction was 
concentrated, and the residue was purified via silica gel chromatography to afford 2-84 as a white 
solid (84 mg, 67% Yield).   
 
1H NMR (d6-acetone, 500 MHz): δ 7.68 (d, J = 5.9 Hz, 1H), 5.73 (dt, J = 6.0, 2.5 Hz, 1H), 5.05 
(ddd, J = 3.4, 2.1, 1.2 Hz, 1H), 4.95 (dd, J = 5.5, 1.4 Hz, 1H), 4.91 – 4.87 (m, 1H), 4.66 (t, J = 5.3 
Hz, 1H), 4.22 (t, J = 5.5 Hz, 1H), 4.17 – 4.04 (m, 2H), 3.54 – 3.41 (m, 2H), 3.38 (dd, J = 5.9, 2.7 
Hz, 1H), 2.68 – 2.62 (m, 1H), 2.60 – 2.52 (m, 3H), 2.24 (d, J = 5.8 Hz, 1H), 2.20 (ddt, J = 16.6, 
3.6, 1.9 Hz, 1H), 1.93 – 1.86 (m, 1H), 1.75 – 1.57 (m, 2H), 1.48 – 1.35 (m, 2H), 1.29 (dd, J = 11.0, 
2.8 Hz, 1H), 1.22 (t, J = 7.1 Hz, 3H), 1.09 (s, 3H). (30 non-exchangeable protons) 
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13C NMR (d6-acetone): δ 177.86, 174.87, 172.21, 156.14, 152.87, 113.83, 105.93, 79.01, 75.93, 
74.98, 60.82, 50.93, 50.07, 49.23, 49.14, 46.26, 46.12, 39.60, 38.68, 36.19, 34.79, 19.38, 17.36, 
14.53. 
HRMS(ESI): m/z calc. for C24H32NO7  [M+H]
+: 446.2179, found: 446.2175. 
 
 
Procedure: In a dry round bottom flask under nitrogen, gibberellic acid (325.0 mg, 0.938 mmol) 
was dissolved in benzene (6.0 mL). Diphenylphosphoryl azide (0.25 mL, 1.16 mmol) and 
triethylamine (0.30 mL, 2.15 mmol) were added the reaction was refluxed for 20 minutes. Allyl 
alcohol (0.10 mL, 6.80 mmol) was added and the reaction was allowed to reflux for 12 hours. The 
reaction was then cooled to room temperature, quenched with water, the layers were separated, 
and the aqueous layer was extracted with ethyl acetate (4x). The combined organic layers were 
washed with brine, dried with sodium sulfate, filtered and concentrated in vacuo. The resulting 
residue was purified via silica gel chromatography (1:1 to 4:1 ethyl acetate/hexanes). The product 
was then recrystallized from methanol and the crystals were washed with hexanes to afford 2-85 
(150.0 mg, 40% yield) as clear crystals.  
 
1H NMR (CD3OD, 500 MHz): δ 6.34 (dt, J = 9.4, 1.2 Hz, 1H), 5.93 (ddt, J = 17.2, 10.5, 5.3 Hz, 
1H), 5.86 (dd, J = 9.3, 3.7 Hz, 1H), 5.30 (dq, J = 17.2, 1.7 Hz, 1H), 5.23 – 5.15 (m, 2H), 4.96 – 
4.93 (m, 1H), 4.55 (dq, J = 5.2, 1.7 Hz, 2H), 4.02 (dd, J = 3.7, 0.9 Hz, 1H), 3.93 (d, J = 10.3 Hz, 
1H), 2.67 (d, J = 10.2 Hz, 1H), 2.41 (dt, J = 15.9, 3.1 Hz, 1H), 2.09 (ddt, J = 15.6, 2.9, 1.6 Hz, 
1H), 2.05 – 1.98 (m, 1H), 1.94 (dd, J = 11.3, 6.0 Hz, 1H), 1.88 – 1.66 (m, 3H), 1.66 – 1.61 (m, 
1H), 1.26 (s, 3H). (23 non-exchangeable protons) 
13C NMR (d6-acetone, 125 MHz): δ 179.15, 159.32, 156.72, 134.59, 134.05, 132.95, 116.97, 
106.14, 89.45, 78.36, 70.24, 65.60, 57.59, 55.09, 54.31, 51.33, 50.69, 44.72, 42.32, 39.88, 17.65, 
14.69. 
HRMS(ESI): m/z calc. for C22H26NO6 [M-H]






Procedure: In a round bottom flask under nitrogen, isomannide (309.6 mg, 2.12 mmol) and 
triethylamine (1.5mL, 10.7 mmol) were dissolved in dichloromethane. The reaction was cooled to 
0°C, mesyl chloride was added dropwise, and the reaction was slowly warmed to room temperature 
and allowed to stir for 2 hours. The reaction was then quenched with saturated aqueous sodium 
bicarbonate, and the aqueous layer was extracted with dichloromethane (3x). The combined 
organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo. The resulting residue was purified via silica gel column chromatography (9:1 ethyl 
acetate/hexanes) to yield 2-91 as a white solid (430.0 mg, 67% yield).   
 
1H NMR (CDCl3, 500 MHz): δ 5.08 (dddd, J = 8.4, 5.9, 2.9, 1.1 Hz, 2H), 4.71 (dt, J = 5.0, 2.5 Hz, 
2H), 4.12 (ddd, J = 9.7, 6.4, 0.7 Hz, 2H), 3.93 (dd, J = 9.7, 6.9 Hz, 2H), 3.12 (s, 6H). 
13C NMR (CDCl3, 125 MHz): δ 80.38, 77.67, 70.84, 38.76. (4 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C8H15O8S2 [M+H]
+: 303.0208, found: 303.0203. 
 
 
Procedure: In a flame-dried round bottom flask under N2, 2-85 (70.0 mg, 0.173 mmol) was 
dissolved in dichloromethane (6.5 mL) and pyridine (1.0 mL). Dess Martin Periodinane (115 mg, 
0.271 mmol) was added in one portion and the reaction stirred at room temperature. After 1 hours, 
the reaction was quenched with 10% sodium thiosulfate (5.0 mL). After stirring for 1 hour, the 
layers were separated and the aqueous layer was extracted with ethyl acetate (3x). The combined 
organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and 
concentrated. The resulting residue was purified via silica gel chromatography (1:1 to 7:3 ethyl 




1H NMR (d6-acetone, 500 MHz) δ 7.58 (d, J = 9.4 Hz, 1H), 6.72 (d, J = 9.3 Hz, 1H), 6.04 (d, J = 
9.4 Hz, 1H), 5.92 (ddt, J = 17.2, 10.6, 5.3 Hz, 1H), 5.31 – 5.12 (m, 3H), 4.60 – 4.48 (m, 2H), 4.10 
(t, J = 9.7 Hz, 1H), 3.26 (d, J = 10.1 Hz, 1H), 2.46 (dt, J = 15.9, 3.0 Hz, 1H), 2.27 – 2.18 (m, 2H), 
2.00 – 1.71 (m, 6H), 1.30 (s, 3H). (23 non-exchangeable protons) 
13C NMR (d6-acetone, 125 MHz): δ 193.38, 174.02, 158.76, 156.72, 149.55, 134.38, 129.17, 
117.16, 106.48, 89.00, 78.18, 65.79, 64.38, 58.27, 50.77, 50.51, 44.79, 44.73, 42.00, 39.60, 17.56, 
11.44. 
HRMS(ESI): m/z calc. for C22H26NO6 [M+H]
+: 400.1760, found: 400.1754. 
 
 
Procedure: In a round bottom flask under nitrogen, isomannide (258.9 mg, 1.83 mmol) was 
dissolved in pyridine (9.0 mL) and cooled to 0°C. 2-nitrobenzenesulfonyl chloride (517.5 mg, 2.34 
mmol) was added in one portion and the reaction as allowed to stir at room temperature. After 14 
hours, the reaction was diluted in water and extracted with ethyl acetate (3x). The combined 
organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated. The 
reaction was purified via silica gel chromatography (6:4 to 3:7 hexanes/ethyl acetate to afford 2-




1H NMR (CDCl3, 500 MHz): δ 8.22 – 8.16 (m, 1H), 7.88 – 7.73 (m, 3H), 5.22 (q, J = 5.8 Hz, 1H), 
4.67 (t, J = 5.1 Hz, 1H), 4.46 (t, J = 5.2 Hz, 1H), 4.33 – 4.23 (m, 1H), 4.10 (dd, J = 9.9, 6.0 Hz, 
1H), 3.98 (dd, J = 10.0, 6.1 Hz, 1H), 3.93 (dd, J = 9.3, 6.4 Hz, 1H), 3.55 (dd, J = 9.2, 7.4 Hz, 1H), 
2.59 (d, J = 8.6 Hz, 1H). 
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13C NMR (CDCl3, 125 MHz): δ 135.15, 132.58, 131.54, 130.06, 124.98, 81.57, 80.97, 80.44, 
73.87, 72.23, 70.79, 70.77. 
HRMS(EI): m/z calc. for C12H14NO8S [M+H]
+: 332.0440, found: 332.0447. 
 
Precursor to 2-98 
1H NMR (CDCl3, 500 MHz): δ 8.22 – 8.19 (m, 2H), 7.84 – 7.80 (m, 4H), 7.80 – 7.73 (m, 2H), 
5.23 – 5.16 (m, 2H), 4.73 – 4.66 (m, 2H), 4.06 (dd, J = 9.9, 6.3 Hz, 2H), 3.98 (dd, J = 9.9, 6.7 Hz, 
2H). 
13C NMR (CDCl3, 125 MHz): δ 135.27, 132.70, 131.82, 130.27, 125.14, 110.01, 80.50, 80.02, 
70.76. (9 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C18H17N2O12S2 [M+H]
+: 517.0223, found: 517.0219. 
 
 
Procedure: In a round bottom flask under nitrogen, isomannide (250.8 mg, 1.78 mmol) was 
dissolved in pyridine (9.0 mL) and cooled to 0°C. 4-nitrobenzenesulfonyl chloride (529.9 mg, 2.39 
mmol) was added in one portion and the reaction as allowed to stir at room temperature. After 12 
hours, the reaction was diluted in water and extracted with ethyl acetate (3x). The combined 
organic layers were washed with brine, dried with sodium sulfate, filtered, and concentrated. The 
reaction was purified via silica gel chromatography (6:4 to 3:7 hexanes/ethyl acetate to afford the 
precursor to 2-95 (181.9 mg, 30% yield) and the precursor to 2-97 (264.6 mg, 29% yield) as 
white solids. Due to limited solubility, the precursor to 2-97 was not fully characterized.  
 




1H NMR (CDCl3, 500 MHz): δ 8.53 – 8.30 (m, 2H), 8.30 – 8.05 (m, 2H), 5.07 (td, J = 6.2, 5.2 Hz, 
1H), 4.54 (t, J = 5.1 Hz, 1H), 4.44 (t, J = 5.2 Hz, 1H), 4.26 (q, J = 6.5 Hz, 1H), 4.07 (dd, J = 9.8, 
6.1 Hz, 1H), 3.89 (ddd, J = 11.1, 9.5, 6.3 Hz, 2H), 3.48 (dd, J = 9.3, 7.1 Hz, 1H), 2.51 (bs, 1H).  
13C NMR (CDCl3, 125 MHz): δ 150.95, 142.09, 129.46, 124.49, 81.71, 80.16, 79.88, 74.00, 72.17, 
70.72. (10 carbons due to symmetry) 
HRMS(EI): m/z calc. for C12H14NO8S M
+: 332.0440, found: 332.0447. 
 
Procedure: In a flame dried round bottom flask, 5% palladium on activated charcoal (26.4 mg, 
0.0124 mmol) was loaded under nitrogen, and dampened with toluene. Anhydrous methanol (0.8 
mL) was slowly added, and purged with nitrogen. The precursor to 2-95 (38 mg, 0. 0.115 mmol) 
was then transferred to the round bottom with anhydrous methanol (0.2 mL) and re-purged with 
nitrogen gas. The round bottom was then fitted with a balloon of hydrogen gas and purged for 1 
min. The reaction was stirred under an atmosphere of hydrogen gas at room temperature for 7 
hours. The palladium was then filtered over Celite and the flow through was concentrated to afford 
2-95 (34.6 mg, quantitative yield).  
 
1H NMR (CD3OD, 500 MHz): δ 7.62 – 7.55 (m, 2H), 6.73 – 6.68 (m, 2H), 4.84 – 4.77 (m, 1H), 
4.43 (t, J = 4.8 Hz, 1H), 4.34 (t, J = 4.7 Hz, 1H), 4.23 (ddd, J = 8.4, 6.8, 5.0 Hz, 1H), 3.88 (ddd, J 
= 10.8, 8.9, 6.7 Hz, 2H), 3.65 (dd, J = 9.2, 7.5 Hz, 1H), 3.49 (t, J = 8.5 Hz, 1H). (12 non-
exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 155.68, 131.18, 121.94, 114.27, 82.94, 81.73, 79.81, 73.74, 
73.38, 71.09. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H16O6NS [M+H]





Procedure: In a flame dried round bottom flask, 10% palladium on activated charcoal (9.7 mg, 
0.00911 mmol) was loaded under nitrogen, and dampened with toluene. Anhydrous methanol (0.5 
mL) was slowly added, and purged with nitrogen. 2-94 (30.0 mg, 0. 0.0964 mmol) was then 
transferred to the round bottom with anhydrous methanol (0.5 mL) and re-purged with nitrogen 
gas. The round bottom was then fitted with a balloon of hydrogen gas and purged for 1 min. The 
reaction was stirred under an atmosphere of hydrogen gas at room temperature for 4 hours. The 
palladium was then filtered over Celite and the flow through was concentrated to afford 2-96 as a 
clear oil (29.0 mg, quantitative yield).  
 
1H NMR (CD3OD, 500 MHz): δ 7.64 (dd, J = 8.1, 1.6 Hz, 1H), 7.37 (ddd, J = 8.6, 7.1, 1.6 Hz, 
1H), 6.86 (dd, J = 8.4, 1.1 Hz, 1H), 6.70 (ddd, J = 8.2, 7.1, 1.1 Hz, 1H), 4.87 – 4.83 (m, 1H), 4.54 
(t, J = 4.9 Hz, 1H), 4.35 (t, J = 4.8 Hz, 1H), 4.25 (ddd, J = 8.4, 6.8, 5.0 Hz, 1H), 3.91 (dd, J = 8.6, 
6.8 Hz, 1H), 3.85 (dd, J = 9.3, 6.5 Hz, 1H), 3.71 (dd, J = 9.3, 7.2 Hz, 1H), 3.52 (t, J = 8.5 Hz, 1H). 
(12 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 149.02, 136.54, 131.00, 118.43, 116.96, 116.78, 82.98, 81.90, 
80.05, 73.70, 73.40, 71.04. 
HRMS(ESI): m/z calc. for C12H16NO6S [M+H]
+: 302.0698, found: 302.0696. 
 
 
Procedure: In a flame dried round bottom flask, 10% palladium on activated charcoal (10.0 mg, 
0.00940 mmol) was loaded under N2, and dampened with toluene. Anhydrous methanol (0.8 mL) 
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was slowly added, and purged with N2. The precursor to 2-97 (38.9 mg, 0. 0.0852 mmol) was 
then transferred to the round bottom with anhydrous methanol (0.2 mL) and re-purged with N2 
gas. The round bottom was then fitted with a balloon of hydrogen gas and purged for 1 min. The 
reaction was stirred under an atmosphere of hydrogen gas at room temperature for 7 hours. The 
palladium was then filtered over celite and the flow through was concentrated to afford 2-97 (38.8 
mg, quantitative yield).  
1H NMR (CDCl3, 500 MHz): δ 7.53 (d, J = 8.8 Hz, 4H), 6.59 (d, J = 8.8 Hz, 4H), 4.70 – 4.63 (m, 
2H), 4.34 (dt, J = 4.6, 2.3 Hz, 2H), 3.80 (dd, J = 9.5, 6.8 Hz, 2H), 3.59 (dd, J = 9.4, 7.9 Hz, 2H). 
(16 non exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 152.74, 130.12, 121.84, 113.69, 79.91, 77.49, 69.95. (7 carbons 
due to symmetry). 
NMR spectra contain CD3OD for solubility. 
HRMS(ESI): m/z calc. for C18H21N2O8S2 [M+H]
+: 457.0739, found: 457.0733. 
 
 
Procedure: In a flame dried round bottom flask, 10% palladium on activated charcoal (9.1 mg, 
0.00855 mmol) was loaded under nitrogen, and dampened with toluene. Anhydrous methanol (0.4 
mL) was slowly added, and purged with nitrogen. The precursor to 2-98 (11.4 mg, 0.0211 mmol) 
was then transferred to the round bottom with anhydrous methanol (0.2 mL) and re-purged with 
nitrogen gas. The round bottom was then fitted with a balloon of hydrogen gas and purged for 1 
min. The reaction was stirred under an atmosphere of hydrogen gas at room temperature for 7 
hours. The palladium was then filtered over Celite and the flow through was concentrated to afford 
2-98 (3.9 mg, quantitative yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.61 (dd, J = 8.1, 1.6 Hz, 2H), 7.36 (ddd, J = 8.6, 7.1, 1.6 Hz, 2H), 
6.85 (dd, J = 8.3, 1.1 Hz, 2H), 6.69 (ddd, J = 8.2, 7.1, 1.2 Hz, 2H), 4.82 (ddq, J = 10.4, 5.2, 1.8 
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Hz, 2H), 4.48 (dd, J = 3.9, 1.6 Hz, 2H), 3.82 (dd, J = 9.4, 6.5 Hz, 2H), 3.68 (dd, J = 9.4, 7.3 Hz, 
2H). (16 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 146.55, 135.80, 130.36, 117.60, 117.28, 116.51, 80.22, 77.71, 
70.24. (9 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C18H21N2O8S2 [M+H]




Procedure:  In a dry round bottom flask under nitrogen, 2-85 (32.7 mg, 0.0815 mmol) was 
dissolved in tetrahydrofuran (0.75 mL). Tetrakis(triphenylphosphine) palladium (14.5 mg, 0.0125 
mmol) and dimedone (22.0 mg, 0.157 mmol) were added in one portion and stirred at room 
temperature for 1 hour. The reaction was quenched with 1 mL of water and the aqueous layer was 
washed 5 times with dichloromethane. The aqueous layer was concentrated and purified via silica 
gel chromatography (89:20:1 ethyl ecetate/methanol/triethylamine) to afford 4-30 as a white solid 
(11.6 mg, 45% Yield).  
 
1H NMR (CDCl3, 500 MHz): δ 5.78 – 5.72 (m, 1H), 5.08 (td, J = 2.1, 1.0 Hz, 1H), 5.00 (td, J = 
1.8, 0.9 Hz, 1H), 4.68 (t, J = 5.3 Hz, 1H), 4.18 (d, J = 5.4 Hz, 1H), 2.89 (d, J = 4.3 Hz, 1H), 2.66 
(dt, J = 16.5, 3.1 Hz, 1H), 2.64 – 2.61 (m, 1H),  2.55 (t, J = 3.5 Hz, 1H), 2.35 (ddd, J = 16.3, 3.1, 
1.7 Hz, 1H), 2.01 – 1.95 (m, 1H), 1.78 – 1.69 (m, 2H), 1.49 (ddt, J = 4.7, 3.2, 2.1 Hz, 1H), 1.35 
(dd, J = 10.9, 2.9 Hz, 1H), 1.31 (s, 3H), 1.23 (ddd, J = 10.9, 3.0, 1.2 Hz, 1H). (19 non-exchangeable 
protons) 
13C NMR (CDCl3, 125 MHz): δ 179.92, 155.15, 152.04, 114.78, 106.76, 79.92, 76.21, 75.84, 
57.52, 52.74, 51.71, 49.76, 47.80, 44.87, 38.77, 38.64, 19.64, 17.62. 
HRMS(ESI): m/z calc. for C18H24NO4 [M+H]





Procedure: In a round bottom flask, 4-30 (80 mg, 0.252 mmol) and sodium hydroxide (49.4 mg, 
1.24 mmol) were dissolved in water (10.0 mL). The reaction was stirred at room temperature for 
17 hours. After acidifying to pH 3 with hydrochloric acid, the reaction was concentrated in vacuo 
to 1 mL and purified by C18 chromatography to afford 2-99 (7 mg, 8% yield) as a white solid. 
1H NMR (CD3OD, 500 MHz): δ 5.35 (q, J = 2.3 Hz, 1H), 5.11 (t, J = 2.4 Hz, 1H), 5.03 (s, 1H), 
4.05 (h, J = 2.4 Hz, 1H), 3.71 (d, J = 4.8 Hz, 1H), 3.44 (s, 1H), 2.75 (dt, J = 15.9, 2.9 Hz, 1H), 
2.60 – 2.53 (m, 1H), 2.42 – 2.33 (m, 2H), 2.01 (q, J = 5.8, 4.9 Hz, 1H), 1.83 – 1.68 (m, 2H), 1.63 
(dd, J = 10.9, 2.8 Hz, 1H), 1.57 – 1.37 (m, 2H), 1.35 (s, 3H). (19 non-exchangeable protons) 
HRMS(ESI): m/z calc. for C18H26NO5 [M+H]
+: 336.1811, found: 336.1807. 
 
 
Procedure: In a round bottom flask under nitrogen, 16 (2-1, 3-1, 4-1) (72.6 mg, 0.200 mmol) was 
dissolved in dichloromethane (2.0 mL). Triethylamine (42.0 µL, 0.301 mmol) and acetic anhydride 
(27 µL, 0.286 mmol) were added and the reaction was allowed to stir at room temperature. The 
reaction was quenched with water, and extracted with dichloromethane (3x). The combined 
organic layers were washed with brine, dried withs sodium sulfate, filtered, and concentrated. The 
resulting residue was purified by silica gel chromatography to afford 3-2 (49.6 mg, 62% yield) as 
white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 8.03 – 7.96 (m, 2H), 7.80 – 7.74 (m, 2H), 7.65 – 7.58 (m, 2H), 
7.53 – 7.47 (m, 2H), 7.47 – 7.41 (m, 1H), 4.95 (q, J = 5.8 Hz, 1H), 4.68 (t, J = 4.8 Hz, 1H), 4.46 – 
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4.38 (m, 2H), 3.96 (dd, J = 9.9, 4.2 Hz, 1H), 3.87 – 3.77 (m, 3H), 1.96 (s, 3H). (20 non-
exchangeable protons) 
13C NMR (CDCl3, 125 MHz,) δ 169.97, 147.16, 138.96, 134.78, 129.27, 128.97, 128.52, 127.99, 
127.48, 86.93, 80.33, 79.10, 73.47, 70.29, 56.63, 23.28. (16 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C20H22NO6S  [M+H]




Procedure: In a flame dried round bottom flask under nitrogen, 2 (2-2, 3-3, 4-5) (77.5 mg, 0.219 
mmol) was dissolved in anhydrous methanol (2.1 mL), and 37% formaldedyde in H2O (70.0 µL, 
0.862 mmol) was added. After 10 minutes, sodium cyanoborohydride (60.2 mg, 0.960 mmol) was 
added in a single portion. The reaction stirred at room temperature for 18 hours. The reaction was 
concentrated and purified by C18 chromatography to give 8 (3-5) (65.8 mg, 77% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.82 – 7.78 (m, 2H), 7.71 – 7.67 (m, 2H), 4.82 – 4.77 (m, 1H), 
4.51 – 4.46 (m, 2H), 4.01 (dd, J = 9.4, 6.3 Hz, 1H), 3.86 (dd, J = 9.7, 5.9 Hz, 1H), 3.79 (dd, J = 
9.7, 6.7 Hz, 1H), 3.71 (dd, J = 9.4, 6.2 Hz, 1H), 2.81 (td, J = 6.3, 1.9 Hz, 1H), 2.23 (s, 6H). 
13C NMR (CDCl3, 125 MHz): δ 135.51, 132.74, 129.60, 129.45, 86.26, 80.41, 78.62, 73.00, 72.74, 
68.87, 43.79. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C14H19BrNO5S [M+H]
+: 392.0167, found: 392.0166. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 8 (3-5) (27.4 mg, 0.0699 mmol), 
iodomethane (20.0 µL, 0.321 mmol), and potassium carbonate (118.2 mg, 0.855 mmol) were 
dissolved in acetonitrile (0.7 mL). The reaction was stirred at room temperature for 14 hours, at 
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which point it was neutralized with formic acid and purified via C18 chromatography to afford 11 
(3-6) (8.0 mg, 22% yield) as a white solid.  
 
1H NMR (CD3OD, 500 MHz): δ 7.85 – 7.79 (m, 2H), 7.79 – 7.75 (m, 2H), 5.05 – 5.01 (m, 2H), 
4.88 (t, J = 5.9 Hz, 1H), 4.44 – 4.34 (m, 1H), 4.15 (dd, J = 12.1, 6.2 Hz, 1H), 4.10 (dt, J = 5.8, 2.0 
Hz, 1H), 3.96 (dd, J = 11.0, 3.0 Hz, 1H), 3.84 (dd, J = 11.0, 4.4 Hz, 1H), 3.19 (s, 9H). 
13C NMR (CD3OD, 125 MHz): δ 134.94, 132.39, 129.02, 128.96, 81.49, 81.21, 79.23, 79.00, 
71.15, 67.63, 51.72. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C15H21O5SBr [M]
+: 406.0324, found: 406.0320. 
 
 
Procedure:  In a flame dried round bottom flask under nitrogen, 2 (2-2, 3-3, 4-5) (49.2 mg, 0.135 
mmol) was dissolved in dichloromethane (2.6 mL). Triethylamine (20.0 µL, 0.212 mmol) and 
acetic anhydride (20.0 µL, 0.143 mmol) were added and the reaction was stirred at room 
temperature for 18 hours. The reaction was concentrated and purified by C18 chromatography to 
give 14 (3-7) (46.8 mg, 85% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.83 – 7.76 (m, 2H), 7.72 – 7.68 (m, 2H), 6.04 (d, J = 7.3 Hz, 1H), 
4.93 (q, J = 5.6 Hz, 1H), 4.64 (t, J = 4.9 Hz, 1H), 4.39 (m, 2H), 3.42 – 4.35 (dd, J = 9.9, 4.3 Hz, 
1H), 3.83 – 3.75 (m, 3H), 1.95 (d, J = 0.7 Hz, 3H). 
13C NMR (CDCl3, 125 MHz): δ 170.02, 135.50, 132.80, 129.53, 129.50, 87.03, 80.32, 79.48, 
73.42, 70.50, 56.56, 23.32. (12 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C14H17BrNO6S [M+H]





Procedure: In a round bottom flask under nitrogen containing a small needle for ventilation, 1 (2-
3, 3-8, 4-7) (28.8 mg, 0.107 mmol), diisopropylethylamine (50 µL, 0.287 mmol), and di-t-butyl 
dicarbonate  (40.0 µL, 0.174 mmol) were dissolved in dichloromethane (1.1 mL) and stirred at 
room temperature for 13 hours. The reaction was concentrated in vacuo and purified via silica gel 
chromatography with 8:2 to 1:1 hexanes/ethyl acetate to afford the precursor to 4 (39.0 mg, 99% 
Yield) as a clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.10 (t, J = 7.4 Hz, 1H), 6.95 (dd, J = 13.7, 7.4 Hz, 2H), 5.02 (t, J 
= 2.6 Hz, 1H), 4.78 (d, J = 2.2 Hz, 1H), 4.56 (d, J = 6.2 Hz, 1H), 3.90 (dt, J = 13.9, 5.0 Hz, 1H), 
3.52 (ddd, J = 13.3, 7.5, 4.7 Hz, 1H), 3.29 (t, J = 5.9 Hz, 1H), 2.70 (dd, J = 12.6, 5.0 Hz, 1H), 2.36 
(s, 3H), 2.33 – 2.15 (m, 3H), 2.01 – 1.92 (m, 2H), 1.84 (dd, J = 10.3, 2.6 Hz, 1H), 1.78 – 1.70 (m, 
2H), 1.60 – 1.50 (m, 1H), 1.44 (s, 9H). 
13C NMR (CDCl3, 125 MHz): δ 155.85, 155.02, 145.47, 140.43, 134.28, 129.73, 126.94, 120.15, 
103.55, 80.35, 79.67, 53.58, 51.74, 49.50, 48.59, 39.61, 39.38, 32.17, 28.60, 22.15, 20.61.  
HRMS(ESI): m/z calc. for C21H32NO3 [M+H]
+: 370.2382, found: 370.2376. 
 
 
Procedure: Tetrahydrofuran (0.6 mL) was loaded in a dry round bottom flask under nitrogen and 
cooled to 0°C. Lithium aluminum hydride (7.8 mg, 0.206 mmol) was added, followed by the drop 
wise addition of the precursor to 4 (22.2 mg, 0.0601 mmol) in 0.6 mL of tetrahydrofuran. After 
the compound was fully added, the reaction was refluxed for 13 hours. The reaction was then 
cooled to 0°C and quenched by the addition of water (10 µL), a 10% solution of sodium hydroxide 
(10 µL), and finally water (30 µL). The reaction was allowed to warm to room temperature, stirred 
for 1 hour, and filtered over Celite. The flow through was concentrated in vacuo and the resulting 
residue was purified via silica gel chromatography (100% ethyl acetate to 20% methanol in ethyl 




1H NMR (CD3OD, 500 MHz): δ 7.05 (t, J = 7.5 Hz, 1H), 6.92 (t, J = 7.1 Hz, 2H), 5.02 (t, J = 2.5 
Hz, 1H), 4.79 (t, J = 1.9 Hz, 1H), 3.46 (dd, J = 12.8, 5.6 Hz, 1H), 3.23 (t, J = 6.1 Hz, 1H), 3.01 
(dd, J = 12.6, 6.8 Hz, 1H), 2.73 (dd, J = 12.4, 5.1 Hz, 1H), 2.59 (s, 3H), 2.38 (s, 3H), 2.29 – 2.12 
(m, 2H), 2.00 – 1.88 (m, 2H), 1.87 – 1.79 (m, 1H), 1.69 (ddt, J = 11.8, 4.6, 1.9 Hz, 1H), 1.57 – 
1.37 (m, 1H), 1.30 – 1.15 (m, 2H). (24 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 155.45, 145.28, 142.06, 133.99, 129.49, 126.34, 119.87, 103.18, 
80.27, 53.71, 51.61, 51.13, 49.48, 49.37, 39.59, 36.98, 31.78, 22.20, 20.30. 
HRMS(ESI): m/z calc. for C19H26NO [M+H]
+: 284.2014, found: 284.2015. 
 
 
Procedure: In a vial with a stir bar, 1 (2-3, 3-8, 4-7) (11.5 mg, 0.0427 mmol) was dissolved in 
acetonitrile (3 mL) and cooled to 0 ºC. Potassium carbonate (30.6 mg, 0.2214 mmol) and 
iodomethane (0.1 mL, 1.606 mmol) were added to the reaction. The contents of the vial were 
stirred for 5 hours. The reaction was diluted with H2O and extracted with dichloromethane (4x). 
The organic layers were combined, dried over sodium sulfate, and concentrated under reduced 
pressure. The crude residue was purified by column chromatography to afford 7 (3-10) (1.2 mg, 
10% yield) as a white solid. The aqueous fraction was extracted with dichloromethane (10x) to 




1H NMR (CDCl3, 500 MHz): δ 7.05 (t, J = 7.3 Hz, 1H), 6.93 (d, J = 7.6 Hz, 1H), 6.90 (d, J = 7.4 
Hz, 1H), 5.00 (t, J = 2.6 Hz, 1H), 4.77 (t, J = 2.2 Hz, 1H), 3.20 (t, J = 6.8 Hz, 1H), 2.94 (dd, J = 
12.6, 6.4 Hz, 1H), 2.68 (dd, J = 12.5, 5.0 Hz, 1H), 2.43 (s, 3H), 2.42 – 2.36 (m, 2H), 2.32 (dt, J = 
17.0, 2.80 Hz, 1H), 2.26 (s, 6H), 2.21 (dtd, J = 13.3, 5.3, 1.3 Hz, 1H), 1.96 (td, J = 12.3, 5.3 Hz, 




13C NMR (CDCl3, 125 MHz): δ 155.9, 145.4, 143.0, 134.3, 129.6, 126.3, 119.8, 103.0, 80.4, 59.5, 
54.0, 51.6, 49.1, 46.8, 46.0, 39.8, 31.6, 22.4, 20.8. (19 carbons due to symmetry) 




1H NMR (CDCl3, 500 MHz): δ 7.02 (t, J = 7.3 Hz, 1H), 6.89 (t, J = 8.0 Hz, 2H), 4.98 (s, 1H), 4.58 
(s, 1H), 4.09 (d, J = 12.9 Hz, 1H), 3.83 (d, J = 13.4 1H), 3.41 (s, 9H), 3.40 (s, 1H), 2.76 (dd, J = 
11.1, 3.9 Hz, 1H), 2.45 (s, 3H), 2.49-2.40 (m, 1H), 2.18 – 2.06 (m, 2H), 1.90 (td, J = 12.6, 4.5 Hz, 
1H), 1.76 (d, J = 8.5 Hz, 1H), 1.68 – 1.58 (m, 2H), 1.40 (qd, J = 12.8, 4.1 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 153.8, 146.2, 138.1, 132.1, 130.9, 127.6, 121.5, 104.6, 79.7, 63.1, 
56.0, 54.3, 50.7, 47.0, 45.3, 39.4, 32.7, 22.8, 21.6. (19 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C21H30NO  [M]+: 312.2329, found: 312.2327. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 1 (2-3, 3-8, 4-7) (33.1 mg, 0.113 mmol), 
triethylamine (30.0 µL, 0.215 mmol) and acetyl chloride (8.0 µL, 0.112 mmol) were dissolved in 
dichloromethane (2.2 mL) and stirred at room temperature for 14 hours. The reaction was 
quenched with a saturated solution of sodium bicarbonate, and the aqueous layer was extracted 
with ethyl acetate (3x). The combined organic layers were washed with brine, dried with sodium 
sulfate, filtered, and concentrated. The resulting residue was purified via silica gel chromatography 
(10% methanol in ethyl acetate) to afford 13 (3-12) (21.0 mg, 55% yield) as a clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.11 (td, J = 7.5, 0.9 Hz, 1H), 6.99 – 6.93 (m, 2H), 5.50 (br s, 1H), 
5.02 (t, J = 2.6 Hz, 1H), 4.79 (t, J = 2.2 Hz, 1H), 3.93 (ddd, J = 14.2, 5.4, 4.1 Hz, 1H), 3.64 (ddd, 
J = 14.2, 7.2, 4.6 Hz, 1H), 3.30 (dd, J = 7.3, 4.1 Hz, 1H), 2.69 (dd, J = 12.6, 5.0 Hz, 1H), 2.35 (s, 
3H), 2.28 – 2.19 (m, 2H), 2.13 (dd, J = 10.2, 2.4 Hz, 1H), 1.97 (s, 3H), 1.96 – 1.92 (m, 2H), 1.87 
(br s 1H), 1.83 (dd, J = 10.1, 2.6 Hz, 1H), 1.73 (ddt, J = 11.8, 5.3, 2.0 Hz, 1H) 1.61 – 1.48 (m, 1H).  
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13C NMR (CDCl3, 125 MHz): δ 170.18, 154.79, 145.63, 140.17, 134.25, 129.87, 127.24, 120.39, 
103.90, 80.40, 53.79, 51.81, 49.44, 48.28, 39.77, 38.50, 32.39, 23.65, 22.25, 20.54. 
HRMS(ESI): m/z calc. for C20H26NO2  [M+H]+: 312.1964, found: 312.2327. 
 
 
Procedure: In a dry round bottom flask under nitrogen, 30 (2-5, 3-16, 4-13) (53.1 mg, 0.208 mmol) 
was dissolved in 1,2-dichloroethane (2.0 mL). 37% formaldehyde (20.0 µL, 0.246 mmol) and 
triethylamine (55 µL, 0.394 mmol) were added. After stirring at room temperature for 5 minutes, 
sodium triacetoxyborohydride (159.8 mg, 0.754 mmol) was added and the reaction stirred at room 
temperature for 14 hours. The reaction was quenched with a saturated solution of sodium 
bicarbonate, and the layers were separated. The aqueous layer was extracted with ethyl acetate 
(6x) and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, 
and concentrated in vacuo. The residue was purified via C18 chromatography to afford 3-17 (22.6 
mg, 40% yield) as a clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.07 (t, J = 7.4 Hz, 1H), 6.97 – 6.91 (m, 1H), 6.90 (d, J = 7.3 Hz, 
1H), 5.02 (t, J = 2.6 Hz, 1H), 4.81 (t, J = 2.2 Hz, 1H), 4.01 (s, 1H), 2.67 (s, 3H), 2.66 – 2.60 (m, 
1H), 2.51 (dt, J = 17.5, 3.0 Hz, 1H), 2.44 (s, 3H), 2.30 – 2.19 (m, 2H), 1.95 (td, J = 12.2, 5.2 Hz, 
1H), 1.89 (dd, J = 10.1, 2.6 Hz, 1H), 1.81 (dq, J = 17.3, 2.4 Hz, 1H), 1.72 (ddt, J = 11.8, 4.4, 2.1 
Hz, 1H), 1.55 (qd, J = 12.7, 5.3 Hz, 1H). (21 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz,): δ 154.97, 154.73, 143.88, 140.85, 135.58, 129.32, 127.53, 120.18, 
103.22, 80.07, 79.44, 55.97, 50.05, 46.62, 39.83, 31.56, 22.37, 19.36. 
HRMS(ESI): m/z calc. for C18H24NO [M+H]+: 270.1858, found: 270.1855. 
 
 
Procedure: In a round bottom flask under nitrogen, Q1d (38.8 mg, 0.101 mmol) was dissolved in 
anhydrous methanol (1.0 mL). A 37% solution of formaldehyde (40.0 µL, 0.488 mmol) was added, 
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followed by sodium cyanoborohydride (29.2 mg, 0. 465 mmol) 5 minutes later. The reaction was 
stirred at room temperature for 17 hours. The reaction was then concentrated and purified via C18 
chromatography to afford 9 (3-24) (34.0 mg, 82% yield) as a clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 8.78 (d, J = 4.6 Hz, 1H), 8.07 (d, J = 9.2 Hz, 1H), 7.66 (d, J = 4.6 
Hz, 1H), 7.43 (dt, J = 9.2, 1.8 Hz, 1H), 7.30 (d, J = 2.7 Hz, 1H), 5.48 (dt, J = 17.0, 9.8 Hz, 1H), 
5.16 – 5.08 (m, 2H), 5.02 (dd, J = 17.1, 1.6 Hz, 1H), 4.12 (ddd, J = 11.8, 9.0, 3.0 Hz, 1H), 4.00 – 
3.94 (m, 1H) 3.97 (s, 3H), 3.03 (td, J = 13.2, 3.4 Hz, 1H), 2.43 – 2.34 (m, 1H), 2.19 (dq, J = 13.3, 
2.6 Hz, 1H), 2.14 – 2.07 (m, 2H), 1.94 (s, 6H), 1.87 (dq, J = 13.9, 2.8 Hz, 1H), 1.83 – 1.63 (m, 
2H), 1.58 (tt, J = 13.4, 4.9 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 170.66, 158.41, 147.72, 144.83, 141.21, 140.05, 132.29, 128.09, 
122.09, 119.67, 116.37, 101.18, 64.28, 60.16, 55.83, 48.43, 45.74, 41.00, 39.26, 35.38, 33.36, 
26.37. (22 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C23H30N3O2S  [M+H]
+: 412.2059, found: 412.2054. 
 
 
Procedure: In a round bottom flask under nitrogen, Q1d (19.4 mg, 0.0506 mmol) was dissolved 
in acetonitrile (0.5 mL). Iodomethane (60.0 µL, 0.964 mmol) and potassium carbonate (109.4 mg, 
0.792 mmol) were added and the reaction was allowed to stir at room temperature for 14 hours. 
The reaction was then acidified to pH 2 with hydrochloric acid and purified via C18 
chromatography to afford 12 (3-25) (7.2 mg, 31% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 8.60 (d, J = 4.7 Hz, 1H), 7.91 (d, J = 9.3 Hz, 1H), 7.68 (d, J = 4.7 
Hz, 1H), 7.34 (dd, J = 9.2, 2.6 Hz, 1H), 7.20 (d, J = 2.7 Hz, 1H), 5.66 (dt, J = 17.3, 10.0 Hz, 1H), 
5.37 – 5.30 (m, 1H), 5.25 (dd, J = 10.1, 1.1 Hz, 1H), 5.17 (d, J = 6.4 Hz, 1H), 4.29 (q, J = 7.3 Hz, 
1H), 3.91 (s, 3H), 3.80 – 3.72 (m, 1H), 3.49 – 3.36 (m, 2H), 3.09 (ddd, J = 14.0, 10.8, 3.7 Hz, 1H), 
3.02 (s, 9H), 2.97 – 2.88 (m, 1H), 1.96 (dd, J = 7.8, 4.7 Hz, 2H), 1.84 (dt, J = 9.6, 4.7 Hz, 1H), 
1.78 – 1.69 (m, 1H), 1.59 (ddt, J = 15.4, 10.2, 5.0 Hz, 1H). 
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13C NMR (CDCl3, 125 MHz): δ 170.93, 158.59, 147.20, 143.88, 143.20, 138.19, 131.13, 127.60, 
122.36, 120.44, 119.68, 101.13, 69.37, 59.81, 55.96, 54.27, 46.57, 40.10, 39.36, 33.71, 32.30, 
24.83. (22 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C24H32N3O2S  [M]
+: 426.2215, found: 426.2209. 
 
Procedure for 3-35: Prepared with 4-toluenesulfonyl chloride according to general procedure A.  
Yield: 312.8 mg, 68% yield.  
 
1H NMR (CDCl3, 500 MHz) δ 7.81 (d, J = 8.3 Hz, 2H), 7.39 – 7.32 (m, 2H), 4.92 – 4.85 (m, 1H), 
4.60 (t, J = 4.9 Hz, 1H), 4.42 (dd, J = 4.6, 1.0 Hz, 1H), 4.01 (d, J = 3.9 Hz, 1H), 3.97 (dd, J = 10.4, 
1.1 Hz, 1H), 3.93 (dd, J = 10.4, 3.9 Hz, 1H), 3.85 (dd, J = 9.9, 6.0 Hz, 1H), 3.77 (dd, J = 9.9, 6.0 
Hz, 1H), 2.44 (s, 3H). (11 carbons due to symmetry) 
13C NMR (CDCl3, 125 MHz): δ 145.40, 133.28, 130.07, 128.13, 86.47, 80.55, 78.54, 72.88, 70.35, 
66.04, 21.85. 
HRMS(ESI): m/z calc. for C13H16N3O5S [M+H]
+: 326.0811, found: 326.0806. 
 
 
Procedure for 23 (3-34, 4-10): Prepared according to general procedure B.  




1H NMR (CDCl3, 500 MHz): δ 7.82 (d, J = 8.3 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 4.90 – 4.84 (m, 
1H), 4.65 (t, J = 4.8 Hz, 1H), 4.24 (d, J = 4.4 Hz, 1H), 3.91 (dd, J = 9.5, 4.2 Hz, 1H), 3.82 (dd, J 
= 9.7, 6.1 Hz, 1H), 3.76 – 3.71 (m, 2H), 3.53 (d, J = 4.2 Hz, 1H), 2.44 (s, 3H), 1.75 (br s, 2H). 
13C NMR (CDCl3, 125 MHz): δ 145.32, 133.49, 130.10, 128.18, 89.74, 80.17, 79.07, 76.34, 70.02, 
58.42, 21.92. 
HRMS(ESI): m/z calc. for C13H18NO5S [M+H]
+: 300.0906, found: 300.0901. 
 
Procedure: In a dry round bottom flask under nitrogen, 23 (3-34, 4-10) (182.0 mg, 0.608 mmol) 
was dissolved in tetrahydrofuran (6.1 mL). Triethylamine (85 µL, 0.609 mmol) and acetyl chloride 
(90 µL, 1.26 mmol) were added and the reaction was stirred at room temperature for one hour. The 
reaction was quenched with water and extracted with ethyl acetate (3x). The combined organic 
layers were washed with brine, dried over sodium sulfate, filtered, and concentrated. The resulting 
residue was purified via silica gel chromatography (9:1 ethyl acetate/hexanes) to afford 3-36 as a 
white solid (99.6 mg, 48% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.85 – 7.80 (m, 2H), 7.39 – 7.33 (m, 2H), 5.67 (d, J = 7.3 Hz, 1H), 
4.89 (q, J = 5.8 Hz, 1H), 4.63 (dd, J = 5.3, 4.4 Hz, 1H), 4.45 – 4.37 (m, 2H), 3.94 (dd, J = 10.0, 
4.2 Hz, 1H), 3.84 – 3.78 (m, 2H), 3.75 (dd, J = 10.0, 5.9 Hz, 1H), 2.45 (s, 3H), 1.96 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 169.96, 145.45, 133.48, 130.16, 128.16, 86.99, 80.42, 78.92, 
73.55, 70.42, 56.76, 23.44, 21.96. (13 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C15H20NO6S [M+H]




Procedure: In a round bottom flask, isomannide (5.05g, 3.46 mmol) was dissolved in pyridine 
(6.0 mL), and cooled to 0˚C. 4-toluenesulfonyl chloride (662.3 mg, 3.47 mmol) was added in one 
portion, slowly warmed to room temperature, and stirred for 12 hours. The reaction was 
concentrated in vacuo. The residue was purified by silica gel chromatography (4:1 to 1:1 
hexanes/ethyl acetate) to afford 3-37 (401.0 mg, 39% yield).   
 
1H NMR (CDCl3, 500 MHz) δ 7.89 – 7.81 (m, 2H), 7.38 – 7.33 (m, 2H), 4.91 (ddd, J = 7.4, 6.6, 
5.1 Hz, 1H), 4.49 (t, J = 4.9 Hz, 1H), 4.43 (t, J = 5.1 Hz, 1H), 4.29 (dtd, J = 8.6, 6.8, 5.5 Hz, 1H), 
4.03 (dd, J = 9.3, 6.6 Hz, 1H), 3.96 (dd, J = 9.4, 6.4 Hz, 1H), 3.79 (dd, J = 9.4, 7.5 Hz, 1H), 3.55 
(dd, J = 9.4, 7.2 Hz, 1H), 2.46 (s, 3H). (15 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 145.40, 130.04, 128.17, 121.40, 81.54, 80.19, 78.51, 74.22, 72.48, 
70.22, 21.87. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C13H17O6S [M+H]
+: 301.0746, found: 301.0746. 
 
 
Procedure for the precursor to 22: Prepared with benzenesulfonyl chloride according to 
general procedure A. 
Yield: 110.6 mg, 79%. 
 
1H NMR (CDCl3, 500 MHz): δ 7.98 – 7.92 (m, 2H), 7.71 – 7.64 (m, 1H), 7.60 – 7.53 (m, 2H), 
4.93 (q, J = 5.7 Hz, 1H), 4.62 (t, J = 4.9 Hz, 1H), 4.43 (d, J = 4.6 Hz, 1H), 4.02 (d, J = 3.9 Hz, 
1H), 3.99 – 3.95 (m, 1H), 3.93 (dd, J = 10.4, 3.9 Hz, 1H), 3.87 (dd, J = 10.0, 6.0 Hz, 1H), 3.80 
(dd, J = 10.0, 5.9 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 136.29, 134.27, 129.46, 128.07, 86.48, 80.57, 78.79, 72.86, 70.39, 
65.97. (10 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C12H13N3O5SNa [M+Na]





Procedure for 22 (3-38, 4-19): Prepared according to general procedure B.  
Yield: 49.5 mg, quantitative yield. 
 
1H NMR (CD3OD, 500 MHz): δ 7.96 (dt, J = 7.2, 1.4 Hz, 2H), 7.77 – 7.71 (m, 1H), 7.67 – 7.60 
(m, 2H), 4.97 (q, J = 5.4 Hz, 1H), 4.65 (t, J = 5.0 Hz, 1H), 4.23 (d, J = 4.6 Hz, 1H), 3.86 (dd, J = 
9.4, 4.2 Hz, 1H), 3.75 (dd, J = 9.8, 5.8 Hz, 1H), 3.72 – 3.65 (m, 2H), 3.40 (d, J = 4.3 Hz, 1H). (13 
non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 136.35, 134.00, 129.26, 127.90, 89.79, 79.91, 79.09, 76.35, 69.76, 
58.24. 
HRMS(ESI): m/z calc. for C12H16NO5S [M+H]
+: 286.0749, found: 286.0751. 
 
 
Procedure: In a dry round bottom flask under nitrogen, (22) 3-38, 4-19 (55.2 mg, 0.193 mmol) 
was dissolved in methanol (1.9mL). 37% formaldehyde (20.0 µL, 0.246 mmol) was added. After 
stirring at room temperature for 5 minutes, sodium cyanoborohydride (64.1 mg, 1.02 mmol) was 
added and the reaction stirred at room temperature for 14 hours. The reaction was concentrated 
and purified via C18 chromatography to afford 3-39 (10.4 mg, 18% yield) as a clear oil.  
 
1H NMR (CD3OD, 400 MHz): δ 7.96 (dt, J = 8.0, 1.0 Hz, 2H), 7.77 – 7.71 (m, 1H), 7.67 – 7.61 
(m, 2H), 4.96 (q, J = 5.4 Hz, 1H), 4.58 (t, J = 5.1 Hz, 1H), 4.31 (d, J = 4.9 Hz, 1H), 3.87 (dd, J = 




HRMS(ESI): m/z calc. for C13H18NO5S  [M+H]
+: 328.0855, found: 328.0856. 
 
 
Procedure: In a round bottom flask under nitrogen 22 (3-38, 4-19) (48.9 mg, 0.17 mmol) was 
dissolved in dichloromethane (1.7 mL). Triethylamine (50 µL, 0.709 mmol) and acetic anhydride 
(50 µL, 0.710 mmol) were added and the reaction as allowed to stir at room temperature for 13 
hours. The reaction was then quenched with water and extracted with dichloromethane (3x). The 
combined organic layers were washed with brine, dried over sodium sulfate, filtered and 
concentrated. The residue was purified via silica gel chromatography (9:1 ethyl acetate/hexanes to 
100% ethyl acetate) to afford 3-41 (27.8 mg, 50% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.93 (dt, J = 8.5, 1.2 Hz, 2H), 7.76 – 7.63 (m, 1H), 7.61 – 7.46 (m, 
2H), 5.92 (d, J = 7.3 Hz, 1H), 4.91 (q, J = 5.7 Hz, 1H), 4.64 (t, J = 4.9 Hz, 1H), 4.44 – 4.36 (m, 
2H), 3.93 (dd, J = 9.9, 4.3 Hz, 1H), 3.84 – 3.71 (m, 3H), 1.95 (d, J = 2.3 Hz, 3H). 
13C NMR (CDCl3, 150 MHz): δ 170.08, 136.43, 134.21, 129.44, 127.95, 86.93, 80.32, 79.12, 
73.45, 70.24, 56.62, 23.21. 
HRMS(ESI): m/z calc. for C14H18NO6S  [M+H]
+: 328.0855, found: 328.0856. 
 
 
Procedure: In a dry round bottom flask under nitrogen, isomannide azide (53.2 mg, 0.312 mmol) 
was dissolved in N,N-dimethylformamide (3.0 mL) and cooled to 0°C. 60% sodium hydride in 
mineral oil (22.5 mg, 0.563 mmol) and benzyl bromide (60.0 µL, 0.505 mmol) were added and the 
reaction was allowed to slowly warm to room temperature. After 6 hours, the reaction was cooled 
to 0°C and slowly quenched with water. The reaction was extracted with dichloromethane (3x). 
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The combined organic layers were washed with brine (2x), dried over sodium sulfate, filtered, and 
concentrated. The remaining N,N-dimethylformamide was removed under a stream of nitrogen. 
The resulting residue was purified via silica gel chromatography (9:1 to 8:2 hexanes/ethyl acetate) 
to afford 3-43 (60.3 mg, 74% yield) as a white solid.  
 
1H NMR 1H NMR (CDCl3, 500 MHz): δ 7.34 (m, 5H), 4.78 (d, J = 11.8 Hz, 1H), 4.67 (t, J = 4.6 
Hz, 1H), 4.55 (d, J = 11.8 Hz, 1H), 4.49 (d, J = 5.4 Hz, 1H), 4.08 (td, J = 4.8, 7.0 Hz, 1H), 4.05 
(d, J = 1.6 Hz, 1H), 4.04 (s, 1H), 4.00 (m, 1H), 3.86 (dd, J = 6.5, 9.0 Hz, 1H), 3.66 (dd, J = 7.3, 
9.0 Hz, 1H). 
13C NMR 13C NMR (CDCl3, 125 MHz): δ 137.64, 128.52, 127.99, 127.97, 86.59, 80.65, 78.98, 
72.78, 72.56, 70.89, 66.39. (11 carbons due to symmetry) 
HRMS(EI): m/z calc. for C13H16N3O3, [M+H]
+: 261.1113, found: 261.1114. 
 
 
Procedure for 3-42 (4-21): Prepared according to general procedure B.  
Yield: 32.2 mg, quantitative yield. 
 
1H NMR (CD3OD, 500 MHz): δ 7.40 – 7.31 (m, 4H), 7.31 – 7.26 (m, 1H), 4.77 – 4.70 (m, 2H), 
4.54 (d, J = 11.6 Hz, 1H), 4.31 (d, J = 4.5 Hz, 1H), 4.12 (td, J = 6.8, 4.8 Hz, 1H), 3.97 (dd, J = 9.2, 
4.4 Hz, 1H), 3.82 (dd, J = 8.9, 6.5 Hz, 1H), 3.74 (dd, J = 9.1, 1.7 Hz, 1H), 3.59 (dd, J = 8.9, 7.1 
Hz, 1H), 3.41 (dt, J = 4.6, 1.5 Hz, 1H). (15 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 139.42, 129.38, 129.08, 128.84, 90.46, 81.51, 80.86, 76.47, 
73.43, 71.53, 59.42. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C13H18NO3  [M+H]





Procedure: In a round bottom flask under nitrogen 3-42 (4-21) (33.4 mg, 0.142 mmol) was 
dissolved in dichloromethane (1.5 mL). Triethylamine (100 µL, 0.709 mmol) and acetic anhydride 
(67 µL, 0.710 mmol) were added and the reaction as allowed to stir at room temperature for 13 
hours. The reaction was then quenched with water and extracted with dichloromethane (3x). The 
combined organic layers were washed with brine, dried over sodium sulfate, filtered and 
concentrated. The residue was purified via C18 chromatography to afford 3-44 (20.5 mg, 52% 
yield) as a white solid.  
 
1H NMR (CD3OD, 400 MHz): δ 7.41 – 7.25 (m, 5H), 4.73 (d, J = 11.5 Hz, 1H), 4.67 (t, J = 4.6 
Hz, 1H), 4.55 (d, J = 11.5 Hz, 1H), 4.40 (d, J = 4.4 Hz, 1H), 4.24 (d, J = 4.6 Hz, 1H), 4.14 (td, J = 
6.7, 4.9 Hz, 1H), 4.00 (dd, J = 9.5, 4.7 Hz, 1H), 3.89 – 3.80 (m, 2H), 3.63 (dd, J = 9.0, 7.0 Hz, 
1H), 1.94 (s, 3H). (18 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 169.55, 137.68, 128.51, 127.97, 127.91, 86.92, 80.35, 79.11, 
73.52, 72.62, 70.86, 57.03, 23.28. 
HRMS(ESI): m/z calc. for C15H20NO4 [M+H]




Procedure: In a vial with a stir bar, 3-45 (4-22) (6.6 mg, 0.0243 mmol) and potassium carbonate 
(24.5 mg, 0.1773 mmol) were added to acetonitrile (4 mL) and cooled to 0 ºC in an ice bath for 10 
minutes. Methyl iodide (0.15 mL, 2.4195 mmol) was added to the reaction and was stirred for 8 
hours. The reaction was diluted with saturated sodium bicarbonate and brine, extracted with 
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dichloromethane (3x), and dried over sodium sulfate. The combined organic layers were 
concentrated under reduced pressure. The residue was purified by flash chromatography on silica 
gel (7:3 hexanes/ethyl acetate) to yield white solid 3-46 (2.4 mg, 35% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.16 (t, J = 7.5 Hz, 1H), 7.02 (d, J = 7.4 Hz, 1H), 6.98 (d, J = 7.4 
Hz, 1H), 4.15 (s, 1H), 3.69 (d, J = 11.3 Hz, 1H), 3.54 (d, J = 11.4 Hz, 1H), 2.83 (t, J = 7.1 Hz, 
1H), 2.66 (s, 3H), 2.64 (d, J = 18.1 Hz, 1H), 2.44 (s, 3H), 2.42 (dd, J = 17.4, 3.6 Hz, 1H), 2.06 
(sep, J = 7.3 Hz, 1H), 2.00 - 1.91 (m, 2H), 1.82 (dtd, J = 13.8, 7.2, 1.4 Hz, 1H), 1.62 (dt, J = 13.7, 
7.1 Hz, 1H), 1.52 (dd, J = 11.7, 3.6 Hz, 1H). (21 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 223.50, 144.74, 141.26, 135.60, 129.64, 127.72, 120.20, 68.80, 
66.06, 53.44, 53.17, 51.10, 49.83, 36.75, 31.87, 30.26, 21.89, 19.12. 
HRMS(ESI): m/z calc. for C18H24NO2 [M+H]
+: 286.1807, found: 286.1811. 
 
 
Procedure: In a vial with a stir bar, 3-45 (4-22) (9.9 mg, 0.0365 mmol) was dissolved in pyridine 
(5 mL) and was cooled to 0 ºC ice bath capped under nitrogen. Acetyl chloride (60 μL, 0.8439 
mmol) was added to the reaction and stirred for 25 min. The reaction was quenched with saturated 
sodium bicarbonate and brine, extracted with dichloromethane (3x), and dried over sodium sulfate. 
The combined organic layers were concentrated under reduced pressure. The residue was purified 
by flash chromatography on silica gel (1:1 hexanes/ethyl acetate) to yield white solid 3-49 (6.3 
mg, 55% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.21 (t, J = 7.5 Hz, 1H), 7.05 (d, J = 7.4 Hz, 1H), 7.01 (d, J = 7.5 
Hz, 1H), 5.74 (d, J = 9.4 Hz, 1H), 5.65 (d, J = 9.6 Hz, 1H), 3.73 (d, J = 11.3 Hz, 1H), 3.49 (d, J = 
11.4 Hz, 1H), 2.95 (t, J = 7.5 Hz, 1H), 2.75 (d, J = 18.1 Hz, 1H), 2.45 (dd, J = 18.3, 3.6 Hz, 1H), 
2.30 (s, 3H), 2.16 – 2.08 (m, 2H), 2.01 (s, 3H), 1.86 (dq, J = 15.1, 8.2 Hz, 1H), 1.79 – 1.72 (m, 
2H), 1.68 – 1.61 (m, 1H), 1.59 (dd, J = 11.5, 3.7 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 222.14, 170.10, 145.33, 138.28, 135.19, 129.81, 128.73, 120.77, 
65.55, 57.76, 53.52, 51.64, 50.40, 49.96, 32.04, 29.61, 23.38, 22.40, 18.58. 
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HRMS(ESI): m/z calc. for C19H23NO3Na [M+Na]
+: 336.1576, found: 336.1569. 
 
 
Procedure: In an oven-dried round bottom flask with a stir bar under nitrogen, loaded 3-50 (4-23) 
(53.4 mg, 0.209 mmol), and dissolved in tetrahydrofuran (2.4 mL). To the flask, added 
triethylamine (90.0 µL, 0.645 mmol) and acetyl chloride (20.0 µL, 0.280 mmol). The reaction was 
stirred at room temperature for 1 hour before it was quenched with water (3 mL) and extracted 
with ethyl acetate (3x), washed with brine, dried over sodium sulfate, filtered, and concentrated in 
vacuo. The residue was purified by flash chromatography on silica gel (7:3 to 3:7 hexanes/ethyl 
acetate) to yield 3-53 as a white solid (31.6 mg, 51% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 7.19 (t, J = 7.5 Hz, 1H), 7.05 – 6.98 (m, 2H), 5.75 – 5.67 (m, 2H), 
2.89 (t, J = 7.2 Hz, 1H), 2.67 (d, J = 17.9 Hz, 1H), 2.39 (dd, J = 17.9, 3.7 Hz, 1H), 2.29 (s, 3H), 
2.10 (s, 3H), 2.04 (dq, J = 14.3, 7.1 Hz, 1H), 1.90 (dq, J = 14.5, 7.3 Hz, 1H), 1.75 (dtd, J = 14.4, 
7.3, 1.6 Hz, 1H), 1.65 (dd, J = 11.4, 3.7 Hz, 1H), 1.56 (dt, J = 14.1, 7.2 Hz, 1H), 1.43 (dt, J = 11.6, 
1.3 Hz, 1H), 1.04 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 221.76, 169.99, 145.44, 138.42, 135.11, 129.67, 128.51, 120.56, 
57.58, 52.10, 49.33, 48.96, 47.71, 37.73, 35.16, 23.34, 22.28, 21.73, 18.54. 
HRMS(ESI): m/z calc. for C19H24NO2 [M+H]




Procedure: In a dry round bottom flask under nitrogen, oxalyl chloride (50.0 µL, 0.583 mmol) 
was dissolved in dichloromethane (1.9 mL). The reaction was cooled to -78°C, and dimethyl 
sulfoxide (70.0 µL, 0.986 mmol) was added. After stirring for 10 minutes, 3-45-Cbz (103.0 mg, 
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0.254 mmol) in dichloromethane (0.40 mL) was added and the reaction was allowed to stir at -
78°C for one hour. Triethylamine (0.20 mL, 1.42 mmol) was then added, stirred at -78°C for 30 
minutes, and then the reaction was allowed to slowly warm to 0°C. After one hour of stirring, the 
reaction was diluted in ethyl acetate, washed with brine, dried over sodium sulfate, filtered and 
concentrated. The resulting residue was purified via silica gel chromatography in 3:2 hexanes/ethyl 
acetate to afford the precursor to 3-54 (41.0 mg, 40% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 9.63 (s, 1H), 7.45 – 7.28 (m, 5H), 7.20 (t, J = 7.6 Hz, 1H), 7.04 
(d, J = 7.5 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 5.48 (d, J = 9.7 Hz, 1H), 5.22 (d, J = 12.1 Hz, 1H), 
5.15 (d, J = 12.2 Hz, 1H), 5.04 (d, J = 9.8 Hz, 1H), 2.97 (t, J = 7.3 Hz, 1H), 2.85 (d, J = 18.1 Hz, 
1H), 2.50 (dd, J = 18.1, 3.6 Hz, 1H), 2.29 (s, 3H), 2.25 – 1.82 (m, 5H), 1.69 (dd, J = 11.9, 3.6 Hz, 
1H). 
13C NMR (CDCl3, 125 MHz): δ 215.19, 199.89, 156.52, 144.31, 137.70, 136.33, 135.49, 130.06, 
128.88, 128.74, 128.48, 128.24, 120.62, 67.42, 63.68, 59.53, 52.42, 49.77, 49.30, 31.05, 28.32, 
21.85, 18.55. (23 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C25H26NO4 [M+H]
+: 404.1862, found: 404.1867. 
 
 
Procedure: In a dry round bottom flask under nitrogen, combined the precursor to 3-54 (85.0 
mg, 0.211 mmol) and 2-methyl-2-butene (2 M in hexanes, 1.6 mL, 3.4 mmol) in t-butanol (3.4 
mL) and water (1.7 mL). Sodium dihydrogen phosphate monohydrate (175.1 mg) and sodium 
chlorite (148.0 mg) were slowly added. The reaction was stirred at room temperature for one hour, 
diluted in brine, and extracted with ethyl acetate (3x), and concentrated in vacuo. The resulting 
residue was crudely purified via C18 chromatography. 
A portion of the resulting material (24.0 mg, 0.0572 mmol) was dissolved in methanol (0.5 mL) 
and water (0.5 mL). Potassium hydroxide (137 mg, 2.44 mmol) was added and the reaction was 
allowed to stir overnight at room temperature. The reaction was purified directly via C18 




1H NMR (CD3OD, 500 MHz): δ 7.27 (t, J = 7.5 Hz, 1H), 7.14 – 7.10 (m, 2H), 3.01 – 2.89 (m, 
2H), 2.46 (s, 3H), 2.44 – 2.36 (m, 3H), 2.14 – 2.00 (m, 4H), 1.77 (dd, J = 11.5, 3.6 Hz, 1H). 
13C NMR (CD3OD, 125 MHz): δ 218.42, 178.07, 146.47, 136.69, 135.80, 130.91, 130.48, 121.79, 
61.74, 59.67, 52.92, 52.83, 49.92, 35.68, 32.06, 22.25, 19.36. 
HRMS(ESI): m/z calc. for C17H17NO3 [M+H]
+: 284.1287, found: 284.1282. 
 
 
Procedure: In a flame-dried round-bottom flask with a stir bar, lithium aluminum hydride (18.8 
mg, 0.495 mmol) was added to anhydrous tetrahydrofuran (1.0 mL). The solution was cooled to 
0°C. 2-76 (3-13) (31.4 mg, 0.112 mmol) was dissolved in anhydrous tetrahydrofuran (1.5 mL), 
and added drop wise to the cooled lithium aluminum hydride in tetrahydrofuran. The reaction was 
then refluxed for 4 hours. Upon cooling to 0°C, the reaction was quenched with water and 10% 
sodium hydroxide. The quenched reaction was filtered over Celite, concentrated, and purified via 
C18 chromatography to afford 31 (4-3) as a formate salt (1.9 mg, 5% yield) 
 
1H NMR (CD3OD, 500 MHz): δ 8.54 (bs, 1H), 7.11 – 7.00 (m, 1H), 6.92 (ddd, J = 7.2, 4.6, 2.4 
Hz, 2H), 5.04 – 5.02 (m, 1H), 4.81 (d, J = 2.2 Hz, 1H), 3.20 – 3.10 (m, 3H), 2.76 – 2.70 (m, 1H), 
2.63 – 2.55 (m, 1H), 2.39 (s, 3H), 2.25 (dddd, J = 11.6, 10.2, 5.7, 2.4 Hz, 2H), 2.05 (dd, J = 10.2, 
2.3 Hz, 1H), 1.99 – 1.89 (m, 2H), 1.89 – 1.79 (m, 2H), 1.70 (ddt, J = 11.8, 5.3, 2.0 Hz, 1H), 1.51 
(qd, J = 12.8, 5.3 Hz, 1H). (23 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 155.72, 146.23, 142.84, 134.71, 130.89, 127.76, 121.07, 104.33, 
80.69, 55.21, 52.88, 49.65, 48.00, 40.84, 40.63, 32.26, 28.40, 23.32, 21.03. (formate carbon did 
not resolve) 
HRMS(ESI): m/z calc. for C19H26NO  [M+H]





Procedure: In a round bottom flask with a stir bar, 1 (2-3, 3-8, 4-7) (41.1 mg, 0.153 mmol) was 
dissolved in 7.6 mL of 2.4 M HCl, and refluxed over night. The reaction was cooled to room 
temperature and concentration in vacuo to afford 42.3 mg of 4-3-a as a hydrochloride salt (92% 
Yield). 
 
1H NMR (CD3OD, 500 MHz): δ 7.17 (t, J = 7.5 Hz, 1H), 7.08 – 7.00 (m, 2H), 3.76 – 3.68 (m, 
1H), 3.68 – 3.58 (m, 1H), 3.44 (dd, J = 13.9, 7.0 Hz, 1H), 2.92 (t, J = 6.9 Hz, 1H), 2.66 (d, J = 
17.8 Hz, 1H), 2.49 – 2.37 (m, 1H), 2.43 (s, 3H), 2.04 (q, J = 7.1 Hz, 2H), 1.77 (dd, J = 11.3, 3.3 
Hz, 1H), 1.74 – 1.65 (m, 2H), 1.61 (dt, J = 14.1, 7.4 Hz, 1H), 1.06 (s, 3H). (21 non-exchangeable 
protons) 
13C NMR (CD3OD, 125 MHz): δ 223.60, 147.10, 139.00, 135.44, 131.12, 129.08, 121.61, 52.17, 
51.72, 50.74, 49.08, 39.45, 38.35, 36.40, 22.65, 21.78, 20.30. 
HRMS(ESI): m/z calc. for C18H24NO [M+H]




Procedure: In a flame dried round bottom flask, 10% palladium on activated charcoal (25.9 mg, 
0.0243 mmol) was loaded under nitrogen, and dampened with toluene. Anhydrous methanol (1.3 
mL) was slowly added, and purged with nitrogen. Azide 2-52 (74.4 mg, 0.252 mmol) was then 
transferred to the round bottom with anhydrous methanol (1.3 mL) and re-purged with nitrogen 
gas. The round bottom was then fitted with a balloon of hydrogen gas and purged for 1 min. The 
reaction was stirred under an atmosphere of hydrogen gas at room temperature for 16 hours. The 
palladium was then filtered over Celite and the flow through was concentrated to afford 4-4 (61.03 




1H NMR (CD3OD, 500 MHz): δ 7.03 – 6.98 (m, 1H), 6.90 – 6.84 (m, 2H), 3.52 (dd, J = 12.6, 4.9 
Hz, 1H), 3.12 – 3.02 (m, 2H), 2.60 (dd, J = 12.1, 5.4 Hz, 1H), 2.35 (s, 3H), 2.22 (dd, J = 10.3, 2.3 
Hz, 1H), 2.16 (dtd, J = 13.1, 5.6, 1.5 Hz, 1H), 2.05 – 1.95 (m, 1H), 1.95 – 1.83 (m, 1H), 1.79 – 
1.67 (m, 3H), 1.61 (qd, J = 12.7, 5.7 Hz, 1H), 0.96 (d, J = 7.1 Hz, 3H), 0.69 (ddd, J = 13.8, 7.6, 
1.8 Hz, 1H). (22 non-exchangeable protons) 
13C NMR (CD3OD, 125 MHz): δ 146.52, 142.83, 134.60, 130.49, 127.51, 121.08, 79.66, 56.55, 
53.31, 53.04, 51.71, 42.15, 41.62, 34.39, 31.41, 23.08, 20.91, 11.93. 
HRMS(ESI): m/z calc. for C18H26NO [M+H]






Procedure: In a round-bottom flask with a stir bar, tosylated 2-52 (80.6 mg, 0.1898 mmol) was 
dissolved in dichloromethane (80 mL) over an atmosphere of air. In a separate round-bottom flask, 
trifluoroacetic anhydride (0.7 mL), trifluoroacetic acid (0.5 mL) and 30-32% H2O2 (0.2 mL) were 
added to dichloromethane (20 mL), creating trifluoroperacetic acid in situ. The contents of both 
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flasks were combined and were stirred open to air for 30 minutes. The reaction was quenched with 
a saturated solution of sodium bicarbonate and was extracted with ethyl acetate (4x). The organic 
layers were combined, dried over sodium sulfate, and concentrated under reduced pressure. The 
crude residue was submitted to column chromatography (100% ethyl acetate) to afford precursor 
A to 4-6 (58.9 mg, 70% yield) as a white solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.79 (d, J = 8.28 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H), 7.15 (t, J = 7.5 
Hz, 1H), 6.97 (t, J = 6.6 Hz, 2H), 4.77 (dd, J = 10.3, 3.4 Hz, 1H), 4.29 (dd, J = 10.3, 8.8 Hz, 1H), 
3.65 - 3.59 (m, 2H), 3.44 (dd, J = 11.4, 5.24 Hz, 1H), 2.89 (t, J = 7.2 Hz, 1H), 2.59 (d, J = 17.9 
Hz, 1H), 2.45 (s, 3H), 2.37 (dd, J = 17.9, 3.5 Hz, 1H), 2.24 (s, 3H), 2.14 (dd, J = 7.2, 5.2 Hz, 1H), 
2.06 (sext, J = 7.0 Hz, 1H), 1.88 (sext, J = 7.5, Hz, 1H), 1.81 - 1.71 (m, 2H), 1.67 - 1.60 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 222.8, 145.9, 145.4, 137.3, 134.7, 132.8, 130.2, 129.9, 128.2, 
128.1, 120.7, 68.7, 65.8, 53.3, 52.0, 51.9, 50.1, 48.9, 32.1, 29.9, 22.0, 21.9, 20.5. (23 carbons due 
to symmetry) 
HRMS(ESI): m/z calc. for C25H29O5S  [M+H]




Procedure: In a flame-dried round-bottom flask with a stir bar, precursor A to 4-6 (43.8 mg, 
0.0994 mmol) was dissolved in N, N-dimethylformamide (7 mL). Sodium azide (23.3 mg, 3.605 
mmol) was added to the mixture. The round-bottom flask was attached to a reflux condenser and 
was allowed to stir at 80 ºC in an oil bath. After 8 hours, saturated sodium bicarbonate was added 
to the mixture. The contents of the flask were extracted with ethyl acetate (4x). The organic layers 
were combined, dried over sodium sulfate, and concentrated under reduced pressure. The 
remaining N,N-dimethylformamide was removed under a stream of nitrogen. The crude residue 
was purified by flash chromatography (2:1 hexanes/ethyl acetate) on silica gel to afford precursor 




1H NMR (CDCl3, 500 MHz): δ 7.18 (t, J = 7.5 Hz, 1H), 7.03 (d, J = 7.5 Hz, 1H), 7.00 (d, J = 7.5 
Hz, 1H), 4.14 (dd, J = 12.8, 3.4 Hz, 1H), 3.78 (dd, J = 12.8, 8.7 Hz, 1H), 3.72 (dd, J = 11.3, 7.0 
Hz, 1H), 3.56 – 3.49 (m, 2H), 2.92 (t, J = 7.5 Hz, 1H), 2.72 (d, J = 17.9 Hz, 1H), 2.44 (d, J = 3.6 
Hz, 1H), 2.40 (s, 3H), 2.16 – 2.06 (m, 2H), 1.98 – 1.86 (m, 2H), 1.84 – 1.73 (m, 2H), 1.66 (ddd, J 
= 13.6, 7.2, 5.9 Hz, 1H). 
13C NMR (CDCl3, 125 MHz): δ 222.9, 145.9, 138.9, 134.6, 129.9, 128.0, 120.8, 65.8, 53.6, 52.1, 
52.0, 51.0, 50.1, 48.9, 32.1, 29.9, 22.2, 20.8. 
HRMS(ESI): m/z calc. for C18H22N3O2  [M+H]
+: 312.1712, found: 312.1703. 
 
 
Procedure: In a flame-dried round-bottom flask with a stir bar, precursor B to 4-6 (13.7 mg, 
0.0440 mmol) was dissolved in THF (5 mL) and H2O (0.1 mL). Triphenylphosphine (22 mg, 
0.0839 mmol) was added to the reaction and was allowed to stir under nitrogen for 22 hours. The 
mixture was concentrated under reduced pressure and dissolved in water. The mixture was 
acidified with 1 M HCl and extracted with diethyl ether. The reaction aqueous layer was basified 
with a saturated solution of sodium bicarbonae and 15% ammonium hydroxide. The reaction was 
extracted with dichloromethane (8x). The organic layers were combined, dried with sodium 
sulfate, and concentrated under reduced pressure. The crude residue was purified by C-18 
chromatography to afford 4-6 (1.1 mg, 9% yield) as a white solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.15 (t, J = 7.5 Hz, 1H), 7.02 (d, J = 7.6 Hz, 1H), 6.98 (d, J = 7.5 
Hz, 1H), 3.74 (d, J = 11.3 Hz, 1H), 3.52 (d, J = 11.3 Hz, 1H), 3.47 – 3.23 (m, 3H), 2.91 (t, J = 8.0 
Hz, 1H), 2.70 (d, J = 17.9 Hz, 1H), 2.40 (s, 3H) 2.45 – 2.37 (m, 1H), 2.17 – 2.07 (m, 1H), 2.05 (d, 
J = 11.7 Hz, 1H), 1.86 (ddt, J = 16.6, 14.1, 6.2 Hz, 2H), 1.77 – 1.71 (m, 1H), 1.65 (ddd, J = 13.6, 
7.5, 4.8 Hz, 1H). (20 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 223.4, 146.4, 139.9, 134.7, 129.8, 127.6, 120.8, 65.7, 53.8, 52.9, 
52.3, 49.9, 40.6, 32.1, 29.9, 29.7, 22.7, 20.4. 






Procedure: In a round bottom flask, AA1826 (47.0 mg, 0.142 mmol, 7 :7  = 8:2) was dissolved 
in tetrahydrofuran (1.4 mL). 1,8-Diazabicyclo[5.4.0]undec-7-ene (0.028 mL, 0.185 mmol) and 
diphenylphosphoryl azide (0.040 mL, 0.185 mmol) were added and the reaction was stirred at 
room temperature for 24 hours. The reaction was then quenched with 1 N HCl, and the aqueous 
layer was extracted with diethyl ether (3x). The combined organic layers were washed with 
saturated aqueous sodium bicarbonate and brine, dried over anhydrous magnesium sulfate, filtered 
and the diethylether was removed in vacuo. The residue was purified via column chromatography 
(1:9 ethyl acetate:hexanes) to afford the precursor to 4-6-a and 4-25 as a colorless oil (43.2 mg, 
86% yield, 7:7 = 2:8). 
 
1H NMR (CDCl3, 500 MHz): δ 7.25-7.06 (m, 3H), 4.63 (dd, J = 5.0, 1.5 Hz, 0.2H), 4.60 (dd, J = 
10.3, 7.6 Hz, 0.8H), 3.73 (s, 0.6H), 3.69 (s, 2.4H), 2.89 (qq, J = 6.9, 6.9 Hz, 1H), 2.51 (dd, J = 
12.7, 1.5 Hz, 0.2H), 2.30 (dd, J = 12.4, 1.9 Hz, 1.6H), 2.30 (m, 0.2H), 2.10 (ddd, J = 14.2, 12.7, 
4.8 Hz, 0.2H), 2.04-1.96 (m, 1H), 1.93-1.87 (m, 1H), 1.84-1.63 (m, 4.8H), 1.57-1.38 (m, 2H), 1.32 
(s, 2.4H), 1.28 (s, 0.6H), 1.28 (s, 2.4H), 1.25 (d, J = 6.9 Hz, 6H), 1.18 (s, 0.6H). 
13C NMR (CDCl3, 125 MHz): δ 178.5 (), 178.3 (), 147.3 (), 146.8 (), 146.7 (), 146.5 (), 
132.6 (), 131.1 (), 127.7 (), 127.0 (), 126.2 (), 126.0 (), 124.6 (), 124.3 (), 61.3 (), 60.1 
(), 52.1 (), 47.3 (), 47.2 (), 43.5 (), 40.5 (), 37.8 (), 37.5 (), 37.3 (), 37.2 (), 36.6 
(), 36.0 (), 33.6 (), 33.4 (), 28.5 (), 28.0 (), 25.4 (), 24.7 (), 23.9-23.8 ( 2C), 18.5 
(), 18.3 (), 16.5 (), 16.4 ().   
HRMS(ESI): m/z calc. for C21H29N3O2Na [M+Na]






Procedure: In a vial, dissolved precursor to 4-6-a and 4-25 (25.0 mg, 0.703 mmol) and potassium 
hydroxide (137.2 mg, 2.54 mmol) in methanol (1.4 mL) and water (0.2 mL). The vial was sealed 
and heated to reflux for 24 hours. The reaction was then cooled, acidified to pH2 with concentrated 
hydrochloric acid, and concentrated in vacuo. The salts were removed via C18 chromatography. 
In a round bottom flask under nitrogen, the resulting residue, benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (41.8 mg, 0.0803 mmol), and Hunig’s base 
(0.200 mL, 1.15 mmol) were dissolved in dichloromethane (1.2 mL). Ethylenediamine (40.0 µL, 
0.599 mmol) was added and the reaction stirred at room temperature for 13 hours. The reaction 
was then concentrated and purified via silica gel chromatography (9:1 dichloromethane/methanol). 
The product was dissolved in chloroform and washed 3 times with 1 M aqueous sodium hydroxide 
to remove any salts. The organic layer was concentrated to afford precursor to 4-6-a as a white 
solid (12.9 mg, 48% Yield over two steps, 7:7 = 2:8).  
 
1H NMR (CDCl3, 500 MHz): δ 7.25 – 7.01 (m, 3H), 6.50 (t, J = 5.8 Hz, 0.2 H), 6.38 (t, J = 5.4 
Hz, 0.8H), 4.71 (dd, J = 4.4, 1.9 Hz, 0.2 H), 4.61 (dd, J = 9.9, 8.0 Hz, 0.8 H), 3.41 – 3.28 (m, 2H), 
2.92 – 2.82 (m, 3H), 2.35 – 2.20 (m, 2H), 2.21 – 2.03 (m, 0.4H), 1.96 – 1.97 (m, 1.6 H), 1.87 – 
1.63 (m, 5H), 1.55 – 1.45 (m, 2H), 1.32 (s, 2.4H), 1.28 (s, 0.6H), 1.28 (s, 3H), 1.26 – 1.22 (m, 6H). 
13C NMR (CDCl3, 125 MHz): δ 178.23 ( 2C), 147.75 (), 147.05 (), 146.89 (), 146.86 (), 
132.94 (), 131.41 (), 127.66 (), 127.64 (), 126.46 (), 126.23 (), 125.36 (), 124.49 
(),61.62 (), 61.45 (), 47.23 (), 47.06 (), 44.00 (), 43.15 (), 42.28 (), 41.78 (), 41.51 (), 
41.33 (), 38.24 (), 38.04 (), 37.93 (), 37.52 (, C), 37.30 (), 33.85 (), 33.73 (), 28.29 
(), 28.18 (), 25.78 (), 25.36 (), 24.20 (), 24.16 (), 24.15 (), 23.97 (), 19.0 (), 18.77 (), 
16.84 (), 16.72 (). 
HRMS(ESI): m/z calc. for C22H34N5O [M+H]





Procedure: In a round bottom flask under nitrogen, 10% palladium on activated charcoal (6.9 mg, 
0.00648 mmol) and precursor to 4-6-a (12.9 mg, 0.0336 mmol) were dissolved in methanol (0.5 
mL). The reaction was stirred under an atmosphere of hydrogen gas at room temperature for 6 
hours. The palladium was then filtered over Celite, and the methanol was concentration in vacuo 
to afford 4-6-a as a white solid (6.2 mg, 52% yield,7α:7β = 2:8). 
 
 1H NMR (CDCl3, 500 MHz): δ 7.31 – 7.02 (m, 3H), 4.2 – 4.17 (m, 0.2H), 4.02 (dd, J = 10.2, 7.5, 
0.8H), 3.35 – 3.14 (m, 2H), 2.93 – 2.75 (m, 3H), 2.33 – 2.17 (m, 3H), 1.89 – 1.66 (m, 5H, 1.63 – 
1.37 (m, 6H), 1.32 – 1.20 (m, 12H).  
HRMS(ESI): m/z calc. for C22H36N3O [M+H]
+: 358.2858, found: 358.2868.  
 
 
Procedure: In a round bottom flask under nitrogen, azide 2-52 (54.1 mg, 0.183 mmol) was 
dissolved in pyridine. Acetic anhydride (80.0 µL, 0.846 mmol) and 4-dimethylaminopyridine (11.9 
mg, 0.0976 mmol) were added and the reaction was allowed to stir for 17 hours at room 
temperature. The reaction was quenched with a 6 M solution of hydrochloric acid (3.2 mL), and 
then extracted with ethyl acetate (3x). The combined organic layers were washed with brine, dried 
over sodium sulfate, filtered, and concentrated in vacuo. The resulting reside was purified via silica 
gel chromatography (95:5 to 80:2 hexanes/ethyl acetate) to afford the precursor for 18 (33.8 mg, 
55% yield) as a white solid.   
 
1H NMR (CDCl3, 500 MHz): δ 7.11 – 7.07 (m, 1H), 6.95 (dd, J = 7.5, 1.2 Hz, 1H), 6.92 (d, J = 
7.3 Hz, 1H), 5.04 (t, J = 2.6 Hz, 1H), 4.86 (t, J = 2.2 Hz, 1H), 4.17 (dd, J = 12.7, 5.2 Hz, 1H), 3.66 
152 
 
(dd, J = 12.7, 8.5 Hz, 1H), 3.30 (dd, J = 8.0, 5.7 Hz, 1H), 2.77 (dd, J = 12.4, 5.0 Hz, 1H), 2.62 (td, 
J = 11.8, 5.2 Hz, 1H), 2.54 (qd, J = 10.4, 2.3 Hz, 2H), 2.37 (s, 3H), 2.29 (dt, J = 17.2, 3.3 Hz, 1H), 
2.26 – 2.18 (m, 1H), 2.10 (s, 3H), 1.88 (dq, J = 17.2, 2.2 Hz, 1H), 1.67 – 1.52 (m, 2H). 
13C NMR (CDCl3, 125 MHz): δ 170.22, 150.98, 145.14, 140.18, 134.08, 129.71, 127.10, 120.11, 
104.75, 86.86, 54.53, 51.51, 50.73, 48.04, 44.88, 36.51, 31.10, 22.27, 22.00, 20.96. 
HRMS(ESI): m/z calc. for C20H24N3O2 [M+H]
+: 338.1869, found: 338.1863. 
 
 
Procedure: In a round bottom flask, the precursor for 18 (20.0 mg, 0.0592 mmol) was dissolved 
in tetrahydrofuran (0.6 mL). Triphenylphosphine (19.0 mg, 0.0724 mmol) and water (3.0 µL) were 
added and the reaction was allowed to stir at room temperature 18 hours. The reaction was then 
concentrated and purified via C18 chromatography to afford 18 (4-9) (10.1 mg, 54% yield) as a 
clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 7.07 (t, J = 7.6 Hz, 1H), 6.98 – 6.92 (m, 1H), 6.91 (d, J = 7.3 Hz, 
1H), 5.01 (t, J = 2.7 Hz, 1H), 4.85 (t, J = 2.3 Hz, 1H), 3.52 (dd, J = 12.1, 3.7 Hz, 1H), 3.18 – 3.06 
(m, 2H), 2.76 (dd, J = 12.3, 5.0 Hz, 1H), 2.63 – 2.54 (m, 2H), 2.50 (dd, J = 10.4, 2.6 Hz, 1H), 2.43 
– 2.37 (m, 1H), 2.39 (s, 3H), 2.25 – 2.18 (m, 1H), 2.08 (s, 3H), 1.9 (dq, J = 17.2, 2.3 Hz, 1H), 1.69 
– 1.52 (m, 2H). (23 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 170.20, 151.47, 145.38, 141.72, 134.23, 129.64, 126.57, 119.95, 
104.43, 87.08, 54.60, 51.97, 51.81, 45.78, 41.03, 36.79, 31.43, 22.30, 22.07, 20.92. 
HRMS(ESI): m/z calc. for C20H26NO2 [M+H]





Procedure: A solution of pleuromutilin (1.0 g, 2.6 mmol) in dichloromethane was cooled to -78 
ºC and a stream of ozone was passed through the reaction mixture until a blue color persisted (12 
minutes). The reaction mixture was then purged with oxygen, dimethyl sulfide (0.57 mL, 7.8 
mmol) was added, and the reaction was allowed to warm to room temperature while stirring for 
24 hours. The crude reaction mixture was washed with brine, extracted with dichloromethane, and 
the combined organic layers were dried with magnesium sulfate and evaporated. Purification by 
flash chromatography (2:1 ethyl acetate:hexanes) provided precursor A to 4-16 (503 mg, 51%) 
as a white solid.  
 
1H-NMR (CDCl3, 500 MHz): δ 9.53 (s, 1H), 5.33 (d, J = 8.5 Hz, 1H), 4.12 (d, J = 17.4 Hz, 1H), 
4.04 (d, J = 17.0 Hz, 1H), 3.37 (s, 1H), 3.00 – 2.66 (m, 1H), 2.33 (dt, J = 13.6, 6.6 Hz, 1H), 2.30 
– 2.13 (m, 2H), 2.05 (dd, J = 16.6, 8.8 Hz, 1H), 2.00 – 1.91 (m, 2H), 1.83 – 1.69 (m, 2H), 1.69 – 
1.58 (m, 2H), 1.46 (dt, J = 19.7, 7.8 Hz, 1H), 1.42 (s, 3H), 1.40 – 1.32 (m, 2H), 1.25 (s, 3H), 1.16 
– 1.10 (m, 1H), 1.07 (d, J = 6.8 Hz, 3H), 0.66 (d, J = 6.8 Hz, 3H). 
13C-NMR (CDCl3, 125 MHz, 60 C): δ 216.8, 208.3, 172.9, 74.1, 71.2, 61.3, 57.8, 54.5, 45.6, 
41.8, 40.6, 38.2, 36.6, 34.5, 30.4, 27.0, 24.8, 23.1, 17.2, 14.8, 11.6. 
HRMS(ESI): m/z calc. for C21H32O6Na [M+Na]
+: 403.2097, found: 403.2100. 
 
 
Procedure: Precursor A to 4-16 (450 mg, 1.18 mmol), hydroxylamine hydrochloride (164 mg, 
2.36 mmol), and sodium acetate (387, 4.72 mmol) were dissolved in acetonitrile (11.8 mL) and 
water (2.95 mL) and heated to 50 ºC in a sealed vial for 6 hours. The reaction mixture was then 
cooled to room temperature, diluted with water and extracted with ethyl acetate. The combined 
organic layers were washed with brine, dried with magnesium sulfate, and evaporated. Purification 
by flash chromatography (2:1 ethyl acetate:hexanes) provided precursor B to 4-16 (425 mg, 91%) 




1H-NMR (CDCl3, 500 MHz): δ 7.69 (s, 1H), 5.49 (d, J = 8.3 Hz, 1H), 4.11 (d, J = 17.2 Hz, 1H), 
4.03 (d, J = 17.2 Hz, 1H), 3.41 (d, J = 6.3 Hz, 1H), 2.35 (p, J = 6.5 Hz, 1H), 2.31 – 2.11 (m, 2H), 
2.09 – 1.99 (m, 3H), 1.97 (s, 1H), 1.76 (d, J = 13.0 Hz, 1H), 1.69 – 1.58 (m, 2H), 1.53 (s, 1H), 
1.50 – 1.48 (m, 1H), 1.48 – 1.45 (m, 1H), 1.46 – 1.42 (m, 1H), 1.41 (s, 3H), 1.39 – 1.30 (m, 1H), 
1.27 (s, 3H), 1.11 (td, J = 14.3, 4.4 Hz, 1H), 0.98 (d, J = 6.8 Hz, 3H), 0.66 (d, J = 7.0 Hz, 3H). 
13C-NMR (CDCl3, 125 MHz, 60 C): δ 217.3, 172.9, 157.1, 75.7, 71.0, 61.5, 58.1, 45.7, 45.3, 
43.6, 41.9, 37.7, 36.6, 34.6, 30.5, 28.0, 27.0, 25.1, 17.0, 14.9, 11.9. 
HRMS(ESI): m/z calc. for C21H34NO6 [M+H]
+: 396.2386, found: 396.2375. 
 
 
Procedure: In a flame-dried round bottom flask added Precursor B to 4-16 (301.5 mg, 0.766 
mmol) and ammonium acetate (240 mg, 3.1 mmol) and dissolved in methanol (8.0 mL). To the 
stirring solution at RT, added sodium cyanoborohydride (194 mg, 3.1 mmol) in one portion. The 
reaction mixture was cooled to 0 °C and titanium (III) chloride (0.99 mL, 1.192 g/mL, 0.766 mmol) 
was added as a 10% wt. solution in 20-30% wt. HCl. Reaction mixture was allowed to warm to 
RT and stirred for an additional 24 h. Reaction was quenched with the addition of 10% wt. NaOH 
and extracted with ethyl acetate (5x). Combined organic layers were dried over anhydrous sodium 
sulfate, filtered, and evaporated. The resulting residue was purified twice by silica gel 
chromatography eluting first with 83:15:2 CH2Cl2:CH3OH:Et3N and second with 89:10:1 
CHCl3:CH3OH:NH4OH to provide 4-16 (45.8 mg, 16%) as a clear oil. 
 
1H NMR (500 MHz, CD3OD) δ 5.58 (d, J = 8.6 Hz, 1H), 4.06 (d, J = 17.1 Hz, 1H), 3.99 (d, J = 
17.1 Hz, 1H), 3.57 (d, J = 6.3 Hz, 1H), 3.36 (d, J = 13.5 Hz, 1H), 2.81 (dd, J = 13.6, 0.8 Hz, 1H), 
2.41 (p, J = 7.0 Hz, 1H), 2.33 – 2.23 (m, 2H), 2.15 (dt, J = 19.1, 9.4 Hz, 1H), 1.97 (dd, J = 16.3, 
8.7 Hz, 1H), 1.83 (dq, J = 14.5, 3.1 Hz, 1H), 1.72 – 1.59 (m, 2H), 1.54 (qd, J = 13.8, 3.6 Hz, 1H), 
1.47 (dt, J = 10.1, 2.7 Hz, 1H), 1.43 (s, 3H), 1.39 (ddt, J = 14.19, 4.36, 3.04 Hz, 1H), 1.19 (d, J = 
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16.3 Hz, 1H), 1.22 – 1.11 (m, 1H), 1.15 (s, 3H), 0.99 (d, J = 7.1 Hz, 3H), 0.73 (d, J = 6.9 Hz, 3H). 
(31-nonexchangeable protons) 
13C NMR (126 MHz, CD3OD) δ 217.97, 172.32, 75.23, 68.97, 60.43, 57.43, 45.32, 43.96, 41.60, 
41.54, 40.69, 36.59, 35.40, 33.83, 30.12, 26.77, 24.46, 24.23, 15.96, 13.75, 10.50. 
HRMS(ESI): m/z calc. for C21H36NO5 [M+H]




Procedure: In a round bottom flask, the precursor to 4-6-a and 4-25 (43.2 mg, 0.121 mmol, 
7:7 = 2:8) was dissolved in tetrahydrofuran (1 mL) and water (0.2 mL). Triphenylphosphine 
(38.3 mg, 0.146 mmol) was added and the reaction was stirred at 50˚C for 2 days. The reaction 
was then diluted with diethylether and saturated aqueous sodium bicarbonate, and the aqueous 
layer was extracted three times with diethylether. The combined organic layers were dried over 
anhydrous magnesium sulfate, filtered and the diethylether was removed in vacuo. The residue 
was purified via column chromatography (1:9 methanol:chloroform) to afford 4-25 as a colorless 
oil (28.5 mg, 71% yield, 7:7 = 2:8).  
 
1H NMR (CDCl3, 500 MHz): δ 7.31 (s, 0.8H), 7.18-7.13 (m, 1.2H), 7.08-7.05 (m, 1H), 4.04 (dd, 
J = 10.2, 7.3 Hz, 1H), 3.67 (s, 0.6H), 3.66 (s, 2.4H), 2.87 (m, 0.2H), 2.87 (qq, J = 6.9, 6.9 Hz, 
0.8H), 2.45 (d, J = 12.9 Hz, 0.2H), 2.28 (d, J = 12.3 Hz, 1.8H), 2.13 (ddd, J = 13.3, 13.3, 5.4 Hz, 
0.2H), 1.98 (br, 2.8H), 1.82-1.61 (m, 6H), 1.50-1.32 (m, 2H), 1.28-1.23 (m, 11.4 H), 1.17 (s, 0.6H). 
13C NMR (CDCl3, 125 MHz): δ 178.8 (), 146.6 (), 146.4 (), 146.3 (), 146.1 (), 139.1 (), 
138.3 (), 127.6 (), 125.4 (), 125.2 (), 124.9 (), 124.2 (), 52.0 (), 51.6 (), 49.5 (), 
47.4 (), 43.9 (), 39.7 (), 38.0 (), 37.8 (), 37.5 (), 36.6 (), 36.4 (), 33.8 (), 33.6 (), 
33.5 (), 31.2 (), 25.6 (), 24.5 (), 24.1 (), 24.0 (), 23.9 (), 23.8 (), 18.6 (), 18.4 (), 16.4 
(). 
HRMS: m/z calc. for C21H32NO2 [M+H]





Procedure: In a vial, osteltamivir phosphate (60.3 mg, 0.15 mmol) was suspended in ethanol (1.8 
mL). Ethylene diamine (150.0 μL, 2.2 mmol) was added and the vial was sealed before being 
heated to 85°C with stirring. After 36 hours, the mixture was cooled to room temperature and 
concentrated in vacuo. The residue was purified via C18 chromatography with 0.1% formic acid 
in the running buffer. The product was concentrated, dissolved in 1 M HCl (aq) and concentrated 
again to afford 4-28-a (9.7 mg, 20% yield) as a hydrochloride salt. 
 
 1H NMR (CD3OD, 500 MHz): δ 6.58 (t, J = 2.2 Hz, 1H), 4.32 – 4.23 (m, 1H), 3.97 (dd, J = 11.5, 
8.5 Hz, 1H), 3.60 – 3.43 (m, 4H), 3.12 (t, J = 6.0 Hz, 2H), 2.93 (ddt, J = 17.1, 5.7, 1.2 Hz, 1H), 
2.58 – 2.45 (m, 1H), 2.05 (s, 3H), 1.63 – 1.44 (m, 4H), 0.91 (dt, J = 15.6, 7.4 Hz, 6H). (24 non-
exchangable protons) 
13C NMR (CD3OD, 125 MHz): δ 173.38, 168.41, 133.01, 129.75, 82.37, 74.27, 53.12, 49.53, 
39.42, 37.10, 28.43, 25.79, 25.08, 21.84, 8.38, 8.15. 
HRMS (ESI): m/z calc. for C16H31N4O3 [M+H]




Procedure: Lovastatin (1.01 g, 2.5 mmol) was diluted in tetrahydrofuran (10.0 mL) in a round 
bottom flask. 28% aqueous ammonia (1.6 mL, 25 mmol) was slowly added drop wise and the 
reaction was allowed to stir at room temperature for 14 hours. The reaction mixture was then  
diluted in a saturated solution of sodium carbonate and extracted with ethyl acetate (3x). The 
combined organic layers were washed with brine, dried over magnesium sulfate, filtered and 
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concentrated. The resulting residue was purified via silica gel chromatography (100% ethyl acetate 
to 10% methanol in ethyl acetate) to afford the intermediate (533.6 mg, 51% yield) as a white 
solid.  
In a dry round bottom flask under nitrogen, tetrahydrofuran (2.0 mL) was cooled to 0°C. Lithium 
aluminum hydride (32.3 mg, 0.851 mmol) was added. The intermediate (79.8 mg, 0.189 mmol) 
was dissolved in tetrahydrofuran (1.0 mL) and slowly added to the lithium aluminum hydride 
mixture. The reaction was then allowed to reflux for 17 hours. The reaction was cooled to 0°C and 
diluted with tetrahydrofuran (1 mL). The lithium aluminum hydride was quenched with water 
(0.05 mL), a 10% solution of sodium hydroxide (0.05 mL) and water (0.150 mL). The mixture 
was allowed to stir at room temperature for 20 minutes, at which point it was filtered over Celite. 
The flow through was concentrated and purified via C18 chromatography to afford 4-35 (4.2 mg, 
7% yield; 4% yield over 2 steps) as a clear oil.  
 
1H NMR (CDCl3, 500 MHz): δ 5.99 (d, J = 9.6 Hz, 1H), 5.80 (dd, J = 9.6, 6.0 Hz, 1H), 5.56 (t, J 
= 3.3 Hz, 1H), 4.33 (t, J = 3.3 Hz, 1H), 4.11 (ddt, J = 11.1, 8.8, 2.7 Hz, 1H), 4.06 – 3.95 (m, 1H), 
3.17 (ddd, J = 12.4, 5.3, 3.8 Hz, 1H), 2.90 (ddd, J = 12.7, 9.9, 3.6 Hz, 1H), 2.43 (ddd, J = 17.7, 
9.9, 5.1 Hz, 2H), 2.14 (dd, J = 12.1, 2.9 Hz, 1H), 1.97 – 1.80 (m, 4H), 1.66 – 1.45 (m, 5H), 1.40 
(dtd, J = 12.4, 8.0, 4.1 Hz, 1H), 1.31 (tdd, J = 13.8, 9.8, 5.8 Hz, 1H), 1.21 (d, J = 7.5 Hz, 3H), 0.92 
(d, J = 7.0 Hz, 3H). (28 non-exchangeable protons) 
HRMS(ESI): m/z calc. for C19H34NO3 [M+H]
+: 324.2539, found: 324.2534. 
 
 
Procedure: In a dry round bottom flask, isomannide azide (43.4 mg, 0.254 mmol) was dissolved 
in dichloromethane (5 mL). The reaction was treated with acetyl chloride (0.09 mL, 1.27 mmol)  
and dimethylaminopyridine (61.9 mg, 0.507 mmol) and allowed to stir overnight. The reaction 
was then quenched with 1 M HCl (10 mL) and extracted with dichloromethane (3 x 10 mL). The 
combined organic layers were washed with NaHCO3 (10 mL), dried over Na2SO4 and concentrated 
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in vacuo. The resulting residue was purified by flash chromatography on silica gel (5:1 
hexanes/ethyl acetate) to yield clear oil precursor to 4-37-a (33.3 mg, 62%). 
 
1H NMR (CDCl3, 500 MHz): δ 5.15 (q, J = 5.54 Hz, 1H), 4.80 (t, J = 5.04 Hz, 1H), 4.46 (d, J = 
4.58 Hz, 1H), 4.01 (m, 2H), 3.92 (m, 2H), 3.79 (dd, J = 5.18, 9.89 Hz, 1H), 2.10 (s, 3H). 
13C NMR (CDCl3,125 MHz): δ 170.33, 86.55, 80.84, 73.91, 72.55, 70.65, 65.92, 20.74. 
HRMS(ESI): m/z calc. for C8H12N3O4 [M+H]
+: 214.0828 , found: 214.0832. 
 
 
Procedure for 4-37-a: Prepared according to general procedure B, then purified by flash 
chromatography on silica gel (10% methanol/chloroform) to yield 4-37-a as a white solid (23.1 
mg, 72%) 
 
1H NMR (CDCl3, 500 MHz): 5.12 (q, J = 5.5 Hz, 1H), 4.80 (dd, J = 5.5, 4.6 Hz, 1H), 4.24 (d, J = 
4.5 Hz, 1H), 3.91 (dd, J = 8.4, 3.4 Hz, 1H), 3.89 (dd, J = 9.0, 5.2 Hz, 1H), 3.78 (dd, J = 9.9, 5.1 
Hz, 1H), 3.74 (dt, J = 9.1, 1.0 Hz, 1H), 3.53 (d, J = 4.0 Hz, 1H), 2.11 (s, 3H). (12 non-exchangeable 
protons) 
13C NMR (CDCl3,125 MHz): δ 170.59, 90.10, 80.32, 76.09, 74.32, 70.40, 58.24, 20.83. 
HRMS(ESI): m/z calc. for C8H14NO4 [M+H]




Procedure for 4-41: Prepared according to general procedure B.  




1H NMR (CD3OD, 500 MHz): δ 4.77 (t, J = 4.9 Hz, 1H), 4.36 (d, J = 4.7 Hz, 1H), 4.35 – 4.29 (m, 
1H), 4.27 – 4.12 (m, 2H), 3.99 (dd, J = 9.7, 4.3 Hz, 1H), 3.85 (dd, J = 9.5, 5.9 Hz, 1H), 3.80 (d, J 
= 9.7 Hz, 1H), 3.76 – 3.71 (m, 1H), 3.74 (s, 3H), 3.53 (d, J = 4.3 Hz, 1H). (13 non-exchangeable 
protons) 
13C NMR (CD3OD, 125 MHz): δ 172.42, 89.16, 82.03, 81.55, 75.13, 72.30, 68.37, 58.83, 52.26. 
HRMS(ESI): m/z calc. for C9H16NO5 [M+H]




Procedure: In a dry round bottom flask under nitrogen, lisinopril·2H2O (97.0 mg, 0.220 mmol) 
was dissolved in toluene (2.4 mL) and methanol (0.5 mL). Trimethylsilyldiazomethane (2.0 M in 
hexanes, 0.30 mL, 0.600 mmol) was added and the reaction stirred for 14 hours at room 
temperature. The reaction was concentrated in vacuo and purified via C18 chromatography to 
afford 4-44 (52.3 mg, 55% yield) as a yellow solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.26 – 7.23 (m, 1H), 7.19 – 7.13 (m, 4H), 4.55 – 4.47 (m, 1H), 
3.71 (s, 3H), 3.68 (s, 3H), 3.60 (ddd, J = 9.7, 7.7, 5.6 Hz, 1H), 3.53 (dt, J = 9.4, 6.5 Hz, 1H), 3.39 
(dd, J = 7.0, 5.8 Hz, 1H), 3.27 – 3.15 (m, 1H), 2.77 – 2.35 (m, 4H), 2.28 – 2.13 (m, 1H), 2.10 – 
1.78 (m, 4H), 1.72 – 1.37 (m, 7H). (32 non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 174.92, 173.42, 172.73, 141.30, 128.56, 128.47, 126.09, 59.85, 
58.88, 58.00, 52.36, 52.00, 46.78, 41.86, 34.93, 33.45, 33.32, 32.15, 29.01, 25.09, 22.81. (21 
carbons due to symmetry) 
HRMS(ESI): m/z calc. for C23H36N3O5 [M+H]






Procedure for the precursor to 17: Prepared with dodecanesulfonyl chloride according to 
general procedure A. 
Yield: 38.0 mg, 23% 
 
1H NMR (CDCl3, 500 MHz): δ 5.09 (q, J = 5.7 Hz, 1H), 4.80 (t, J = 4.9 Hz, 1H), 4.50 (d, J = 4.5 
Hz, 1H), 4.09 –  4.04 (m, 2H), 4.00 (dd, J = 11.5, 4.2 Hz, 1H),  3.98 (dd, J = 11.3, 5.9 Hz, 1H) 
3.87 (dd, J = 10.0, 5.7 Hz, 1H), 3.22 – 3.17 (m, 2H), 1.88 (ddd, J = 15.5, 8.4, 6.8 Hz, 2H), 1.47 – 
1.39 (m, 2H), 1.37 – 1.19 (m, 17H), 0.88 (t, J = 6.9 Hz, 2H). 
13C NMR (CDCl3, 125 MHz): δ 86.67, 80.75, 78.09, 72.95, 70.86, 66.01, 51.76, 32.09, 29.78, 
29.67 (2C), 29.51, 29.43, 29.15, 28.32, 23.56, 22.87, 14.31. (To establish that carbon resonances 
overlapped, an inversed gated 13C NMR experiment was performed to obtain a quantitative 13C 
NMR.) 
HRMS(ESI): m/z calc. for C18H33N3O5SNa [M+Na]




Procedure for 17 (4-50): Prepared according to general procedure B.  




1H NMR (CDCl3, 500 MHz):  δ 5.07 (q, J = 5.8 Hz, 1H), 4.80 (t, J = 4.8 Hz, 1H), 4.28 (d, J = 4.4 
Hz, 1H), 3.98 (dd, J = 9.1, 4.0 Hz, 1H), 3.96 – 3.92 (m, 1H), 3.85 (dd, J = 9.8, 6.0 Hz, 1H), 3.79 
(d, J = 9.3 Hz, 1H), 3.58 (d, J = 4.2 Hz, 1H), 3.25 – 3.14 (m, 2H), 1.88 (p, J = 7.8 Hz, 2H), 1.55 – 
1.37 (m, 4H), 1.35 – 1.20 (m, 17H), 0.88 (t, J = 6.9 Hz, 2H).  
13C NMR (CDCl3, 125 MHz): δ 90.08, 80.20, 78.46, 76.45, 70.45, 58.33, 51.68, 32.04, 29.74 (2C), 
29.64, 29.47 (2C), 29.40, 29.12, 28.30, 23.53, 22.83, 14.27. (To establish that carbon resonances 
overlapped, an inversed gated 13C NMR experiment was performed to obtain a quantitative 13C 
NMR.) 
HRMS(ESI): m/z calc. for C18H36N3O5S [M+H]




Procedure: In a dry round bottom flask under argon, G16m (29.8 mg, 0.077 mmol), N-Fmoc-L-
valine chloride (112.7 mg, 0.315 mmol), and 4-dimethylaminopyridine (6.8 mg, 0.056 mmol) were 
dissolved in dichloromethane (1.0 mL) and cooled to 0°C. Diisopropylethylamine (0.60 mL, 3.44 
mmol) was slowly added, the reaction was stirred for one hour and then quenched with water. The 
aqueous layer was extracted with ethyl acetate (3x), the combined organic layers were washed 
with brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The 
resulting residue was purified via silica gel chromatography (1:1 to 3:2 ethyl acetate/hexanes) to 
afford the precursor to 4-51 (23.0 mg, 41% yield) as a white solid.  
 
1H NMR (CDCl3, 500 MHz): δ 7.77 (dd, J = 7.6, 1.0 Hz, 2H), 7.61 (d, J = 7.5 Hz, 2H), 7.40 (tdd, 
J = 7.4, 2.0, 1.0 Hz, 2H), 7.32 (tdd, J = 7.5, 4.0, 1.1 Hz, 2H), 6.66 – 6.56 (m, 1H), 5.74 – 5.70 (m, 
1H), 5.33 (d, J = 9.2 Hz, 1H), 5.10 – 5.06 (m, 2H), 5.03 (t, J = 5.2 Hz, 1H), 4.98 (s, 1H), 4.48 – 
4.33 (m, 3H), 4.23 (t, J = 7.1 Hz, 1H), 2.75 (tt, J = 7.2, 3.6 Hz, 2H), 2.53 – 2.44 (m, 1H), 2.38 – 
2.29 (m, 2H), 2.20 (d, J = 6.1 Hz, 2H), 1.97 – 1.83 (m, 1H), 1.77 – 1.49 (m, 2H), 1.46 (dd, J = 
11.0, 2.7 Hz, 1H), 1.35 (dd, J = 10.3, 2.6 Hz, 1H), 1.21 (d, J = 1.9 Hz, 3H), 1.00 (d, J = 6.8 Hz, 
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3H), 0.91 (d, J = 6.8 Hz, 3H), 0.90 – 0.86 (m, 1H), 0.76 (dtt, J = 14.4, 6.9, 4.8 Hz, 2H), 0.53 – 0.45 
(m, 2H). 
13C NMR (CDCl3, 125 MHz): 176.34, 175.15, 171.95, 156.47, 153.70, 152.92, 144.06, 143.92, 
141.53, 127.97, 127.31, 125.29, 120.25, 120.23, 112.74, 107.16, 79.18, 76.40, 72.78, 67.42, 59.22, 
50.62, 49.51, 48.95, 47.99, 47.38, 46.27, 45.55, 38.83, 37.46, 31.40, 23.15, 19.36, 18.88, 17.64, 
17.45, 7.01, 6.69. (38 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C42H46N2O8 [M+H]




Procedure: In a round bottom flask, abietic acid (235 mg, 0.777 mmol) was dissolved in 
dichloromethane (5 mL). Diisopropylethylamine (0.105 mL, 0.600 mmol) and (Benzotriazol-1-
yloxy)tripyrrolidinophosphonium hexafluorophosphate (312 mg, 0.600 mmol) were added and the 
reaction was stirred at room temperature for 3 hours. Diisopropylamine (0.19 mL, 1.09 mmol) and 
monoFmoc-ethylenediamine (308 mg, 1.09 mmol) were then added and the reaction was stirred 
further 2 hours. The reaction was quenched with 1 N hydrochloric acid, and the aqueous layer was 
extracted three times with dichloromethane. The combined organic layers were washed with brine, 
dried over anhydrous magnesium sulfate, filtered and the dichloromethane was removed in vacuo. 
The residue was purified via column chromatography (2:3 ethyl acetate:hexanes) to afford the 
precursor to 4-54 as a white solid (258 mg, 83% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 7.76 (d, J = 7.5 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.40 (dd, J = 
7.5, 7.5 Hz, 2H), 7.31 (dd, J = 7.5, 7.5 Hz, 2H), 6.33 (br, 1H), 5.68 (s, 1H), 5.29 (br, 1H), 5.25 (m, 
1H), 4.37 (d, J = 7.1 Hz, 2H), 4.20 (t, J = 7.1 Hz, 1H), 3.42-3.34 (m, 4H), 2.17 (m, 1H), 2.05-1.77 
(m, 9H), 1.59-1.48 (m, 3H), 1.24 (s, 3H), 1.22-1.12 (m, 2H), 0.98 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 
6.8 Hz, 3H), 0.81 (s, 3H). 
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13C NMR (CDCl3, 125 MHz): δ 179.64, 145.22, 143.97, 143.92, 141.36, 135.60, 127.79, 127.15, 
125.20, 125.17, 122.44, 120.46, 120.05, 67.05, 50.96, 47.24, 46.39, 45.63, 41.10, 40.77, 38.33, 
37.53, 34.91, 34.69, 27.45, 25.39, 22.53, 21.46, 20.92, 18.36, 17.04, 14.21.  (31 carbons due to 
symmetry) 
HRMS: m/z calc. for C37H47N2O3 [M+H]




Procedure: In a round bottom flask, the precursor to 4-54 (58.6 mg, 0.103 mmol) was dissolved 
in dichloromethane (1 mL). Piperidine (0.20 mL) was added and the reaction was stirred at room 
temperature for 1 hour. The reaction was then diluted with acetonitrile, filtered and the solvents 
were removed in vacuo. The residue was purified via C18 chromatography to afford 4-54 as a 
colorless oil (21.9 mg, 62% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 6.25 (br, 1H), 5.73 (s, 1H), 5.32 (m, 1H), 3.26 (m, 2H), 2.80 (t, J 
= 5.8 Hz, 2H), 2.20 (qq, J = 6.7, 6.7 Hz, 1H), 2.09 – 1.77 (m, 9H), 1.59 – 1.49 (m, 5H), 1.26 (s, 
3H), 1.25 – 1.13 (m, 2H), 0.99 (d, J = 6.7 Hz, 3H), 0.98 (d, J = 6.7 Hz, 3H), 0.82 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 178.86, 145.43, 135.77, 122.58, 120.68, 51.14, 46.59, 45.90, 
42.42, 41.59, 38.50, 37.77, 35.08, 34.84, 27.62, 25.57, 22.68, 21.62, 21.06, 18.53, 17.20, 14.35. 
HRMS: m/z calc. for C22H37N2O [M+H]






Procedure: In a round bottom flask, abietic acid (235 mg, 0.777 mmol) was dissolved in toluene 
(7 mL). Triethylamine (0.32 mL, 2.33 mmol) and diphenylphosphoryl azide (0.33 mL, 1.55 mmol) 
were added and the reaction was stirred at 80˚C for 3 hours. The reaction was then quenched with 
brine, and the aqueous layer was extracted with diethyl ether (3x). The combined organic layers 
were washed with brine, dried over anhydrous magnesium sulfate, filtered and the diethylether 
was removed in vacuo. The residue was purified via column chromatography (1:99 ethyl 
acetate:hexanes) to afford precursor to 29 as a colorless oil (154 mg, 66% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 5.79 (s, 1H), 5.44 (m, 1H), 2.35 – 2.20 (m, 2H), 2.09 – 1.77 (m, 
7H), 1.69 – 1.56 (m, 3H), 1.47 (m, 1H), 1.35 (s, 3H), 1.22 (m, 1H), 1.09 (td, J = 13.2, 3.7 Hz, 1H), 
1.02 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H), 0.77 (s, 3H). 
13C NMR (CDCl3, 125 MHz): δ 145.54, 135.52, 122.41, 122.17, 120.33, 61.59, 51.58, 50.90, 
43.45, 38.30, 35.91, 35.00, 27.55, 24.20, 24.03, 22.87, 21.54, 20.97, 19.52, 13.68. 
HRMS: m/z calc. for C20H30NO [M+H]
+: 300.2327, found: 300.2325. 
 
 
Procedure: In a round bottom flask, the precursor to 29 (41.7 mg, 0.139 mmol) was dissolved in 
THF (1.4 mL). Concentrated hydrochloric acid (0.2 mL) was added and the reaction was stirred at 
room temperature for 2 hours. The reaction was then basified with 2 N sodium hydroxide, and the 
aqueous layer was extracted with chloroform (3x). The combined organic layers were dried over 
anhydrous magnesium sulfate, filtered and the chloroform was removed in vacuo. The residue was 
purified via column chromatography (1:4 methanol:chloroform including 0.5% triethylamine) to 
afford 29 (4-55) as a white solid (36.2 mg, 95% yield).  
 
1H NMR (CDCl3, 500 MHz): δ 5.77 (s, 1H), 5.43 (m, 1H), 2.30 (m, 1H), 2.20 (p, J = 6.8 Hz, 1H), 
2.08 (br, 2H), 2.08 – 1.92 (m, 3H), 1.88-1.75 (m, 3H), 1.69 (m, 1H), 1.59 – 1.43 (m, 2H), 1.30 (dd, 
J = 12.3, 4.7 Hz, 1H), 1.29 – 1.15 (m, 2H), 1.06 (s, 3H), 1.03 (m, 1H), 0.99 (d, J = 6.8 Hz, 3H), 
0.98 (d, J = 6.8 Hz, 3H), 0.76 (s, 3H). 
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13C NMR (CDCl3, 125 MHz): δ 145.26, 135.58, 122.52, 121.03, 53.25, 51.37, 51.01, 44.36, 38.99, 
35.70, 34.97, 27.61, 23.28, 22.98, 21.52, 20.95, 19.94, 13.47. (18 carbons due to symmetry) 
HRMS: m/z calc. for C19H32N [M+H]
+: 274.2535, found: 274.2534. 
 
 
Procedure: To a dry round bottom flask was added N-Boc-glycine (52.4, 0.299 mmol), 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (57.3 mg, 0.299 mmol), 4-dimethylaminopyridine (36.5 
mg, 0.299 mmol), and isomannide azide (34.1 mg, 0.199 mmol). The mixture was dissolved in 
dichloromethane (2 mL) and allowed to stir overnight. The reaction was then diluted with 
dichloromethane (10 mL) and rinsed with 0.5 M HCl (10 mL) and saturated NaHCO3 (10 mL). 
The organic layer was dried over Na2SO4 then concentrated in vacuo. The residue was purified by 
flash column chromatography on silica gel (1:1 ethyl acetate/hexanes) to yield precursor A to 4-
55-a as a clear oil (44. 6 mg, 72%) 
 
1H NMR (CDCl3, 500 MHz): δ 5.22 (td, J = 4.58, 5.63 Hz, 1H), 5.04 (m, 1H), 4.83 (t, J = 5.14 
Hz, 1H), 4.45 (d, J = 4.66 Hz, 1H), 4.01 (m, 3H), 3.88 (m, 4H), 1.44 (s, 9H). 
13C NMR (CDCl3,125 MHz): δ 169.92, 155.76, 86.66, 80.83, 80.23, 74.67, 72.53, 70.80, 65.78, 
42.29, 28.42. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C13H21N4O6 [M+H]




Procedure for precursor B to 4-55-a: Prepared according to general procedure B and purified by 




1H NMR (CDCl3, 500 MHz): δ 5.18 (q, J = 5.16 Hz, 1H), 5.11 (s, 1H), 4.81 (t, J = 5.13 Hz, 1H), 
4.22 (d, J = 4.65 Hz, 1H), 4.02 (dd, J = 6.15, 18.38 Hz, 1H), 3.89 (dd, J = 5.30, 18.29 Hz, 1H), 
3.85 (m, 3H), 3.72 (d, J = 8.83 Hz, 1H), 3.52 (d, J = 3.94 Hz, 1H), 1.43 (s, 9H). (20 non-
exchangeable protons) 
13C NMR (CDCl3,126 MHz): δ 170.07, 155.77, 90.09, 80.30, 80.12, 75.99, 75.06, 70.55, 58.02, 
42.29, 28.42. (11 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C13H23N2O6 [M+H]




Procedure: To a flask containing precursor B to 4-55-a (36.9 mg, 0.122 mmol) in 
dichloromethane (2 mL) was added trifluoroacetic acid (0.5 mL). After stirring for 1.5 h, the 
reaction was diluted with 2 mL toluene and concentrated in vacuo. The residue was triturated with 
dichloromethane (3 mL), to yield 4-55-a (35.8 mg, 98% yield). 
 
1H NMR (CD3OD, 500 MHz): δ 5.38 (ddd, J = 6.1, 4.9, 2.7 Hz, 1H), 5.00 (dd, J = 6.1, 5.2 Hz, 
1H), 4.55 (d, J = 5.1 Hz, 1H), 4.04 – 3.99 (m, 2H), 3.98 – 3.96 (m, 1H), 3.93 (d, J = 6.2 Hz, 2H), 
3.92 – 3.89 (m, 1H), 3.84 (d, J = 4.1 Hz, 1H), 3.31 (p, J = 1.6 Hz, 1H). (11 non-exchanged protons) 
13C NMR (CD3OD, 125 MHz): δ 166.631, 61.18 (q, J = 35.3 Hz), 116.55 (q, J = 291.9 Hz), 84.86, 
81.07, 75.51, 71.11, 70.83, 56.11, 39.34. (Extra carbons due to TFA salt) 
HRMS(ESI): m/z calc. for C8H15N2O4 [M+H]






Procedure: To a solution of pleuromutilin (757 mg, 2 mmol) and p-tosyl chloride (763 mg, 4 
mmol) in methyl t-butyl ether (2 mL) and water (0.5 mL) was added a solution of 10 M sodium 
hydroxide (0.5 mL) dropwise. The reaction mixture was then heated to reflux for 1 hour, cooled 
to room temperature, diluted with water, and extracted with ethyl acetate. The combined organic 
layers were washed with brine, dried with magnesium sulfate, and evaporated. Purification by flash 
chromatography (2:3 ethyl acetate:hexanes) provide the precursor to 4-57 (706 mg, 66%) as a 
white solid. 
 
1H NMR (CDCl3, 500 MHz): δ 7.76 (d, J = 8.3 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 6.35 (dd, J = 
17.4, 11.0 Hz, 1H), 5.71 (d, J = 8.5 Hz, 1H), 5.27 (dd, J = 11.0, 1.5 Hz, 1H), 5.14 (dd, J = 17.5, 
1.6 Hz, 1H), 4.44 (s, 2H), 3.32 (dd, J = 10.3, 6.4 Hz, 1H), 2.41 (s, 3H), 2.26 – 2.09 (m, 3H), 2.06 
– 2.04 (m, 1H), 2.00 (dd, J = 16.1, 8.6 Hz, 1H), 1.71 (dq, J = 14.5, 3.1 Hz, 1H), 1.65 – 1.55 (m, 
3H), 1.49 – 1.37 (m, 2H), 1.36 (s, 3H), 1.34 – 1.25 (m, 1H), 1.20 (d, J = 16.0 Hz, 1H), 1.11 (s, 
3H), 1.10 – 1.02 (m, 1H), 0.83 (d, J = 7.0 Hz, 3H), 0.57 (d, J = 7.0 Hz, 3H). 
13C NMR (CDCl3, 125 MHz, 60 C): δ 216.84, 164.83, 145.34, 138.78, 132.50, 129.95, 128.07, 
117.27, 74.47, 70.31, 65.10, 57.99ism, 45.38, 44.47, 43.96, 41.82, 36.52, 36.04, 34.41, 30.32, 
26.77, 26.51, 24.81, 21.71, 16.53, 14.76, 11.50. (27 carbons due to symmetry) 
HRMS(ESI): m/z calc. for C29H40O7SNa [M+Na]
+: 555.2392, found: 555.2406. 
 
 
Procedure: To a solution of cysteamine hydrochloride (9 mg, 0.11 mmol) in ethanol (903 µL) at 
room temperature was added a solution of sodium ethoxide (97 µL, 0.26 mmol, 21% in ethanol) 
and the mixture was stirred for 30 minutes. The solution was then cooled to 0 ºC, the precursor 
168 
 
to 4-57 (53 mg, 0.1 mmol) was added, and the reaction was stirred at 0 ºC for 3.5 hours. The crude 
reaction mixture was then warmed to room temperature diluted with water and extracted with ethyl 
acetate. The combined organic layers were washed with brine, dried with magnesium sulfate, and 
evaporated. Purification by flash chromatography (10% methanol and 2% triethylamine in ethyl 
acetate) provided 4-57 (25 mg, 58%) as a white solid. 
 
1H-NMR (CD3OD, 500 MHz): δ 6.32 (dd, J = 17.5, 11.2 Hz, 1H), 5.74 (d, J = 8.3 Hz, 1H), 5.35 – 
5.03 (m, 2H), 3.50 (d, J = 6.2 Hz, 1H), 3.29 – 3.19 (m, 2H), 2.97 – 2.89 (m, 2H), 2.78 (td, J = 6.6, 
3.1 Hz, 2H), 2.41 – 2.37 (m, 1H), 2.37 – 2.22 (m, 2H), 2.23 – 2.11 (m, 2H), 1.82 (dq, J = 14.1, 2.9 
Hz, 1H), 1.75 – 1.52 (m, 3H), 1.52 – 1.41 (m, 4H), 1.42 – 1.33 (m, 2H), 1.26 – 1.17 (m, 1H), 1.16 
(s, 3H), 1.14 – 1.05 (m, 1H), 0.94 (d, J = 7.0 Hz, 3H), 0.74 (d, J = 6.7 Hz, 3H). (37 non-
exchangeable protons) 
13C-NMR (CD3OD, 125 MHz, 60 C): δ 219.6, 170.7, 141.3, 116.5, 75.4, 71.3, 59.3, 46.8, 46.0, 
45.3, 43.1, 40.6, 38.2, 37.7, 35.3, 34.9, 34.7, 31.5, 28.2, 28.0, 25.8, 17.1, 15.4, 11.8. 
HRMS(ESI): m/z calc. for C24H40NO4S [M+H]
+: 438.2678, found: 438.2680. 
 
 
Procedure: In a round bottom flask, AA1026 (19.5 mg, 0.0497 mmol) was dissolved in pyridine 
(0.5 mL). Hydroxylamine hydrochloride (10.4 mg, 0.149 mmol) was added and the reaction was 
stirred at room temperature for 1 hour. The reaction was then quenched with 1 N HCl, and the 
aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with 
brine, dried over anhydrous magnesium sulfate, filtered and the ethyl acetate was removed in 
vacuo. The residue was purified via column chromatography (4:6 ethyl acetate:hexanes) to afford 
an oxime as a white solid (17.5 mg). 
The oxime (17.0 mg, 0.0401 mmol) was dissolved in methanol (0.4 mL). Ammonium acetate (30.9 
mg, 0.401 mmol) and sodium cyanoborohydride (25.2 mg, 0.401 mmol) were added, and then 
titanium trichloride  (10wt% in aqueous hydrochloric acid, 0.35 mL, 0.225 mmol) was added 
slowly. After being stirred at room temperature for 14 hours, the reaction was quenched with 
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aqueous sodium bicarbonate. The aqueous layer was extracted with chloroform. The organic layer 
was washed with brine, dried over anhydrous magnesium sulfate, filtered, and the solvents were 
removed in vacuo. The residue was purified via silica gel chromatography (1:9 
methanol:chloroform) to afford 4-59 as a colorless oil (14.0 mg, 70% for 2 steps). 
 
1H NMR (CDCl3, 500 MHz): δ 4.52 (s, 1H), 3.68 (s, 3H), 3.06 (dd, J = 13.4, 3.9 Hz, 1H), 2.73 
(dd, J = 13.4, 4.5 Hz, 1H), 2.31 (d, J = 13.6 Hz, 1H), 2.01 – 1.93 (m, 3H), 1.78-1.55 (m, 8H), 1.32 
– 1.22 (m, 2H), 1.24 (s, 3H), 1.05 (d, J = 6.8 Hz, 3H), 1.04 (d, J = 6.8 Hz, 3H), 0.87 (s, 3H). (32 
non-exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 180.56, 154.51, 89.09, 79.89, 78.84, 60.11, 52.47, 48.70, 45.19, 
40.85, 39.89, 38.99, 38.77, 38.41, 36.49, 28.65, 18.92, 16.72, 16.58,16.51, 16.45, 15.51. 
HRMS(ESI): m/z calc. for C22H36NO6 [M+H]
+: 410.2543, found: 410.2540. 
 
 
Procedure: In a round bottom flask, AA1326 (63.3 mg, 0.181 mmol) was dissolved in 
dichloromethane (1.8 mL). Diisopropylethylamine (0.063 mL, 0.361 mmol), Tosyl chloride (51.6 
mg, 0.271 mmol), and 4-dimethylaminopyridine (26.4 mg, 0.216 mmol) were added and the 
reaction was stirred at room temperature for 2 days. The reaction was then quenched with saturated 
aqueous ammonium chloride, and the aqueous layer was extracted with dichloromethane (3x). The 
combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, 
filtered and the dichloromethane was removed in vacuo. The residue was purified via silica gel 
chromatography (1:9 to 1:3 ethyl acetate:hexanes) to afford precursor A to 4-62 as a white solid 
(25.0 mg, 41% yield) and the starting material (22.6 mg, 36%). 
 
1H NMR (CDCl3, 500 MHz): δ 5.81 (m, 1H), 3.64 (s, 3H), 3.12 (s, 1H), 2.09 – 1.97 (m, 2H), 1.80 
–1.67 (m, 4H), 1.63 – 1.53 (m, 6H), 1.37 (m, 1H), 1.22 (m, 1H), 1.22 (s, 3H), 1.05 (m, 1H), 0.97 
(d, J = 6.9 Hz, 3H), 0.93 (d, J = 7.0 Hz, 3H), 0.79 (s, 3H). 
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13C NMR (CDCl3, 125 MHz): δ 178.9, 132.8, 129.7, 64.2, 61.0, 51.9, 50.5, 46.6, 45.2, 37.6, 37.1, 
34.4, 34.0, 25.9, 24.2, 18.2, 18.0, 17.7, 16.7, 16.4, 14.1.   
HRMS(ESI): m/z calc. for C21H33O3 [M+H]
+: 333.2430, found: 333.2417. 
 
 
Procedure: In a round bottom flask, precursor A to 4-62 (53.6 mg, 0.161 mmol) was dissolved 
in N,N-dimethylformamide (1.6 mL). Sodium azide (210 mg, 3.22 mmol) was added and the 
reaction was stirred at 80˚C for 5 days. The reaction was then quenched with brine, and the aqueous 
layer was extracted with diethyl ether (3x). The combined organic layers were washed with brine, 
dried over anhydrous magnesium sulfate, filtered and the diethylether was removed in vacuo. The 
residue was purified via silica gelchromatography (1:19 to 1:4 ethyl acetate:hexanes) to afford the 
precursor B to 4-62 as a colorless oil (27.7 mg, 46% yield) and the starting material (14.4 mg, 
27%). 
 
1H NMR (CDCl3, 500 MHz): δ 5.68 (m, 1H), 4.06 (dd, J = 3.6, 2.4 Hz, 1H), 3.67 (s, 3H), 2.23 
(dd, J = 12.8, 2.4 Hz, 1H), 2.05 (m, 1H), 1.80 – 1.40 (m, 10H), 1.35 (br, 1H), 1.25 (m, 1H), 1.17 
(m, 1H), 1.17 (s, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H), 0.82 (s, 3H). (32 non-
exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 178.5, 138.9, 132.5, 71.6, 65.3, 52.0, 47.7, 46.8, 42.7, 37.8, 37.5, 
37.4, 36.6, 29.7, 29.4, 17.9, 17.4, 17.0, 16.9, 16.6, 14.6. 
HRMS: m/z calc. for C21H33N3O3Na [M+Na]
+: 398.2420, found: 398.2412. 
 
 
Procedure: In a round bottom flask, precursor B to 4-62 (10.0 mg, 0.0266 mmol) was dissolved 
in ethyl acetate (1 mL). 10% palladium on activated charcoal (7.0 mg) was added under nitrogen 
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and the flask was then fitted with a balloon of hydrogen gas after nitrogen was removed under 
vacuum gently. The reaction was stirred under an atmosphere of hydrogen gas at room temperature 
for 6 hours. The palladium was then filtered over Celite and the ethyl acetate was removed in 
vacuo. The residue was purified via silica gel chromatography (1:9 to 1:5 methanol:chloroform) 
to afford 4-62 as a white solid (4.3 mg, 46% yield). 
 
1H NMR (CDCl3, 500 MHz): δ 5.60 (m, 1H), 3.67 (s, 3H), 3.56 (d, J = 3.4 Hz, 1H), 2.35 (dd, J = 
13.4, 2.4 Hz, 1H), 2.20 (m, 1H), 1.99 (br, 2H), 1.81-1.52 (m, 10H), 1.38 (m, 1H), 1.25-1.15 (m, 
1H), 1.20 (s, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.88 (J = 6.9 Hz, 3H), 0.80 (s, 3H). (33 non-
exchangeable protons) 
13C NMR (CDCl3, 125 MHz): δ 179.22, 130.05, 71.77, 53.88, 52.34, 47.32, 47.30, 42.21, 38.33, 
38.17, 38.08, 37.23, 31.28, 29.89, 18.29, 17.74, 17.33, 17.13, 16.83, 14.66. (20 carbons due to 
symmetry) 
HRMS: m/z calc. for C21H36NO3 [M+H]
+: 350.2695, found: 350.2690. 
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Chapter 3: Development of predictive guidelines for small-molecule accumulation in  
Gram-negative bacteria 
 
Portions of this Chapter are reprinted with permission from Richter, M. F.; Drown, B. S.; Riley, A. 
P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J., Predictive compound accumulation rules 
yield a broad-spectrum antibiotic. Nature 2017, 545, 299-304.1 and Richter, M.F.; Hergenrother, 
P.J., Broad-spectrum antibiotics, a call for chemists. Chem 2017, 3, 10-13.2 Contributions of others 
are noted where applicable. 
3.1 Introduction – the need to study compound accumulation in Gram-negative bacteria 
Drug-resistant bacteria are a major public health concern,3-5 and Gram-negative bacteria 
are particularly troubling as they are insensitive to many commonly used antibiotics.4, 6-10 
Exacerbating this problem is the fact that a new class of antibiotics that are active against Gram-
negative bacteria has not been introduced into the clinic since the quinolones in 1968.6 This void 
in discovery is not due to a lack of effort; as one example, in 2007 GlaxoSmithKline reported 
screening around 500,000 synthetic compounds for activity against Escherichia coli, but no 
tractable hits were identified.3 
 The development of Gram-negative antibacterials is impeded by a lack of understanding 
of the types of small molecules that are capable of accumulating in Gram-negative bacteria. Gram-
negative bacteria have two cellular membranes, and the lipopolysaccharide-coated outer 
membrane is very challenging for small molecules to cross.7-8, 11 Compounds that are able to 
traverse this outer membrane typically do so through narrow β-barrel proteins called porins, 
channels that are lined with charged amino acids.12 Once inside the cell, small molecules are 
susceptible to efflux pumps; thus, to accumulate in Gram-negative bacteria to a level that is 
sufficient for activity, small molecules typically must traverse porins faster than they are pumped 
out.7-9 As was discussed in section 1.3, a small handful of retrospective13-14 and intracellular 
accumulation studies15-17 have been performed to better understand compound accumulation in 
Gram-negative bacteria, and these studies suggest very polar and relatively small compounds 
(molecular weight < 600 Da) are the most likely to accumulate. However, these analyses are 
skewed by sample bias, the over-representation of certain drug classes, and lack of compound 
diversity.  Ultimately, the canonical view about the importance of polarity and molecular weight 
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for Gram-negative activity has not led to general strategies to convert Gram-positive-only 
compounds into broad-spectrum antibiotics. 
The need to better understand compound accumulation in Gram-negative bacteria is well-
recognized. In a review discussing the failures of Gram-negative antibacterial discovery at 
GlaxoSmithKline, the authors note that a “better understanding of which physical chemical 
properties are important for antibacterials is necessary.”3 Professor Kim Lewis further advocated 
for rules to understand compound accumulation in Gram-negative bacteria, stating “Lipinski's 
guidelines were formulated by extracting the useful properties from a large set of known drugs and 
drug candidates. Rules of penetration for antibiotics could be similarly established, based on data 
from a sufficiently large number of compounds that effectively penetrate into cells of Gram-
negative bacteria, as well as those that do not.” Lewis goes on to write that the largest barrier in 
developing these guidelines is finding a panel of compounds that effectively penetrate Gram-
negative bacteria.6  
 Given that the majority of antibacterial drugs are natural products or their derivatives, 
critical to studying compound accumulation in Gram-negative bacteria would be access to a 
collection of compounds whose members possess natural-product-like properties, but also are 
synthetically accessible so that various properties are tunable, enabling structure-activity 
relationship (SAR) studies. As is discussed in Chapter 2, in 2013, the Hergenrother lab published 
a method, called Complexity-to-Diversity (CtD), for the rapid synthesis of natural product-like 
compounds.18-22 Using CtD, structurally complex natural products are converted into new scaffolds 
that are structurally distinct. Through ring-distortion reactions, including ring cleavage, ring 
expansion, ring fusion, and ring rearrangement, new complex scaffolds are obtained in an average 
of three steps. As the synthetic sequences are short, the compounds are amenable to SAR studies, 
making CtD an ideal method for studying the properties important for compound accumulation in 
Gram-negative bacteria. For a more thorough discussion on the benefits of the CtD library, see 
Chapter 2. We utilized the unique CtD library to develop guidelines for compound accumulation 
in Gram-negative bacteria; the synthesis of these compounds is discussed in Chapter 2.   
3.2 Assay design, optimization, and validation  
Before beginning to test CtD compounds for accumulation, it was important to have a 
general assay that was well-validated (see section 1.3.2 for a discussion on previous accumulation 
assays). The assay was adapted from known protocols,17, 23-24 with liquid chromatography tandem 
175 
 
mass spectrometry (LC-MS/MS) chosen as the analytical method because it is highly sensitive and 
can detect most compounds. Briefly, a culture of bacteria is incubated with a compound of interest, 
the extracellular compound is washed away, and the bacteria are lysed to enable measurement how 
much compound accumulated in the bacteria (Fig. 3.1). Many variables were taken into 
consideration while optimizing the assay. First, to ensure sufficient signal-to-noise, a high density 
of bacteria is utilized for each sample. To accomplish this, after growing the bacteria in a large 
volume of media, the bacteria are harvested and washed with phosphate buffered saline (PBS). 
The bacteria pellet is then resuspended in a substantially smaller volume of PBS compared to the 
original volume of media (the theoretical optical density measured at a wavelength of 600 nm 
(OD600) of the samples are about 14) (Fig. 3.1). The next variable that required optimization was 
how to wash away extracellular compound. We want to rapidly separate the bacterial pellets from 
the buffer   to prevent compound loss through efflux. This is done by layering the bacteria on cold 
silicone oil in an Eppendorf tube and centrifuging; the bacteria pellets below the oil and the 
aqueous layers stays above the oil (Fig. 3.1). The ideal oil was carefully considered so that the 
layers form in the correct order as both bacteria and water have very similar densities (Fig. 3.1). 
We observed that a 9:1 AR20/Sigma High Temperature silicone oil, cooled to -78 ˚C, enabled the 
layers to form correctly. Additional aqueous washes were assessed, but no improvements in signal-
to-noise with the controls was observed. The final aspect of the assay that required optimization 
was how to lyse the bacteria. We chose to avoid boiling the samples to prevent compound 
degradation, and we avoided sonification because only one sample can be lysed at a time, limiting 




The assay was evaluated with antibiotics that have known high (tetracycline, ciprofloxacin, 
and chloramphenicol) and low (novobiocin, erythromycin, rifampicin, vancomycin, daptomycin, 
clindamycin, mupirocin, and fusidic acid) levels of accumulation. Ampicillin was also used as a 
“low-accumulation” control as it is rapidly covalently appended to penicillin-binding proteins, 
preventing measurement by LC-MS/MS.  To account for the possibility of non-specific binding to 
the outer membrane, Gram-negative active antibiotics with various charged states at physiological 
Grow bacteria to 
OD600 = 0.55
Harvest and wash 
bacteria







Lyse bacteria and 
analyze lysate via 
LC-MS/MS














Layer culture on 
top of oil
Centrifuge
Fig. 3.1. Workflow for the accumulation assay. After bacteria is grown to mid-log phase, they 
are harvested and washed with sterile phosphate-buffered saline (PBS). The pellet is then 
resuspended in a much smaller volume of PBS (theoretical OD600 = 14), and aliquoted into 
Eppendorf tubes. The cultures are then incubated with compound of interest for 10 minutes. To 
separate the bacteria from extracellular compound, cultures are layered on cold silicone oil and 
centrifuged. The oil forms a layer between the bacterial pellet and the supernatant. After disposal 
of both the supernatant and the oil, the pellets are resuspended in water and the bacteria is lysed. 




pH were chosen: tetracycline (positively charged), ciprofloxacin (zwitterionic), and 
chloramphenicol (neutral) (structures, physiochemical properties, and accumulation values shown 
in Supplementary Table 3.1 in section 3.6). The results show a significantly higher level of 
accumulation in E. coli for the Gram-negative-active compounds as compared to compounds with 
low Gram-negative antibacterial activity and ampicillin, consistent with measuring accumulation 
as opposed to non-specific binding (Fig. 3.2A).  
 
To further ensure that variations in observed accumulation levels were not due to 
differences in non-specific affinity for the membrane, penetrance was perturbed using two different 
methods. First, E. coli was co-treated with the membrane permeabilizing agent colistin25-26; an 
increase in accumulation for low-accumulating antibiotics (novobiocin, erythromycin, rifampicin, 
Fig. 3.2. Validation of compound accumulation assay in E. coli. A) Compounds that are 
active against E. coli have significantly higher accumulation than low-activity antibiotics and 
ampicillin; structures in Supplementary Table 3.1. Statistical significance was determined by 
using a two-sample Welch’s t-test (one-tailed test, assuming unequal variance) relative to the 
negative controls. P values relative to the average of the low-accumulating controls; B) Co-
treatment with colistin enhances the accumulation of low-accumulating antibiotics. Statistical 
significance was determined by using a two-sample Student’s t-test (two-tailed test, assuming 
equal variance). *P < 0.05, *P < 0.01, *P < 0.001 All experiments were performed in biological 
























































































































































































and fusidic acid) is observed in this experiment (Fig. 3.2B).  Additionally, as small molecules that 
traverse the outer membrane of Gram-negative bacteria predominately cross through porins, 
knocking out the major porins of E. coli would be expected to decrease compound accumulation.27-
29 Although there are many porins present in E. coli, the two major non-specific porins are OmpF 
and OmpC, which are differentially expressed (based on the extracellular osmolarity) by the 
EnvZ/OmpR two-component regulatory system. An ∆ompR strain of E. coli from the KEIO 
knockout collection was therefore chosen to effectively knockout both OmpF and OmpC (Fig. 
3.3A for validation of knockout). (See Chapter 4 for a more thorough discussion of why knocking 
out ompR results in no expression of OmpF and OmpC). For the high-accumulating controls 
ciprofloxacin, tetracycline, and chloramphenicol, a significant decrease in accumulation is 
observed in the ∆ompR strain of E. coli compared to the parental strain E. coli BW25113 (Fig. 
3.3B), further validating that the assay is reporting on accumulation instead of non-specific binding 







3.3 Development of predictive guidelines for Gram-negative accumulation 
3.3.1 Accumulation of the set of 100 compounds 
To begin the accumulation analysis, a set of 100 compounds, including positively charged, 
negatively charged and neutral compounds, were synthesized and tested (synthesis discussed in 
Chapter 2). The structure, molecular weight, ClogD7.4 and charge of all 100 compounds tested are 
provided in Supplementary Table 2. Retrospective studies suggest that compound accumulation is 









































Fig. 3.3. Accumulation of antibiotic controls in porin knockout strain of E. coli. A) SDS–
PAGE analysis of outer membrane proteins of E. coli BW25113 and E. coli BW25113 ∆ompR 
from the KEIO collection. E. coli outer membrane proteins were separated using SDS-12% 
PAGE, and visualized with Coomassie stain. Lane 1, protein ladder; lane 2, E. coli BW25113; 
lane 3, E. coli BW25113 ∆ompR. Representative of three replicates. B) Accumulation 
comparison of ciprofloxacin, tetracycline, and chloramphenicol for E. coli ∆ompR vs parental 
strain E. coli BW25113.   Statistical significance was determined by using a two-sample 
Student’s t-test (two-tailed test, assuming equal variance). *P < 0.05, *P < 0.01, *P < 0.001 
All experiments were performed in biological triplicate. Error bars represent s.e.m. 
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polarity metric.13-14 Thus, the accumulation data for all 100 compounds were plotted vs ClogD7.4 
(Fig. 3.4).  These results strikingly differ from the conclusions gleaned from retrospective studies.  
Within this set of 100 compounds, charge is the primary factor dictating accumulation in E. coli. 
The positively-charged compounds are the most likely to accumulate, with 12 of 41 positively-
charged compounds showing a significant level of accumulation compared to the low-
accumulating controls.  In contrast, 0 of 39 neutral compounds and 0 of 20 negatively-charged 
compounds show significant accumulation.  Notably, even carboxylic acids with strongly negative 
ClogD7.4 values (< -5) do not accumulate.  
 
3.3.2 SAR analysis on amine accumulators 
All 12 accumulating compounds contain amines, and the majority of these compounds (8 
out of 12) are primary amines. To further examine the importance of the primary amine, a SAR 
analysis was performed for multiple different classes of accumulating compounds by replacing the 
Fig. 3.4. Accumulation of 100 CtD compounds in E. coli MG1655. Assessment of 100 
compounds for accumulation, labeled by ionic state; structures in Supplementary Table 3.2 in 
section 3.6. Statistical significance was determined by using a two-sample Welch’s t-test (one-
tailed test, assuming unequal variance) relative to the negative controls. P values relative to the 
average of the low-accumulating controls; *P < 0.05, *P < 0.01. All experiments were performed 
























































primary amines with a carboxylic acid, an amide, an ester, an azide, a secondary amine, a tertiary 
amine, or a quaternary amine (synthesis discussed in Chapter 2). Any change from the primary 
amine dramatically reduces accumulation (Supplementary Table 3.3 in section 3.6).  Even 
conversion of the primary amine to a more substituted amine has a deleterious effect on 
accumulation.  Shown in Fig. 3.5 are three primary amines (1-3) alongside their methylated (4-6), 
di-methylated (7-9), tri-methylated (10-12), and acetylated derivatives (13-15).  In all cases, the 




Fig. 3.5. Primary amines aid small-molecule accumulation in E. coli. Modification of a high-
accumulating primary amine to a mono-methyl, di-methyl, tri-methyl or acylated derivative has 
a deleterious effect on compound accumulation in E. coli MG1655. Accumulation reported in 
nmol per 1012 colony-forming units (CFUs). All experiments were performed in biological 
triplicate. The s.e.m. is reported for accumulation values. 
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3.3.3 Testing of an extended primary amine library 
To further explore the effect of a primary amine library on accumulation, an extended 
primary amine library was required. As with the initial library, many of these compounds were 
synthesized via the CtD strategy (synthesis discussed in Chapter 2). In addition to the CtD 
compounds, commercially available primary amines that more closely mimic the types of 
compounds found in commercial screening libraries were added to the screening collection. In 
total, 68 primary amines (all the structures are presented in Supplementary Table 3.4, Section 3.6) 
were tested for accumulation in E. coli, and showed that even within the primary amine set, neither 
polarity nor size are strong predictors of accumulation. For the expanded primary amine set, 
accumulation does not increase with lower ClogD7.4 (Fig. 3.6A), and there is also no correlation 
between accumulation and MW (Fig. 3.6B).  SAR analysis on several of these compounds further 




























































































































































































Fig. 3.6. ClogD7.4 and molecular weight do not correlate with accumulation of primary 
amines. A, and B, The accumulation of 68 primary amine containing compounds in E. coli 
MG1655 compared to ClogD7.4 (A) and molecular weight (B). High-accumulating controls 
(black x)=tetracycline, ciprofloxacin and chloramphenicol; low accumulating controls (open 
circles)=novobiocin, erythromycin, rifampicin, clindamycin, mupirocin and fusidic acid, 
clindamycin and ampicillin. Statistical significance was determined by using a two-sample 
Welch’s t-test (one-tailed test, assuming unequal variance) relative to the negative controls. P 
values are relative to the average of the low-accumulating controls. P values relative to the 
average of the low-accumulating controls; *P < 0.05, *P < 0.01. All experiments were 
performed in biological triplicate. 
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3.3.4 Development of predictive guidelines for accumulation in Gram-negative bacteria 
While the presence of a primary amine is clearly important for accumulation in E. coli, it 
is not sufficient: although 36 of the primary amines within the test set do accumulate, 32 of them 
do not.  We hypothesized that shape and rigidity are important variables that affect accumulation 
in E. coli, but it was unclear how to best capture these parameters or if additional properties are 
also important. Therefore, a chemoinformatic approach was implemented to understand which 
factors contribute to amine accumulation. All chemoinformatic work was performed by Bryon 
Drown. For this set of 68 primary amines, 297 molecular descriptors were calculated for conformer 
ensembles of each compound.1  These descriptors were used to train a random forest classification 
model that predicts amine accumulation.30  Through this analysis it was revealed that the flexibility 
and shape of a compound are important factors that govern accumulation.  Flexibility was best 
captured by measuring the number of rotatable bonds (RB),31 whereas shape was best described 
by the term globularity.  This globularity analysis (Glob)32 is routinely used to provide information 
on the three-dimensionality of compounds,33-36 where a completely flat compound (e.g. benzene) 
has a Glob of 0 and a spherical compound (e.g. adamantane) has a Glob of 1.  Case studies 
demonstrate the importance of the flexibility and globularity parameters for accumulation of the 
primary amines: as shown in Fig. 3.7A, amine 16 with four RBs accumulates at a high level; 
however, amine 17, a compound of similar molecular weight and Glob but with 13 RBs, shows 
virtually no accumulation.  Analogous results are observed in Fig. 3.7B when comparing a 
compound with low globularity (18, Glob = 0.14) to a compound with similar functional groups, 
MW, and RBs but with high globularity (19, Glob = 0.49); compound globularity is most easily 
observed in their three-dimensional models, Fig. 3.7B.  
While in general primary amines with five or fewer RBs and a globularity of 0.25 or less 
have a markedly higher likelihood of accumulation, two additional factors related to the placement 
of the primary amine are important.  First, the random forest model identified increased 
amphiphilic moment (vsurf_A), which measures the distance between hydrophobic and 
hydrophilic portions of a compound,37 as favoring accumulation.  Strikingly, while mono-amine 
isomannide (20) does not accumulate, derivatives with increased vsurf_A do accumulate (21-23, 
2 and 16), and similar trends are observed for other compound classes (24-27) (Fig. 3.7C).  
Accordingly, some degree of hydrophobicity appears necessary for accumulation, although in 
practice most organic compounds possess this feature.  Secondly, compounds with sterically 
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encumbered primary amines are not high accumulators, for example 28 and 29 (Fig. 3.7D), which 
both have low flexibility and globularity but contain a primary amine on a tetra-substituted carbon, 
do not show significant accumulation.  This result is consistent with the increased accumulation 
of compounds where the primary amine is systematically extended from a sterically congested ring 









Fig. 3.7. Properties affecting small-molecule accumulation in E. coli. A) and B) Case studies 
comparing the importance of flexibility (A) and globularity (B). C) Derivative sets demonstrate 
how accumulation can rise as amphiphilic moment (vsurf_A) increases within a structural class. 
D) Two compounds with primary amines attached to tertiary centers, both are low 
accumulators. E) Systematic separation of the primary amine from a sterically congested ring 
system results in increased compound accumulation. Accumulation in E. coli MG1655 is 
reported in nmol per 1012 CFUs. All experiments were performed in biological triplicate. The 
s.e.m. is reported for accumulation values. 
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Based on these analyses the following guiding principles for compound accumulation in 
E. coli (called “eNTRy Rules”) were developed: compounds are most likely to accumulate if they 
contain a non-sterically encumbered ionizable nitrogen (we observed primary amines are the best), 
have some non-polar functionality, have low three-dimensionality (Glob ≤ 0.25), and have few 
rotatable bonds (RB ≤ 5) (Fig. 3.8).  As shown in Fig. 3.9A, the vast majority of compounds that 
meet these criteria in the test set accumulate in E. coli.  
 
 
To further test the validity of these guidelines, the set of antibacterials assessed by O’Shea 
and Moser14 was evaluated for charge, flexibility, and globularity.  For the charge analysis, 
antibacterial drugs containing an ionizable nitrogen were accepted.  For Gram-negative 
antibacterials, only those predicted to enter through porins were included, and due to the sheer 
number of β-lactams they have been left off the graph in Fig. 3.9B (the structures of compounds 
in Fig. 3.9B are in Supplementary Table 3.5, Section 3.6).  As is shown in Fig. 3.9B, for these 
drugs with ionizable nitrogens, compounds active against Gram-negative bacteria cleanly separate 
from those with Gram-positive-only activity based on these two physicochemical parameters. No 
Gram-positive-only antibacterial with an ionizable nitrogen has the correct rigidity and globularity 
for accumulation in E. coli.   
eNTRy Rules
Nitrogen (Primary amine)
Three-Dimensionality (Glob ≤ 0.25)
Rotatable bonds (RB ≤ 5)






The findings presented here are congruent with what is known about β-lactams and explain 
why their spectrum could be broadened where other classes could not.  In previous analyses, 
positive charge has been found to greatly accelerate penetration of β-lactams through porins, while 
negative charge and bulky substituents impede penetration.38  Indeed, early generation β-lactams 
lacking an amine, such as penicillin G, are inactive against Gram-negative bacteria. Penicillin G 
has flexibility/shape parameters (RB = 4, Glob = 0.17) that make it an outstanding candidate for 
conversion, and addition of an amine results in ampicillin (RB = 4, Glob = 0.12), which now meets 
all criteria for accumulation (Fig. 3.10).  Although there are third and fourth generation β-lactams 
with Gram-negative activity that do not meet the guidelines outlined here, these β-lactams have 
greatly reduced accumulation in Gram-negative bacteria compared to their positively-charged 









































































Fig. 3.9. Flexibility and globularity are important for accumulation in E. coli. A) 
Flexibility (as measured by the number of rotatable bonds) plotted against globularity for the 
primary amines with proper amphiphilic moment and amine steric hindrance; compounds 
included in this analysis are noted in Supplementary Table 3.4. B) Flexibility versus 
globularity for antibiotics. Antibiotics included are Gram-positive-only drugs containing an 
ionizable nitrogen (circles), and Gram-negative actives that are believed to enter cells through 
porins (triangles); all compounds included in plot are listed in Supplementary Table 3.5 in 
section 3.6.  
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lactamases than the early 
generation β-lactams, thus 
requiring lower levels of 
accumulation for antibacterial 
activity.38  As delineated herein, to 
favor Gram-negative 
accumulation, an amine should be 
embedded on a compound with 
proper flexibility and shape 
parameters; these results explain 
why simple addition of an amine 
has not been a generalizable 
strategy to increase Gram-negative  
accumulation and activity for 
other antibiotic classes.  As one 
example, there are no differences 
in the spectrum of activity 
observed for erythromycin versus 
9(S)-erythromycylamine;39-40 as 
shown in Fig. 3.10 these 
compounds do not possess the 
appropriate RB and/or Glob parameters for accumulation. For more examples of successful and 
unsuccessful conversions, see Chapter 1.4.  
3.4 Design of antibiotics for Gram-negatives 
Our findings, in principle, should be able to guide the conversion of certain Gram-positive-
only antibacterials to those that also have activity against Gram-negative bacteria.  This would be 
a valuable and directly actionable feature of these results, one that could enable the production of 
candidate broad-spectrum antibacterials.  The most straightforward method to accomplish this 
conversion would be to identify Gram-positive-only antibacterials already imbued with the proper 
flexibility and shape to accumulate in E. coli, and then append a primary amine without disrupting 
the ability of the compound to interact with its cellular target.  A RB and Glob analysis of 
Fig. 3.10. Gram-positive-only antibiotics with proper 
rotatable bond and globularity scores can be 
converted to broad-spectrum drugs via strategic 
placement of a primary amine. This is demonstrated 
with ampicillin. However, for drugs that do not possess 
the proper flexibility and three-dimensionality 
parameters, such as erythromycin, addition of the amine 
does not broaden the antibacterial spectrum. 
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antibacterial agents with Gram-positive-only activity results in a plethora of potential candidates 
for conversion that either fit within in the predicted guidelines or are very close. Beyond shape and 
flexibility, there are many variables to consider when choosing a compound. First and foremost, 
the target must be conserved between Gram-positive and Gram-negative bacteria, and essential for 
Gram-negative bacterial growth and/or survival. Before beginning any synthetic modifications, 
this can be confirmed by testing the Gram-positive only antibiotic for activity against a 
hyperpermeable Gram-negative strain and/or a Gram-negative strain lacking major efflux pumps.  
Additionally, the compound must be accessible, either through a relatively short synthetic 
sequence or be commercially available at a reasonable price.  Finally, it is helpful, although not 
necessary, if a thorough SAR analysis has been performed and/or a crystal structure of the 
compound bound to its target exists to help direct placement of the amine to a location that does 
not interfere with target engagement.  
Based on these criteria, the natural product deoxynybomycin (DNM) was selected as a 
good candidate for conversion to a broad-spectrum agent.  DNM has antibacterial activity through 
inhibition of wild-type and mutant DNA gyrase, and DNM and its derivatives are only active 
against Gram-positive bacteria.41-42  DNA gyrase is a highly-conserved target, and DNM is active 
against permeabilized E. coli. DNM can be synthesized in seven steps, and some preliminary SAR 
data demonstrates that DNM can tolerate small modifications.42 Chemoinformatic analysis shows 
that DNM has zero rotatable bonds and a Glob of 0.02, suggesting that the addition of an amine to 
a position that does not alter the DNM antibacterial activity would provide a derivative able to 
accumulate in and be active against Gram-negative pathogens.  To facilitate construction of a 
derivative with a primary amine, an analogue of DNM was first synthesized by Dr. Andrew Riley 
where the five-membered ring in DNM is expanded to a six-membered ring (6DNM, Fig. 3.11).  
6DNM is active against Staphylococcus aureus (MIC = 0.06 – 1 µg/mL) but shows no activity 
versus E. coli (MIC > 32 µg/mL, Fig. 3.11).  Assessment in the accumulation assay reveals 6DNM 
has low accumulation in E. coli (Fig. 3.11).  
A derivative of 6DNM was then synthesized by Dr. Andrew Riley that maintains low RB 
and Glob, but that also contains a primary amine; (6DNM-NH3, Fig. 311).  6DNM-NH3 retains 
activity against S. aureus, but it also accumulates in E. coli to a high degree.  Consistent with this 
enhanced accumulation, 6DNM-NH3 shows significant activity against E. coli MG1655 (MIC = 
0.5 µg/mL) (Fig. 3.11).  Similar to observed patterns of accumulation from the test compounds, 
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when the amine of 6DNM-NH3 is acetylated or replaced with a carboxylic acid, the resulting 
compounds (6DNM-amide and 6DNM-acid) do not accumulate in E. coli and also show no activity 
against E. coli (Fig. 3.11). In collaboration with Dr. Andrew Riley, 6DNM and its derivatives were 
further evaluated against an expanded panel of Gram-negative pathogens, laboratory strains and 
clinical isolates of ESKAPE pathogens E. coli, Acinetobacter baumannii, Klebsiella pneumoniae, 
Enterobacter cloacae, and Pseudomonas aeruginosa (Fig. 3.11).  Although 6DNM possesses no 
notable activity against these Gram-negative organisms, 6DNM-NH3 has antibacterial activity 
against all of these Gram-negative pathogens except P. aeruginosa. Encouragingly, 6DNM-NH3 
possesses activity against a multidrug resistant New Delhi metallo-β-lactamase-1 producing strain 
of E. coli (ATCC BAA-246943); this clinical isolate is highly resistant to ciprofloxacin (MIC > 64 
µg/mL, Fig. 3.11) and many other antibiotics but is killed by 6DNM-NH3 with an MIC of 4 µg/mL 
(Fig. 3.11).  
The limited activity against P. aeruginosa is unsurprising. P. aeruginosa is highly distinct 
from E. coli. It has no general porin channels and has more efflux pumps.8-9 Many clinically 
employed antibiotics are active against E. coli, but show no activity against P. aeruginosa, 
including chloramphenicol, nalidixic acid, the tetracyclines, the sulfa drugs, and certain β-lactams 
(particularly the penicillins).14 Based on the unique properties of P. aeruginosa, accumulation will 
need to be assessed separately. This work has already been begun by Emily Geddes, and key 
differences between accumulation in E. coli and P. aeruginosa are already being observed. 














































































































































































RB = 0; Glob = 0.04





RB = 1; Glob = 0.09
MW = 325 Da
ClogD7.4 = -0.87
Accum =  1114 135
6DNM-amide
No primary amine
RB = 1; Glob = 0.13
MW = 367 Da
ClogD7.4 =  0.30
Accum =  134 32
6DNM-acid
No primary amine
RB = 1; Glob = 0.07
MW = 354 Da
ClogD7.4 = -2.32



















Fig. 3.11. Conversion of DNM to a broad-spectrum antibacterial. Strategic placement of 
a primary amine (but not an acid or amide) on 6DNM leads to 6DNM-NH3, a broad-spectrum 
antibacterial. 6DNM and three derivatives were synthesized and evaluated against a panel of 
Gram-positive and Gram-negative organisms; ciprofloxacin was also evaluated. Flexibility 
(as measured by the number of rotatable bonds, RB), globularity (Glob), molecular weight, 
ClogD7.4, and E. coli accumulation (in nmol per 10
12 CFUs) is provided. The s.e.m. for 
accumulation values are reported. MIC values were determined using the micro-dilution broth 
method as outlined by the Clinical and Laboratory Standards Institute and are listed in μg ml−1. 
All experiments were performed in biological triplicate. 
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3.5 Summary and outlook 
The combined analysis of the test set compounds and antibacterials shows the benefit of 
an ionizable nitrogen on small-molecule accumulation in E. coli, and suggests that this nitrogen 
should be embedded in a compound that has strict geometrical constraints (shape and flexibility).  
Analysis of antibiotics active against Gram-negative bacteria suggests that the ionizable nitrogen 
can take many different forms; for our test set, we observe that accumulation diminishes with 
increasing substitution on the amine, although some non-primary amines still accumulate.  
We anticipate the guidelines for predicting small-molecule accumulation in E. coli 
described herein will be useful in multiple contexts: 
1) Conversion of Gram-positive only antibacterials into broad-spectrum agents.  As shown 
in Fig. 3.9B, Gram-positive only antibiotics with an ionizable nitrogen do not have the proper 
rigidity/shape parameters for accumulation, and it is also true that those with the proper 
rigidity/shape do not contain an ionizable nitrogen.  As demonstrated with DNM, addition of a 
primary amine to compounds that meet the rigidity/shape requirements is an effective method to 
facilitate accumulation in E. coli, and many other serendipitous conversions have been performed 
historically (see Chapter 1.4 for examples).  Our own chemoinformatic analysis shows that there 
are multiple outstanding candidates for conversion to broad-spectrum agents (Fig. 3.12), and the 
conversion of other Gram-positive antibacterials into broad-spectrum antibiotics is an on-going 
project within the lab.  
Thus far, amine-containing derivatives of Gram-positive-only antibiotics have been 
synthesized that can accumulate in E. coli, but unfortunately the amine often abolishes activity in 
both Gram-positive and Gram-negative species. The addition of a primary amine to a compound 
introduces two additional hydrogen bond-donors, and can significantly affect drug-target 
interactions. For the development of the eNTRy Rules, primary amines were thoroughly assessed, 
but ionizable nitrogens can take other forms that may alter the physicochemical properties of a 
compound less than a primary amine. Further exploration of the other forms the ionizable nitrogen 
can take, including anilines, heterocycles, and nitro groups, will be critical to the more rapid 





2) Guiding the construction of collections of compounds that are predisposed for 
accumulation in Gram-negative bacteria.   Primary amines are not common in natural products: 
only 3,047 out of 161,322 (2%) compounds from the Natural Products subset of the ZINC database 
and 112 out of 3,497 (3%) MLSMR natural products contain a primary amine (Fig. 3.13).  
Furthermore, primary amines are vanishingly rare in standard screening collections with only 192 
out of 149,997 (0.1%) compounds in the ChemBridge Microformat Set containing a primary amine 
(Fig. 3.13) (analysis performed by Bryon Drown). These very low percentages are likely a major 
reason why screening compound collections for novel chemical matter active against Gram-
negative pathogens has been unproductive.3 Primary amines are likely absent from screening 
Fig. 3.12. Some FDA-approved drugs or compounds in phase II or III clinical trials that 
are good candidates for derivative synthesis and expansion to broad-spectrum agents. 
Placement of a primary amine at a position that does not alter interaction with the biological 




collections due to synthesis and purification challenges, as well as concerns about amine 
metabolism if the amine were to make it into a drug.  However, it is important to note that the 
primary amine functional group is frequently present in approved drugs, including widely used 
medicines Januvia, Adderall, Tamiflu, L-Dopa, Lyrica, Vyvanse, Mematine, Valtrex, Synthroid, in 
addition to antibiotics such as ampicillin and vancomycin.  In fact, our analysis shows that almost 
8% of all drugs in the World Drug Database contain a primary amine, and these drugs are used for 
a variety of indications (some examples in Fig 3.13B). The majority of these amines are attached 
to primary and secondary carbons (Fig 3.13C), showing that sterically unencumbered amine-
containing compounds can indeed make outstanding drugs. The continued development of facile 
methods to synthesize and purify large numbers of compounds that meet the predictive guidelines 
will be critical, and we are optimistic that implementation of modern synthetic tools and thinking 






ZINC NP (n = 161,322) MLSMR-NP (n = 3,497) Chembridge Microformat 
Library (n = 149,997)












Fig. 3.13. Primary amines are largely absent from many screening collections. A) 
Comparison of the abundance of primary amines, secondary amines, tertiary amines, and 
carboxylic acids in the natural products subset of the ZINC database, the Molecular Libraries 
Small-molecule Repository – Natural Products (MLSMR-NP), and the Chembridge 
Microformat library. B) Examples of drugs with primary amines; they are used for a variety of 
indications. C) Primary amines in drugs are mostly present on primary and secondary carbons, 
showing that unhindered amines are common in drugs. A world drug database was analyzed 
with the assistance of Prof. Jo´n Njarðarson (University of Arizona) through a search for all 
compounds that contained a nitrogen atom attached to a carbon and two hydrogens. The 
resulting compounds were then manually sorted to include only amines attached to an sp3 -
hybridized carbon.)  
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We anticipate the eNTRy rules will provide a strong starting place to advance Gram-
negative antibacterial discovery, but further studies will still be necessary. From a compound 
standpoint, a larger diversity of compounds still need to be assessed. We have very little data on 
the accumulation of anilines, diamines (see Chapter 4), zwitterions, and heterocycles. In terms of 
biological questions, as is discussed in Section 3.4, different species of bacteria will likely have 
different guidelines for accumulation. Using the work discussed above as a blueprint, a series of 
experiments similar to that described herein for E. coli will be needed to define traits that dictate 
accumulation of small-molecules in P. aeruginosa and other problematic pathogens. Furthermore, 
as pathogens develop resistance or are in different environments, they can change the expression 
of efflux pumps, porins, and LPS structure, all of which can affect small-molecule accumulation.44 
Studies to understand how these different variables affect accumulation in Gram-negative bacteria 
have begun (see Chapter 4), but significant work is still needed. The accumulation assay will be 
indispensable in these studies, as a more diverse panel of compounds can be studied than using 
antibacterial activity alone. Although only time will tell, we are optimistic that the eNTRy Rules 
that have been developed, and the new information that will be obtained using the same blueprint, 
will greatly facilitate the discovery of much needed Gram-negative antibacterials. 
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3.6 Supplementary tables 
Supplementary Table 3.1. Data for all control antibiotics. Structures, spectrum of activity, MW, 
ClogD7.4, number of rotational bonds (RB), globularity (Glob), the plane-of-best-fit score 
(PBF)45, normalized first principal moment of inertia (PMI1/MW)47, and the accumulation for 





























































































































































































































































































































































































































































































































































































































Supplementary Table 3.2. Data for initial test set of 100 compounds. Structures, functional groups 
present, MW, ClogD7.4, number of rotational bonds (RB), globularity (Glob), the plane-of-best-fit 
score (PBF), normalized first principal moment of inertia (PMI1/MW), and the accumulation in E. 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 3.3. Data for compounds involved in structure-activity relationship 
analysis. Structures, functional groups present, MW, ClogD7.4, number of rotational bonds (RB), 
globularity (Glob), the plane-of-best-fit score (PBF), normalized first principal moment of inertia 
(PMI1/MW), and the accumulation in E. coli MG1655 for each compound is provided, as well as 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 3.4. Data for all primary amines compounds tested. Structures, functional 
groups present, MW, ClogD7.4, number of rotational bonds (RB), globularity (Glob), the plane-of-
best-fit score (PBF), normalized first principal moment of inertia (PMI1/MW) and the 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 3.5. All antibiotics analyzed in chemoinformatic analysis (derived from 
the compounds assessed by O’Shea and Moser). Structures, spectrum of activity, MW, ClogD7.4, 
number of rotational bonds (RB), globularity (Glob), the plane-of-best-fit score (PBF), normalized 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 3.6. All ß-lactams analyzed in chemoinformatic analysis (derived from the 
compounds assessed by O’Shea and Moser). Structures, spectrum of activity, MW, ClogD7.4, 
number of rotational bonds (RB), globularity (Glob), the plane-of-best-fit score (PBF), normalized 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.7 Experimental protocols 
Accumulation assay. The accumulation assay was performed in triplicate in batches of ten 
samples, with each batch containing either tetracycline or ciprofloxacin as a positive control. E. 
coli MG1655 was utilized for these experiments as this strain has been only minimally altered 
from its K-12 progenitor.45 For each replicate, 2.5 mL of an overnight culture of E. coli was diluted 
into 250 mL of fresh Luria Bertani (LB) broth (Lennox) and grown at 37˚C with shaking to an 
OD600 = 0.55. The bacteria were pelleted at 3,220 rcf for 10 minutes at 4° C and the supernatant 
was discarded. The pellets were re-suspended in 40 mL of phosphate buffered saline (PBS) and 
pelleted as before, and the supernatant was discarded. The pellets were re-suspended in 8.8 mL of 
fresh PBS and aliquoted into ten 1.5 mL eppendorf tubes (875 µL each). The number of colony 
forming units (CFUs) was determined via a calibration curve. The samples were equilibrated at 
37˚C with shaking for 5 minutes, compound was added ([final] = 50 µM), and then samples were 
incubated at 37˚C with shaking for 10 minutes. A 10 minute time point was chosen because it is 
longer than the predicted amount of time required to reach a steady-state concentration,46 but short 
enough to minimize metabolic and growth changes (no changes in OD600 observed; CFUs were 
reduced by a factor of five after ciprofloxacin treatment for 10 minutes, but no other antibiotics 
had an effect). After incubation, 800 µL of the cultures were carefully layered on 700 µL of silicone 
oil (9:1 AR20/Sigma High Temperature, cooled to -78˚C). Bacteria were pelleted through the oil 
by centrifuging at 13,000 rcf for 2 minutes at room temperature (supernatant remains above the 
oil); the supernatant and oil were then removed by pipetting. To lyse the samples, each pellet was 
dissolved in 200 µL of water, and then they were subjected to three freeze-thaw cycle of three 
minutes in liquid nitrogen followed by three minutes in a water bath at 65˚C. The lysates was 
pelleted at 13,000 rcf for 2 minutes at room temperature and the supernatant was collected (180 
µL). The debris was re-suspended in 100 µL of methanol and pelleted as before. The supernatants 
were removed and combined with the previous supernatants collected. Finally, remaining debris 
was removed by centrifuging at 20,000 rcf for 10 minutes at room temperature. Supernatants were 
analyzed by LC-MS/MS.  
Samples were analyzed with the 5500 QTRAP LC/MS/MS system (AB Sciex, Foster City, 
CA) with a 1200 series HPLC system (Agilent Technologies, Santa Clara, CA) including a 
degasser, an autosampler, and a binary pump.  The LC separation was performed on an Agilent 
SB-Aq column (4.6 x 50mm, 5µm) (Agilent Technologies, Santa Clara, CA) with mobile phase A 
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(0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). The flow rate 
was 0.3 mL/min.  The linear gradient was as follows: 0-3min, 100%A; 10-15min, 2%A; 15.5-
21min, 100%A.  The autosampler was set at 5ºC.  The injection volume was 15 µL.  Mass spectra 
were acquired with both positive electrospray ionization (ESI) at the ion spray voltage of 5500 V 
and negative ESI at the ion spray voltage of -4500 V.  The source temperature was 450 ºC. The 
curtain gas, ion source gas 1, and ion source gas 2 were 33, 50, and 65, respectively. Multiple 
reaction monitoring (MRM) was used to quantify metabolites. 
Power analysis was not used to determine the number of replicates. Error bars represent 
the standard error of the mean of three biological replicates. All compounds evaluated in biological 
assays were ≥95% pure.  
Colistin assay. Assays measuring permeabilization by colistin were performed as above, with the 
addition of 6.0 µM colistin sulfate immediately before the compound of interest was added.  
Bacterial strains. MRSA and P. aeruginosa isolates were from Cubist Pharmaceuticals 
(Lexington, MA). E. coli MG1655 was provided by Professor Cari Vanderpool (UIUC). E. coli 
clinical isolated were provided by Dr. Lynn Zechiedrich (Baylor School of Medicine). E. cloacae 
ATCC 29893 was provided by Dr. Wilfred van der Donk (UIUC).  A. baumannii isolates 
were provided by Dr. John Quale. E. cloacae and K. pneumonia clinical isolates were provided by 
Dr. Dennis Hooper (Massachusetts General Hospital).   
Antibiotic susceptibility tests. Susceptibility testing was performed in biological triplicate, using 
the microdilution broth method as outlined by the Clinical and Laboratory Standards Institute. 
Mueller Hinton (MH) broth was used. 
Outer membrane protein profiles. The method used to compare the outer membrane proteins of 
E. coli BW25113 to outer membrane of the ∆ompR E. coli from the KEIO collection was adapted 
from Adler and coworkers47. Briefly, bacteria were grown to OD600 = 1.0 at 37°C in LB broth. 4 
mL were centrifuged for 10 min at 2,350 g at 4° C, washed with 1 mL of 100 mM Tris-HCl, pH 
8.0, with 20% sucrose and incubated on ice for 10 min. Cells were pelleted as before and taken up 
in 1 mL of 100 mM Tris-HCl, pH 8.0, 20% sucrose containing 10 mM sodium 
ethylenediaminetetraacetate (EDTA). Lysozyme was added to a final concentration of 100 mg/mL 
and incubated on ice for 10 min. MgSO4 was added to 20 mM final concentration and RNAseA 
and DNAseI were added to a final concentration of 10 mg/mL. Cells were disrupted with five 
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freeze–thaw cycles in dry ice/ethanol and room temperature/water bath. A sixth freezing sample 
was left to thaw on ice for 2 hours. Membranes were pelleted for 25 min at 16,100 g at 4°C. The 
supernatants were discarded, and the pellet was washed and pelleted three times in 1 mL of 20 mM 
NaPO4, pH 7 and 0.5% sarkosyl. The protein extracts were taken up in 60 mL of Laemmli sample 
buffer (80 mM Tris-HCl, pH 6.8, 3% SDS, 10% glycerol, 5% β-mercaptoethanol, 0.02% 
bromophenol blue), boiled for 5 min and subjected to SDS-PAGE (12% polyacrylamide). Proteins 
were visualized via staining with Coomassie Blue-G.  
Accumulation analysis in protoplasts: The method for preparing protoplasts was adapted from 
Weiss48. 85 µL of an overnight culture of E. coli MG1655 was diluted into 85 mL of fresh LB 
broth and grown at 37˚C with shaking to an OD600 = 1.0. The bacteria were pelleted at 3,220 rcf 
for 10 minutes at 4°C and the supernatant was discarded. The pellet was washed 3 times with 10 
mL of 10 mM Tris HCl buffer (pH 8), and the pellet was resuspended in 30 mL of 10 mM Tris 
HCl (pH 8) containing 0.5 M sucrose. Potassium ethylenediaminetetraacetate (EDTA, 0.5 M, pH 
8.0) was added slowly over a period of 20 minutes to a final concentration of 0.01 M. The bacteria 
were shaken at 130 rpm for 20 minutes at 37°C, and then harvested as before. The supernatant was 
discarded and the pellets were washed two times with SMM buffer (0.5 M sucrose, 20 mM sodium 
maleate, 20 mM MgCl2, pH 6.5). The bacteria were then resuspended in 30 mL of SMM buffer, 
30 mg of lysozyme was added, and the bacteria were shaken at 130 rpm for 1.5 hour at 37°C. The 
protoplasts were harvested by centrifuging at 2000 rcf for 20 minutes at 4°C.  
 The protoplast pellet was resuspended in 20 mL of SMM buffer, and protoplast formation 
was confirmed by diluting an aliquot in water and observing a 3-fold decrease on OD600. To test 
accumulation, 500 µL aliquots containing 10 µM compound were shaken at 130 rpm for 5 minutes 
at 37°C. Samples were pelleted at 2000 rcf for 10 minutes at room temperature and the supernatants 
were discarded. The pellets were resuspended in 200 µL of water and incubated at room 
temperature for 5 minutes. The lysed protoplasts were pelleted by centrifuging at 21,130 rcf for 10 
minutes, and the supernatant was analyzed by LC-MS/MS for compound concentration as before.  
Data Analysis and Statistics:  Statistical significance of accumulation was determined by using 
a two sample Welch’s t-test (one-tailed test, assuming unequal variance) relative to the negative 
controls. Variance in accumulation across molecules was found to be unequal by Bartlett’s test. 
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For all other experiments, statistical significance was determined using an unpaired Student’s t-
test assuming equal variance as determined by an F-test. 
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Chapter 4: A deeper understanding of compound accumulation in  
Gram-negative bacteria 
 
Portions of this Chapter are reprinted with permission from Richter, M. F.; Drown, B. S.; Riley, A. 
P.; Garcia, A.; Shirai, T.; Svec, R. L.; Hergenrother, P. J., Predictive compound accumulation rules 
yield a broad-spectrum antibiotic. Nature 2017, 545, 299-304.1 Contributions of others are noted 
where applicable. 
4.1 Introduction  
 As is discussed in Chapter 1, compound accumulation in Gram-negative bacteria is affected 
by many different cellular components, including multiple porins, efflux pumps, and the 
lipopolysaccharide layer.2-4 To account for all of these variables, the compound accumulation 
studies in Gram-negative bacteria (discussed in Chapter 3) were all performed in wild-type whole 
cell E. coli instead of model systems. Although general predictive guidelines for compound 
accumulation in Gram-negative bacteria were developed (eNTRy Rules), several questions 
remain, including the mode of compound permeation, why relatively rigid and flat compounds 
with a primary amine are the most likely to accumulate, if additional amines are helpful, the 
location of compound accumulation (periplasm vs cytoplasm), the role of efflux pumps, and finally 
if the predictive guidelines are applicable to other species of Gram-negative organisms. Discussed 
herein are further experiments to begin to better understand compound accumulation in Gram-
negative bacteria.  
4.2 Accumulation studies in a porin knockout strain of E. coli 
The two major pathways of small-molecule permeation into Gram-negative bacteria are 
through porins3 and by the self-promoted uptake pathway.5-8 Likely, many compounds, such as the 
fluoroquinolones and tetracycline,9-11 enter Gram-negative bacteria through a combination of both 
pathways. Compounds that predominately utilize the self-promoted uptake pathway are usually 
either polycationic8 or contain a cation-chelation motif (such as the presence of 1,3-ketoacid). Our 
test set contains very few polycationic compounds and cation-chelation motifs. We therefore 




The E. coli genome encodes several general porins.3 The two major porins are OmpF and 
OmpC, and downregulation and mutation of these porins are often associated with antibiotic 
resistance.12-16 The expression of these porins are carefully regulated and depends on many 
variables, including extracellular osmolarity.17 The channel of OmpF is slightly wider than the 
channel of OmpC.18 Therefore, in high osmolarity conditions, OmpC is preferentially expressed, 
while OmpF is preferentially expressed in low osmolarity conditions. The expression of both 
OmpF and OmpC are controlled by a two-component system, EnvZ-OmpR. EnvZ acts as both a 
kinase and a phosphatase. It senses the external osmolarity, and phosphorylates OmpR when the 
external osmolarity is high and dephosphorylates OmpR when osmolarity is low. When 
extracellular osmolarity is low, the level of phospho-OmpR in the cell is relatively low. The 
phospho-OmpR complex binds to sites of the ompF gene that have high affinity for phospho-
OmpR. These sites are directly upstream of the promoter region and results in activation of the 
ompF gene. When extracellular osmolarity is high, on the other hand, the level of phospho-OmpR 
in the cell is relatively high. The excess phospho-OmpR can bind to additional low-affinity sites 
of the genome, including a site that represses ompF transcription and a site that activates ompC 
transcription. Thus OmpR serves as both a transcriptional activator of both ompF and ompC and a 
transcriptional repressor of ompF,17 and the inactivation of OmpR results in significantly decreased 
expression of both OmpF and OmpC.19  
We utilized the ∆ompR strain to test the hypothesis that the compounds in our CtD test 
collection permeate E. coli through porins. In Chapter 3, we validated that ∆ompR E. coli 
negligibly expresses OmpF and OmpC, and demonstrated that antibiotic accumulation in the 
∆ompR strain is lower than in wild-type E. coli. Expanding on those initial experiments, eight 
compounds from the test set and 6DNM-NH3 were tested for accumulation. The compounds tested 
are structurally distinct, including compounds derived from gibberellic acid, isomannide, as well 
as simple commercially available amines. In all cases, the accumulation is significantly less in the 
porin knockout strain than in wild-type E. coli (Fig. 4.1), indicating the compounds permeate 
bacteria through porins, as hypothesized.  
For all compounds tested, accumulation does not drop to zero in the porin knockout strain, 
and in certain cases (especially 4-11, 4-18, 4-4, and 6DNM-NH3) accumulation remains relatively 
high. The reason for this incomplete reduction is unknown, but the compounds may accumulate 
through a self-promoted uptake mechanism, or through different porins encoded in the E. coli 
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genome, including PhoE (a general porin that slightly prefers anions),20 OmpN (a channel that is 
similar to OmpC but is expressed at low levels in wild-type strains),21 and OmpG (a large porin 
that is expressed at trace levels in wild-type E. coli).22 It is challenging to determine exactly how 
compounds get into Gram-negative bacteria, and if additional changes to the outer membrane 
occur when OmpF and OmpC are knocked out. Nevertheless, the studies in the ∆ompR strain of 
E. coli clearly indicate that most of the compounds tested permeate through the major porins OmpF 
and OmpC.  
 
4.3 Understanding the observed accumulation trends 
Also discussed in Chapter 3, compounds are most likely to accumulate in Gram-negative 
bacteria if they contain a non-sterically encumbered amine, are relatively rigid, and have low three-











































Fig. 4.1 Accumulation comparison of compounds for E. coli ∆ompR vs parental strain E. 
coli BW25113. All structures of compounds from the test set are provided under the graph. 
Statistical significance was determined by using a two-sample Student’s t-test (two-tailed test, 
assuming equal variance). *P < 0.05; **P < 0.01; ***P < 0.001. All experiments were performed 
in biological triplicate. Error bars represent s.e.m. 
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porins, to better understand the observed accumulation trends, molecular modeling was performed 
on a subset of test set compounds and antibacterials as they traverse the bacterial porin OmpF. 
This work was performed by Bryon Drown, and thus will only be quickly summarized here. 
Steered molecular dynamics (SMD) simulations were performed such that molecules were pulled 
through the constriction site of OmpF. While it does not directly provide the free energy landscape, 
SMD is frequently employed to map the pathway for long time-scale processes and has been 
previously utilized to study OmpF.23  The trajectory of high-accumulating compound 1 (structure 
shown in Fig. 4.1) reveals a key interaction between the pendant amine and acidic residues (most 
often Asp113) that assisted in movement through the constriction site (Fig. 4.2A,B). This finding 
is in accord with previous reports of the importance of Asp113 in producing the cation selectivity 
of OmpF.24-25 This interaction was absent in the trajectory of a low-accumulating analogue of 1 
(amide 13) (Fig. 4.2C, D), in agreement with accumulation data. The molecular modeling data also 
demonstrated that the compounds fit narrowly within the porin channel, suggesting that more 
three-dimensional compounds would not diffuse through these channels as readily. Additionally, 
we speculate that compounds diffuse more readily if they are relatively rigid due to the entropy 
cost of a highly flexible compound moving through the channel, but this hypothesis has not yet 




4.4 Comparison of the accumulation of compounds with one versus two primary amines 
 Given that the presence of one primary amine greatly aids in compound accumulation in 
E. coli, we were curious if compounds with two primary amines accumulate even more. We 
synthesized six pairs of compounds to compare the accumulation of the mono-amines to the 
accumulation of the diamines (synthesis discussed in Chapter 2), and no trend was observed (Fig. 
4.3). In some cases, the mono-amine accumulates more, while in other cases the diamine 
accumulates more.  
Given the complexity of the bacterial outer membrane, it is unsurprising that the effect of 
the second amine is not consistent. For example, for compounds that traverse the outer membrane 
via porins, the second amine may make positive or negative interactions with the porin channel, 
depending on placement. As can be seen clearly in Fig. 4.2B, the constriction zone of the porin 
has negatively-charged amino acids on one side and positively-charged amino acids on the other. 
A) B)
C) D)
Fig. 4.2. Snapshots of trajectories as select compounds traverse OmpF porin. A) Compound 
1 is capable of making a key interaction with Asp113 that assists in movement past constriction 
site. B) Same pose as a, viewed from above. C) Compound 13 makes no interactions with 
Asp113 and thus faces additional barriers to penetrance. D) Same pose as c, viewed from above. 
In all images arginine 42, 82, and 132 are depicted in blue. 
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SMD simulations demonstrate that a single primary amine is able to interact with the negatively 
charged residues, which helps with diffusion through the OmpF porin. One could imagine a second 
primary amine directly across the molecule that might interact with the positively charged residues 
and impede permeation. Thus, the distance between the amines may affect the ability of a molecule 
to diffuse through porins, and this relationship will need to be carefully studied. It is also important 
to consider that the second amine may lead to accumulation through the self-promoted uptake 
pathway for certain compounds, and an entirely different set of properties favoring permeation 
may be at play. Another possibility is that the effect on accumulation of the second primary amine 
is dependent on the amine steric hindrance. 4-6-a and 4-28-a show the highest increase in 
accumulation compared to their mono-amine analogous. According to the predictive guidelines 
for compound accumulation into Gram-negative bacteria, sterically unencumbered amines tend to 
have the most positive effect on accumulation (Chapter 3). As the second amine on 4-6-a and 4-
28-a are on primary carbons, the magnitude of the effect of the second amine may simply be in 
line with the predictive guidelines we observe when only one amine is present. To truly understand 
the effect of the second amine on accumulation, it will be essential to differentiate accumulation 
through porins and accumulation through the self-promoted uptake pathway using porin knockout 
strains and an assay to determine if a compound enters through the self-promoted assay.26 As only 
a relatively limited number of diamines were tested and the mode of permeation was not 
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Fig. 4.3. Accumulation of paired set of compounds containing one or two primary 
amines. Error bars equal s.e.m. Statistical significance was determined by using a two-
sample Student’s t-test (two-tailed test, assuming equal variance). *P < 0.05; **P < 0.01. All 
experiments were performed in biological triplicate. Error bars represent s.e.m. 
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4.5 Periplasmic versus cytoplasmic accumulation 
A limitation to measuring accumulation in whole cells is that no distinction is made 
between periplasmic and cytoplasmic accumulation. To reach the cytoplasm of E. coli compounds 
must also diffuse through the inner membrane, whose filtering properties may be different from 
the filtering properties of the outer membrane.27 To examine this, high-accumulating compounds 
and some of their derivatives were tested for accumulation in E. coli protoplasts, cells lacking the 
outer membrane and peptidoglycan. Protoplasts are made by removing the outer membrane slowly 
with potassium ethylenediaminetetraacetate (EDTA), followed by removal of the periplasm with 
lysosome. Protoplasts are stabilized by high concentrations of sucrose. As shown in Fig. 4.4, 
minimal variation was observed between the ability of different compounds to accumulate in the 
protoplasts, supporting the hypothesis that traversing the outer membrane is the main barrier to 
small-molecule accumulation in Gram-negative bacteria. In fact, it was very challenging to find a 
compound that does not permeate protoplasts to use a negative control, further suggesting that the 
inner membrane does not prevent the passive diffusion of most small molecules. In the end, we 
had to use ADP-HPD,28-29 a non-cell permeable pyrophosphate (pyrophosphates are known to be 
unable to diffuse across lipid bilayer). Although this assay clearly demonstrates that most 
compounds are able to cross the cytoplasmic membrane, it does not provide information on the 
concentration of compound in the cytoplasm versus periplasm. One might assume that once past 
the outer membrane, compounds are freely diffusible between the periplasm and cytoplasm, but a 
more complete understanding of periplasmic versus cytoplasmic accumulation will depend on the 






4.6 The effect of efflux pumps on compound accumulation 
 Gram-negative bacteria have multidrug efflux pumps that function synergistically with the 
highly impermeable outer membrane to prevent the accumulation of toxic chemicals.2 Most efflux 
pumps have limited specificity and can expel a broad range of substrates, including almost all 
known antibiotics. As such, compounds must permeate the outer membrane faster than they are 
pumped out in order to accumulate and be efficacioius.  
Within bacteria there are five major families of efflux transporters: the adenosine 
triphosphate (ATP)-binding cassette (ABC) superfamily,30 the resistance-nodulation-division 
(RND) family,31 the small multidrug resistance (SMR) family,32 the major facilitator 
superfamily (MFS),33 and the multidrug and toxic compound extrusion (MATE) family.34-38 E. 
coli contain efflux pumps from all five of these families, but the efflux pump complex that is 


















































Fig. 4.4. Small-molecule accumulation in protoplasts prepared from E. coli MG1655. Test 
compounds and known antibiotics are able to accumulate in the protoplast. ADP-HPD, a non-
cell permeable pyrophosphate, was used as a negative control. *P < 0.05; **P < 0.01; ***P < 
0.001. All experiments were performed in biological triplicate. Error bars represent s.e.m. 
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40 AcrAB-TolC is a complex of proteins, with AcrB in the inner membrane, TolC in the outer 
membrane, and AcrA connecting the complex.41-42 Overexpression of AcrAB-TolC is rarely the 
sole cause of multidrug antibiotic resistance in E. coli, but it can contribute to resistance by 
lowering intracellular antibiotic concentration, which promotes mutations.36  
When one of the genes for the AcrAB-TolC complex is knocked out, bacteria are more 
susceptible to most antibiotics.39 In conjunction with the summer undergraduate researcher Kristen 
Muñoz, we compared the 24 hour minimum inhibitory concencentrations (MICs) of a panel of 
antibiotics against wild-type E. coli and E. coli ∆tolC. As is shown in Table 4.1, E. coli ∆tolC is 
more susceptible to every antibiotic tested, especially antibiotics that are not used to treat Gram-
negative infections.  
Table 4.1. MICs of antibiotics against E. coli BW25113 and E. coli ∆tolC 
WT ∆tolC Ratio
Tetracycline 1 0.5 2
Ciprofloxacin 0.0078 0.0039 2
Ampicillin 2 1 2
Chloramphenicol 4 1 4
Azithromycin 8 2 4
6DNM-NH3 0.5 0.0625 8
Vancomycin 128 64 2
Erythromycin 8 2 4
Rifampicin 8 2 4
Clindamycin 32 2 16
Novobiocin 32 1 32
Linezolid 1024 16 64
Mupirocin 128 1 128






















  These MIC results are consistent with work done by others, and have led many to believe 
that drug efflux is the major reason Gram-negative bacteria are resistant to most antibiotics, as 
opposed to slow drug permeation.43 To investiage this hypothesis, we tested Gram-positive only 
antibiotics for accumulation in both the wild-type strain of E. coli and E. coli ∆tolC. Under various 
assay conditions, the changes in antibiotic accumulation levels were negligible. For the 
accumulation assay, bacteria are incubated with compound for 10 minutes, whereas bacteria are 
allowed to slowly grow over 24 hours with compound when determining the MIC. We therefore 
hypothesized that slow compound permeation is in fact the main reason certain antibiotics are 
ineffective against Gram-negative bacteria, 
but when an efflux pump is knocked out, 
these slow permeators can buildup in the cell 
over time. To test this, we treated both wild-
type and ∆tolC E. coli with the Gram-
positive only antibiotic novobiocin, which is 
32-times more active against E. coli ∆tolC 
than wild-type E. coli. Accumulation was 
tested at 10 minutes, 1 hour, and 2 hours. As 
is shown in Fig. 4.5, the accumulation of 
novobiocin in wild-type E. coli is relatively 
stable over time, while the accumulation of 
novobiocin in E. coli ∆tolC increases over 
time, consistent with our hypothesis. 
Although this work is only preliminary and 
additional antibiotics need to be tested, it 
does support the notion that getting 
compounds across the membrane rapidly is still the major challenge in Gram-negative drug 
discovery. This is not to say efflux is never responsible for resistance to antibiotics. For example, 
we tested a small subset of our test set compounds for accumulation in E. coli ∆tolC compared to 
accumulation in wild-type E. coli, and three of the compounds were able to accumulate 
significantly more in the efflux deficient strain in only 10 minutes (Fig. 4.6). Going forward, we 
plan to expand on these time course assays comparing accumulation in wild-type E. coli to 
Fig. 4.5. Accumulation of novobiocin over 
time in E. coli BW25113 versus E. coli 









































accumulation in E. coli ∆tolC. As measuring accumulation is a much more sensitive method to 
differentiate compound accumulation than determining MICs, we hope we can better understand 
the role of efflux in compound accumulation in Gram-negative bacteria. Our data are consistent 
with the view that the outer membrane of Gram-negative bacteria still allows some minimal level 
of passive diffusion of most compounds, but any compound that enters too slowly is fully effluxed 
out. In contrast, compounds that are able to traverse porins and reach high cellular concentrations 
overwhelm the efflux mechanisms and lead to net accumulation.  
 
4.7 Accumulation studies in Acinetobacter baumannii 
 The original accumulation studies (Chapter 3) were performed in E. coli as a model 




































Fig. 4.6 Accumulation comparison of compounds for E. coli ∆tolC vs parental strain E. coli 
BW25113. All structures of compounds from the test set are provided under the graph. Statistical 
significance was determined by using a two-sample Student’s t-test (two-tailed test, assuming 
equal variance). *P < 0.05; **P < 0.01; ***P < 0.001. All experiments were performed in 
biological triplicate. Error bars represent s.e.m. 
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organism, genetic knockouts are readily available, and wild-type E. coli is safe to work with on a 
benchtop. However, all Gram-negative species have slightly different outer membrane 
components, which can greatly affect accumulation properties. In addition to E. coli, the World 
Health Organization lists Klebsiella pneumoniaea, Pseudomonas aeruginosa, and A. baumannii 
as pathogens for which new antibiotics are urgently needed.44 K. pneumoniaea is closely related 
to E. coli (both part of the Enterobacteriaceae family, along with Salmonella) and have similar 
porins and efflux pumps;45-47 thus, accumulation studies on K. pneumoniae are not a high priority. 
P. aeruginosa and A. baumannii, on the other hand, have very different outer membrane 
components in comparison to E. coli, which is evidenced by variations in antibiotic susceptibility, 
including P. aerugionsa not being suscpetible to 6DNM-NH3.4 As such, Emily Geddes, who 
joined the Hergenrother lab in the Fall of 2016, is studying accumulation in P. aeruginosa, and I 
am beginning the accumulation studies for A. baumannii.  
4.7.1 Background on A. baumannii 
 A. baumannii is an opportunistic pathogen that often infects patients with a compromised 
immune system.48-49 A. baumannii can infect many different systems, including the lungs,50 the 
blood stream,51 battlefield wounds,52 and around the brain/spinal chord (meningitis).53 A. 
baumannii is an intracellular pathogen that promotes release of cytochrome c from the 
mitochondria leading to cellular apoptosis.54 Strains of A. baumannii exist that are resistant to all 
or nearly all available antibiotics, including carbapenems, which are often considered the drug-of-
last-resort; resistance to the polymyxins and tigecycline has also been observed. Although not 
prevalent in the community, A. baumannii is considered an emerging pathogen that already leads 
to >500 deaths per year in the United States.55  
 Structurally, the outer membrane of A baumannii is quite distinct from E. coli, particularly 
in terms of porins and efflux pumps. A. baumannii is devoid of general porins, such as OmpF and 
OmpC in E. coli.3 Instead, A. baumannii has a series of more specific porins. There is some debate 
in the literature about the major porin channels in A. baumannii,56 but recent studies suggest the 
five outer membrane carboxylate channel family (OccAB) porins are most likely the porins utilized  
for uptake by antibiotics.57 OccAB porins are significantly more narrow than OmpF and OmpC 
porins, with a diameter of only about 5.5 Å, as opposed to 7.5 Å for OmpF. Additionally, OccAB 
porins contain an internal arginine ladder down one side of the porin, leading to the hypothesis 
that OccAB porins favor the uptake of carboxylate containing compounds.57 However, the 
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discovery of the OccAB porin family is still very recent, and detailed substrate specificity is yet to 
be determined. Like E. coli, the main efflux pumps that contribute to multidrug resistance in A. 
baumannii are RND pumps, but instead of just one major efflux pump system, A. baumannii has 
three major efflux pump systems, AdeABC, AdeFGH, and AdeIJK, each with slightly different 
substrate specificity.58-59 Between the more specific porins and greater number of efflux pumps, 
A. baumannii is typically less suscpetible to most antibiotics than E. coli. As such, studying 
compound accumulation trends in A. baumannii  will be important in differentiating the properties 
necessary for accumulation, and hopefully will improve our ability to discover broad-spectrum 
antibiotics.   
4.7.2 Accumulation of controls in A. baumannii 
 Before accumulation studies can 
begin, it is important to validate the 
accumulation assay in A. baumannii. The 
validation was attempted with two 
different wild-type strains of A. 
baumannii, A. baumannii ATCC 19606 
and A. baumannii BAA-2093. A. 
baumannii BAA-2093 provided more 
reproducible results, and was thus 
chosen to use for initial accumulation 
studies. To choose the appropriate 
antibiotic controls, the MIC of a panel of 
antibiotics was tested against A. 
baumannii BAA-2093 (Table 4.2). 
Antibiotics with an MIC < 1 µg/mL were 
chosen as positive (‘high-accumulating’) controls and antibiotics with an MIC ≥ 128 µg/mL were 
chosen as negative (‘low-accumulating’) controls. The positive controls show a statistically 
significant higher level of accumulation in A. baumannii than the negative controls, suggesting 
that the assay is measuring compound accumulation (Fig. 4.7). Similar to the validation studies 
performed with E. coli in Chapter 3, the assay will need to be further confirmed by co-treating 
with the membrane permeabilizing agent colistin, and looking for an increase in compound 

















accumulation, as well as performing accumulation studies with permeability mutants. With the 
assay conditions, compound collection (from Chapter 2), and machine learning mechanism in 
place (from Chapter 3), comparing the accumulation of compounds in E. coli to A. baumannii 
should be rapid.  
  
4.8 Summary and outlook 
 Compound accumulation in Gram-negative bacteria is affected by a complex array of 
cellular components. We have begun work to understand the contribution of each of these variables 
to accumulation. It is evident that compounds from our test set permeate at least partially through 
porin channels into E. coli and that most compounds are able to diffuse across the inner membrane. 
Early work with time course studies comparing accumulation in wild-type E. coli with E. coli 
∆tolC suggests that slow permeation, as opposed to efflux, is the main reason Gram-negative 
bacteria are intrinsically resistant to many antibiotics.  In order to accumulate, compounds must 
permeate the outer membrane faster than they are effluxed. Therefore, for drugs that accumulate 
rapidly, efflux pumps should have a minimal effect on activity, while the effect is more pronounced 
for drugs that permeate the cell slowly and can be efficiently cleared. Relying solely on MICs, this 
difference would have been nearly impossible to determine. Even though all of these studies are 
still in their preliminary phases, we hope this information compliments the whole-cell studies in 
wild-type bacteria and will help us better understand why certain parameters aid in accumulation.  
Overall, whole-cell studies in wild-type bacteria are likely still the most important tool for 
understanding accumulation in Gram-negative species. However, there may be some instances 


































* Fig. 4.7. Validation of compound 
accumulation assay in E. coli.  
Compounds that are active against E. 
coli have significantly higher 
accumulation than low-activity 
antibiotics and ampicillin. Statistical 
significance was determined by using a 
two-sample Welch’s t-test (one-tailed 
test, assuming unequal variance) 
relative to the negative controls. P 
values relative to the average of the 
low-accumulating controls. *P < 0.01. 
279 
 
accumulation. For example, we predict that more rigid compounds accumulate better than highly 
flexible compounds due to an entropic benefit when moving through the porin cavity. However, it 
may be that rigid compounds are better able to evade efflux. Understanding this difference could 
help in designing antibiotics to treat multidrug resistant pathogens, which often have upregulated 
efflux pumps. In the future, we plan to study accumulation in clinical isolates of multidrug resistant 
bacteria, and these preliminary mechanistic studies should help make sense of the data.  
 Going forward, we also hope to further define the guidelines for accumulation in Gram-
negative bacteria through additional whole-cell studies. This will be done by increasing the number 
and diversity of compounds tested in the assay, as well as increasing the number of species studied. 
To date, only limited numbers of diamines, zwitterions, anilines, and heterocycles have been 
studied. Expanding the compound set into these areas will help to define the effect of different 
functional groups on accumulation. As net accumulation is affected by many variables, including 
influx through porins and/or the the self-promoted pathway, it will be critical to understand the 
contributions of each variable to most accurately develop the predictive guidelines. From the 
limited number of diamines tested, this already appears to be true. The introduction of a second 
primary amine onto compounds does not have a consistent effect, and additional mechanistic 
studies will likely be needed to develop predictive guidelines for the accumulation of diamines. 
Finally, although E. coli was a good model organism to develop guidelines to predict accumulation 
in bacteria, we predict the guidelines will vary slightly from species-to-species. With the 
compound collection, assay conditions, and machine learning method in hand, the work that has 
been discussed throughout Chapters 2-4 should rapidly translate into an improved understanding 
of compound accumulation across a diversity of Gram-negative pathogens.  
 
4.9 Experimental protocols 
Accumulation assay. The accumulation assay was performed in triplicate in batches of ten 
samples, with each batch containing either tetracycline or ciprofloxacin as a positive control. For 
each replicate, 2.5 mL of an overnight culture of bacteria was diluted into 250.0 mL of fresh Luria 
Bertani (LB) broth (Lennox) (or tryptic soy broth for A. baumannii) and grown at 37˚C with 
shaking to an OD600 = 0.55. 200.0 mL of bacteria culture were pelleted at 3,220 rcf for 10 minutes 
at 4° C and the supernatant was discarded. The pellets were re-suspended in 40.0 mL of phosphate 
buffered saline (PBS, pH 7.4) and pelleted as before, and the supernatant was discarded. The 
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pellets were re-suspended in 9 mL of fresh PBS and aliquoted into ten 1.5 mL Eppendorf tubes 
(875 µL each). The number of colony forming units (CFUs) was determined via a calibration 
curve. The samples were equilibrated at 37˚C with shaking for 5 minutes, compound was added 
([final] = 50.0 µM), and then samples were incubated at 37˚C with shaking for 10 minutes. A 10 
minute time point was chosen because it is longer than the predicted amount of time required to 
reach a steady-state concentration,60 but short enough to minimize metabolic and growth changes 
(no changes in OD600 observed; CFUs were reduced by a factor of five after ciprofloxacin 
treatment for 10 minutes, but no other antibiotics had an effect). After incubation, 800.0 µL of the 
cultures were carefully layered on 700.0 µL of silicone oil (9:1 AR20/Sigma High Temperature, 
cooled to -78˚C). Bacteria were pelleted through the oil by centrifuging at 13,000 rcf for 2 minutes 
at room temperature (supernatant remains above the oil); the supernatant and oil were then 
removed by pipetting. To lyse the samples, each pellet was dissolved in 200.0 µL of water, and 
then they were subjected to three freeze-thaw cycles of three minutes in liquid nitrogen followed 
by three minutes in a water bath at 65˚C. The lysates were pelleted at 13,000 rcf for 2 minutes at 
room temperature and the supernatant was collected (180 µL). The debris was re-suspended in 
100.0 µL of methanol and pelleted as before. The supernatants were removed and combined with 
the previous supernatants collected. Finally, remaining debris was removed by centrifuging at 
20,000 rcf for 10 minutes at room temperature. Supernatants were analyzed by LC-MS/MS.  
Samples were analyzed with the 5500 QTRAP LC/MS/MS system (AB Sciex, Foster City, 
CA) with a 1200 series HPLC system (Agilent Technologies, Santa Clara, CA) including a 
degasser, an autosampler, and a binary pump.  The LC separation was performed on an Agilent 
SB-Aq column (4.6 x 50mm, 5µm) (Agilent Technologies, Santa Clara, CA) with mobile phase A 
(0.1% formic acid in water) and mobile phase B (0.1% formic acid in acetonitrile). The flow rate 
was 0.3 mL/min.  The linear gradient was as follows: 0-3min, 100%A; 10-15min, 2%A; 15.5-
21min, 100%A.  The autosampler was set at 5ºC.  The injection volume was 15 µL.  Mass spectra 
were acquired with both positive electrospray ionization (ESI) at the ion spray voltage of 5500 V 
and negative ESI at the ion spray voltage of -4500 V.  The source temperature was 450 ºC. The 
curtain gas, ion source gas 1, and ion source gas 2 were 33, 50, and 65, respectively. Multiple 
reaction monitoring (MRM) was used to quantify metabolites. 
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Antibiotic susceptibility tests. Susceptibility testing was performed in biological triplicate, using 
the microdilution broth method as outlined by the Clinical and Laboratory Standards Institute. 
Mueller Hinton (MH) broth was used. 
Accumulation analysis in protoplasts: The method for preparing protoplasts was adapted from 
Weiss.61 85 µL of an overnight culture of E. coli MG1655 was diluted into 85 mL of fresh LB 
broth and grown at 37˚C with shaking to an OD600 = 1.0. The bacteria were pelleted at 3,220 rcf 
for 10 minutes at 4°C and the supernatant was discarded. The pellet was washed 3 times with 10 
mL of 10 mM Tris HCl buffer (pH 8), and the pellet was resuspended in 30 mL of 10 mM Tris 
HCl (pH 8) containing 0.5 M sucrose. Potassium ethylenediaminetetraacetate (EDTA, 0.5 M, pH 
8.0) was added slowly over a period of 20 minutes to a final concentration of 0.01 M. The bacteria 
were shaken at 130 rpm for 20 minutes at 37°C, and then harvested as before. The supernatant was 
discarded and the pellets were washed two times with SMM buffer (0.5 M sucrose, 20 mM sodium 
maleate, 20 mM MgCl2, pH 6.5). The bacteria were then resuspended in 30 mL of SMM buffer, 
30 mg of lysozyme was added, and the bacteria were shaken at 130 rpm for 1.5 hour at 37°C. The 
protoplasts were harvested by centrifuging at 2000 rcf for 20 minutes at 4°C.  
 The protoplast pellet was resuspended in 20 mL of SMM buffer, and protoplast formation 
was confirmed by diluting an aliquot in water and observing a 3-fold decrease on OD600. To test 
accumulation, 500 µL aliquots containing 10 µM compound were shaken at 130 rpm for 5 minutes 
at 37°C. Samples were pelleted at 2000 rcf for 10 minutes at room temperature and the supernatants 
were discarded. The pellets were resuspended in 200 µL of water and incubated at room 
temperature for 5 minutes. The lysed protoplasts were pelleted by centrifuging at 21,130 rcf for 10 
minutes, and the supernatant was analyzed by LC-MS/MS for compound concentration as before.  
Data Analysis and Statistics:  Statistical significance of accumulation was determined by using 
a two sample Welch’s t-test (one-tailed test, assuming unequal variance) relative to the negative 
controls. Variance in accumulation across molecules was found to be unequal by Bartlett’s test. 
For all other experiments, statistical significance was determined using an unpaired Student’s t-
test assuming equal variance as determined by an F-test. 
All-atom Molecular Dynamics Simulations (performed by Bryon Drown) 
The simulation model was constructed using CHARMM-GUI62-64 and comprised one OmpF 
monomer (PDB 3POX), 108 (90%) 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine 
(POPE) lipid molecules, 12 (10%) 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) 
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(POPG),65 and solvated with 8,234 water molecules in 150 mM NaCl (36 Na+ and 15 Cl-) for a 
total of 45,402 atoms. Hexagonal periodic boundary conditions were applied with a distance of 
77.3 Å in the XY-direction and 92.8 Å in the Z-direction. Electrostatic interactions were calculated 
using the Particle-Mesh Ewald (PME) method. Protein residues E296, D312, and D127 were 
protonated.66-68 The simulations were performed at constant pressure (1 atm) and temperature (303 
K) with a time step of 2 fs. Each small molecule under investigation was manually placed directly 
above the pore. Restraints were initially applied to protein backbone and small molecule analyte 
atoms and then removed to equilibrate the system. For SMD production simulations, each small 
molecule analyte was pulled at the molecules center of mass (5 kcal/mol Å2) at a constant velocity 
(10 Å/ns) along the Z-axis for 4 ns. The all-atom CHARMM force field was used for protein and 
lipids.69-70 TIP3P was used for water.71 All the MD simulations were carried out using the NAMD 
2.11 scalable molecular dynamics program and run on Stampede at TACC. CHARMM residue 
topology and parameter files for the small molecules were constructed using CGenFF.72 SMD 
trajectories were analyzed and visualized using VMD 1.9.2 and rendered using Pov-Ray 3.6.73 
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